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Abstract
Galectin-3 is an apoptosis-related gene previously found to be over-expressed in invasive  
tumours and to cause in v itro  invasiveness and metastasis in colon, breast and thyroid 
follicular cancer cells. Galectin-3 over-expressing clones were obtained follow ing stable 
transfection o f  galectin-3 cD N A  into the non-invasive human lung carcinoma cell line 
DLKP. These clones exhibited increased in v itro  invasiveness and m otility and altered cell 
adhesion properties, but did not exhibit a drug resistant phenotype. Survivin is an anti- 
apoptotic gene highly expressed in all cancer types and during fetal development, but not in  
most normal adult tissue. To determine whether survivin over-expression plays a role in  
drug-resistance, transient transfections o f  survivin cD N A  into SK OV-3 ‘Tet o f f ,  M CF-7 
‘Tet o f f  and DLKP cells, were carried out. A ll three transfections resulted in an over­
expression o f  survivin m RNA, but not survivin protein.
To further investigate the role o f  galectin-3 and survivin in drug resistance and 
invasiveness, RT-PCR and western blot analysis were carried out on DLKP and RPMI- 
2650 cells w hich had been exposed to sequential pulsing w ith three (vincristine, taxotere 
and 5-fluorouracil) and five (vincristine, 5-fluorouracil, CC NU, carboplatin and epirubicin) 
chemotherapy drugs, respectively. Drug selection o f  DLKP resulted in two M D R  variants, 
DLKP-taxotere and DLKP-vincristine. The taxotere-resistant variant displayed a highly  
invasive phenotype. Drug selection o f  R PM I-2650 cells resulted in unstable M D R  variants, 
with no induction o f  invasiveness. Galectin-3 expression was examined in the drug-selected 
variants, along w ith the expression o f  the M DR-related genes, by  RT-PCR analysis. 
Galectin-3 m R N A  expression was unaltered in all the drug-selected variants o f  DLKP and 
RPM I-2650. Survivin expression was examined in the drug-selected variants by RT-PCR  
and western blot analysis. Survivin protein expression was dramatically down-regulated in  
DLKP-vincristine and DLKP-taxotere M D R  variants. This decrease w as not observed at 
the m R N A  level, indicating that this down-regulation o f  survivin protein m ay be at the 
post-transcriptional level in this cell system. In addition, D N A  microarray technology was 
used to investigate differences in gene expression between the DLKP M D R  variants and to 
identify new  targets involved in M D R  and invasion/m etastasis. Results indicated a dramatic 
increase o f  Mdr-1 expression and a slight increase o f  M RP2 expression in DLKP-taxotere 
and DLKP-vincristine. The expression o f  other genes studied were unaltered in the M DR  
variants compared to the parental cells.
Finally, to establish a role for apoptosis-related and drug resistance-related genes as 
potential clinical markers in breast cancer, the expression o f  survivin, galectin-3 and MRP1 
genes were examined in breast tumour specim ens, by RT-PCR analysis. The expression o f  
these genes was correlated with clinicopathological parameters to investigate an association  
between them and gene expression. A s galectin-3 was expressed in almost all the tumour 
specim ens, it w as not possible to correlate its expression w ith any o f  the parameters. N o  
significant association was detected between disease outcom e and the m RNA expression o f  
either survivin or M RP1.
Introduction
1.1 Treatment of Cancer
Chem otherapy has a m ajor role in controlling m etastatic cancers which cannot be cured by 
surgery. Radiotherapy, also an effective treatm ent for cancer, has been used alone and in 
com bination with chem otherapy and surgery. Surgery and radiotherapy can often eradicate 
prim ary or localised disease but m ay ultim ately fail because the cancer has m etastasised to 
other areas o f  the body. In such instances, chem otherapy m ay control or elim inate 
m etastatic disease and reduce mortality. Chem otherapy com bined w ith surgery or 
radiotherapy (or both), know n as adjuvant therapy, has increased survival rates for a 
num ber o f  solid  tum ours that were previously treated by only one therapeutic m odality.
M any o f  the drugs used in chem otherapy are directed a t disrupting the cell cycle, w ith 
RNA, D N A  and protein m olecules as the targets. M ost synthetic chem otherapeutic agents 
currently in use can be categorised according to  w hether they alkylate D N A  (alkylating 
agents) or antagonise metabolites required for D N A  synthesis (antim etabolites). A  th ird  
group (including vinca alkaloids and epipodophyllotoxins) are natural products from  plants 
and fungi. D ifferent groups o f agents will be discussed in section 1.1.1
The ultim ate clinical effectiveness o f  any anticancer drug requires tha t it kill m alignant 
tum our cells in vivo at doses that allow  enough cells in the patien t’s critical tissues to 
survive so that recovery can occur. In general, anticancer drugs are m ost useful against 
m alignant tum ours with a high proportion o f  dividing cells. Thus, in practical term s, drugs 
alone are prim arily effective against the leukem ias and lymphomas. T he m ost com m on 
m alignant tum ours, however, are “solid” tumours, including those o f  the  colon, rectum, 
lung and breast. These tumours usually have a low  proportion o f  d ividing cells and 
therefore are less susceptible to treatm ent by drugs alone (Pratt et a i ,  1994).
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1.1 .1 Chemotherapy Drugs involved in Cancer therapy
The first cancer treatm ent to be adm inistered to a cancer patient was in 1931, w hen A dair 
and B agg applied sulfur m ustard, a precursor o f  nitrogen m ustard (a drug developed for use 
as a  w ar gas), to  squam ous carcinom as and also injected it directly into tum ours in hum ans. 
This was however, too toxic for system atic use. In 1942, the first clinical trials began, using 
nitrogen m ustard to treat patients w ith lymphosarcom a. The second successful anti-cancer 
drug to be used clinically belongs to a class o f  drugs called antim etabolites. There are three 
types o f  anti-m etabolites: antifolates, antipurines and antipyrim idines. O ver a decade later, 
cytotoxic antibiotics were introduced. These include the anthracyclines, w hich are 
discussed below. In 1965, the platinum  compounds were discovered to  inhibit proliferation 
o f E.coli and were used in clinical trials seven years later. This group o f  com pound will 
also be discussed below  along with other classes o f anti-cancer drugs.
A  total o f  n ine chem otherapeutic drugs were utilised in this study to exam ine the role o f  
certain genes in drug resistance and to exam ine the effect o f  drug treatm ent on the 
developm ent o f  m ultiple drug resistance on cancer cells. The nine drugs utilised here are 
V incristine, Taxol (Paclitaxel), Taxotere (Docetaxol), 5-Fluorouracil (5-FU), A driam ycin 
(Doxorubicin), Epirubicin, Cisplatin (CDDP), Carboplatin, and CC N U  (Lomustine); their 
m echanism s o f  action w ill be discussed in the follow ing section.
C om m on n am e G eneric  nam e
Taxol Paclitaxel
Taxotere D ocetaxol
Adriam ycin D oxorubicin
Cisplatin CDDP
CCNU Lom ustine
Etoposide VP-16
Table 1.1.1 Chemotherapy drugs and their various names.
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1.1.1.1 The Vinca Alkaloids
V incristine (Figure 1.1.1.1) and Vinblastine are com plex plant alkaloids isolated from  the 
periw inkle plant Catharanthus roseus. They are m em bers o f  a general class o f drugs that 
function as m itotic inhibitors which act by interfering with the function o f  m icrotubules, a 
class o f long, tube-like cellular organelles approxim ately 250nm  in diam eter (Pratt and 
Ruddon, 1994). M icrotubules and m icrofilam ents play an im portant role in the m ovem ent 
o f  cells relative to each other and in the m ovem ent o f  organelles w ithin the cytoplasm  o f  a 
single cell. The cytotoxicity o f  vincristine and vinblastine is attributed to their ability to 
interrupt cell division in m etaphase (Bruchovsky et al., 1965), but other effects could also 
contribute to cell death. Their action is specific to the M  phase o f  the cell cycle (W ilson et 
a l ,  1975).
The vinca alkaloids specifically exert their effect by binding to tubulin and preventing its 
polym erisation (K ing et al., 2000). As polym erised m icrotubules form  the spindles that 
retract chrom osom es into daughter cells at m itosis, their disruption results in blocked 
mitosis. Exposure o f  m itotic cells to the drugs is followed by the rapid disappearance o f  the 
spindle apparatus and the m aintenance o f  the  chrom osom es in the condensed state. 
A lthough the effects are seen at the time, the actual vincristine-tubulin interaction occurs 
during interphase.
V incristine and vinblastine have very sim ilar chem ical structures and behave in essentially 
the same way at the level o f drug-tubulin interaction; however, there are differences in die 
spectrum  o f  the antitum our activity o f  the two drugs in both experim ental anim al tum ours 
and clinical cancer. N o reason for these differences is currently known. These compounds 
are effective against a broad spectrum  o f  cancers such as lung, ovarian and testicular cancer 
(Culine et al., 1994; E inhom , 1997; Schiller, 2001; Schuette, 2001). They induce bone 
m arrow and neural toxicities, and developm ent o f drug resistance to both agents is via 
overproduction o f  P-glycoprotein (Bradley et al., 1989).
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1 .1 .1 .2 The Taxanes
The taxanes are a group o f  drugs including paclitaxel (taxol) and docetaxol (taxotere).
Taxol was originally isolated from  the Taxus brecifolia yew  tree. D espite the elucidation o f  
its broad activity and its unique structure (W ani et al., 1971), it is still in an early stage o f  
clinical developm ent in so far as its role/potential role in the treatm ent o f  m any cancer 
types has yet to be conclusively defined. Taxotere (docetaxel) is a sem i-synthetic taxane 
extracted from the needles o f Taxus baccata, and slightly m ore soluble than taxol. The 
chemical structure o f  taxotere is shown in figure 1.1.1.2. Sim ilar to the vinca alkaloids, the 
taxanes exert their anti-tum our effect through the disruption o f  m itosis. They interfere w ith 
chrom osom e changes during the cell cycle and are toxic to  proliferating cells. They induce 
a shift in the physiological equilibrium  betw een m icrotubules and tubulin tow ard 
polym erization and form ation o f dysfunctional microtubules.
Taxol and taxotere have been shown to be very active in the treatm ent o f  refractory ovarian 
cancer (Rowinsky et al., 1990). Encouraging results have been obtained in patients w ith 
m etastatic breast cancer (Holmes et al., 1991 and M arty e t al., 1999). L ike the m ajority o f 
chem otherapy drugs, the taxanes also have some side effects. B one m arrow  suppression 
(principally neutropenia), com plete alopecia (hair loss), and hypersensitivity reactions are 
the m ost com m on does-lim iting toxicities for the taxanes (M arkm an et al., 2003). O ther 
side effects include, hypersensitivity reaction characterised by dyspnea, urticaria, and 
hypotension. A  variety o f  cardiac abnorm alities have also been associated with taxol 
treatm ent (Pratt et al., 1994), Six new  taxane derivatives are currently in  clinical trial. All 
sharing the sam e feature, which is a decreased recognition by P-glycoprotein (Lavelle et 
al., 2002).
Resistance to taxol and taxotere arises through the sam e m echanism s involved in resistance 
to  vinca alkaloids, i.e. m ultidrug resistance, resulting from  over-expression o f  P- 
glycoprotein (Roy et al., 1985 and G reenberger et al., 1987). A  second m echanism  o f  drug 
resistance is due to the m utation o f the gene coding for one o f  the tubulin subunits (Schibler 
et al., 1986). By this m echanism , it is thought that, in the absence o f  drug, the equilibrium  
between free tubulin and m icrotubules is shifted tow ard disaggregation (Cabral et al.,
1986); therefore the m utant cells have slightly greater tolerance for taxol-induced 
stabilization than that o f  the  parent cells. Some m utants w ere not only resistant to taxol, bu t 
they also required it for growth, as a result o f  an extrem e shift tow ard disaggregation (Pratt 
etal.,  1994).
F ig u re  1.1.1.1 Chem ical structure o f  V incristine
Figure 1.1.1.2 Chemical structure o f Taxotere
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1.1.1.3 The antimetabolites (5-Fluorouracil)
The antim etabolites are drugs that are chem ically related to naturally occurring com pounds 
and interfere w ith cellular m etabolic pathways, especially those involved in the synthesis o f  
DNA. This group o f  cytotoxic drugs is divided into three groups: 1) folate antagonists, 2) 
pyrim idine analogues and 3) purine analogues (Skovsgaard et ah, 1994).
5-Fluorouracil (5-FU) is an anti-pyrim idine and is one o f  the m ost w idely used agents in 
the treatm ent o f  hum an cancer. It is effective in the treatm ent o f  the  m ost com m only 
occurring solid tum ours, including colorectal, breast, head and neck, gastric and pancreatic 
cancers (Pratt et ah, 1994). It is m ore toxic to proliferating than non-proliferating cells, 
leading to toxic side effects in tissues o f  the  gastrointestinal tract and bone marrow. It is a 
sim ple derivative o f  uracil where the hydrogen a t position 5 is replaced by a fluorine atom. 
5-FU was first synthesised in 1957 and is a m em ber o f the  antim etabolite group o f  drugs. 
Its m ajor m echanism  o f action is through inhibition o f nucleotide synthesis and through 
incorporation into R N A  (W ilkinson et ah, 1973 and Parker et ah, 1990). 5-FU  is the  m ost 
im portant pyrim idine antagonist and can be m etabolised to 5-fluorodeoxyuridine 
m onophosphate (FdUM P), which inhibits thym idylate synthesis and consequently D N A  
synthesis and transcription, translation and intracellular distribution o f  mRNA.
Figure 1.1.1.3 The Chemical structure o f 5-Fluoruracil
Another m em ber o f  the antimetabolite fam ily o f  dm gs is m ethotrexate. An analogue o f  
folic acid, it is the m ost im portant anti-folate as it is successfully used to treat osteogenic 
sacrcom a and head and neck cancer (Ackland et al., 1987). It is also effective in 
com bination with other drugs for the adjuvant therapy o f  breast cancer (Stoller et al., 1977) 
and since its introduction in the clinic in 1984, it is the best understood antineoplastic 
com pound to date. M ethotrexate exerts its cytotoxic effect by com petitive inhibition o f  the 
cytosolic enzym e dihydrofolate reductase (DHFR) (W altham  et al., 1988), w hich is the key 
enzyme in the biosynthesis o f  pyrim dines and purines.
1.1.1.4 T he  A n th racyclines
The anthracyclines are a class o f anti-tum our antibiotics derived from  the Streptomyces 
species (Tannock and Hill, 1992). They have a  characteristic four-ring structure, linked to 
the sugar residue by a glycosidic bond (Figure 1.1.1.4). Included in this fam ily are 
adriam ycin (doxorubicin), daunorubicin and epirubicin. A driam ycin is one o f  the  m ost 
im portant agents in the treatm ent o f  hum an cancer (Tritton and Yee, 1982). It is effective 
against acute m yelogenous leukem ia (AM L), acute lym phoblastic leukem ia (ALL), bladder 
carcinom a, breast, ovarian, lung, bronchi and thyroid cancer as w ell as non-H odgkin’s 
lym phom a and neuroblastom a (Carter et al., 1987). Serious side effects are seen w ith the 
use o f  this drug, however. Adriam ycin is carcinogenic and m utagenic and causes 
im m unosuppression in patients receiving this treatment. D am age to heart m uscle is the 
w orst side effect docum ented (Tannock and Hill, 1992).
The prim ary m echanism  o f  action o f  the anthracyclines is due to the drugs’ ability to bind 
DNA, involving intercalation betw een the tw o strands o f  the double helix, resulting in 
inhibition o f  replication, transcription and translation. It is th is D N A  binding tha t results in 
their cytotoxicity. Adriam ycin has been show n to induce double strand D N A  breaks in 
cultured m am m alian cells (Nelson et al., 1984). The DN A breaks are caused by the enzym e 
topoisom erase H  This enzym e controls the degree o f D N A  supercoiling by  cleaving and 
reannealing D N A  such that the coil is relaxed by one turn. The observation that a direct 
correlation betw een topoisom erase II activity and adriam ycin resistance exists in several
cell lines strongly supports the involvem ent o f  topoisom erase II in the cytotoxicity pathw ay 
(Glisson etal., 1986; Pom m ier etal.,  1986; D effie etal.,  1989).
The m ost com m on resistance m echanism  in cells treated with adriam ycin in vitro is 
increased drug efflux. This is due to the over-expression o f  a num ber o f  proteins including 
P-glycoprotein, m ultiple drug resistance protein (M RP) fam ily m em bers and lung 
resistance protein (LRP) (see section 1.2.1).
Figure 1.1.1.4 Chemical structure of adriamycin and epirubicin
1.1.1.5 The Platinum Compounds (Cisplatin and Carboplatin)
Platinum  com pounds were discovered by R osenberg and co-w orkers (1969) w hile studying 
the effect o f  electric current on bacterial cell division. They w ere found to be effective at 
preventing cell division in E. coli. It becam e clear that cell division was being inhibited by 
an electrolysis product o f  the platinum  electrode. R osenberg then tested the anti-tum our 
activity o f  several platinum  compounds and dem onstrated that cisplatin (Cis- 
diam m inedichloroplatinum (II) (CDDP)) was effective against leukem ia in m ice (Rosenberg 
etal.,  1969). This led to clinical trials in 1972.
The platinum  com pounds exert their toxicity by binding to base pairs o f  DNA, resulting in 
the form ation o f  intra-strand cross-links and adducts, and ultim ately leads to the disruption 
and unw inding o f  the D N A  double helix. Cisplatin is currently one o f  the m ost effective 
anti-cancer drugs used in the treatm ent o f  ovarian, testicular, head and neck, non-sm all cell 
lung and brain tum ours (Einhom , 1997; Gregory et al., 2000; Nardi e t al., 2001; Schiller, 
2001; Novello & Chevalier, 2001). The side effects o f  cisplatin include nephrotoxicity, 
which may ultim ately lead to renal failure, gastrointestinal toxicities, m yelosuppression, 
tinnitus and loss o f  hearing. To avoid these side effects, other platinum  com pounds, 
including carboplatin, have been designed. No dom inant m echanism  o f  resistance to 
cisplatin has been identified. O ften resistant cells have an increased capacity to repair 
intrastrand adducts (Fox, 1984), bu t in m any studies the increase in repair capacity has not 
been sufficient to explain the extent o f resistance (Eastm an etal.,  1987).
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1 .1 .1 .6 Nitrosoureas (CCNU)
This fam ily o f  alkylating agents, synthesised and tested for anti-tum our activity, consists o f  
four compounds that are available for clinical use. These are: carm ustin (BCNU), lom ustine 
(CCNU), Sem ustine (M ethyl-CCNU) and streptozotocin. The chem ical structure o f  CC N U  
is shown in figure 1.1.1.6. The m echanism  o f  action o f  CC N U  is not very well understood, 
however, evidence suggests that it can produce interstrand cross-links in D N A  (K ohn et al., 
1977).
CCNU is rapidly absorbed from  the gastrointestinal tract and is routinely adm inistered 
orally. This group o f  drugs is very lipophilic and therefore, distributes w idely in the tissues. 
Their lipophilic nature allows them  to readily pass across the blood-brain barrier into the 
cerebrospinal fluid and into brain tum our tissue w here drug concentrations can exceed 
those o f plasm a (W alker et al., 1976). This has led to clinical application o f  these drugs in 
the treatm ent o f  brain tum ours and m eningeal leukemia. Side effects include nausea and 
vom iting, but m ajor side effects such as, renal damage, CNS toxicity, throm bocytopenia 
and leukopenia, can also occur.
O
Cl-CH2-CH2-N-CfNH  
NO
Lomustine (CCNU)
Figure 1.1.1.6 Chemical structure o f CCNU
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1.2 Multidrug resistance (MDR) in cancer
C ancer treatm ent using chem otherapy has a lim ited potential to cure the disease due to 
acquired or intrinsic resistance o f  cancer cells to anticancer agents. R esistance to one drug 
is often associated with resistance to a series o f  different drugs. This is term ed m ultidrug 
resistance, (MDR), and it often results in few  therapeutic options and so worse prognosis 
for the cancer that is being treated. Com bination chem otherapy using chem ically unrelated 
drugs was introduced to overcom e this problem. H ow ever, cancers can develop m ulti-drug 
resistant variants, which display resistance to a range o f  chem ically unrelated drugs, thus 
dim inishing the effectiveness o f  com bination therapy (C lynes etal.,  1990).
Gastrointestinal, hepatobiliary and renal cancers are usually unresponsive to  chem otherapy 
and therefore have a high degree o f intrinsic M DR, w hereas leukem ias, lym phom as, 
ovarian and breast cancers often respond to treatm ent initially, bu t acquire resistance during 
the course o f the  disease (Lehne et a l ,  2000). M ultidrug resistance com prom ises the 
efficacy o f  cancer chem otherapy treatm ent in the clinic. It m ay occur w hen tum ours that 
may have been sensitive, becom e resistant to a variety o f  anticancer drugs that are 
structurally unrelated and have diverse cellular targets. M D R  m ay be observed in prim ary 
therapy (inherent resistance) or be acquired during or after treatm ent (acquired resistance) 
(Yu et a l ,  1999). A lthough the m ajority o f  tum ours show  an initial response to 
chemotherapy, a relapse that neither responds to the drugs initially used nor to other 
anticancer drugs often follows. In vitro studies have shown that M D R  is frequently 
accom panied by reduced intracellular drug accum ulation due to increased drug efflux by 
energy-dependant trans-m em brane drug transport proteins (Endicott and Ling, 1989).
One m ajor m echanism  o f  resistance to such drugs is linked to decreased cellular 
accum ulation o f  anticancer drugs through enhanced cellular efflux o f  the  anti-tum our 
com pounds, as m entioned above. Such m ultidrug resistance can be conferred in vivo and in 
vitro, by a num ber o f  proteins. The m ost im portant genes m ediating drug resistance in vivo 
are the 170kDa P-glycoprotein (encoded by the MDR\ gene) (Higgins et al., 1992; 
Gottesm an and Pastan, 1993), the 190kDa M RP1 (Ling e t a l ,  1984; Cole e t a l ,  1992) and 
its hom ologues (Kool et al., 1997). All o f  these proteins are m em bers o f  the  ABC (ATP- 
binding cassette) transporter fam ily and function as A TP-dependent active transporters.
1.2.1 M echan ism s o f M D R
1 .2 .1.1 P -gp  an d  its ro le in  M D R
One o f  the m ost im portant and commonly reported m echanism s o f  M D R  involves the 
m ultidrug transporter, P-glycoprotein (Pgp), a plasm a m em brane efflux pum p w ith ATP- 
ase activity. Expression o f  Pgp enables the cells to survive lethal doses o f  certain cytotoxic 
drugs by pum ping the drugs out o f  the cells and, thus, reducing their cytotoxic effect 
(Juliano et al., 1976; Endicott and Ling, 1989). Several clinically im portant anticancer 
drugs m ay be excluded from  neoplastic cells by Pgp-m ediated transport, despite the 
diversity in chemical structures and m echanism s o f action o f  these drugs.
Pgp belongs to the A TP binding cassette (ABC) fam ily o f  transporter m olecules (G erm ann 
et al., 1993; Breuninger et al., 1995), which also include the M D R -associated proteins 
(M RPs) (Cole et al., 1992) and the breast cancer resistant protein (BCRP) (Ross e t al., 
1997). The gene encoding Pgp belongs to the M D R  m ultigene family, which consists o f 
tw o highly hom ologous genes MDR1 and M DR2, situated on chrom osom e 7q21.1 in 
hum ans (Lincke et al., 1991). Pgp transverses the plasm a m em brane and consists o f  tw o 
hom ologous halves, each o f  which contains six hydrophobic domains and a hydrophilic 
nucleotide binding fold (Figure 1.2.1.1) (Germ ann et al., 1996). The hydrophobic regions 
represent putative transm em brane domains form ing a pore-like structure (Rosenberg et al., 
1997). The two adenosine triphosphate (A TP)-binding folds are located intracellularly and 
exhibit significant A TPase activity (A m budkar et al., 1992). The drug binding sites are 
localized in the transm em brane domains close to the cytosolic surface (Bruggem ann et al.,
1992). Pgp transports drugs out o f the cell, w hich is a process that requires the presence o f  
two ATP-binding domains. These domains are a defining characteristic o f  this fam ily o f 
ATP-binding cassette (ABC) transporters. The exact m echanism  o f  drug efflux is no t well 
understood, but m ight involve either direct transport out o f  the  cytoplasm  or redistribution 
o f the drug as it transverses the plasm a m em brane, resulting in the reduction o f  intracellular 
drug concentration. Som e o f  the cytotoxic drugs that are know n substrates for Pgp include 
etoposide, taxol, vincristine, actinom ycin D, m itoxantone and adriam ycin (Clynes e t al.,
1993) (see Figure 1.2.1.3).
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P-glycoprotein expression is not, however, lim ited to cancer cells. Its expression has been 
reported in a variety o f  norm al tissues (van der V alk et al., 1990) and it is thought to play a 
role in xenobiotics efflux. P-gp is expressed in norm al tissue from  liver (Fojo et al., 1987; 
K am im oto et a l ,  1989), kidney (Thiebaut et al., 1987), pancreas (Fojo et al., 1987; 
Thiebaut et al., 1987), adrenal gland (Fojo et al., 1987; Thiebaut et al., 1987; Croop et al., 
1989) and intestine (Thiebaut et al., 1987), as well as a subset o f  norm al bone m arrow  cells. 
P-gp also plays a role as a chlorine channel and is related to the cystic fibrosis gene 
product, CFTR, also associated w ith chloride channel activity (B rem er et a l ,  1992; 
Germ ann et al., 1993).
Overcom ing Pgp-m ediated M D R  has been the focus o f  m any researchers. This has been 
investigated in many ways. Theoretically, using cytotoxic drugs that are not substrates o f 
Pgp and thus retain activity in cells that express Pgp at high levels would be a useful 
approach; however, due to the lack o f suitable “non-M D R” drugs, in practice this is not 
always a feasible option. Both anthracyclines and taxanes, w hich are M D R  related drugs, 
are currently irreplaceable in a range o f chem otherapy regim ens because o f  their unique 
antineoplastic activity. The use o f  drug sensitisers that interfere w ith the drug efflux driven 
by Pgp may restore drug sensitivity in M D R  cells. Several classes o f  m odulators have been 
identified that act as drug sensitisers including calcium  channel blockers, calm odulin 
antagonists, and im m unosuppressive agents (Ferry etal.,  1996). These are now  term ed first 
generation P-gp modulators. The calcium  channel blocker, verapam il, was the first agent 
show n to m odify M D R  in vivo and in vitro (Tsuruo et al., 1981), but unfortunately the 
M D R  m odulating activity required concentrations that are associated with severe cardiac 
toxicity in patients (de Faire e t al., 1977). Im m unosuppressive agents present a sim ilar 
problem. Although the im m unosuppressive agent cyclosporin A  has been shown to be a 
highly potent inhibitor o f  Pgp, and it inhibits Pgp at clinically tolerable concentrations, the 
im m unosuppression activity restricts its utility in the clinic (Slater et al., 1986). There is a 
need, therefore, for m ore potent and less toxic modulators. Second generation P-gp 
m odulators have been developed. These include dexverapam il, dexniguldipine and 
valspodar. These agents are m ore potent than the first generation m odulators and are also 
less toxic (Krishna et a l ,  2000). These com pound also have their lim itations, however. 
They significantly inhibit the m etabolism  and excretion o f  cytotoxic agents, leading to
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toxicity. Third generation P-gp m odulators have recently been developed and are currently 
undergoing clinical trials (Duffy etal.,  1998; Touhey etal.,  2003; Thom as etal.,  2003).
A ntisense oligonucleotides to m dr-1 have also been developed and proved a direct causal 
role for P-gp over-expression in M DR. A ntisense oligonucleotides transfections in 
adriam ycin-resistant cells caused partial reversal in adriam ycin resistance in D LK P-A  
resistant cells (Clynes et al., 1992). MDR1 ribozym e studies have also been carried out 
successfully, inhibiting MDR1 gene expression and preventing the developm ent o f  drug 
resistance (Daly et al., 1996). The use o f  siR N A  to  inhibit P-gp expression and reverse 
M D R  has recently been demonstrated. SiRN A generated from  double-stranded R N A  can 
trigger silencing o f  hom ologous gene expression by inducing degradation o f  the 
complem entary mRNA. This newly identified m echanism  is term ed R N A  interference or 
post-transcriptional gene silencing (Tuschl et al., 1999) and is em erging as a new  tool for 
down-regulating gene expression, in vitro. Through the use o f  siRNA , expression o f 
endogenous, as well as transfected, m dr-1 gene transcripts were dram atically down- 
regulated in the breast carcinom a cell line, M CF-7, as seen by R T -PC R  and w estern b lot 
analysis. In addition, the m dr-1-targeted siR N A  reversed resistance to  P-gp-transportable 
drugs, such as vinblastine, adriam ycin and taxol, but did not affect th e  sensitivity to 
hydroxyurea, a non-P-gp substrate. Furtherm ore, treatm ent o f  M D R  cells w ith mdr-1 - 
targeted siR N A  increased the intracellular accum ulation o f  taxol and adriam ycin (W u etal., 
2003). Sim ilar experim ents using siR N A  have been carried out recently on pancreatic and 
gastric cell lines. Mdr-1 expression in these cells was also dram atically reduced due to 
expression o f  siR N A  constructs, as seen by R T -PC R  and western blot analysis. R esistance 
to daunorubicin was reduced dram atically in both cell lines (N ieth et al., 2003). This 
m ethod o f  reversing/preventing M D R  is very promising.
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ATP-binding
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Adriamycin
F ig u re  1.2.1.1 P-glycoprotein (Pgp) as a transm em brane drug efflux pum p. Pgp
transports drugs out o f  the  cell, which is a process that requires the presence o f  tw o ATP- 
binding domains. These dom ains are a defining characteristic o f  th is fam ily o f  ATP- 
binding cassette (ABC) transporters. Som e cytotoxic drugs that are know n substrates for 
Pgp include etoposide, taxol, vincristine and adriamycin. Pgp is m odified by  sugar m oieties 
(brown) on the external surface o f  the protein. (Nature Reviews Cancer 2; 431-441 (2002)).
15
1 .2 .1 .2 MRP and its role in MDR
Studies o f  a Pgp negative m ultidrug resistant hum an lung cancer cell line, H 69A R , led to 
the identification o f  another transm em brane protein, the p-190 m ultidrug resistance- 
associated protein (M RP) (Cole et ah,  1992). A BC transporters belonging to  the M R P 
fam ily have been identified in a variety o f  organism s including yeast, nem atodes and plants 
(Jedlitschky et ah, 1996 and 1997). The fam ily o f  hum an M RPs consists o f at least eight 
m em bers know  as M RP1, M RP2 (cM OAT), M RP3, M R P4, M RP5, M R P6, M R P7 and 
M R P 8 (Allikmets et  ah, 1996; K ool et ah, 1997; H opper et  ah, 2001). The m em brane 
topology is a com m on feature to at least four o f the six M R P m em bers. In contrast to the 12 
transm em brane organisation for P-glycoprotein (section 1.2.1.1 and Figure 1.2.1.1), the 
M RPs exhibit an additional am ino-proxim al m em brane-spanning dom ain, represented by 
an extension o f approxim ately 200 amino acids. The best characterised m em bers o f  this 
fam ily are MRP1 and M RP2. MRP1 was cloned from  a drug-selected hum an lung cancer 
cell line (Cole e tah ,  1992) and consists o f  1531 amino acids. T h e M R P l gene is located on 
chrom osom e 16p 13.12-13 (Grant e tah ,  1997). MRP1 confers resistance to anthracyclines, 
epipodophyllotoxins, vinca alkaloids (Cole et  ah, 1994; Zam an e t  ah,  1994; B reuninger et  
ah, 1995; Lorica et  ah, 1996), m ethotrexate (Hooijberg e t  ah, 1999), and actinom ycin D 
(Lorico et ah, 1996). U nlike Pgp, MRP1 does not affect resistance to taxol (Cole et  ah, 
1994; Zam an e t a h , 1994) or m itoxantrone (Cole e tah ,  1994) (see Figure 1.2.1.3).
M RP2 is an apical isoform o f  M RP1. A  close relationship exists betw een MRP1 and 
M RP2, as evident from  the com parison o f  the topology o f  both transporters. They both 
consist o f an M D R -like core structure o f  tw o transm em brane regions and tw o A TP-binding 
domains, as well as a  third amino proxim al transm em brane region (Figure 1.2.1.2) (Buchler 
et  ah, 1996). The identification o f M R P3, M RP4 and M RP5 was m ainly based on 
expressed sequence tags (EST) database analysis follow ed by cloning o f  cD N A  fragm ents 
(Allikm ets et ah, 1996; K ool et ah, 1997). Recently, a significant overlap in the transport 
capacity o f  MRP1 and M RP3 has been found (Bodo etah ,  2003). MRP1 over-expression in 
cells results in m ultiple drug resistance (Cole et ah, 1998). M R P2, which shares a sim ilar 
substrate spectrum  to M RP1, may also confer drug resistance through pum ping drug 
conjugated by glutathione S-transferase out o f  the cell (Konig e t  ah, 1999). D espite their
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sim ilar function in M DR, MRP1 and Pgp show  little sequence hom ology, w hich is 
restricted to the ATP binding site. D rug cross-resistance profiles are sim ilar b u t no t 
identical for M RP1 and Pgp over-expressing cells (Lautier et al., 1996) and agents that 
reverse Pgp are usually less effective on M R P1.
F ig u re  1.2.1.2 Schem atic representation o f M RP1. MRP1 is a representative o f  the
second m ajor subfam ily, M RP, o f  m ultidrug ABC transporters. M RPs have an extra 
transm em brane dom ain (adapted from this website: w w w .sigm a-aldrich.com ). PM =Plasm a 
m em brane; l-17=Transm em brane dom ains 1-17; CO O H =Carboxy term inus; N H 2=A m ino 
term inus
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The predictive significance o f  M R P in cancer patients is no t fully established. Since the 
discovery o f  M R P 1 in the small cell lung cancer cell line, H 69A R  (Cole e t  ah, 1992), 
MRP1 has been identified in non-Pgp m ultidrug resistant cell lines from  a variety  o f  
tum our types, including leukemias, fibrosarcom a, non-sm all cell lung, hum an sm all cell 
lung, breast, cervix, prostate, and bladder carcinom as (Izquierdo et  al., 1996). M RP1 has 
also been detected, either at the protein or m RN A  level, in norm al hum an tissues including 
lung, stom ach, colon, peripheral blood m acrophages, thyroid, testis, nerve, bladder, 
adrenal, ovary, pancreas, gall-bladder, duodenum , heart, m uscle, placenta, brain, kidney, 
liver and spleen (Loe etal .,  1996a; Zam an etah,  1993; Cole e t  ah, 1992; K ool e t a l ,  1997).
The expression o f  M R P 1 has been detected in alm ost all tum our types exam ined, including 
both solid tum ours (lung, gastrointestinal and urothelial carcinom as, neuroblastom a, 
gliom a, retinoblastom a, melanoma, cancers o f  the  breast, endom etrium , ovary, p rostate and 
thyroid) (Ito et  ah, 1998; C anitrot e ta h ,  1998; Chan et  ah, 1997; N anashim a e ta h ,  1999; 
H ipfner e tah ,  1999; Oshika etah ,  1998; Loe e tah ,  1996), and hem atological m alignancies 
(Filipits e ta h ,  1997; A bbaszadegan et ah, 1994; Loe et  ah, 1996b). A m ong the com m on 
tum our types, expression o f  high levels o f  M RP1 is particularly frequent in the m ajor 
histologic form s o f  non-sm all cell lung cancer (N ooter et ah,  1996; H ipfner et ah, 1999). 
There are reports o f  MRP1 as a m arker o f  poor prognosis in lung cancer (O ta et  ah, 1995) 
and neuroblastom a (Bordow  et al., 1994), whereas other studies have failed to  dem onstrate 
correlation betw een MRP1 expression and prognosis in colorectal carcinom a (Filipits et  ah, 
1997), childhood leukem ia (den Boer e tah ,  1998) and breast cancer (Linn et ah, 1997; also 
see section 3.5.3 and 4.5.5 for relevant results arising from  this study).
Reports o f  MRP1 expression in breast cancer have resulted in a lot o f  conflicting results on 
the role o f  MRP1 in disease outcom e (for full update see review  by L eonessa and Clarke, 
2003). MRP1 is expressed in both norm al breast tissue and breast cancer as show n by RT- 
PC R  and im m unohistochem istry analysis (Linn et ah, 1997; D exter et  ah, 1998; F ilipits et  
ah, 1997 and 1999; K anzaki e ta h ,  2001). M RP1 expression m ay correlate w ith previous 
chemotherapy treatm ent in breast cancer patients. N ooter et  ah (1997) found that in 
untreated breast cancer patients, the presence o f  MRP1 protein was associated with a lower 
response rate, w hereas, in patients who w ere treated w ith chem otherapy agents, no 
correlation betw een MRP1 and response rate was found (Nooter e tah ,  1997). Furtherm ore,
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patients who had MRP1 negative tumours had longer overall survival and disease free 
survival compared to  patients who had MRP1 positive tum ours (Filipits e t ah, 1999). 
F urther studies o f  M RP1 expression in breast tum ours is required to  determ ine if  M RP1 
could be a m olecular target for the treatm ent o f  breast cancer. M RP1 expression pattern  and 
its correlation to  prognosis in different hum an cancers is sum m arised in Table 1.2.
19
T ab le  1.2 Sum m ary o f  MRP1 Expression in different types o f  hum an cancers and its 
relationship to  prognosis.
C a n c e r  T y p e  T echn ique (% ) P rognosis&
C o rre la tio n
L oca lisation R efe ren ce
C olo rectal m e
RT-PCR
100
82
No correlation 
No correlation
Nuclear &
cytoplasmic
N/A
Filipits et al., 1997
O v arian IHC 44 No correlation Cytoplasmic Arts et al., 1999
RT-PCR N/A Correlated w/ 
Bad prognosis
N/A Ohishi et al., 2002
A d u lt T -cell 
L eu k em ia
Slot blot N/A Correlated w/ 
short survival 
&poor prognosis
N/A Ohno et al., 2001
B re a s t IHC 100 No correlation Cytoplasmic Dexter et al., 1998
IHC 80 Inversely
Correlated w/ 
good prognosis
Cytoplasmic
1999
Stiglbauer et al.,
IHC 100 Correlation w/ 
Lymph node 
Metastasis
N/A Zauchb aur-Muller 
et al., 2001
QRT-PCR N/A Correlation w/
progression-free
survival
N/A Burger et al., 2003
U ro thelia l NB
IHC
50 Involved in 
drug resistance
N/A
Cytoplasmic
Kubo et al., 1996
IHC=Immunohistochemistry; QRT-PCR= Quantitative reverse transcrisptase polymerase chain reaction; 
NB=Northem blot; N/A= Not applicable.
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O ver-expression o f  M R P2 (cM OAT) in cancer cells could potentially  lead to drug 
resistance because o f its proven ability to transport vinblastine (Borst et al., 1997). 
How ever, no correlation has been established, thus far, betw een M R P2 over-expression and 
M D R  in cultured cells (Lehne et al., 2000), bu t there was a positive association w ith 
cisplatin resistance, raising the possibility that M RP2 m ight contribute to  cisplatin 
resistance by m ediating excretion o f  cisplatin-glutathione com plexes (B orst et al., 1997), 
M RP2 is found predom inantly in the liver, duodenum  and, in low  levels, in the kidney 
(Kool et al., 1997; Schaub et al., 1997). K ool etal.  (1997) and K iuchi etal.  (1998) reported 
that M RP3 m RN A  is m ainly expressed in the liver, colon, intestine and adrenal gland, and 
to  a lesser extent in several other tissues. Kool et al. (1997) reported that M R P4 was found 
only in a small num ber o f tissues at very low  levels. How ever, L ee et al. (1998) 
demonstrated, using R N A  blot analysis, the expression o f  M R P4 in a w ide range o f  tissues, 
with particularly high levels in prostate, bu t alm ost undetectable levels in the liver. M RP5, 
like M RP1, is readily detected in several tissues w ith highest levels in skeletal muscle, 
interm ediate levels in kidney, testis, heart and brain and low  levels in m ost o ther tissues, 
including lung, liver, spleen, thymus, prostate, ovary and placenta (Belinsky et al., 1999).
Recent investigations have shown that M R P6 is predom inantly expressed in liver and 
kidney cells and to a lesser extent in other tissues (Kool et al., 1999). M R P 6 does not 
appear to  contribute to the cisplatin-resistance o f the cell lines analyzed by K ool et al. 
O ver-expression o f  M R P6 was detected in adriam ycin-resistant lung cancer cell lines 
known to have high over-expression o f  MRP1 (Zaman et al., 1993; B arrand et al., 1994; 
Eijdem s et al., 1995). In each case the over-expression is associated with co-am plification 
o f  M RP 1 and M R P6 (Kool et al., 1999). M R P7 is a recently described m em ber o f  the ABC 
fam ily o f ATP binding cassette proteins (H opper et al., 2001). A  splicing variant o f  hum an 
M RP7, M R P 7 A  expressed in m ost hum an tissues, has recently been characterised (Kao et 
al., 2003). M R P 8, which contains high sequence hom ology with M RP5, has also been 
recently identified. It is highly expressed in breast cancer and is expressed at m oderate 
levels in norm al breast and testis and at very low  levels in liver, brain, and placenta (Bera et 
al., 2001).
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1.2.1.3 BCRP and its role in MDR
B reast cancer resistance protein (BCRP) was first identified in the hum an M CF-7 breast 
cancer cell line, which displayed an ATP-dependant reduction in intracellular anthracycline 
accum ulation (Doyle e ta l.,  1998). Since then, it has been characterised and identified in a 
num ber o f  hum an tissues (M aliepaard et a l ,  2001a). B C R P m R N A  encodes a protein o f  
663 amino acids, which was also identified as a m em ber o f  the  ABC fam ily o f  transporters 
that encompass the M R P hom ologues. A  previous study by M a et al. (1998) had identified 
a novel m echanism  o f  m ultidrug resistance in the ovarian cancer cell line IGROV1 selected 
in topotecan. Further research (M aliepaard et al., 1999; Scheffer et al., 2000; Y ang et al.,
2000) confirm ed the expression o f  the B C R P gene in the IGROV1 and M CF-7 cell lines 
follow ing selection in topotecan. Scheffer et al. (2000) also localised the protein in the 
plasm a m em brane o f  the  IGROV1 cell line. BC RP expression has also been observed in 
cell lines follow ing exposure to m itoxantrone (M aliepaard et al., 1999; Ross et al., 1999), 
and the BC R P gene is som etim es referred to as the M itoxantrone resistance gene (MXR). 
Further studies identified expression o f  BC R P in a flavopiridol-resistant M CF-7 subline 
(Robey etal.,  2001)
Expression o f B C R P has been linked with resistance to m itoxantrone, m ethotrexate (M TX), 
adriam ycin, daunorubicin bisantrene and topotecan (Doyle et al., 1998; V olk et a l ,  2000; 
L itm an et al., 2000) (see Figure 1.2.1.3). A  clinical study R oss et al. (1999) observed a 
sufficiently high level o f  BC R P gene expression in patients w ith A M L to warrant 
additional investigation. Little is currently known o f  how  B C R P m ediates cross-resistance 
to these drugs.
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F ig u re  1.2.1.3 Som e anticancer drugs w hich are substrates for M D R 1, M RP1 and 
BCRP. V C R  =  vincristine; V B L  = Vinblastine; ACT-D  =  A ctinom ycin D; E P IR  
Hpirubicm; A D R  =  Adriam ycin; D N R  =  D aunorabicine; C ISPL =  Cisplatin; C A R M : 
Carmustine; CH LB = Chloram bucil; M T X  =  M ethotrexate; M IT O X  =  M itoxantrone; 
TO POT =  Topotecan (adapted from  w w w .solvo.hu/scientific-background.php).
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1.3 Invasion and metastasis
M etastasis is the spread o f  cancer from a prim ary tum our to distant sites o f  the body. A  
distinguishing feature o f  m alignant cells is their capacity to invade surrounding norm al 
tissues and m etastasise through the blood and lym phatic system s to distant organs. This 
process o f  m etastasis is the m ost devastating aspect o f  cancer. It is estim ated that in nearly 
50%  o f cancer patients, surgical excision o f  a prim ary tum our is not curative, as a  resu lt o f  
metastasis (Fidler et al., 1994). In m ost patients, m etastases develop m any years after the 
resection o f the prim ary neoplasm . This may be caused by a  sudden conversion o f  a tum our 
to  an angiogenic phenotype (Folkman, 1992).
Cancer m etastasis has been described as a com plex series o f  sequential processes that 
involve: (1) the initial transform ing event; (2) proliferation o f  transform ed cells; (3) the 
ability o f  cancer cells to avoid destruction by im m une m echanism s; (4) nutritional supply 
to  the tum our m ass requiring the release o f  tum our angiogenesis factors; (5) local invasion 
and destruction o f  extracellular m atrix com ponents and parenchym al cells; (6) m igration o f  
tum our cells away from  the prim ary tum our mass; (7) penetration o f  cancer cells through 
the blood vessel wall; (8) em bolisation o f cancer cells in ‘clum ps’ to distant organs; (9) 
arrest o f  cancer cells in the lumen o f small blood vessels or lym phatics; (10) reverse 
penetration o f blood vessels; (11 ) repetition o f  the process beginning at step 2 , resulting in 
the form ation o f  a secondary tum our (m etastases) (Fidler etal.,  1994).
One o f  the m ost critical steps in metastasis is invasion. Invasion is the active translocation 
o f neoplastic cells across tissue boundaries and through host cellular and extracellular 
barriers (Liang et al., 2002). L iotta et al. (1977) has proposed a three-step theory o f  
invasion: (1) tum our cell attachm ent via cell surface receptors which specifically bind to 
components o f  the extracellular matrix; (2) the anchored tum our cell secretes hydrolytic 
enzymes, such as m atrix m etalloproteinases, to degrade the extracellular m atrix; (3) tum our 
cell locom otion into the region o f  the m atrix m odified by proteolysis. C ancer invasion 
involves a num ber o f  changes in cell behavior, in particular the production o f  enzym es, 
called proteases, that will break down surrounding tissue as shown in Figure 1.3.1.
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Proteases are enzymes that hydrolyse peptide bonds and therefore, lead to  the disassem bly 
o f  proteins. There are four known categories o f  proteases i.e. serine, cysteine, aspartic 
proteinases, and m etalloproteinases (see section 1.3.1), w hich have all been im plicated in 
the invasive process.
ATTACHMENT
TUMOUR CELL
ENDOTHELIUM
BASEMENT
MEMBRANE
PROTEOLYSIS
TUMOUR CELL 
SE C R E T E S ENZYMES 
THAT CAN DEGRADE
MIGRATION THE ECM
1
F ig u re  1.3.1 The process o f invasion o f  a tum our cell through the endothelium  and 
extracellular m atrix (ECM ) by secretion o f  degradation enzym es (w w w .Ibora.ac.uk).
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1.3.1 The extracellular matrix
The extracellular m atrix (ECM ) is a com plex structure o f  carbohydrate- and protein- 
containing components that m ake up the basem ent m em brane underlying epithelial tissues 
and that surround structural tissues such as bone and m uscle (Yurcheno e t al., 1990). T he 
extracellular m atrix not only provides a supportive and nutritive function for the 
developm ent and organisation o f  tissues, but it also serves as a physical barrier to  lim it the 
m igration o f  m ost norm al cells away from  their sites o f  origin. The extracellular m atrix  
consists o f  a supram olecular aggregate o f connective tissue proteins including collagens, 
elastin, glycoproteins (laminin, fibronectin, enactin, nidogen) and glycosam inoglycans 
(ground substances-heparan sulfate proteoglycans), w hich interact w ith one another 
through covalent, and non covalent bonds to form  highly insoluble m aterials (Zem  and 
Reid, 1993). Changes in E C M  synthesis, deposition, m etabolism  and m atrix receptors are 
im portant components in cancer developm ent and m etastasis (Stetler-Stevenson et al.,
1993).
The basem ent m em branes o f  epithelial tissues serve a com plex role in cell-cell adhesion 
and in the regulation o f  cell proliferation and differentiation. The EC M  that m akes up the 
basem ent m em branes is a target for the lytic enzymes secreted by m etastatic cancer cells. 
Cell attachm ent to specific glycoproteins o f  the extracellular m atrix such as fibronectin, 
collagen, lam inin and entactin, is m ediated through tum our cell receptors o f  the integrin 
and non-integrin variety. Cell-cell adhesion in normal tissue involves interactions betw een 
num erous proteins on the cell surface. Cell adhesion m olecules (CAM ) o f  the  cadherin 
fam ily have an inhibitory role in the process o f  m etastasis. Cadherins are calcium  ion 
dependent CAM s that m ediate cell-cell binding. Three subtypes have been identified in 
mam m als (E-cadherin, P-cadherin, and N-cadherin). Cadherin proteins m ay be dim inished 
in cancer cells, leading to a loss o f intercellular adhesion.
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1.3.2 Matrix Metalloproteinases
The m atrix m etalloproteinases (M M Ps) are a fam ily o f  zinc-dependent endopeptidases. 
Their prim ary function is degradation o f proteins in the ECM. Currently at least 19 
m em bers o f this family are know n to exist (Cham bers et ah, 1997; Duffy et ah, 1998). 
Physiologically, these enzym es play a role in norm al tissue rem odeling events, such as 
em bryonic developm ent, angiogenesis and w ound healing. Abnorm al expression o f  these 
enzymes, however, appears to contribute to various pathological processes including 
tum our growth, invasion and m etastasis (Chambers et ah, 1997).
All M M Ps possess specific domains that are conserved betw een different members. M ost 
M M Ps are synthesised and secreted in a zym ogen form. A ctivation is usually  accom panied 
by loss o f  a 10-kDa am ino-term inal domain (Duffy et ah, 2000). M ost M M Ps cleave at 
least one com ponent o f  the ECM , as listed in Table 1.3. M M Ps are divided into four m ain 
subgroups: the interstitial collagenases, gelatinases, strom elysins and m em brane M M Ps 
(Cham bers et al., 1997; D uffy et al., 1998).
The collagenases com prise interstitial collagenase (M M P-1), neutrophil collagenase 
(M M P-8) and collagenase 3 (M M P-13) (Table 1.3). These M M Ps catalyze degradation o f  
fibrillar forms o f  collagen (i.e. types I, II and III). MMP-1 shows a preference for the  type 
HI form, M M P -8 preferentially degrades type I collagen, and M M P-13 has h ighest affinity 
for type II collagen (Balbin et ah, 1999). The gelatinases, which are also know n as type IV  
collagenases, degrade and types IV, V , VQ, IX  and X  collagen. This subgroup has two 
distinct m em bers, known as gelatinase A  (M M P-2) and gelatinase B (M M P-9) (see Table
1 .3). Generally, these two gelatinases are thought to  have sim ilar substrate specificity w ith 
respect to ECM  substrates, but may have different specificity tow ard growth factor 
receptors (Levi et ah, 1996). The strom elysins (i.e. stromelysin-1 [M M P-3], strom elysin-2 
[M M P-10], stromelysin-3 [M M P-11] and m atrilysin [M M P-7]) have relatively broad 
substrate specificity, catalyzing degradation o f m any different substrates in the EC M  
(Chambers et ah, 1997). The substrates include proteoglycans, noncollagenous proteins 
such as laminin, fibronectin and the non-helical regions o f  collagen IV  (see Table 1.3).
27
The fourth group consists o f  the m em brane-type M M Ps, w hich possess a transm em brane 
dom ain (Seki et al., 1999). F ive m em bers o f this group have been described, the best 
characterised being the transm em brane-type 1 M M P. This M M P ahs been show n to 
catalyse activation o f  progelatinase A  (Ohuchi et al., 1997).
Increased M M P activity is detected in a w ide range o f  cancers and seem s to correlate to 
their invasive and m etastatic potential. M M Ps, therefore, are an attractive target for 
diagnostic and therapeutic purposes (Denis and V erw eij, 1997). Inhibition o f  these 
proteinases m ay lead to prevention o f cancer developm ent and inhibit dissem ination (Duffy 
et al., 2000). Two m ain types o f  M M P inhibitors (M M PIs) exist: the  tissue inhibitors such 
as tissue inhibitors o f  m etalloproteasas (TIM Ps) and low  m olecular-w eight synthetic 
inhibitors (Hiraoka et al., 1998), TIM Ps display a  m ultiplicity o f  actions (lack specificity) 
and m ay not, therefore, be widely used as anticancer m olecules. Several synthetic M M PIs 
have been developed and preclinical studies are prom ising as they suggest inhibition o f  
several steps in the m etastatic process (Denis and V erw eij, 1997).
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T ab le  1 3  M M Ps, their alternative names and their substrates 
(adapted from  w w w .m dsystem s.com )
MMP Alternative Names Substrates
MMP-1 • Collagenase Collagens (I, II, III, VII, VIII and X); Gelatin
MMP-2 • 72-kDa Gelatinase
• Type IV Collagenase
Collagens (I, IV, V, VII, X, XI and XIV); Gelatin; 
elastin; fibronectin; laminin-1, laminin-5; galectin- 
3
MMP-3 • Stromelysln-1
• Transin
Collagens (III, IV, V, IX); Gelatin
MMP-7 • Matrilysin
• PUMP
Collagen IV and X; Gelatin; fibronectin and 
laminin
MMP-8 • Neutrophil Collagenase
• Collagenase I
Collagens (I, II, III, V, VII, VIII and X); Gelatin
MMP-9 • 92 kDa Gelatinase
• Gelatinase B
Collagens (IV, V, VII, X and XIV); Gelatin; elastin; 
galectin-3
MMP-10 • Stromelysin-2 Collagens (III, IV and V); Gelatin; casein; 
aggrecan; elastin;
MMP-11 • Stromelysin-3 Laminin; fibronectin; gelatin; collagen IV and 
carboxymethylated transferrin
MMP-12 • Macrophage 
Metalloelastase
Collagen IV; Gelatin; elastin and K-elastin; 
fibronectin; laminin; plasminogen
MMP-13 • Collagenase-3 Collagens (I, II and III, IV, IX, X and XIV); Gelatin
MMP-14 • MT-MMP-1 Collagen I, II and III, progelatinase A
MMP-15 • MT-MMP-2 Fibronectin; laminin
MMP-16 • MT -MMP-3 Collagen III; Gelatin; casein; fibronectin
MMP-17 • MT-MMP-4 Collagen I, II and III
MMP-19 N/A Gelatin
MMP-20 • Enamelysin Amelogenin
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1.3.3 MDR and Invasion/Metastasis
A n increasing body o f  evidence indicates that the tum our m icro-environm ent m ay 
contribute to cancer progression (Shain and D alton, 2001). Soluble factors such as 
cytokines, horm ones and growth factors (K lein et al., 1995), as well as interactions 
betw een tum our cells and EC M  m olecules (O ’B rien et al., 1996) m ay play a role in 
pathogenesis and progression o f hum an cancers. Studies suggest that these sam e 
environm ental factors m ay also contribute to the survival o f  cancer cells after initial 
therapy, allow ing resistant cells to proliferate and acquire m ultiple drug resistance (see 
section 1 .2).
The relationship betw een invasion/m etastasis and drug resistance has been w idely studied 
since the 1960s. In 1961, enhancem ent o f  m etastases was observed after m ice were treated 
w ith nitrogen m ustard (Kondo et al., 1961). D rug resistance and cancer invasion and 
m etastasis are two phenotypes that result in chem otherapy failure and disease progression. 
Evidence is grow ing that the tw o phenotypes are linked and this has been dem onstrated by 
tw o types o f observations: firstly, som e tum our cells selected for resistance to 
chem otherapeutic drugs becom e m ore invasive relative to sensitive parental cells (Scaddan 
et al., 1993; H aga et al., 1997; De Larco et al., 2001; L iang et al., 2001and m anuscript in 
prep); secondly, in som e cases, secondary m etastatic tum ours are m ore resistant to 
chem otherapeutic drugs than primary, non-m etastatic tum ours (Donelli e t al., 1967; 
Tanigaw a etal., 1984; Staroselsky etal.,  1990; Furukaw a et al., 2000).
Pgp, as discussed in section 1.2.1.1, is a m em brane glycoprotein whose over-expression has 
been detected in m any m ulti-drug resistant cell lines. O ver-expression o f  Pgp has been 
detected in clinical cancer specim ens o f  m any histological types (Goldstein et al., 1989; 
Chan et al., 1991; Leonessa et al., 2003). Pgp protein expression was exam ined in early and 
advanced breast cancer by im m unohistochem istry and was found to be expressed in 10%  o f  
early operable breast cancer com pared to  60% o f  locally advanced breast cancer, 
suggesting a correlation betw een Pgp expression and breast cancer m etastasis (Linn et al., 
1997). In addition, the expression o f Pgp during stepw ise progression to rat liver cancer 
was exam ined to  investigate the possible role o f Pgp in carcinogenesis. A  strong elevation
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o f Pgp m RN A  expression was observed as the m alignant phenotype progressed (Bradley et 
al., 1992).
A lthough there is strong evidence that drug resistance and cancer invasion/m etastasis 
phenotypes are linked to each other in a num ber o f  biological m odels o f  cancer, and 
perhaps also in clinical disease, it is im portant to address the fact tha t there are also 
observations which suggest that these phenotypes are un-related. It has been dem onstrated 
that a m urine cyclophospham ide-resistant tum our obtained in vivo by repeated 
cyclophospham ide treatm ent o f  m ouse ovarian sarcom a, displayed sim ilar m etastatic rate 
and slow er growth rate when com pared with the drug-sensitive parent sarcoma. In addition, 
the survival tim e o f drug-resistant tum our-bearing m ice was longer than that o f  drug- 
sensitive tum our-bearing m ice (Sheng e ta l ., 1997).
Studies in our laboratories indicate that taxol did not prom ote in vitro invasiveness in the 
hum an nasal carcinom a cell line, RPM I-2650, whereas m elphalan exposure did (Liang et 
al., 2001). Furtherm ore, m itoxantrone, 5-FU, m ethotrexate, BCNU, cisplatin and 
chloram bucil induced an invasive phenotype in the hum an lung carcinom a cell line, DLKP, 
whereas VP-16, vincristine, taxotere and CCNU did not (Liang et al., m anuscript in prep.). 
Results in this thesis show  that taxotere-resistance is associated with in vitro invasiveness 
in D LK P cells, whereas vincristine-resistance is not (see sections 3.3.3, 4 4 .2 .3  and
4.4.3.3).
A better understanding o f  the  correlation between drug resistance/drug exposure and 
invasion/m etastasis is needed to help identify im proved cancer treatm ent regim ens and 
better drug targets to circum vent these two phenotypes, sim ultaneously.
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1.4 Apoptosis
A poptosis, or program m ed cell death, is a set o f  ordered events that enables the selective 
rem oval o f  cells from  tissue and is essential for hom eostasis and proper function o f  
m ulticellular organisms. Such a control m echanism  is required for organ form ation during 
developm ent, cellular hom eostasis in adulthood, and proper function o f  the im m une system  
(Los et ah, 2003). N um erous genes are involved in the regulation o f  apoptosis. There are 
tw o m ain pathways in apoptosis. The m itochondrial pathw ay involves the release o f  
cytochrom e c from  the mitochondria. The cell surface pathw ay is stim ulated by cell surface 
death receptors such as Fas receptor (see below). B oth  pathw ays share activation o f 
caspases, which are considered as crucial effectors o f  the  cell death m achinery (K ania et 
ah, 2003). A  num ber o f  caspases have been identified to  date. How ever, it is unclear 
w hether they are all involved in the apoptosis m echanism s. R ecent evidence suggest that 
caspases that are m ost closely related to CED-3 o f the C. elegans, such as capase-3, are the 
m ost involved in the execution and signaling events o f  apoptosis (G ruter et al., 2000).
Certain cells have unique sensors, term ed death receptors, on their surface, including the 
Fas receptor and the tum our necrosis factor (TNF) receptor (Sartorius et ah, 2001). These 
death receptors detect the presence o f  extracellular death signals and rapidly activate the 
cell's intrinsic apoptosis machinery. This biochem ical process is regulated by a group o f 
protein-cutting enzymes, term ed Caspases, which break up the cell into fragm ents that can 
be disposed of, allow ing cell division and renewal o f  cells to take place. Caspases act at 
tw o levels in carrying out cell death; the initial caspases (initiators) are activated in 
response to signals indicating that the cell has been damaged. The initiators in turn activate 
another fam ily o f  caspases, the effectors, which go on to m ake selected cuts in key proteins 
that then break up the cell. In m am m als, there are tw o m ajor pathw ays for caspase 
activation. One is engaged by tum our necrosis factor receptor-fam ily m em bers such as Fas, 
also known as CD-95 (Scaffidi et ah, 1998) and that involves recruitm ent to  the receptor 
and activation o f  proxim al caspases, particularly caspase-8. Bringing together three or m ore 
Fas receptors on the surface o f a cell by FasL  recruits the  adaptor protein FADD (Fas- 
associated death dom ain) (see Figure 1.4.1). This occurs through interaction betw een the 
death domains o f  FA DD and Fas.
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The death-effector dom ain o f  FADD in turn recruits procaspase-8, which is cleaved to 
generate active caspase-8. This com plex is called the D ISC (death-inducing signal 
complex). Caspase-8 activates executioner caspases (such as caspases-3 and -7), w hich 
cleave substrates w ithin the cell. Nucleases are then activated, chrom osom al D N A  is 
degraded and the cell dies by apoptosis. Another protein that contains a death-effector 
dom ain is RIP, which can bind to FADD and generates other types o f  signal, including one 
that results in caspase-independent cell death. Signaling through Fas can be inhibited by the 
action o f  c-FLIP, which resem bles procaspase-8 but has no active site for the protease. The 
full-length form o f  c-FLIP probably also provides signals o f  o ther types to the cell. RIP, 
receptor interacting protein; FLIP, FLICE (FADD-like IL-1 converting enzym e)-inhibitory 
protein (see Figure 1.4.1)
Activation of executioner 
caspases, apoptosis
c-FL
Ce .
DISC
Q Death domain
Death-effector domain
F ig u re  1.4.1 Proposed pathway o f  Fas/FasL-m ediated death. (Nature Reviews
Molecular Cell Biology 2; 917-924 (2001)).
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The second pathw ay involves the release o f cytochrom e c from  the m itochondria, resulting 
in binding o f  cytochrom e c to the apoptotic protease factor, Apaf-1, in the cytoplasm , and 
the activation o f pro-caspase-9. B oth  o f  these pathways converge on dow nstream  effector 
caspases (Nicholson et al., 1999). Cytochrom e c is an essential com ponent o f  the 
m itochondrial respiratory chain, and it is norm ally located in the inner m itochondrial 
m em brane. It has been show n by K luck et al. (1997) that cytochrom e c is released into the 
cytosol during the early stages o f  apoptosis, thus supporting a central role for cytochrom e c 
in the induction o f apoptosis (Ashkenazi et al., 1998). Apoptosis is not, how ever, always 
triggered by receptors receiving specific signals from  outside the cell. Cells can com m it 
suicide, for example, if they are deprived o f  growth factors or i f  they are dam aged by 
radiation (Barinaga et al., 1998) or chem otherapy agents (H ickm ann et al., 1992; D rive et 
al., 1992).
The nem atode Caenorhabditis elegans has been a good m odel organism  for studying the 
core com ponents o f  the cell death machinery. Three C. elegans gene products are essential 
for apoptosis: CED-3 and CED-4 prom ote apoptosis, w hereas CED-9 inhibits apoptosis 
(Smith et al., 1975). CED-3, a caspase, is a cysteine protease that cleaves certain proteins 
after specific aspartic acid residues; it exists as a zym ogen, w hich is activated through self­
cleavage. Pro-C ED -4 binds to Pro-CED-3 and promotes CED-3 activation, w hereas anti- 
CED-9 binds to CED-4 and prevents it from  activating CED-3. Norm ally, CED -9 is 
com plexed with CED-4 and CED-3, keeping CED-3 inactive. Apoptosis stim uli cause 
CED-9 dissociation, allow ing CED-3 activation and thereby com m itting the cell to die by 
apoptosis. V ertebrates have gene fam ilies that resem ble C. elegans cell death genes. 
M am m alian caspases are sim ilar to CED-3 (Keller et al., 1985). The products o f  the 
m am m alian Bcl-2 gene fam ily are related to CED-9 but include two subgroups o f  proteins 
that either inhibit or prom ote apoptosis (Ingo etal.,  1998).
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1.4.1 Chemotherapy and Cell Death
As discussed in section 1.2, M D R in cancer is associated with an over-expression o f  ATP- 
binding cassette proteins (P-gp and M R P) and it may be intrinsic or acquired (induced by 
certain chemotherapy drugs). M any chem otherapeutic agents also induce apoptosis or 
program m ed cell death in cancer cells (Hickm ann et ah, 1992 and D rive et ah, 1992). M D R  
is associated with resistance to apoptosis induced by chem otherapy agents (Reed et al., 
1995). There is a strong correlation betw een the expression o f  genes regulating apoptosis 
and those conferring M D R  in cancer cells (Kim  et ah, 1997). K im  et ah (1997) reported 
that M D R  H L60 cells over-expressing M RP or P-gp, expressed reduced levels o f apoptosis 
prom oters including Fas, Bcl-xs and Bax, and an increased level o f  apoptosis repressor, 
Bcl-xl, com pared to the parental, drug-sensitive cell line.
Cisplatin and V P-16 were used to study the induction o f  apoptosis in Panc-1 cells and the 
effect o f  these drugs on the expression level o f  B ax (a pro-apoptotic gene) and B cl-2 (an 
anti-apoptotic gene) was determ ined (Lee et ah, 1997). The group found up-regulation o f  
Bax expression, but no change in the expression o f  Bcl-2 in the cells. C isplatin exposure 
also caused prolonged cell cycle arrest, accom panied by induction o f  the p21 gene. 
Cisplatin was observed to induce expression o f the ERCC-1 gene in hum an ovarian A2780 
cells. ERCC-1 is an im portant gene in nucleotide excision repair. The capability o f  
vincristine and adriam ycin to induce apoptosis was studied in m urine T cell leukem ia cell 
lines. Resistance to these two drug resulted in a decrease in apoptosis, w hile cyclosporin-A  
and its analogue PSC 833, which are P-gp modulators (and, as discussed in section 1.2.1.1, 
are im m unosuppressive agents) that inhibit P-gp, increased sensitivity o f  M D R  cells to 
anticancer agents, as well as triggering apoptosis in these cell lines. Failure to  induce 
apoptosis is a recognized pathw ay for m ultiple drug resistance that m ay explain some 
aspects o f  cancer treatm ent failure (Lopes etah,  2003).
Further knowledge o f  apoptosis-regulating genes and their role in m ultiple drug resistance 
may greatly im prove chem otherapy treatm ent, if the correct approach to targeting these 
genes can be achieved. (For a m ore com prehensive discussion on drug resistance and 
apoptosis see review  paper in Clynes e ta h , 1998).
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1.5 Galectin-3
Anim al lectins are proteins involved in cell-cell interactions and cell-extracellular m atrix  
interactions. These events are very im portant during invasion and m etastasis as discussed in 
section 1.3. Galectins are a fam ily o f  galactose-specific lectins (Barondes e ta l.,  1994). To 
date, 14 m am m alian galectins have been identified (Liu etal.,  2002). They are galactoside- 
binding proteins that play an im portant role in tum our progression by prom oting cancer cell 
invasion and m etastasis (Akahani etal.,  1997; Berberat etal.,  2001; T akenaka etal.,  2003). 
Galectin-1 and Galectin-3 are the m ost w idely studied m em bers o f  the  galectin fam ily, w ith 
m olecular w eights o f  14.5 kDa and approx. 30 kDa, respectively (Xu et al., 1995).
Galectin-3 has been reported to bind lam inin, a glycoprotein involved in developm ent and 
tum our invasion and m etastasis (Hughes et al., 1994) and its expression has been noted in 
m any cell types and tissues (Barondes etal.,  1994b) as discussed in section 1.5.3. Galectin- 
3 has a num ber o f  intracellular activities, including: regulation o f the cell cycle through G1 
or G2/M  arrest; regulation o f  cell growth through an anti-apoptotic effect, i.e. protects cells 
from  a variety o f  death signals, including Fas receptor cross-linking and loss o f  cell 
anchorage; nuclear splicing o f  pre-m RN A  (Liu et al., 2002) and cell adhesion and 
m igration. There is also evidence o f galectin-3 being involved in neoplastic progression 
and cancer m etastasis (Bresalier et al., 1997; N angia-M akker et al., 1998; Song et al.,
2002). The role o f  galectin-3 in apoptosis and invasion/m etastasis w ill be discussed in m ore 
detail in sections 1.5.2 and 1.5.3, respectively.
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1.5.1 Intracellular localisation o f Galectin-3
A num ber o f studies have docum ented galectin-3 localisation in both the nucleus and the 
cytoplasm  o f  various cell types (W ang et al., 1995; H ubert et al., 1995; Craig el al., 1995). 
The localisation o f  galectin-3 in fibroblasts was found to be in both the nucleus and the 
cytoplasm. The distribution o f galectin-3 protein was dependent on the proliferation state o f 
the cells under analysis. Galectin-3 was expressed in the cytoplasm  o f  fibroblasts in their 
quiescent state. How ever, when the cells w ere proliferating, galectin-3 was highly 
expressed in the nucleus o f  the cells (M outsatsos el al., 1987). In colonic epithelia, the 
progression from  norm al mucosa, to adenoma, to carcinom a is characterised by down- 
regulation o f galectin-3 and a shift o f  expression from  the nuclei to the cytoplasm. Sanjuan 
et al. (1997) found strong nuclear expression o f  galectin-3 in norm al colorectal m ucosa, 
which was down-regulated in neoplastic progression. In later phases o f  tum our progression, 
galectin-3 shows increased cytoplasm ic expression in colorectal cancer (Sanjuan et al., 
1997). Similar findings were previously docum ented by Lotz et al. (Lotz et al., 1993), 
while galectin-3 was highly expressed in the nucleus o f  cancerous thyroid cells (Paron et 
al., 2003).
1.5.2 R ole  o f G alectin-3  in  A poptosis
Several researchers have dem onstrated the involvem ent o f  galectin-3 in cell grow th and 
proliferation, suggesting a role for galectin-3 in inhibiting apoptosis and prom oting cell 
growth. Transfection o f  the hum an T lym phom a Jurkat cells with galectin-3 caused an 
increase in growth rate o f these cells com pared to the control cells, w hich do not express 
galectin-3. The cells were also more resistance to apoptosis induced by anti-Fas receptor 
antibody (which cross-links Fas receptor causing apoptosis) and by staurosporine (a protein 
kinase inhibitor) (Yang et al., 1996). Similarly, transfection o f a hum an breast carcinom a 
cell line, Evsa-T, w ith galectin-3 cDNA, caused the cells to be m ore resistant when 
exposed to apoptotic stimuli such as cyclohexim ide/TN F-a and UVB irradiation 
(M ataresse et al., 2000). Galectin-3 expression in another breast carcinom a cell lines, 
BT549, also resulted in resistance to cisplatin-induced apoptosis (Akahani et al., 1997).
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Studies o f  galectin-3 over-expression in the hum an breast carcinom a cell line, BT549, have 
been carried out by K im  et ah (1999). They found tha t galectin-3 protects the cells against 
apoptosis induced by anoikis (the loss o f  cell anchorage). In  this study, w ild-type BT549 
cells readily underw ent anoikis, whereas transfectants over-expressing galectin-3 
responded to the loss o f  cell adhesion by cell cycle arrest w ithout detectable apoptosis (Kim  
et ah, 1999). Similarly, the transfectants underw ent cell cycle arrest w ithout cell death 
when treated w ith genistein, an isoflavonoid com pound found to inhibit protein tyrosine 
kinase and other critical enzymes involved in signal transduction and induce apoptosis. 
Parental cells underw ent apoptosis in response to genistein w ithout detectable cell cycle 
arrest (Lin et ah, 2000). Further studies on this breast carcinom a cell line, dem onstrate that 
galectin-3 over-expression protects these cells from  nitric oxide-induced cytotoxicity 
during liver ischem ia (M oon et at., 2001; Lee et al., 2002). Galectin-3 inhibited apoptosis 
by protecting m itochondrial integrity, inhibition o f  cytochrom e c release and caspase 
activation (M oon et ah, 2001).
Further evidence for a role o f galectin-3 in cell grow th and apoptosis is dem onstrated 
through the use o f  antisense oligonucleotides to suppress galecin-3 expression. Galectin-3 
antisense was transfected into the breast carcinom a cell lines, M D A -M B435, and resulted 
in  decreased cell proliferation compared to parental cells (van den B rule etah,  1997; H onjo 
et ah, 2001), proving that when the anti-apoptotic activity o f  galectin-3 is blocked, cell 
growth is greatly reduced, due to spontaneous apoptosis. R N A  interference experim ents 
have recently been carried out pituitary tum our cells, causing an inhibition o f  galectin-3 
expression, thereby resulting in a decrease o f cell proliferation and an increase o f  apoptosis, 
suggesting that galectin-3 plays a role in cell proliferation and tum our progression o f 
pituitary tum ours (Riss etah,  2003).
1.5.2.1 M echan ism  o f  galectin -3’s ro le  in  apop tosis
The m echanism  o f  action o f  galectin-3 in inhibiting apoptosis m ay be linked to the anti- 
apoptotic gene, B cl-2 (Akahani et ah, 1997). The reason for this m ay lie in the fact that 
galectin-3 shares significant sequence sim ilarity w ith Bcl-2. Both proteins are rich in 
proline, glycine and alanine in the N -term inal region and contain an N W G R  quartet in the
38
C-term inal region. The N W G R  quartet is found in the BH1 dom ain o f  B cl-2  and has been 
shown to critical for anti-apoptotic function o f  Bcl-2 (Reed et al., 1998). This sequence is 
highly conserved among galectin-3 from  different anim al species and is essential for the 
carbohydrate-binding activity o f  this protein. Substitution o f  glycine to alanine in this m otif 
abrogates its anti-apoptotic activity (Akahani eta l.,  1997). In  addition, sim ilar to other B cl- 
2 fam ily m em bers, which form heterodim ers with Bcl-2, galectin-3 binds Bcl-2 in vitro 
(Yang etal.,  1996).
A nother possible m echanism  o f  action for anti-apoptotic activity o f  galectin-3 m ay be 
linked to the IN K  (c-jun N-term inal kinase) pathway. Studies o f  cells from  galectin-3 
deficient m ice have provided further evidence o f  the anti-apoptotic function o f galectin-3 
(Hsu et al., 2000). Bone m arrow-derived m ast cells from  galectin-3-deficient m ice w ere 
found to be m ore susceptible to apoptosis than those o f  w ild-type m ice w hen grown in the 
absence o f  grow th factors. These cells were also defective in the expression o f  JNK, w hich 
is one o f  the m itogen-activated kinases (MAPK). Since JN K  is a regulator o f apoptosis, it is 
possible that galectin-3 exerts its anti-apoptotic activity by regulating the level o f  JNK. 
H owever, this m echanism  is not applicable to all cell types, as other cell types in galectin- 
3-deficient m ice are not defective in JN K  expression (Liu et al., 2002).
The proposed m echanism s o f  action for the anti-apoptotic role o f  galectin-3 would suggest 
that galectin-3 regulates cell survival through intracellular processes. How ever, 
extracellular process m ay also be involved. It is possible that galectin-3 exerts its anti- 
apoptotic activity through its adhesion m echanism s, since increased cell adhesion can 
protect cells from  apoptosis (as m entioned in section 1.5.2). The role o f galectin-3 in 
adhesion, invasion and metastasis will be discussed in section 1.5.3. Further investigation 
into the m olecular m echanism s by which galectin-3 regulates intrinsic and extrinsic 
apoptosis is needed for a better understanding o f the role o f  this protein in apoptosis 
inhibition.
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1.5.3 Role of Galectin-3 in Invasion and Metastasis
A dhesion and m igration o f  cells are m ediated by the interaction betw een cells and 
extracellular m atrix (ECM ) glycoproteins and they are involved in inflam m ation and 
m etastasis o f cancer cells. Galectins are found on the cell surface and w ithin the 
extracellular m atrix (Perillo et ah, 1998) as w ell as in the cytoplasm  and the nucleus o f 
cells (as discussed earlier). Galectins bind specifically to  oligosaccharide ligands, w hich 
can be found on a num ber o f glycoproteins. However, despite the specific b inding o f  
galectins to these glycoproteins, controversies still rem ain as to w hether galectin-3 
expression facilitates or inhibits cell adhesion. Lam inin, an E C M  protein, has been show n 
to be a receptor for galectin-3. Galectin-3 has been shown to m ediate cell-to-cell and cell- 
to-m atrix adhesion; however, it doesn’t  behave consistently as an adhesion molecule. 
Galectin-3 m ediates the adhesion o f  neutrophils (Kuwabara et ah, 1996), bu t no t m elanom a 
cells (van den B rule etal., 1995), to lam inin (Perillo etal., 1998).
Recently, there is increasing evidence that galectin-3 is in fact involved in invasion and 
m etastasis o f cancer cells in vitro. This has been dem onstrated in non-sm all-cell lung 
cancer cell line, PC 9 (Yoshim ura etal.,  2003), squam ous cell lung cancer cell line, D LK P 
(O ’D riscoll et al., 2002), breast carcinom a cell line, M DA -M B-435 (K haldoyanidi et al., 
2003) and BT549 (Song et al., 2002), colon cancer cell lines, H M 7 and LS174T (Bresalier 
etal., 1998), thyroid follicular cell line, TA D-2 (Takenaka etal.,  2003) and m etastatic liver 
adenom carcinom a cell lines, XK4-A3 andR P M I4788  (Inufusa etal., 2001).
D ow n-regulation o f  galectin-3 using antisense m ethods resulted in m arked decrease in the 
m etastatic potential o f a highly m etastatic colon cell line, H M 7, while the up-regulation o f 
galectin-3 enhanced the m etastatic potential o f  a low  m etastatic colon cell line, LS174T 
(Bresalier et al., 1998). In a separate study, hum an breast cancer cell line, BT549, was 
transfected with galectin-3 cDNA and injected into the spleen o f nude mice. The m ice 
developed tum ours in both the spleen and the liver, indicating that galectin-3 can enhance 
the m etastatic potential o f  BT549 cells (Song et al., 2002). Furtherm ore, the  over­
expression o f  galectin-3 also confers a m alignant phenotype on TAD-2 thyroid  follicular 
cells (Takenaka et ah, 2003). TAD-2 cells transfected with galectin-3 show ed anchorage-
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independent growth and loss o f  contact inhibition, suggesting that galectin-3 plays an 
im portant role in m alignant transform ation in thyroid follicular cells (Takenaka et al., 
2003).
Stable transfection o f  galectin-3 cDNA into the lung cancer cell line, D LK P, resulting in 
galectin-3 over-expression caused an increase in invasion, m otility and adhesion to ECM , 
fibronectin and laminin, compared to the DLK P parent cell line (O ’D riscoll etal.,  2002) (as 
discussed in section 4.1.4). A  sim ilar study was carried out on the breast carcinom a cell 
line, BT549, where it was found that galectin-3 over-expressing clones w ere m ore adherent 
to laminin, collagen IV and fibronectin. In addition, they w ere also able to invade through 
m atrigel-coated filters at approx. three tim es the rate o f  parental cells. Galectin-3 was found 
to  be critical for adhesion to lam inin and collagen IV, bu t no t to  fibronectin by breast 
carcinom a cells (W arfield et al., 1997). Galectin-3 was also found to play a role in the 
interactions betw een breast carcinom a cells and elastin (O chieng etal.,  1999),
1.5.4 G alectin-3  E xpression
There have been many conflicting reports regarding the expression o f  galectin-3 in tum our 
and norm al cells and tissues. Som e groups have reported galectin-3 dow n-regulation in 
cancer (van den Brule etal., 1994; Castronovo etal., 1996; Idikio etal.,  1998; M ollenhauer 
et al., 2003), com pared to normal tissue, which correlates with disease progression and 
metastasis, while others have reported galectin-3 up-regulation in cancer com pared to 
normal tissue (Xu et al., 1995; Schaffert et al., 1998; Berberat et al., 2001; R iss et al., 
2003), especially in m etastatic and/or advanced cancer, which, in som e cases, correlated 
with poor prognosis (Lotan etal., 1994; Fernandez etal., 1997; Strik etal.,  2001; M iyazaki 
et al., 2002). (There is increasing evidence for the latter scenario).
Galectin-3 expression has been shown to be down-regulated in colon (Castronovo et al., 
1992; Lotz et al., 1993), ovary (van den B rule et al., 1994), breast and endom etrium  
carcinom a (van den Brule et al., 1995). This down-regulation seems to be associated w ith 
tum our progression. Castronovo et al. (1996) found high levels o f  galectin-3 m RN A  and 
protein expression in normal breast tissue and in benign lesions. The expression o f  galectin-
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3 was dram atically decreased in in situ carcinom a and further dow n-regulation was 
observed in invasive ductal carcinoma. It is speculated that this dow n-regulation could 
enable cancer cells to interact with laminin, thereby facilitating invasion and m etastasis 
(Castronova et al., 1996). D ow n-regulation o f  galectin-3 was found to  be a prognostic 
m arker for poor outcom e in laryngeal squam ous-cell carcinom a patients (Piantelli et al., 
2002).
In contrast, galectin-3 expression has been found in thyroid tum ours, but n o t norm al 
thyroid tissue or benign thyroid adenomas (Xu et al., 1995), suggesting a role for galectin-3 
in thyroid cancer. In thyroid follicular cells, TA D-2, galectin-3 cD N A  transfection induced 
a m alignant phenotype (Takenaka et al., 2003). Galectin-3 expression has been found in 
norm al hum an monocytes, which increases dram atically as the m onocytes differentiate into 
m acrophages in vitro (Liu et ah, 1995). N akam ura et ah (1999) reported galectin-3 
expression in norm al and tum our colorectal mucosa. Expression o f  galectin-3 was at higher 
levels in prim ary lesions o f  cancer than in norm al m ucosa. Furtherm ore, galectin-3 
expression increased dram atically in liver m etastatic lesions and correlated w ith 
progression o f  disease, liver m etastasis and poor prognosis (N akam ura et ah, 1999). In 
gastric cancer, galectin-3 expression correlated significantly with tum our progression and 
was dram atically stronger in m etastatic lym ph nodes than in prim ary gastric cancers 
(M iyazaki et ah, 2002). In pancreatic cancer, galectin-3 m RN A  and protein was 
predom inately expressed in cancer cells, w ith very w eak expression in norm al tissue. 
Galectin-3 expression was strongest in m etastatic pancreatic cancer cells (Berberat et ah,
2001) (see Table 1.5 for sum m ary o f  galectin-3 expression in hum an cancer and its 
correlation w ith prognosis).
Galectin-3 expression has also been dem onstrated in a large num ber o f  cancer cell lines, 
including breast (Ochieng etal.,  1999; H onjo etah,  2001; L ahm  et ah, 2001; K haldoyanidi 
et ah, 2003), colorectal (Huflejt et al., 1997; Lahm  etah,  2001), lung (Lahm  e tah ,  2001; 
O ’D riscoll et ah, 2002; Yoshim ura et ah, 2003), brain (Lahm  et ah, 2001), prostate (Lahm  
et ah, 2001), pancreatic (Schaffert et ah, 1998), nasal (O’D riscoll et ah, 2002) and ovarian 
carcinom as (Lahm  etah,  2001), as well as m elanom a (Lahm  etah,  2001) and leukem ia cell 
lines (Lahm  et ah, 2001). Further analysis o f  galectin-3 expression in invasive carcinomas 
is needed for a better understanding o f  this gene.
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T ab le  1.5 Sum m ary o f  Galectin-3 Expression in different types o f  hum an cancers and 
its relationship to prognosis.
C a n c e r  T ype  T ech n iq u e (% ) P rognosis&
C o rre la tio n
L oca lisa tion R efe ren ce
L a ry n x IHC 57.5 Correlated w/ 
Good prognosis
N/A Piantelli et al., 2002
B re a s t IHC 69 Inversely 
Correlated w/ 
progression
N/A Castronovo et al., 1996
C olorectal IHC 68 Correlation 
w/progression 
& poor prognosis
Cytoplasmic Nakamura et al., 1999
IHC 59C
49N
Inversely 
Correlated w/ 
progression
Cytoplasmic
&Nuclear
Sanjuan etal., 1997
P an c re a s IHC 95 N/A Ductal cells Scharffertei al., 1998
IHC
NB
N/A
77
No correlation
N/A
Ductal cells 
N/A
Berberat et al., 2001
G astric m e 84 Correlation 
w/ Tumour 
progression
Nuclear Miyazaki et al., 2002
T h y ro id m e
WB
100
100
Correlation 
w/ malignant 
transformation
Cytoplasmic Xu etal., 1995
IHC=Immunohistochemistry; WB=Westem blot; N/A= Not applicable; C=Cytoplasmic; N=Nuclear.
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1.6 The Inhibitors of Apoptosis (LAP) family
Inhibitors o f  apoptosis proteins (IAPs) are an evolutionary conserved fam ily o f  proteins 
that interfere with the process o f  cell death by inhibiting caspases. IAPs w ere discovered in 
baculovirus by M iller et al. in 1993. These researchers found that viruses deploy such 
proteins to  keep host cells alive w hile the viruses replicate and spread. In 1994, A lex M ac 
K enzie et al. reported the first cellular LAP, a protein that inhibits apoptosis in nerve cells, 
namely NIAP. Since then, researchers have reported a num ber o f IAPs in m am m alian cells 
alone. The identifying signature o f  these m olecules is the presence o f  at least one 
approxim ately 70 am ino acid zinc finger m odule, designated baculovirus IAP repeat (BIR). 
Several groups have shown that IAPs, including XIAP, N IA P, cIA Pi, cIA P2, L ivin  and 
Survivin (see figure 1), bind to caspases and block their activity. It is the BER region that, in 
several m am m alian IAPs, binds initiator and effector caspases, thus suppressing the 
enzym e’s activity and /or interfering with its activation (Deveraux et al., 1999). H ow ever, 
like Bel proteins, IAPs may function in m ore than one way. In  studies investigating 
inhibitors o f  apoptosis, M iller et al. (1999) found that IAPs apparently can arrest apoptosis 
before the caspases are involved.
1.6.1 T h e  B IR  m o tif
B IR  (baculovirus IAP repeat) was identified originally as a sequence o f  approxim ately 70 
amino acids that was tandem ly repeated in a class o f  proteins blocking apoptosis-induced 
during baculovirus infection (Birrnbaum  et al., 1994). At least one BER m o tif  is essential 
for anti-apoptotic activity o f  m em bers o f  the IAP family. Som e IAPs also contain a C- 
term inal R IN G  (C3H C 4) finger, bu t the requirem ent o f  this R IN G  finger for anti-apoptotic 
activity differs depending on the IAP and /or the nature o f  the apoptotic stim ulus (Cleu et 
al., 1994, Takahash et al., 1998, V ucic et al., 1997; Hay et al., 1995). Structure analysis 
shows that a B IR  folds into a structure w ith a highly hydrophobic center that includes a 
C2HC m otif coordinating a zinc ion. This core structure includes a num ber o f  h ighly 
conserved residues, which are required for anti-apoptotic activity (Li et al., 1998). As a 
num ber o f  IAPs interact with caspases through regions encom passing BIRs, it is often
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assum ed that BIRs are caspase-interacting regions. W hy there  are m ultiple B IR  dom ains in 
som e IAPs and BIRPs (BIR proteins) is unknown, although both BIRs are required for full 
anti-apoptotic activity o f  Op-IAP (Orgyia pseudotsugata). How ever, m inim al anti- 
apoptotic activity is associated with the C-term inal B IR  m o tif o f  O p-IA P and the m iddle 
B IR  (B1R2) o f  XLAP, and survivin has only a single B IR  (Figure 1.6.1).
1.6.2 F u n c tio n  o f IA Ps
R ecom binant purified m am m alian IAPs, XLAP, cIA Pl and cIAP2 directly inhibit the 
term inal effector proteases, caspase-3 and -7 ,  providing evidence for the specific 
m echanism  o f  action for these m am malian cell-death suppressors (D everaux et al., 1997 
and Roy et al., 1997). N ot all B IR-containing proteins (BIRPs) are anti-apoptotic. Recent 
genetic analysis o f C. elegans BIR-1 dem onstrated an essential role in cytokinesis instead 
o f  apoptosis (Fraser et al., 1999). In yeasts containing no caspases, B IRPs are found whose 
gene knockouts result in the defects in m eiosis and m itosis (Uren et al., 1999). These 
results suggest that BIRs have evolved to acquire divergent biological roles (Shin et al., 
2001).
1.6.2.1 M a m m a lian  IA P s as C asp ase  In h ib ito rs
Eight IAP-fam ily m em bers have been identified to date including N IA P (neuronal 
apoptosis inhibitor), cIA Pl (cellular IAP 1), cIAP2, XIAP (X Chrom osom e-linked inhibitor 
o f apoptosis), Livin, Bruce, apollon and Survivin (see Figure 1.6.1). The spectrum  o f 
apoptosis stim uli that are blocked by these IAPs is broad and includes anti-fas antibody 
(D uckett et al., 1996), T N F a  (tum our necrosis factor), viral infection (D uckett etal.  1996), 
chem otherapy agents, exposure to U V  radiation (D uckett et al., 1998), serum  withdrawal 
(Liston etal.,  1996), and over-expression o f  caspase fam ily proteins (D uckett et al., 1996; 
Uren et al., 1996), w ith XIAP having the  broadest and strongest anti-apoptotic activity. 
XIAP, cIA Pl and cIAP2 have been show n to bind to specific cell death proteases, i.e. 
caspases-3 and 7 and procaspase-9 and to  inhibit their proteolytic activity in vitro 
(Deveraux et al., 1997; R oy et al., 1997). X IA P contains three B IR  domains. BIR2 and the
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am ino acids im m ediately N -term inal to BIR2 interact w ith caspase-3, w hile the BIR3 
dom ain binds capase-9 thereby preventing activation o f  the intrinsic apoptotic cascade 
(Takahashi et ah, 1998; Silke et ah, 2001). As w ill be  discussed later (see section 1 .6 .8), 
survivin has been proposed to  interact physically w ith caspase-3 and -7 (Conw ay et ah, 
2000; Shin etah,  2001; Suzuki etah,  2001).
RIR
R IN G
B aculovira l
Op-IAP
M a m m a lian
clAPI
cIAP2
XIAP
NIAP
Survivin
Livin
t
N em atode
BIR-1
BIR-2
F ig u re  1.6.1 Schem atic representation o f  selected baculovirus IA P repeat (BIR)
containing proteins. B IR  m otifs (yellow  boxes) occupy the N -term inal portion o f  the 
proteins. R IN G  finger dom ain (red boxes) are p resent at som e C-termini.
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1.6.3 Survivin
Survivin is the sm allest IAP cloned to date, consisting o f  only 142 amino acids. It is a 16.5 
kDa protein, containing only a single N -term inal B IR  dom ain and it lacks a C-term inal 
R IN G  finger (Am brosini et a l ,  1997). Survivin was originally identified by hybridisation 
screening o f  hum an genom e libraries with the cDNA o f  a factor X a receptor, E ffector 
Protease Receptor 1 (EPR1) (Am brosini et a l ,  1997), a protein involved in blood 
coagulation (Zam an and Conway, 2000). A lthough survivin has generally been described 
as a cytoplasm ic protein (Am brosini et al., 1997; K aw asaki et al., 1998; Lu et al., 1998; 
Adida et al., 1998; Tanaka et al., 2000; A dida et al., 2000; M uzio et al., 2001; Satoh et al., 
2001; Sasaki et al., 2002; A dida et al. 2002; Trieb et al., 2003), nuclear localisation has 
also been reported (Ito et al., 2000; Okada et al., 2001; Trieb et al., 2003; K ennedy et al.,
2003).
Survivin is expressed during fetal developm ent and at low  levels in norm al, adult 
differentiated, tissue (Ambrosini et al. 1997; A dida et al., 1998a). A dida et al. (1998) 
reported strong expression o f  survivin in several apoptos is-regulated fetal tissues, including 
the stem cell layer o f stratified epithelia, endocrine pancreas, and thym ic m edulla; 
exhibiting a pattern that did not overlap w ith that o f  Bcl-2. Survivin was also detected in 
hum an fetal lung, liver heart, kidney and gastrointestinal tract (Adida et al., 1998). T h is 
suggests that survivin expression in em bryonic and fetal developm ent m ay contribute to 
tissue hom eostasis and differentiation, independently o f  Bcl-2.
Interestingly, survivin becomes prom inently expressed in all o f  the m ost com m on hum an 
cancers, including breast (Tanaka et al., 2000; Nasu et al., 2002; K ennedy et al., 2003), 
bladder (Swana et al., 1999), blood (M oriai et a l ,  2001; A dida e t a l ,  2000), colon (Sarela 
et al., 2000; K aw asaki et a l ,  1998; 2001; L in  et a l ,  2003), esophageal (Kato et a l ,  2001; 
Ikeguchi et al., 2003), liver (Ito et al., 2000), brain (Nakagawara et al., 1998; Islam  et al.,
2000), lung (M onzo eta l.,  1999; Choi e ta l.,  2001), pancreas (Satoh e t a l ,  2001), Gastric 
(Lu eta l.,  1998; Okada et al., 2001; Ikeguchi; K aibara 2001; K rieg et al., 2002; K ania et 
al., 2003), ovarian (Hattori et al., 2001; Chen et a l ,  2003) prostate (X ing et al., 2001),
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kidney (Takam izaw a et al., 2001) and high-grade lym phom as but no t low -grade 
lym phom as (Am brosini etal., 1997; A dida etal.,  1998a; L u  etal.,  1998).
Survivin is predom inantly expressed in cancer, and has been associated w ith cancer 
prognosis and diagnosis (see Table 1.6), m aking it a very interesting drug target as will be 
discussed in section 1.6.8. Recently, however, survivin was detected in several norm al 
tissues, such as bone m arrow (Fukuda et al., 2001), endom etrium  (Takai e t a l ., 2002), 
thym us (Kobayashi et al., 2002) and colonic m ucosa (G ianani et al., 2001). In a study by 
Shiozaki et al. (2003), survivin m RNA and protein was expressed in cytotrophoblasts o f  
norm al hum an placenta (Shiozaki et al., 2003). Survivin m RN A  is expressed at low  levels 
in hum an liver, w ith up-regulation in liver tissue o f  hepatitis o r cirrhosis under the stress o f  
inflam m atory cytokines or regeneration (Shiraki etal.,  2003). Survivin is also expressed at 
a high basal level in  normal hum an (and rat) gastric m ucosa (Chiou et al., 2003). The 
gastric m ucosa undergoes continuous surface epithelial cell renew al with a turnover rate o f  
3-5 days. The results by Chiou et al. suggest that survivin expression m ay be im portant for 
regulating this process and may help to prom ote m ucosal surface epithelial cell viability 
and regeneration after ulceration or injury by dam aging agents, such as alcohol and 
NSAIDS (Chiou et al., 2003). In addition, survivin is reported to be a crucial regulator o f  
normal sm ooth m uscle cells apoptosis after acute vascular injury (B lanc-Brude e t al.,
2002). Taken together, these findings suggest that survivin plays an im portant role in 
controlling cell proliferation, differentiation, and death in hum an non-transform ed cells, as 
well as m alignant cells.
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1.6.4 Discovery o f Survivin
First discovered when screening a hum an genom ic library with EPR-1 (see section 1.6.3), 
the survivin gene has a coding strand that is highly hom ologous to the sequence o f  EPR-1, 
but oriented in the opposite direction (Am brosini et al., 1997). This suggests the existence 
o f tw o separate genes duplicated in a head-to-head configuration w ith potential functional 
interaction betw een these two transcripts (Am brosini etal.,  1997).
Am brosini et al. (1998) reported successful down-regulation o f  survivin by transiently 
transfecting an EPR-1 cD N A  into tum our cells, resulting in an increase in apoptosis and 
inhibited grow th o f transform ed cells. Further studies included a stable transfection o f  H ela 
cells with an EPR-1 cD N A  under the control o f  a m etallothionein-inducible prom oter. It 
was found that ZnSC>4 induction o f  EPR-1 m RN A  suppressed the expression o f  endogenous 
survivin. Furtherm ore, antisense down-regulation o f  survivin resulted in m assive apoptosis 
(detected by TU N EL assay) in growth factor-deprived H ela cells (A m brosini e ta l.,  1998). 
Suppression o f  Survivin by an endogenous EPR-1 transcript potentially acting as a natural 
antisense m ay overcom e the drawbacks o f  lim ited specificity and insufficient delivery 
com m only observed with antisense oligonucleotides (Henry etal.,  1997). E lucidation o f the 
m echanism s regulating survivin and EPR-1 gene expression should further facilitate the 
selective disruption o f  this novel anti-apoptosis pathw ay in cancer w ithout affecting 
viability o f  norm al tissue.
Shinozaw a et al. (2000) reported an investigation o f  the  m utual expression o f  
survivin/EPR-1 genes in a variety o f hem atological m alignancies. R esults show ed that 
expression o f  survivin/EPR-1 genes occur in m any types o f  hem atologically m alignant 
cells and that coordination o f  the EPR-1 and survivin gene expression m ay be independent 
(Shinozawa et al., 2000), leaving a doubt as to whether EPR-1 m RN A  can dow n-regulate 
survivin expression by acting as a natural antisense transcript.
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1.6.5 Survivin Structure
As the interest in survivin’s function and expression in hum an tissue develops, increasing 
efforts have been invested in elucidating its crystal structure. B oth hum an and m ouse 
survivin crystal structures have been described by three independent research groups 
(M uchm ore et al., 2000; Chantalat et al., 2000; V erdecia et al., 2000). The N-term inal 
Zn2+- binding B IR  dom ain o f  survivin consists o f  a three-stranded anti-parallel P-sheets 
surrounded by four small a-helices (M uchm ore et al., 2000, C hantalat et a l ., 2000, 
V erdecia et al., 2000). There have been som e discrepancies betw een the  identity o f  the 
dimeric interface. Chantalat and V erdecia’s groups report a bow -tie m odel w ith a 
predom inantly hydrophobic interface on the B IR  dom ain o f  each survivin monomer. On the 
other hand, M uchm ore’s group reports a zinc chelation m odel whereby a zinc atom  was 
observed to m ediate the dim eric interface. D espite the discrepancies, how ever, the three 
structures reveal im portant insights on survivin and provide a m olecular fram ew ork to help 
design future experim ents to clarify surv iv in’s biological functions (Shi et al., 2000). 
Contrary to A m brosini’s coiled-coil m odel o f  the C-term inal (A m brosini e t al., 1997), it 
was found that the c-terminal dom ain o f  survivin forms a long, extended helix  (a.6) and is 
no t involved in the dim eric form ation; elim ination o f  this interface by deleting the bulk o f 
a 6, did not affect the form ation o f a survivin hom odim er in solution (V erdecia et al., 2000; 
Chantalat et al., 2000).
The survivin structures reveal three chem ically distinct surfaces, the first com prising m any 
acidic residues, the second containing basic residues, and the third rich in hydrophobic 
residues on helix a 6. Expression o f a survivin m utated form o f  the negatively charged 
residues (Asp 71 A) caused spontaneous apoptosis in H ela cells (M uchm ore et al., 2000), 
consistent with the functional significance o f  this region. Survivin associates w ith and is 
phosphorylated on Thr34 by, p34odc2-cyclin. This m odification is required for apoptosis 
inhibition (Fortugno et al., 2002; O ’C onnor et al., 2000). A  T hr 34A  m utation, which 
results in the expression o f a phosphorylation-defective survivin m utant, caused 
spontaneous apoptosis, are seen by flow  cytometry, preventing T 34 phosphorylation. 
Interestingly, tw o m utations, H  80A and E 76A, both affecting the reported zinc-chelating
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residues, also led to spontaneous apoptosis in the  cells. In contrast, other m utations 
exhibited less (E51 A) or no (L64A) effect on cell survival (M uchm ore et al., 2000). These 
data suggest that the negatively charged surface m ay be im portant for interactions w ith 
other proteins (Shi et al., 2000). The determ ination o f the three-dim ensional structure o f 
survivin and the elucidation o f structural requirem ents o f  the  apoptosis/cell division control 
pathway m aintained by survivin in cancer cells should facilitate the identification o f 
selective antagonists o f  this cytoprotective pathway in cancer (Am brosini et al., 1997; Shi 
et al., 2000),
1.6.5.1 S urv iv in  Splice V arian ts
W hile carrying out a study on survivin expression in renal cell carcinom a (RCC), M ahotka 
et al. (2000) discovered two novel alternatively processed survivin transcripts. These were 
designated Survivin-AEx3 (lacking exon 3) and survivin-2B (retaining a part o f  intron 2 as 
a cryptic exon) (Figure 1.6.3). M ahotka’s group found that the expression o f  both survivin 
and survivin-AEx3 was observed in all RC C cell lines tested, with m ost RCCs additionally 
expressing survivin-2B. Survivin splice variants have also been reported by Fogt et al. 
(2001) in normal and tum our colon cells.
Transient transfection o f  H epG 2 cells, revealed m arked differences in the anti-apoptotic 
activity o f  the novel survivin splice variants. Transfection o f  H epG 2 cells w ith survivin 
resulted in a large increase o f  cell survival after exposure to m ethotrexate. This was also the 
case when transfected with survivin-AEx3, although the exon 3 deletion results in a 
fram eshift w ith truncation o f  the B IR  dom ain in addition to a new  CO O H -term inal protein 
segment, which in turn m ight affect functional properties such as subcellular localisation. 
Retention o f  anti-apoptotic activity by the structurally m odified survivin-AEx3 cannot be 
explained (M ahotka et al., 1999). In contrast, HepG 2 cells transfected w ith survivin-2B 
showed a m arked reduction o f  cell survival after exposure to m ethotrexate (M ahotka et al., 
1999). This suggests differential anti-apoptotic properties o f  the novel survivin splice 
variants, show ing a nearly com plete preservation (survivin-AEx3) or a m arked reduction 
(survivin-2B) o f  the anti-apoptotic effects known for the regulatory spliced survivin
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isoforms. The identification o f the two splice variants w ill have im portant im plications for 
the understanding o f  survivin actions.
(a) S urv iv in  (142aa; 16.5 kD a)
E xon  1 E xon  2 E xon 3 E xon  4
(b) Surv iv in -2B  (165aa; 18.6 kD a)
E xon  1 E xon  2 E xon  2B E xon  3 E xon  4
(c) Survivin-A Ex3 (137aa; 15.7 kD a)
E xon  1 E xon  2 E xon  4 O R F -3 'U T R
F ig u re  1.6.3 The three transcripts o f  the  Survivin gene, (a) the  survivin transcript
with four exons, (b) survivin-2B with an additional exon (exon 2B) inserted betw een exon 
2 and 3, and (c) survivin-AEx3, showing a loss o f exon 3 as well as a fram e-shift, w ith  
extension o f  the  reading frame into the open reading frame (ORF) o f  the  3 ’ un-translated 
region (UTR). aa=am ino acids; K da =K ilo D altons (M ahotka et al., 1999).
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1.6.5.2 Livin: A close relative o f Survivin
A  novel m em ber o f  the LAP fam ily has been identified by several groups. It has been 
designated M L-IA P by V ucic et al. (2000), livin by K aso f and Gomes (2001), and KIAP by 
L in  et al. (2000). (This protein will be referred to as livin in this thesis). L ivin encodes a 
protein with a single B IR  dom ain and a CO O H -term inal R IN G  dom ain and it is reported to 
be approxim ately 26%  hom ologous to survivin. Expression o f  livin inhibits apoptosis, 
w hereas a livin antisense construct has been shown to induce apoptosis. The livin antisense, 
however, did not reduce the levels o f  survivin, suggesting that the construct has a specific 
effect on livin and not on related IAP family m em bers (K asof and Gom es, 2001).
Sim ilar to survivin, livin was found to be capable o f  binding to  caspase-3 and - 7  and it has 
been shown to inhibit the proteolytic processing o f  caspase-9 in vitro (K asof and Gomes,
2001). L iv in ’s expression, like survivin’s, was undetected in m any norm al adult tissues, but 
was present in developm ental tissue and several cancer cell line, w ith h ighest levels in 
m elanom a cell lines. L ivin, however, seem s to have m ore restricted expression than 
survivin with a narrow er distribution (i.e. few er cancer types) than survivin in cancer 
(K asof and Gomes, 2001; V ucic et al., 2000),
In  the study reported by K aso f and Gomes in 2001, H ela  cells were transfected with 
apoptotic genes in the P tracer vector containing a GFP m arker for accessing viability. 
Transfection with pro-apoptotic genes, e.g. Bax, led to ~  90%  reduction in viability. C o­
transfection o f  B ax with either livin or survivin caused a 4-6-fold increase in viability. It 
was found that livin showed more anti-apoptotic activity than survivin. Survivin has been 
shown previously to  be less effective at inhibiting apoptosis that other IAP fam ily m em bers 
(Tam m  et al., 1998). K aso f et al. (2000) reported that livin was observed predom inantly in 
the nucleus and in a filam entous pattern throughout the cytoplasm  and that survivin was 
observed in the sam e pattern, indicating that livin and survivin have sim ilar subcellular 
localisation (K asof et al., 2001). In a separate study by A shhab et al. in 2001, tw o splice 
variants o f livin were identified i.e. livin a  and P, representing the longer and shorter 
variants, respectively. The group found the two isoforms to  have different anti-apoptotic 
properties (sim ilar to the findings o f  M ahotka et al. on the survivin variants).
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Differences in expression patterns o f  livin a  and w ere also reported. L iv in  P, but no t livin a  
was found in fetal and adult kidney and in several other fetal tissues, indicating that it m ay 
play a physiological ro le during fetal developm ent. E xpression o f  both variants is m ost 
prom inent in the placenta (Ashhab et al., 2001). Furtherm ore, it was found tha t livin a,  bu t 
no t P protects cells from  apoptosis induced by staurosporine, bu t in contrast, apoptosis 
initiated by etoposide was blocked only by  th e  P isoform. The findings from  these tw o 
studies, suggest that there is no correlation betw een the  expression o f  livin and survivin.
54
1 .6 .6 Survivin expression, localisation and mechanism o f action
The subcellular localisation and function o f  survivin has resulted in m uch controversy and 
has attracted a lot o f  interest in recent years. Studies reveal that survivin is localised at the 
m itotic spindle, binds caspases, and can thus protect cells from  apoptosis. Som e studies 
have dem onstrated that survivin is expressed at the G2/M  phase o f  the  cell cycle (Li et al., 
1998 and K obayashi et al., 1999) and inhibition o f  hum an survivin has been associated 
with cell cycle defects (Li et al., 1998). In addition, survivin expression has been found in 
em bryonic tissue and in proliferating hem atopoietic stem  cells, as w ell as reproductive 
tissue (Konno et al., 2000; Endoh et al., 2001), confirm ing its cell cycle-specific function. 
Survivin may also protect cells from  apoptosis by  binding to caspases. The types o f 
caspases involved, however, are still disputed (Banks et al., 2000; Conw ay et al., 2000; 
O ’Connor et al., 2000; Shin etal., 2001).
1.6.6.1 S urv iv in  as a  caspase  in h ib ito r
There is m uch discrepancy regarding the role o f  survivin as an inhibitor o f  caspase activity. 
Survivin has been proposed to interact physically w ith caspase-3 and -7 (Conway et al., 
2000; Shin et al., 2001; Suzuki et al., 2001). How ever, recom binant survivin expressed as 
an N -term inal histidine-tagged protein was unable to bind caspase-3 or to  inhibit caspase-3 
activity in vitro (Verdecia et al., 2000). O ther reports also suggest that survivin does not 
inhibit caspase-3 activity (Banks etal.,  2000; Reed, 2001).
W hether the interaction betw een survivin and caspase-3 is direct or no t is still unclear. 
How ever, there is evidence o f  an inverse correlation betw een the tw o proteins. Over­
expression o f  survivin in gastric tumours and adjacent m ucosa is accom panied by a down- 
regulation o f caspase-3, indicating that these changes may play a role in the transform ation 
from  norm al gastric m ucosa to gastric cancer (Kania et al., 2003). In ovarian cancer cells, 
exogenous expression o f  procaspase-3 leads to  up-regulation o f  w ild-type survivin 
expression, w hile over-expression o f  procaspase-3 alone does no t induce apoptosis. W hen 
survivin expression is blocked by a dom inant negative m utant (T34A), apoptosis is 
induced. Furtherm ore, this induction o f  apoptosis was caused by a caspase-9/ caspase-3- 
m ediated pathway as show n by western blot analysis (M cK ay etal.,  2003).
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1 .6 .6 .2 Survivin as a regulator o f cell cycle
Survivin has been identified as an interface betw een cell-cycle progression and control o f  
apoptosis. It m ay be required to counteract a constitutive pathw ay that induces apoptosis 
during mitosis. It is expressed prim arily during the G 2/M  phase and associates with 
m icrotubules o f  the m itotic spindle during m etaphase and with m id-bodies during late 
telophase. A ssociation with polym erised m icrotubules is m ediated by a C -term inal coiled- 
coil dom ain, no t the B IR  dom ain (Li et al., 1997).
Survivin appears to be closely linked to the m itotic process. In norm al tissue it is only 
expressed at detectable levels at the G2/M  phase o f  the cell cycle, survivin protein then 
m igrates to the microtubules in a process sim ilar to  chrom osom al passenger proteins 
(Skoufias et al., 2000; Speliotes et al., 2000; Suzuki et al., 2000, Adam s e t al., 2001). 
Survivin has also been classified as a chrom osom al passenger protein (Tem m e et al., 2003) 
that interacts with Aurora-B and INCEN P (Skoufias et al., 2000; U ren et al., 2000; 
W heatley etal.,  2001; Bolton et al., 2002) to form  a chrom osom al passenger com plex that 
is proposed to play a crucial role in the execution o f  cytokenesis. Survivin localises Aurora- 
B to its substrates and enhances it kinase activity in vitro and in vivo (Chen et al., 2003). 
Survivin is also essential for chrom osom e alignm ent and checkpoint responses elicited by 
drugs that interfere w ith tension. Cells lacking survivin entered m itosis with norm al 
kinetics and form ed bipolar spindles, bu t w ere delayed in a prom etaphase state. They also 
were unable to align their chrom osom es, failed to  recruit Aurora B to kinetochores, and 
polyploid at a very high frequency (Lens et al., 2003).
One o f  the critical requirem ents for survivin function is the phosphorylation on Thr34 by 
the mitotic kinase p34cdc2-cyclin B1 (O ’Connor et al., 2000), as shown w hen a 
phosphorylation-m im etic survivin m utant strongly inhibited p53-induced apoptosis 
(Hoffman et al., 2002). This m ethod o f  preventing survivin phosphorylation results in 
caspase-9-dependent apoptosis and anti-cancer activity (M esri et al., 2001). Furtherm ore, 
inhibition o f  survivin phosphorylation on Thr34, by the cyclin-dependent kinase inhibitor 
flavopiridol, resulted in loss o f  survivin expression and enhanced tum our cell apoptosis 
induced by anti-cancer agents and it also suppressed tum our growth, w ithout toxicity, in a 
breast cancer xenograft m odel in vivo (W all eta l.,  2003).
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1.6.7 Survivin’s Role in Cancer
Lung and breast cancers are leading causes o f  cancer death, and their incidence continues 
to rise. The m ain reason for the unfavorable prognosis o f  these tumours is their tendency to 
m etastasize early and develop resistance to a wide range o f functionally unrelated 
anticancer agents. Interestingly, lung and breast cancer cells express the highest levels o f  
Survivin found in hum an tumours (Tamm et al., 1998, Am brosini et al., 1997). Survivin's 
expression, its correlation to prognosis, and its association with other genes in different 
types o f  cancer is sum m erised in Table 1.6.
Survivin may be a m olecular m arker for osteosarcom a, the m ost com m on m alignant 
tum our o f  bone (Trieb et al., 2003). Its localisation w ithin the tum our cell m ay be  a 
prognostic factor o f  this type o f  cancer. 70%  o f  osteosarcom a patients with no survivin 
nuclear staining died o f  their disease, while 80%  of patients with survivin-positive nuclear 
staining were alive after an average follow-up o f  eight years. Thus, survivin localisation 
could be an im portant prognostic m arker for the prediction o f  the survival o f  patients with 
high grade osteosarcom a (Trieb et al., 2003). This finding is in agreem ent with other 
findings in gastric cancer (Okada etal.,  2001), and in breast cancer (K ennedy et al., 2003), 
where survivin nuclear staining is associated w ith a m ore favourable prognosis.
As well as being a potential m olecular m arker for predicting disease outcom e, survivin m ay 
also play an im portant role in tum our response to chemotherapy. Chem otherapy and 
radiation induce apoptosis in neoplastic cells. In patients with rectal cancer, w ho were 
treated by neoadjuvant radiochem otherapy, survivin expression was correlated inversely 
with spontaneous apoptosis rate (Rodel et al., 2003). H igh survivin expression was 
associated with a significantly higher risk o f  tum our recurrence after preoperative 
radiochem otherapy, indicating that over-expression o f survivin may confer a certain degree 
o f radio-resistance to rectal cancer cell in vivo (Rodel et al., 2002). Furtherm ore, this was 
confirmed in vitro in colorectal cancer cell lines. The cell lines expressing the h ighest level 
o f  survivin m RNA and protein had the lowest rate o f  spontaneous and radiation-induced 
apoptosis and w ere the m ost resistant to irradiation, w hereas the cell lines w ith the lowest 
level o f survivin m RN A  and protein expression, showed the highest level o f  apoptosis and
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w ere the m ost sensitive to irradiation, suggesting that survivin m ay ac t as a  constitutive 
radio-resistant factor in colorectal cancer (Rodel et ah, 2003). A  sim ilar relationship 
betw een survivin expression and radio-resistance was reported in pancreatic cells and in 
m elanom a cells, in vitro, where an inverse relationship betw een survivin expression levels 
and radio-sensitivity was found (Asanum a et ah, 2000; Pennati et ah, 2003, respectively). 
Such an association was also reported betw een survivin and chem oresistance in advance 
esophageal, lung and skin cancer (Kato et al., 2001; O lie e t ah, 2000; M esri et ah, 2001, 
respectively).
Furtherm ore, survivin up-regulation in ovarian cancer cells, by survivin cD N A  transfection, 
caused a large increase in cell resistance to taxol and taxotere (Zaffaroni et ah, 2002). In 
addition, this drug resistance was reflected in vivo w here high levels o f  survivin protein 
expression, detected by imm unohistochem istry, w ere highly associated w ith clinical 
resistance to taxol/platinum -based regim en, bu t unrelated to non-taxol based treatm ent, 
suggesting a link betw een survivin expression and tum our cell susceptibility to  taxol 
(Zaffaroni et ah, 2002). Studies o f drug resistant leukem ia cell line, H L60R, revealed an 
increase in survivin m RN A  expression com pared to parental, drug sensitive, cells 
(Notarbartolo et ah, 2002). In two separate studies by Ikeguchi et ah (2001 and 2002), 
exposure o f  gastric cancer cell line, M KN -45, to cisplatin resulted in a large increase in 
survivin m RN A  (Ikeguchi etah,  2001 and 2002) and protein (Ikeguchi et ah, 2002). Taken 
together, these findings suggest that survivin plays an im portant role in chem o- and radio­
resistance o f  m alignant cells.
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T ab le  1.6 Sum mary o f  Survivin Expression in different types o f  hum an Cancers and its
relationship prognosis.
C a n c e r  type  T echn ique (% )S u rv iv in  P rognosis  & 
E xpression  C o rre la tio n
L oca lisation R efe ren ce
L ung RT-PCR 85 Poor survival. N/A Monzo et al., 1999
B re a st m e 70.7 Poor survival; 
Strong correlation 
With Bcl-2.
Cytoplasm Tanakaetai, 2000
RT-PCR 90.2 N/A N/A Nasu et al., 2002
m e 60 Favourable prognosis Nuclear mainly Kennedy et al.,2003
C olo rec ta l m e 53.2 Poor survival; 
Strong correlation 
With Bcl-2.
Cytoplasm Kawasaki et al, 1998
RT-PCR 62 N/A N/A Sarela et al., 2000
m c &
RT-PCR
100 in all 
normal & 
Neoplastic 
Colonic mucosa.
N/A N/A Gianani et al., 2001
m e 0% in normal Correlation with stage
63.2% high-grade
dysplasia
Cytoplasm Lin et al., 2003
Skin m e 93 More aggressive 
tumour.
N/A Grossman et al., 
1999(a)
m e 81 in BCC 
92 in SCC
N/A N/A Grossman et al., 
1999(b)
IHC+WB 64 in skin SCC 
56 in oral SCC
N/A Cytoplasm Muzio et al., 2001
G astric m e 35.4 Correlation with 
Bcl-2 & p53 
expression.
Cytoplasm Lu et al., 1998.
m e 82-88 Nuclear staining 
associated with 
favourable prognosis.
Nuclear +
Cytoplasm
Okada et al., 2001
RT-PCR 13.3 N/A N/A Ikeguchi and 
Kaibara, 2001
RT-PCR 100 Survivin2B inversely 
Correlated with stage
N/A Krieg et al., 2002
RT-PCR 
& WB
N/A Inversely correlated 
with caspase-3
N/A Kania et al., 2003
K idney RPA 50 recurred 
18 didn’t recur
Correlation with 
recurrence
N/A Takamizawa et al., 2001
RT-PCR 100 Survivin 2B inversely 
Correlated with stage
N/A Mahotka et al., 2002
O v a ria n RT-PCR 86 N/A N/A Hatton et al., 2001
m e 73 Correlation with resistance N/A 
Taxol/platinum
Zaffaroni etal., 2002
m e 73.5 Correlation with grade 
& histological type
Nuclear Cohen et al., 2003
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Table 1.6 continued
C a n c e r type  T echn ique S urv iv in
E xp  (% )
P rognosis & 
C o rre la tio n
L o ca lisa tion R efe ren ce
B la d d e r IHC 78 Correlation 
with recurrence 
& tumour grade.
N/A Swana et al., 1999
RT-PCR 100 Correlation 
with tumour grade
N/A Smith et al., 2001
D iffuse la rg e  IHC 
B-cell
55 N/A Cytoplasm Ambrosini et al., 1997
L ym phom a IHC 60 Poor survival N/A Adida et al., 2000
P a n c re a s  IHC 76.9 Higher levels of 
Surv. in malignant 
than in benign.
Cytoplasm Satohef al., 2001
IHC 88 Correlation with high 
proliferation index, low 
apoptotic index&Bcl-2
Cytoplasm Sarela et al., 2002
L iv e r IHC 70 N/A Primarily Ito et al, 2000 
Nuclear,
weak cytoplasmic.
RT-PCR 87.5 N/A N/A
E sophageal RT-PCR 70.6
(47 in paired 
normal tissue)
Poor survival N/A Kato et al., 2001
RT-PCR N/A Correlation with p53 & 
proliferative activity
N/A Ikeguchi et al., 2003
A cute IHC 
M yeloid 
L eukem ia  
(A M L)
60 Poor survival,
Surv. Expression 
strongly associated 
with lower WBC
Cytoplasm Adida et al., 2000
WB 88.8 N/A N/A Carter et al., 2001
N euro- IHC 
b lastom a
47 Poor survival Cytoplasm Adida et al., 1998
Quant. PCR 
RPA
N/A
90 recurred
Poor prognosis 
Correlation with
N/A Tajira et al., 2001
27.7 didn’t 
recur
recurrence N/A Sandler et al., 2002
RPA 100 recurred 
0 didn’t recur
Correlation with 
recurrence
N/A Azuhata et al., 2001
O steosarcom a IHC 57.5
50
no correlation 
Correlation with 
prolonged survival
Cytoplasm
Nuclear
Trieb et al., 2003
IHC=Immunohistochemistry; RPA=Rnase protection assay; WB=westem blot; N/A=not applicable.
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1.6.8 Survivin as a Cancer Therapeutic Target
Com ponents o f the apoptosis signaling pathway, along w ith several other triggers and 
regulators, are am ong the m ost prom ising targets for pharm acological m odulation o f  cell 
death and inflam m ation (Evan etal.,  2001; Schattner etal., 2002). Caspases are am ong the 
apoptosis regulators that are being targeting for cancer therapy, as w ell as the  caspase 
inhibitors, IAPs (Los etal.,  2003).
The notion that survivin is over-expressed in m ost com m on tum ours, bu t absent in the 
m ajority o f  norm al adult tissue, with the few  exceptions discussed in section 1.6.3, has led 
to the proposal o f  survivin as a prom ising therapeutic target for novel anticancer therapies. 
Survivin down-regulation m ay affect the growth o f  transform ed cells, preventing them  
from  continuous growth and metastasis. Experim ents targeting survivin w ith specific 
ribozym es (Pennati et al., 2002 and 2003; Choi et al., 2003), antisense oligonucleotides 
(A m brosini et al., 1998; G rossm an et al., 1999a and 1999b; O lie et al., 2000; Chen et al., 
2000; M esri et al., 2001; Shankar e t al., 2001; Guan et al., 2002; X ia et al., 2002), or w ith 
survivin dom inant negative m utants (Grossm an et al., 1999a and 1999b; M esri e t al., 2001; 
Tran et al., 2002; Asanum a et al., 2000; W all et al., 2003; Zhu et al., 2003; M cK ay et al.,
2003) induced spontaneous and/or chem otherapy-induced apoptosis in various cancer cell 
lines, and/or elim inated drug resistance. Based on these prom ising results, Isis 
Pharm aceuticals and A bbott Laboratories have launched the developm ent o f  antisense- 
based strategies that target the expression o f  survivin (Los etal.,  2003).
Strategies to inhibit survivin expression by anti-sense oligonucleotides o r ribozym e may 
em erge as a new  gene therapeutic treatm ent option in a variety o f  tum our types. This may 
result in the enhancem ent o f  the sensitivity profile o f  radiation-refractory hum an 
m alignancies (Pennati et al., 2003).
Understanding the m echanism s o f  survivin function could, potentially, lead to the 
developm ent o f therapeutic strategies for cancer and other diseases.
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1.7 Aims o f Thesis
Cell death via apoptosis may be induced in tum ours follow ing exposure to toxic agents 
such as chem otherapeutic drugs. Cells which develop resistance to  chem otherapeutic drugs 
do not undergo apoptosis at the sam e rate as non-resistant cells, indicating that apoptosis 
may be inhibited in these cells. The first aim  o f  this thesis was to  use these M D R  variants 
to  identify the roles (if any) played by the anti-apoptotic genes galectin-3 and survivin in 
m ultiple drug resistance and in vitro invasiveness.
Previous studies have shown that galectin-3 induces in vitro invasiveness and inhibits 
apoptosis induced by cisplatin in the breast cancer cell line, BT549, and blocks 
staurosporin-induced apoptosis in hum an leukem ia T-cells. Studies have also dem onstrated 
that survivin up-regulation protects cancer cells from  apoptosis induced by cisplatin and 
taxol in endothelial cells (section 1.5.2). To further exam ine the role o f  these two genes in 
drug resistance and invasion/m etastasis, cDN A transfections o f  galectin-3 into the drug 
sensitive lung cancer, DLKP, and survivin into the drug sensitive lung, ovarian and breast 
cancer cell lines, DLKP, SKOV-3 and M CF-7, respectively, w ere carried out. SKOV-3 and 
M CF-7 cell lines have previously been transfected with an inducible vector (T et Off), 
which allows regulation o f gene expression. It was hoped that over-expression o f  these 
genes (galectin-3 and survivin) follow ed by analysis o f  the transfected cell lines using RT- 
P C R  western blotting, in-vitro toxicity testing and in vitro invasion experim ents, would 
elucidate the roles played by these genes in drug sensitivity and invasiveness.
A  third aim  o f  this thesis was to establish drug resistant variants o f  D LK P and RPM I-2650 
cell lines. The purpose o f  carrying out this procedure was two-fold. Firstly, it w ould allow  
us to analyse the expression o f  galectin-3 and survivin, as w ell as the established m ulti­
drug resistance-related genes (M dr-1, MRP1 and BCRP), in these sub-lines, allowing 
further insight into the roles they play in drug resistance. Secondly, these studies w ould 
contribute to an understanding as to w hether the developm ent o f  drug resistance 
consistently induces an invasive phenotype in cancer cell lines or if  th is correlation is cell- 
type or drug-specific. In addition, this research aim ed to use the recently established
6 2
technique of DNA microarray analysis to analyse gene expression in the DLKP MDR 
variants and to possibly identify novel MDR-related and invasion-related genes for future 
studies.
The final aim of this thesis was to use RT-PCR technique to analyse the gene expression of 
galectin-3, survivin and MRP-1 in a panel of invasive breast tumour biopsies and to 
correlate the results with clinicopathological parameters, in an attempt to investigate 
whether any of these genes may serve as prognostic or predictive indicators in breast cancer 
disease.
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Materials and Methods
2.1 Preparation for cell culture
2.1.1 Water
Ultrapure water was used in the preparation of all media and lx  solutions. Pre-treatment, 
involving initial activated carbon, pre-filtration and anti-scaling. The water was then 
purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP). This 
system is designed to produce purified water from a suitable municipal water supply, 
utilising a semi-permeable reverse osmosis membrane to remove contaminants from the 
feed water. This results in water which is low in organic salts, organic matter, colloids and 
bacteria with a standard of 12-18 MQ/cm resistance.
2.1.2 Glassware
Solutions pertaining to cell culture and maintenance were prepared and stored in sterile 
glass bottles. Bottles (and lids) and all other glassware used for any cell-related work were 
prepared as follows; all glassware and lids were soaked in a 2% (v/v) solution of RBS-25 
(AGB Scientific) for at least 1 hour. This is a deproteinising agent which removes 
proteineous material from the bottles. Following scrubbing and several rinses in tap water, 
the bottles were washed twice by machine (Miele G7783 washer/disinfecter) using 
Neodisher GK detergent and sterilised by autoclaving. Waste bottles containing spent 
medium from cells were autoclaved, rinsed in tap water and treated as above.
2.1.3 Sterilisation
Water, glassware and all thermostable solutions were sterilised by autoclaving at 121 °C for 
20 min under 15 p.s.i. pressure. Thermolabile solutions were filtered through a 0.22jj,m 
sterile filter (Millipore, millex-gv, SLGV-025BS). Low protein-binding filters were used 
for all protein-containing solutions. Acrodisc 0.8/0.2|j,m filters were used for non­
serum/protein solutions.
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2.1.4 M edia Preparation
The basal media used during routine cell culture were prepared, by Mr. Joe Carey, 
according to the formulations shown in Table 2.1.1. lOx media were added to sterile 
ultrapure water, buffered with HEPES (Sigma, H-9136) and NaHCCh (BDH, 30151) and 
adjusted to a pH of 7.45 - 7.55 using sterile 1.5M NaOH and 1.5M HC1. The media were 
filtered through sterile 0.22 fim bell filters (Gelman, 121-58) and stored in 500ml sterile 
bottles at 4°C. Sterility checks were carried out on each 500ml bottle of medium as 
described in Section 2.2.8.
The basal media were stored at 4°C up to their expiry dates as specified on each individual 
lOx medium container. Prior to use, 100ml aliquots of basal media were supplemented with 
2mM L-glutamine (Gibco, 25030-024) and 5 or 10% foetal calf serum and this was used as 
routine culture medium. This was stored for up to 2 weeks at 4°C.
Table 2.1.1 Preparation of basal media
DMEM (Dulbecco’s 
Modified Eagle 
Medium)
(mis)
(Sigma, D-5648)
Hams FI 2 
(mis)
(Sigma, N-6760)
MEM (Modified 
Eagle Medium) 
(mis)
(Gibco, 21430- 
020)
10X Medium Powder Powder 500
Ultrapure H20  (UHP) 4300 4700 4300
1M HEPES* 100 100 100
7.5% NaHC03 45 45 45
The weight equivalent o f 1M N-(2-Hydroxyethyl) piperazine-N’-(2-ethanesulfonic acid) (HEPES) was 
dissolved in an 80% volume o f ultra-pure water and autoclaved. The pH was adjusted to 7.5 with 5M NaOH.
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2.2 Routine m anagem ent o f cell lines
2.2.1 Safety Precautions
All routine cell culture work was carried out in a class II down-flow re-circulating laminar 
flow cabinet (Nuaire Biological Cabinet). Any work which involved toxic compounds was 
carried out in a cytoguard (Gelman). Strict aseptic techniques were adhered to at all times. 
Both laminar flow cabinets and cytoguards were swabbed with 70% industrial methylated 
spirits (IMS) before and after use, as were all items used in the experiment. Each cell line 
was assigned specific media and waste bottles and only one cell line was worked with at a 
time in the cabinet, which was allowed to clear for 15min between different cell lines. The 
cabinet itself was cleaned each week with industrial detergents (Virkon, Antec. 
International; TEGO, T.H.Goldschmidt Ltd.), as were the incubators. A separate laboratory 
coat was kept for aseptic work and gloves were worn at all times during cell work.
2.2.2 Cell Lines
The cell lines used during the course of this study, their sources and their basal media
. . .  2requirements are listed in Table 2.2.1. Cell lines were maintained in 25cm flasks (Costar, 
3050), 75cm2 flasks (Costar, 3075) or 175cm2 flasks (Nulge Nunc, 156502) at 37°C and fed 
every two to three days.
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Table 2.2.1 Cell Lines used in this work
Cell Line Source of 
Cell Line
Media Cell Type
DLKP NCTCC ATCC*
(5% FCS, 1% L-glut)
Poorly differentiated 
human lung squamous 
carcinoma
RPMI-2650 ATCCV MEM
(10% FCS, 1% L-glut, 1% 
NEAA, l%Sodium pyruvate)
Human nasal 
squamous carcinoma 
cell line
SKOV3 ‘Tet ofP ATCCV ATCC*
(10% FCS, l%L-glut)
Human ovarian 
carcinoma
MCF-7 ‘Tet off5 ATCCV ATCC*
(10% FCS, 1% L-glut)
Human breast 
carinoma
ATCC* = Basal media consists of a 1:1 mixture of DMEM and Hams F12.
ATCC'1' = American Tissue Culture Collection.
NCTCC = National Cell and Tissue Culture Centre.
L-glut = L-glutamine
NEAA = Non-essential amino acids
2.2.3 Subculture of Adherent Lines
During routine subculturing or harvesting of adherent lines, cells were removed from their 
flasks by enzymatic detachment.
Cell culture flasks were emptied of waste medium and rinsed with a pre-warmed (37°C) 
trypsin/EDTA (Trypsin Versene - TV) solution (0.25% trypsin (Gibco, 25090-028), 0.01% 
EDTA (Sigma, E-5134) solution in PBS (Oxoid, BR14a)). The purpose of this was to 
inhibit any naturally occurring trypsin inhibitor which would be present in residual serum. 
Fresh TV was then placed on the cells (4ml/25cm2 flask, 7ml/75cm2 flask or 10ml/175 cm2 
flask) and the flasks incubated at 37°C until the cells were seen to have detached (5-10 
min). The flasks were struck once, roughly, to ensure total cell detachment. The trypsin was
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deactivated by addition of an equal volume of growth medium. The entire solution was 
transferred to a 20ml sterile universal tube (Greiner, 201151) and centrifuged at 1,200 rpm 
for 3 min. The resulting cell pellet was resuspended in pre-warmed (37°C) fresh growth 
medium, counted (Section 2.2.5) and used to re-seed a flask at the required cell density or 
to set up an assay.
2.2.4 Cell Counting
Cell counting and viability determinations were carried out using a trypan blue (Gibco, 
15250-012) dye exclusion technique.
1. An aliquot of trypan blue was added to a sample from a single cell suspension in a 
ratio of 1:5.
2. After 3 min incubation at room temperature, a sample of this mixture was applied to 
the chamber of a haemocytometer, over which a glass coverslip had been placed.
3. Cells in the 16 squares of the four outer comer grids of the chamber were counted 
microscopically. An average number per comer was calculated with the dilution 
factor being taken into account and final cell numbers were multiplied by 10 4 to 
determine the number of cells per ml. The volume occupied by a sample in chamber 
is 0 .1 cm x 0 .1 cm x 0 .0 1cm i.e. 0 .0 0 0 1cm3 (therefore cell number x 10 4 is equivalent 
to cells per ml). Non-viable cells were those which stained blue while viable cells 
excluded the trypan blue dye and remained unstained.
2.2.5 Cell Freezing
To allow long term storage of cell stocks, cells were frozen and cryo-preserved in liquid 
nitrogen at temperatures below -180°C. Once frozen properly, such stocks should last 
indefinitely.
1. Cells to be frozen were harvested in the log phase of growth (i.e. actively growing 
and approximately 50 - 70% confluent) and counted as described in Sections 2.2.4.
2. Pelleted cells were re-suspended in serum and an equal volume of a DMSO/serum 
(1:9, v/v) (Sigma, D-5879). This solution was slowly added dropwise to the cell 
suspension to give a final concentration of at least 5xl06 cells/ml. This step was
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very important, as DMSO is toxic to cells. When added slowly, the cells had a 
period of time to adapt to the presence of the DMSO, otherwise cells may have 
lysed.
3. The suspension was aliquoted into cryovials (Greiner, 122 278) which were quickly
placed in the vapour phase of liquid nitrogen containers (approximately -80°C). 
After 2.5 to 3.5 hours, the cryo vials were lowered down into the liquid nitrogen 
where they were stored until required.
2.2.6 Cell Thawing
1. Immediately prior to the removal of a cryovial from the liquid nitrogen stores for 
thawing, a sterile universal tube containing growth medium was prepared for the 
rapid transfer and dilution of thawed cells, to reduce their exposure time to the 
DMSO freezing solution which is toxic at room temperature.
2. The cryovial was removed and thawed quickly under warm running water.
3. When almost fully thawed, the DMSO-cell suspension was quickly transferred to 
the media-containing universal.
4. The suspension was centrifuged at 1,200 rpm. for 3 min, the DMSO-containing 
supernatant removed, and the pellet re-suspended in fresh growth medium.
5. A viability count was carried out (Section 2.2.4) to determine the efficiency of the 
freezing/thawing procedures.
6. Thawed cells were then placed into 25cm2 tissue culture flasks with 7mls of the 
appropriate medium and allowed to attach overnight.
7. After 24 hours, the cells were re-fed with fresh medium to remove any residual 
traces of DMSO.
2.2.7 Sterility Checks
Sterility checks were routinely carried out on all media, supplements and trypsin used for
cell culture. Samples of basal media were inoculated either into TSB (Oxoid CM129)
(incubated at 20-25°C) or thioglycollate broth (Oxoid, CM173) (and incubated at 30-35°C).
Both sets were incubated at their specific temperature for up to 2 weeks checking for
turbidity and sedimentation. TSB supports the growth of yeasts, moulds and aerobes, while
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thioglycollate supports the growth of anaerobes and aerobes. Growth media were sterility 
checked at least 2 days prior to use by incubating samples at 37°C and assessing as before.
2.2.8 Mycoplasma Analysis
Mycoplasma examinations were carried out routinely (at least every 3 months), by Mr. 
Michael Henry and Ms. Aine Adams, on all cell lines used in this study.
2.2.8.1 Indirect Staining Procedure
In this procedure, Mycoplasma-negative NRK cells (a normal rat kidney fibroblast line) 
were used as indicator cells. These cells were incubated with supernatant from test cell 
lines and examined for Mycoplasma contamination. NRK cells were used for this 
procedure because cell integrity is well maintained during fixation. A fluorescent Hoechst 
33258 stain (BDH) was utilised which binds specifically to DNA and so will stain the 
nucleus of the cell in addition to any Mycoplasma DNA present. A Mycoplasma infection 
would thus be seen as small fluorescent bodies in the cytoplasm of the NRK cells and 
sometimes outside the cells.
1. NRK cells were seeded onto sterile coverslips in sterile Petri dishes (Greiner, 
633185) at a cell density of 2x103 cells per ml and allowed to attach overnight at 
37°C in a 5% CO2 humidified incubator.
2. 1ml of cell-free (cleared by centrifugation at 1,200 rpm for 3 min) supernatant from 
each test cell line was inoculated onto an NRK Petri dish and incubated as before 
until the cells reached 20 - 50% confluency (4 -5  days).
3. After this time, the waste medium was removed from the Petri dishes, the coverslips 
washed twice with sterile PBS, once with a cold PBS/Camoys (50/50) solution and 
fixed with 2ml of Camoys solution (acetic acid:methanol-l:3) for 10 mins.
4. The fixative was removed and after air drying, the coverslips were washed twice in 
deionised water and stained with 2 mis of Hoechst 33258 stain (BDH) (50ng/ml) for 
10  mins.
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From this point on, work proceeded in the dark to limit quenching of the fluorescent stain.
1. The coverslips were rinsed three times in PBS.
2. They were then mounted in 50% (v/v) glycerol in 0.05M citric acid and 0.1M
disodium phosphate.
3. Examination was carried out using a fluorescent microscope with a UV filter.
Prior to removing a sample for Mycoplasma analysis, cells should be passaged a min. of 3 
times after thawing to facilitate the detection of low level infection.
• Cells should be subcultured for 3 passages in antibiotic free medium (as antibiotics may 
mask the levels of infection).
• Cell lines routinely cultured in the presence of drugs should be sub-cultured at least once 
in drug free medium before analysis (some drugs such as adriamycin lead to background 
level of autofluorescence).
• Optimum conditions for harvesting supernatant for analysis occur when the culture is in 
log-phase near confluency and the medium has not been renewed in 2-3 days.
2.2.8.2 Direct Staining
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an enriched Mycoplasma culture broth (Oxoid, CM403) - supplemented 
with 20% serum, 10% yeast extract (Oxoid L21, 15% w/v) and 10% stock solution (12.5g 
D-glucose, 2.5g L-arginine and 250mls sterile-filtered UHP). This medium optimised 
growth of any contaminants and incubated at 37°C for 48 hours. Sample of this broth were 
streaked onto plates of Mycoplasma agar base (Oxoid, CM401) which had also been 
supplemented as above and the plates were incubated for 3 weeks at 37°C in a CO2 
environment. The plates were viewed microscopically at least every 7 days and the 
appearance of small, “fried egg” -shaped colonies were indicative of a Mycoplasma 
infection.
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2.3 Specialised techniques in cell culture
2.3.1 Miniaturised in vitro toxicity assays
2.3.1.1 In vitro toxicity assay experimental procedure
Due to the nature of the compounds tested in the assays, precautions were taken to limit the 
risks involved in their handling and disposal. All work involving toxic compounds was 
carried out in a Gelman “Cytoguard” laminar air flow cabinet (CG Series). All 
chemotherapeutic drugs used by this researcher were stored and disposed of as described in 
Table 2.3.1.
1. Cells in the exponential phase of growth were harvested by trypsinisation as described 
in Section 2.2.3.
2. Cell suspensions containing lxlO4 cells/ml (or 2xl04 cells/ml for RPMI-2650) were 
prepared in cell culture medium. Volumes of 100 |j,ls o f these cell suspensions were 
added in to 96 well plates (Costar, 3599) using a multichannel pipette. The plates were 
divided so that each variable was set up with 8 repeats and 12 variables per plate. A 
control lane, on to which no drug would be added, was included on all plates. Plates 
were agitated gently in order to ensure even dispersion of cells over a given well. Cells 
were incubated overnight at 37°C in an atmosphere containing 5% CO2.
3. Cytotoxic drug dilutions were prepared at twice their final concentration (for 
concentrations see Appendix B) in cell culture medium and 100 jal volumes of the drug 
dilutions were added to each well using a multichannel pipette. Plates were mixed 
gently as above.
4. Cells were incubated for 5-7 days at 37°C and 5% C 02. At this point the control wells 
would have reached approximately 80% confluency.
5. Assessment of cell survival in the presence of drug was determined by acid phosphatase 
assay (Section 2.3.1.2). The concentration of drug which caused 50% cell kill (IC50 of 
the drug) was determined from a plot of the % survival (relative to the control cells) 
versus cytotoxic drug concentration.
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Table 2.3.1 Chemotherapeutic drugs used in study
Cytotoxic drug Storage Disposal
Adriamycin Store at 4°C in darkness Incineration
Vincristine Store at 4°C in darkness Incineration
5-Fluorouracil Store at RT in darkness Incineration
Carboplatin Store at RT in darkness Incineration
Cisplatin Store at RT in darkness Incineration
Taxol Store at RT in darkness Incineration
Taxotere Store at RT in darkness Incineration
CCNU Store at RT in darkness Incineration
Epirubicin Store at 4°C in darkness Incineration
2.3.1.2 Assessment of cell number - Acid Phosphatase assay
1. Following the incubation period of 6 days, media was removed from the plates.
2. Each well on the plate was washed twice with 100 (ils PBS. This was removed and 
100 (j,ls of freshly prepared phosphatase substrate (lOmM p-nitrophenol phosphate 
(Sigma 104-0) in 0.1M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 
30632), pH 5.5) was added to each well. The plates were wrapped in aluminium foil 
and incubated in the dark at 37°C for 2 hours.
3. The enzymatic reaction was stopped by the addition of 50 |j,ls of 1M NaOH to each 
well.
4. The plate was read in a dual beam plate reader at 405 nm with a reference 
wavelength of 620 nm.
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2.3.2 Detection o f Apoptosis
2.3.2.1 TUNEL analysis
DNA strand breaks were identified using In Situ Cell Death Detection Kit with a
fluorescein tag (Roche, 1684817). Drug-treated cells or untreated (control) cells were 
trypsinised at the desired times points into single cell suspension, and washed twice with 
sterile PBS. Cytospins were prepared on a glass slide using a lOOul aliquot of cell 
suspension of 5xl04cells/ml. After fixing in 4% formaldehyde, the slides were washed and 
immersed in 0.1% sodium acetate (Sigma, S8625), 0.1% Triton X-100 (BDH, 30632) 
solution to permeabilise the cells. The slides were washed again and TUNEL mixture was 
added to each sample, following manufacturer’s instructions. The glass slides were 
incubated at 37°C in the dark for 1 hour, after which time, they were then mounted using 
fluorescence mounting medium (Dako, S3023) and covered with coverslips (Chance 
Propper, 22 x 22 mm). Fluorescent staining was visualised using a fluorescence microscope 
(Nikon).
2.3.3 Adaptation of Drug-selected Variants
In this study, two cell lines, DLKP and RPMI-2650, were selected with various 
chemotherapeutic drugs and a number of MDR variants were developed. This was achieved 
by pulse selection.
2.3.3.1 Pulse selection
Cells were grown to 50-60% confluency in 75cm2 flasks. In the case of RPMI-2650 
selection, flasks were set up in duplicate for each selection agent. Cells were exposed to an 
initial drug concentration which was equivalent to approx. 90% kill for cells in 96-well 
plate miniature toxicity assay (see section 2.3.1). The cells were exposed to the drug for 4 
hours, after which time the drug was removed and the cells were rinsed with fresh media. 
The cells were then grown in drug-free media at 37°C for 6 days. Cells were re-fed once 
during those 6 days. Drug concentration was gradually increased when the cells appeared
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healthy. Cells were trpysinised as normal when they reached 70% confluent as outlined in 
section 2.2.3. Drug exposure was repeated for approx. 10 pulses (in the case of RPMI- 
2650, some cells received 12 or 14 pulses). After this time, sensitivity to the selecting drug 
was monitored using miniaturized toxicity assay (section 2.3.1).
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2.4 A nalytical Techniques
2.4.1 Western Blot analysis
2.4.1.1 Sample preparation
Cells were grown in flasks until they reached 80-90% confluency. They were then 
trypsinised and centrifuged at 1,200 rpm for 5 min. The pellet was washed in PBS and re­
pelleted (twice). The tube was inverted and drained of supernatant. Further treatment of the 
cell pellet, to isolate protein, was carried out either on the same day or the pellet was stored at 
-80°C until required.
One protease inhibitor tablet from Complete™ Protease Inhibitor (Boehringer Mannheim, 1 
697 498) was added to 2 mis UHP. This was then diluted 1/25 and 200-500 jals of this diluted 
solution was added to the pellet, depending on the size of the pellet. The mix was sonicated 
in a Labsonic U (Braun) 2-3 times at a repeating duty cycle of 0.5s, while checking under a 
microscope to ensure all the cells had been lysed. Before loading on to an SDS-PAGE gel, 2 
fils of the sonicated sample was removed and diluted to 8 (j,ls with UHP for protein 
quantification. Sonicated cell extracts were either used immediately in Western blots or were 
stored at -80°C.
2.4.1.2 Quantification of Protein
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad; 500-0006) with 
a series of bovine serum albumin (BSA) (Sigma, A9543) solutions as standards. A stock 
solution of 25 mg/ml BSA was used to prepare a standard curve. 10 jil samples were diluted 
into Eppendorfs, in a stepwise fashion, from 0 - 2  mg/ml BSA. The Biorad solution was first 
filtered through 3MM filter paper (Schleicher and Schuell, 311647) and then diluted 1/5 with 
UHP, as it was supplied as a 5-fold concentrate. The diluted dye reagent (490 fils) was added 
to each standard and sample Eppendorf and the mixtures vortexed. The 500 (Ltls samples were 
diluted in 100 (j,l aliquots onto a 96-well plate (Costar, 3599). After a period of 5 min to lh,
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the OD570 was measured, against a reagent blank. From the plot of the OD570 of BSA 
standards versus their concentrations, the concentration of protein in the test samples was 
determined. From this, a relative volume for each protein sample was determined for loading 
onto the gels. Usually 10-50 jag protein per lane was loaded.
2.4.1.3 Gel electrophoresis
Proteins for western blot analysis were separated by SDS-polyacylamide gel 
electrophoresis (SDS-PAGE). Resolving and stacking gels were prepared as outlined in 
Table 2.4.1 and poured into clean 10cm x 8cm gel cassettes which consisted of 1 glass and 
1 aluminium plate, separated by 0.75cm plastic spacers. The plates were cleaned by first 
rinsing in RBS, followed by tap water and finally UHP. After drying, the plates were wiped 
down in one direction using tissue paper soaked in 70% Industrial Methylated Spirits 
(IMS). The spacers and comb used were also cleaned in this way. After these had dried, the 
resolving gel was poured first and allowed to set for 1 hour at room temperature. The 
stacking gel was then poured and a comb was placed into the stacking gel in order to create 
wells for sample loading. Once set, the gels could be used immediately or wrapped in 
aluminium foil and stored at 4°C for 24 hours.
IX running buffer (14.4g Glycine, 3.03g Tris and lg  SDS in 1L) was added to the running 
apparatus before samples were loaded. The samples were loaded onto the stacking gels, in 
equal amounts relative to the protein concentration of the sample. The loading buffer (New 
England Biolabs, 7709) was prepared by adding 1/10 volume 30X reducing agent to 1 
volume 3X loading buffer, and this mix was added at V2 volume to each of the test samples. 
The samples, including 5|als of molecular weight broad weight protein markers (New 
England Biolabs, 7708S), were boiled for 5 minutes before being loaded. The gels were run 
at 250V, 45mA for approximately 1 hour. When the bromophenol red dye front was seen to 
have reached the end of the gels, electrophoresis was stopped.
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Table 2.4.1 Preparation o f electrophoresis gels
Components Resolving gel 
(7.5%)
Resolving gel 
(15%)
Stacking gel
Acrylamide stock* 3.8 mis 7.6 mis 0.8 mis
Ultrapure water 7.3 mis 5.3 mis 3.9 mis
1.875M-Tris/HCl, pH 8.8 3.75 mis 1.88 mis -
1.25M-Tris/HCl, pH 6.8 - - 0.31 mis
10% SDS (Sigma, L-4509) 150 |ils 150 |ils 50 |ils
10% Ammonium 
persulphate 
(Sigma, A-1433)
60 |ils 60 |ils 17 fils
TEMED 
(Sigma, T-8133)
10  |ils 10  |ils 5 |ils
* Acrylamide stock solution consists o f 29.lg  acrylamide (Sigma, A8887) and 0.9g N N ’-methylene bis- 
acrylamide (Sigma, 7256) dissolved in 60ml UHP water and made up to 100ml final volume. The solution was 
stored in the dark at 4°C for up to 1 month. All components were purchased from Sigma, SDS (L-4509), NH4- 
persulphate (A-1433) and TEMED, N,N,N,N’-tetramethylethylenediamine (T-8133).
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2.4.1.4 W estern blotting
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer (25mM 
Tris (Sigma T-8524), 192mM glycine (Sigma, G-7126) pH 8 .3-8.5 without adjusting) for 
10 min. Proteins were transferred from gels onto PVDF membranes (Boehringer 
Mannheim, 1722026), by semi-dry electroblotting. Eight sheets of Whatman 3mm filter 
paper (Whatman, 1001824) were soaked in transfer buffer and placed on the cathode plate 
of a semi-dry blotting apparatus (Biorad). Excess air was removed from between the filters 
by rolling a universal tube over the filter paper. A piece of PVDF membrane, cut to the 
same size of the gel, was prepared for transfer (soaked for 30 secs, in methanol, 2 mins. in 
UHP, and finally 5 mins. in transfer buffer) and placed over the filter paper, making sure 
there were no air bubbles. The acrylamide gel was placed over the PVDF membrane and 
eight more sheets of pre-soaked filter paper were placed on top of the gel. Excess air was 
again removed by rolling the universal tube over the filter paper. The proteins were 
transferred from the gel to the nitrocellulose at a current of 34mA at 15V for 24-25 mins.
All incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus (Bellydancer, Stovall) to ensure even exposure of the blot to all 
reagents. The PVDF membranes were blocked for 2 hours at room temperature with fresh 
filtered 5% non-fat dried milk (Cadburys, Marvel skimmed milk) in Tris-buffered saline 
(TBS) with 0.5% Tween (Sigma, P-1379), pH 7.5. After blocking, the membranes were 
rinsed once in IX TBS and incubated with 10 mis diluted primary antibody (see Table 
2.4.2). Bound antibody was detected using enhanced chemiluminescence (ECL).
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Table 2.4.2 Antibodies used for different proteins
l°Antibody Supplier Dilution 2° Antibody Dilution
Galectin-3 Gift from Dr. Fu-Tong Liu 1:10 0 0 Anti-Rabbit HRP 1:10 0 0
Survivin Alpha Diagnostics 
SURV11A
1:500 Anti-Rabbit HRP 1:2000
P-gP
(C219)
Alexis 801-002-C100 1:10 0 0 Anti-mouse HRP 1:10 0 0
MRP-1
(MRPrl)
Alexis 801-007-C125 1:50 Anti-mouse HRP 1:10 0 0
MRP-2
(M2III-6)
Alexis 801-016-C250 1:50 Anti-mouse HRP 1:10 0 0
E-cadherin R&D BTA1 1:20 0 Anti-mouse HRP 1:10 0 0
a-Tubulin Sigma T5168 1:2000 Anti-mouse HRP 1:10 0 0
2.4.1.5 Enhanced chemiluminescence detection
Protein bands were developed using the Enhanced Chemiluminescence Kit (ECL) 
(Amersham, RPN2109) according to the manufacturer’s instructions. The membrane blot 
was removed to a darkroom for all subsequent manipulations. A sheet of parafilm was 
flattened over a smooth surface, e.g. a glass plate, making sure all air bubbles were 
removed. The membrane was placed on the parafilm, and excess fluid removed. 1.5mls of 
ECL detection reagent 1 and 1.5mls of reagent 2 were mixed and covered over the 
membrane. Charges on the parafilm ensured the fluid stayed on the membrane. The reagent 
was removed after one minute and the membrane was wrapped in cling film. The 
membrane was exposed to autoradiographic film (Boehringer Mannheim, 1666916) in an 
autoradiographic cassette for various times, depending on the signal intensity (30s -  5 
mins.). The autoradiographic film was then developed. The exposed film was developed for 
5min in developer (Kodak, LX24, diluted 1:6.5 in water). The film was briefly immersed in 
water and was then fixed (Kodak, FX-40, diluted 1:5 in water), for 5min. The film was 
transferred to water for 5 min and then air-dried. For details o f densitometric analysis see 
section 2 .4.3.7.
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2.4.2 Im m unocytochemistry
The avidin-biotin complex (ABC) immunoperoxidase technique combined with the 
diaminobenzidine (DAB) visualisation procedure was used in all immunocytochemistry 
experiments. The ABC method involves application of a relevant biotin-labelled secondary 
antibody to cells probed with a primary antibody, followed by the addition of avidin-biotin- 
peroxidase complex, which results in a high staining intensity due to the formation of an 
avidin-biotin lattice which contains peroxidase molecules. The peroxidase enzyme then 
reacts with a DAB solution to give an insoluble, brown-coloured precipitate. The formation 
of this brown-coloured precipitate is indicative of primary antibody reactivity.
The procedure used is as follows:
Cell preparations on 6-well tissue culture plates (which had been previously fixed in 
methanol and frozen at -20°C) were allowed to thaw and equilibrate at room temperature. A 
grease pen (DAKO, S2002) was used to encircle cells in the tissue culture plates, to contain 
the various solutions involved. The cells were incubated for 5 minutes with a 3% H2O2 
solution, to quench any endogenous peroxidase activity that may be present in the cells and 
that could lead to false positive results. The cells were then rinsed with UHP and placed in 
TBS for 5 minutes. The plates were then incubated for 20 minutes at room temperature 
(RT) with an appropriate serum diluted 1:5 in TBS to block non-specific binding. This was 
removed and 30-50|,il of optimally diluted primary antibody added. The slides and tissue- 
culture plates were placed on a tray containing moistened tissue paper and incubated at 
37°C for 2 hours. The primary antibodies used in the study are listed in Table 2.4.2. The 
wells were then rinsed in TBS/ 0.1% Tween, x3 for 5 min each, and then incubated for 30 
min with a biotinylated secondary antibody diluted in TBS. The wells were rinsed as before 
and incubated with strepABComplex/ Horse Radish Peroxidase (HRP) (DAKO, K377) for 
30 min at RT, after which they were rinsed x3 in TBS/ 0.1% Tween. The cells were then 
incubated with a DAB solution (DAKO, S3000) for 7-10 min. Excess DAB solution was 
then rinsed off with UHP water. The wells were then mounted using a commercial 
mounting solution (DAKO, S3023).
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2.4.2.1 Immunofluorescence
Frozen 6 well sample plates were removed from the -20°C freezer and allowed to come to 
room temperature (~10 minutes). Grease circles (DAKO pen, DAKO Cat S2002) were then 
drawn within the wells (to contain the solutions used in the subsequent analysis). The cells 
were re-hydrated using IX TBS for 5 minutes. This was tapped off and the relevant serum 
(diluted 1/5) was added as a ‘blocker’ for 20 minutes at room temperature. The serum was 
removed at this point and the primary antibody was applied (antibodies and dilutions are 
listed in Table 2.4.2). This was incubated overnight at 4°C in a moist environment. The 
following day the primary antibody was removed and the wells were washed three times in 
TBS-0.1% Tween at 5 minutes per wash. The fluorescent secondary antibodies were 
prepared in the dark room under dim conditions and were coated in foil upon dilution with 
TBS (they are light sensitive). The secondary antibodies (Table 2.4.2) were incubated for 
60 minutes and the plates were wrapped in foil to maintain dim conditions. All work from 
this point onwards was carried out in the dark to prevent ‘quenching’ fluorescent signal. 
After 60 minutes incubation the antibodies were removed and the plates were washed three 
times in TBS-0.1% tween. The wells were then mounted using fluorescence mounting 
medium (Dako, S3023) and covered with coverslips (Chance Propper, 22 x 22 mm). 
Fluorescent staining was visualised using a fluorescence microscope (Nikon) and the 
appropriate filters, i.e. for FITC labelled mouse IgG (Dako, F0261) the B2 filter was used.
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2.4.3 RNA Analysis
2.4.3.1 Preparation for RNA Analysis
Due to the labile nature of RNA and the high abundance of RNase enzymes in the 
environment, a number of precautionary steps were followed when analysing RNA 
throughout the course of these studies.
• All solutions (which could be autoclaved) that came into contact with RNA were all
prepared from sterile ultra-pure water and treated with 0.1 % diethyl pyrocarbonate
(DEPC) (Sigma, D5758) before autoclaving (autoclaving inactivates DEPC), with the
exception of Tris-containing solutions (DEPC reacts with amines and so is inactivated
by Tris). The Tris-containing solutions were made with DEPC-treated ultra-pure water.
• Disposable gloves were worn at all times to protect both the operator and the
experiment (hands are an abundant source of RNase enzymes). This prevented the 
introduction of RNases and foreign RNA/DNA into the reactions. Gloves were 
changed frequently.
2.4.3.2 RNA Isolation
Total RNA was extracted from cultured cell lines and plasmid-transfected cell lines, as well 
as drug-selected cell lines. The size of the flasks varied, but the method remained the same. 
Human tumour and normal specimens, included throughout the course of these studies, were 
also analysed using the technique outlined below.
A standard method of extracting RNA from cells was as follows: cells were seeded into 
175cm2 flasks (Nulge Nunc, 156502) at a density of approximately 2xl06 per flask and 
were allowed to attach and grow for 48-72 hours at 37°C. The cells were trypsinised and 
the pellet was washed once with PBS. The cells were pelleted and lysed using 1ml of TRI
TM
REAGENT (Sigma, T-9424). The following procedure is that outlined in the protocol for 
TRI REAGENT". The samples were allowed to stand for 5 mins. at room temperature to 
allow complete dissociation of nucleoprotein complexes. 0.2 mis of chloroform was added 
per ml of TRI REAGENT used and the sample was shaken vigorously for 15 sec and
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allowed to stand for 15 min at room temperature. The sample was centrifuged at 13000rpm 
for 15 mins. at 4°C in a microfuge. This step separated the mixture into 3 phases with the 
RNA contained in the colourless upper aqueous layer. The DNA and protein fractions 
resulting from the total RNA isolation were retained, in case they were required at some 
future date. The aqueous layer was transferred to a new Eppendorf and 0.5 mis of 100% 
isopropanol was added per ml of TRI REAGENT™ originally used. The sample was mixed 
and allowed to stand at room temperature for 10-15 mins. before being centrifuged, again, 
at 13000rpm for 10 min at 4°C. The RNA formed a pellet at the bottom of the tube. The 
supernatant was removed and the pellet was washed with 1ml of 75% ethanol per ml of 
TRI REAGENT™ used and centrifuged at 4°C for 5 mins. at 13000rpm. The supernatant 
was removed and the pellet was allowed to air-dry for 10-15 mins. 20-30 (j.ls of DEPC 
water was added to the RNA to resuspend the pellet.
2.4.3.3 RNA Quantitation
RNA was quantified spectrophotometrically at 260nm using the following formula:
OD260nm x Dilution factor x 40 = ng/ml RNA
An A260/A280 ratio of 1.8-2 is indicative of pure RNA, although RNA with ratios from 1.7 —
2.1 were routinely observed and were used in subsequent experiments. Partially solubilised 
RNA has a ratio of <1.6 (Ausubel et al., 1991). The yield of RNA from most lines of cultured 
cells is 100-200|_ig/90mm plate (Sambrook et al., 1989). In these studies approximately 200 
(j.g RNA per 175cm2 flask was retrieved. RNA samples were diluted to 500 ng/|_il and stored 
at -80°C.
2.4.3.4 Micropipette Accuracy Tests
Accuracy and precision tests were carried out routinely on all micropipettes used in all steps 
of the RT-PCR reactions. The accuracy and precision of the pipettes was determined by 
standard methods involving repeatedly pipetting specific volumes of water and weighing 
them on an analytical balance. The specifications for these tests were supplied by Gilson.
84
2.4.3.5 Reverse-Transcription Polymerase Chain Reaction (RT-PCR) analysis of
isolated RNA
2.4.3.5.1 Reverse Transcription of isolated RNA
Reverse transcriptase (RT) reactions were set up on ice using micropipettes, which were 
specifically allocated to this work.
To form the cDNA, the following reagents were mixed in a 0.5ml Eppendorf tube 
(Eppendorf, 0030 121 023), heated to 72°C for 5 min and then chilled on ice.
1 (xl oligo (dT) primers (ljig/fil)*
2|il total RNA (500ng/(jl)
2 (0.1 DEPC water
After chilling on ice, the following reagents were added:
*Exception: For survivin RT reaction, specific reverse transcript primers were used (see 
appendix A).
4|il of a 5X buffer (lOOmM-Tris/HCl, pH 9.0, 50mM-KCl, 1% Triton X-100) (Sigma, 
B-0175)
2(il DTT (Sigma, D-6059)
1 |il dNTP (1 OmM of each dNTP) (Sigma, DNTP-100)
1 f-il Rnasin (40U/|il) (Sigma, R-2520)
1 |il MMLV-RT (40,000U/|il) (Sigma, M-1427)
6 |il DEPC UHP
The solutions were mixed and the RT reaction was carried out by incubating the 
Eppendorfs at 37°C for 1 hour. The MMLV-RT enzyme was then inactivated by heating to 
95°C for 2mins. The cDNA was stored at -20°C until required for use in PCR reactions as 
outlined in Section 2.4.3.5.2.
85
2.4.3.5.2 Polymerase Chain Reaction (PCR) am plification o f cDNA
The cDNA formed in the above reaction was used for subsequent analysis by PCR.
A standardised polymerase chain reaction (PCR) procedure was followed in this study. 
Standard 0.5ml Eppendorf tubes were used, as for the RT reactions. All reagents had been 
aliquoted and were stored at -20°C. A complete list of all PCR primers and reaction 
conditions are included in Appendix A.
A typical PCR reaction contained the following:
5|al lOx buffer (lOOmM-Tris/HCl, pH 9.0, 50mM-KCl, 1% Triton X-100) (Sigma, 
P-2317)
3|il 25mM-MgCl2 (Sigma,M-8787)
1 (4.1 each of first and second strand target primers1 (250ng/ml)
lp,l each of first and second strand endogenous control primer (250ng/ml) (P-actin)
lfil dNTPs (lOmM each of dATP, dCTP, dGTP and dTTP)
0.5(j,l 5U/(j,l Taq DNA polymerase enzyme (Sigma, D-4545)
31.5(0.1 UHP
5(il cDNA
The samples were mixed by pipetting two or three times. A typical reaction would be:
95 °C for 3 min - denaturation
30 cycles: 95°C for 30 sec. - denaturation
X2oC for 30 sec. - annealing
72°C for 30 sec. - extension
And finally,
72 °C for 7 min. - extension
1 All oligonucleotide primers used throughout the course o f this thesis were made to order on an “Applied 
BioSystems 394 DNA/RNA Synthesiser” by Oswel DNA service, Lab 5005, Medical and Biological Services 
building, University of Southampton, Boldrewood, Bassett Cresent East, Southampton, SO 16 7PX.
2 Temperature dependent on primer type. See Appendix A for specific details.
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Following amplification, the PCR products were stored at 4°C for analysis by gel 
electrophoresis.
2.4.3.6 Electrophoresis of PCR products
A 2% agarose gel (Sigma, A-9539) was prepared in IX TBE (10.8g Tris base, 5.5g Boric 
acid, 4 mis 0.5M EDTA, 996mls UHP) and melted in a microwave oven. After allowing to 
cool, 4 |ils of a lOmg/ml ethidium bromide solution was added per lOOmls of gel which 
was then poured into an electrophoresis apparatus (BioRad). Combs were placed in the gel 
to form wells and the gel was allowed to set.
4(j,l of 6X loading buffer loading buffer (50% glycerol, lmg/ml bromophenol blue, ImM 
EDTA) was added to 20jj,1 PCR product of each sample and this was run on the gel at 80- 
90mV for approximately 2 hours. When the dye front was seen to have migrated the 
required distance, the gel was removed from the apparatus and examined on a 
transilluminator and photographed.
2.4.3.7 Densitometric analysis
Densitometric analysis was carried out using the MS Windows 3.1 compatible Molecular 
Analyst software/PC image analysis software available for use on the 670 Imaging 
Densitometer (Bio-Rad. CA) Version 1.3. Developed negatives of gels were scanned using 
transmission light and the image transferred to the computer. The amount of light blocked 
by the DNA band is in direct proportion to the intensity of the DNA present. A standard 
area was selected and scanned and a value was calculated by the software for the Optical
Density (O.D.) of each individual pixel on the screen. The average value of this O.D.
• ■ 2 (withm a set area, usually 1cm ) was corrected for background of an identical set area. The
corrected reading, for a given amplified band of interest was then normlaised by dividing
with a normalised reading obtained from an endogenous control band (usually (3-actin). As
a result, these O.D. readings having arbitrary units.
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1. Breast tumour samples (both Tumour (T) and Normal (N)) were obtained from the 
pathology department under the supervision of Dr. Susan Kennedy, St. Vincent’s 
University hospital, Dublin.
2. These were archival tumour biopsies that were stored at -80°C until RNA isolation.
3. All manipulations of the human material was carried out inside a class II down-flow 
re-circulating laminar flow cabinet (Nuaire Biological Cabinet) to prevent 
contamination and to protect the operator. The floor of the cabinet was lined with 
two sheets of aluminium foil and then covered with two large plastic autoclavable 
sheets.
4. All implements (e.g. scissors, forceps, aluminium foil, test tubes, etc.) used in the 
RNA isolation were baked @ 200°C overnight prior to use.
5. The Tumour/Normal specimens was removed from their wrapping.
6 . The specimens were bisected using a sterile blade and forceps and approx. half the 
tissue was placed in a test tube with 2mls of Tri Reagent. This was then exposed to 
homogenisation using a Braun potter S886 homogeniser, for 5 minutes on ice, at 
medium speed.
7. After homogenisation, the cell homogenate was removed to two Eppendorfs. These 
were spun @ 1300 rpm for 2  mins., in a bench-top microcentrifuge, to remove large 
cellular debris.
8. The specimens then underwent the TRI REAGENT™ protocol for RNA isolation 
(Section 2.4.3.2).
2.4.3.8 Isolation o f RNA from Tum our/Norm al Specimens
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2.4.4 Plasmid DNA manipulation
2.4.4.1 Plasmids and oligonucleotides used
The galectin-3 cDNA was cloned into the pREB9 plasmid and was kindly donated by Dr. 
Fu-Tong Liu (The Scripps Research Institute, CA, USA). The survivin cDNA was cloned 
into the pTarget plasmid and kindly donated by Dr. Kevin Scanlon (Berlix Inc, CA). The 
survivin cDNA was also sub-cloned (by Cytomyx) into the pTRE plasmid for transfection 
into the inducible cell lines.
2.4.4.2 Transformation of Bacteria
lOOjil of competent JM109 bacterial cell suspension (Promega, L2001) was mixed with 
20ng DNA and placed on ice for 40min after which the mixture was heat-shocked at 42°C 
for 90sec and then placed on ice for 3min. 1ml of LB broth ((10g Tryptone (Oxoid, L42), 
5g Yeast Extract (Oxoid, L21) 5g NaCl (Merck, K1880814))/litre LB, autoclaved before 
use) was added to the competent cell suspension and incubated at 37°C for 40min. 400fj.l of 
this suspension was spread on a selecting agar plate (LB agar containing appropriate 
antibiotic conc.) and incubated overnight at 37°C. Single colonies, which grew on these 
selecting plates, were further streaked onto another selecting plate and allowed to grow 
overnight at 37°C.
2.4.4.3 DNA miniprep of plasmid DNA
This was carried out to generate material for subsequent restriction enzyme digestion, in 
order to determine the orientation of the inserted DNA sequence in the transformed 
plasmid.
1. Single colonies were selected off the plates and incubated in universals containing 5 
mis LB/Amp shaking at 180rpm at 37°C overnight. White colonies generally 
contain inserts, but inserts may also be present in blue colonies. For this reason, a
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number of white colonies, blue colonies and white-blue colonies (white colonies 
with a blue centre) were selected for incubation. The positive control reaction 
yielded all blue colonies, which were too numerous to count.
After 16-24 hours incubation, 1.5 mis of culture was removed from each of the 
incubated samples and spun down at 8500rpm in a microfuge. The supernatant was 
decanted and another 1.5 mis of culture was added and again spun down.
The samples were subjected to a plasmid miniprep, as outlined in the Stratagene 
Clearcut™ Miniprep kit (Stratagene, 400732). The cell preps were each 
resuspended in three 105 pis of Solution 1.
125 (0.1s of Solution 2 was added, and the eppendorf was mixed gently by inversion. 
125 |ils of Solution 3 was added, and the eppendorf was mixed gently by inversion. 
The eppendorf was then placed on ice for 5 mins.
The eppendorf tubes were then spun down in a microfuge at 8500rpm and the 
supernatants were carefully transferred to fresh tubes, leaving cell debris behind.
The kit-supplied DNA binding resin was mixed by vortexing until resuspended. 15 
jals of this resin was added to each collected supernatant. The tubes were then 
mixed by inversion.
The samples were loaded into kit-supplied spin cups. The cups were spun down in a 
microfuge at 13,000rpm for 30 secs., which retained the resin and plasmid DNA.
A kit-supplied wash buffer was prepared for each sample by diluting 200 pis of 2X 
wash buffer with 200 |j,ls of 100% (v/v) ethanol. 400 (ils of this wash buffer was 
added to the spin cup and the cups spun at 13,000rpm again for 30 secs. This step 
was repeated for all samples.
The spin cups were transferred to fresh eppendorfs. 50 |ils of UHP was loaded into 
each spin cup to elute the DNA and the samples spun down at 13,000rpm again for 
30 secs. The plasmid DNA was stored at -20°C in the eppendorfs.
2.4.4.4 Restriction enzyme digestion of plasm id D NA
5 |o,ls of each isolated plasmid sample was run out on a 1% agarose gel to check for 
degradation. Restriction digestion was then carried out to confirm orientation of the insert. 
All digestions were carried out using the protocol as outlined in Table 2.4.3. Digestion 
enzymes used and the size of the insert that was cut out are listed in Table 2.4.4. For 
plasmid map see Figures 2.4.1, 2.4.2 and 2.4.3. For gene cDNA sequence see Appendix A.
Table 2.4.3 Standard DNA digestion mix
Component Volume (pis)
DNA sample 10
undiluted enzyme 1
10X Multi-core reaction buffer (Promega, R9991) 1.5
UHP 2.5
Table 2.4.4 Digestion Enzmyes used and size of insert
Plasmid Enzyme Size
Survivin cDNA in pTarget EcoRl 550bp
Survivin cDNA in pTRE EcoRl 642bp
Galectin-3 cDNA in pREB9 EcoRl 427bp
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Figure 2.4.1 Schematic map of pTarget1 Vector, showing location of
enhancer/promoter (CMV), polyadenylation site (SV40 poly A), multiple cloning sites (T 
overhang), and ampicillin and neomycin-resistant genes (Ampr and Neo, respectively) 
(www.promega.com).
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Figure 2.4.2 Schematic map of pTRE Vector, showing the Tet-responsive
promoter ( /W ivm), the minimal CMV promoter (PmimCMv), the ampicillin-resistant gene 
(Amp1), the polyadenylation site (SV40 poly A), and multiple cloning sites (adapted from 
www.cIontech.com).
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Figure 2.4.3 Schematic map of pTK-Hyg Vector, showing the ampicillin-resistant
gene (Ampr), and the hygromycin resistant gene (Hygr) (adapted from www.clontech.com).
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Figure 2.4.4 Schematic map of pREP9 Vector, showing multiple cloning site
(bases 632-691), SV40 polyadenylation signal (SV 40 poly A), TK polyadenylation signal 
(TkpA), ampicillin resistance gene (Amp1), pUC origin: (PUC ori) and the EBNA-1 gene 
(adapted from www.invitrogen.com).
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2A.4.5 Large scale plasmid preparation
A single colony (Section 2.4.4.2) was inoculated into 10ml of LB containing Ampicillin at 
50 |ig/ml and was grown overnight; 2ml of this suspension (1% inoculum) was added to 
200ml of TB (2.4g Tryptone, 4.8g Yeast Extract, 0.8 mis Glycerol, 0.17M KH2PO4 and 
0.72M K2HPO4) with Ampicillin at 50fj,g/ml and left to grow overnight at 37°C for large 
scale isolation of plasmid from JM109 cells. The following day the cells were pelleted and 
lysed in 20ml of an ice-cold solution containing 50mM glucose, 25mM Tris-Cl, lOmM 
EDTA, pH8.0 and 5mg/ml lysozyme (Sigma, L6876) at room temperature, for 10-15min. 
40ml of a 0.2N NaOH and 1.0% SDS solution was gently mixed with the lysate until the 
suspension became clear. This was incubated on ice for lOmin. 30ml of 3M K+-Acetate, 
pH5.2, was added to the above and mixed gently until a flocculent precipitate appeared, at 
which stage the mixture was stored on ice for at least lOmin. The sample was centrifuged at 
35,000xg for lh at 4°C. The supernatant was then recovered and added to 0.6 volume of 
100% isopropanol, mixed gently and left at room temperature for 20-30min. The suspension 
was then centrifuged at 35,000xg for 30min at 20°C, after which the supernatant was 
discarded. The pellet was washed in ice-cold 70% ethanol and resuspended in 5ml of TE, 
pH8.0. To remove any contaminating RNA, the plasmid solution was treated with RNase 
Plus (5 Prime -» 3 Prime Inc.; 5-461036) (to a final dilution of 1:250) for 30min at 37°C, 
followed by phenol:chloroform:isoamyl alcohol extractions (25:24:1). 10M ammonium 
acetate was added to the aqueous phase to a final concentration of 2.0M. 0.6 volume of 100% 
isopropanol was added to the sample, mixed and stored at room temperature for 20-3 Omin. 
The sample was centrifuged at 13,000rpm and the DNA pellet was washed in 70% ethanol 
and resuspended in 3.6ml of lOmM Tris-Cl, ImM EDTA, and 1.0M NaCl, pH8.0. 1.8ml of 
this sample was loaded into one of two pZ523 columns (following the manufacturer’s 
instructions) and the column effluent was precipitated with 0.6 volume 100% isopropanol, as 
described previously. The DNA was pelleted at 13,000rpm in an epifuge, washed in 70% 
ethanol and resuspended in lxTris-EDTA, pH 8.0 (TE). The DNA concentration was 
determined by measuring the OD260nm-
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2.4.5 Transfection o f mammalian cells with exogenous DNA
2.4.5.1 Stable transfection of DNA using lipofectin reagent
On the day prior to transfection, the cells to be transfected were prepared as a single cell 
suspension and were seeded into 25cm2 flasks at 3xl05 cells per flask. On the day of the 
transfection, the plasmid(s) to be transfected were prepared along with the lipid transfection 
reagents, according to the manufacturers protocols (Lipofectin -  GibcoBRL, 18292-011). 
The cells were transfected for four hours in the absence of serum, after which the medium 
was replaced with serum-containing medium. Cells were incubated at 37°C.
2.4.5.2 Cloning Procedure
Examining the effect of transfection of cDNAs of interest (i.e. galectin-3 and survivin) 
involved the selection and establishment of stably-transfected clonal cell lines, where RNA, 
protein and drug profiles were only assayed when the new cell line(s) were obtained.
Single colonies of stably transfected cells were selected and isolated. The selection process 
was carried out by feeding the “transfected” cells with media containing geneticin (Sigma; 
G9516) (or hygromycin B (Clontech 8057-1) in the case of survivin-pTRE/pTK-Hyg 
transfection). The plasmids used had a geneticin-resistant (or hygromycin-resistant) gene, 
therefore, only those cells containing the plasmid should survive treatment with geneticin. 
Two days after transfection, the flask of cells was fed with 3-4 times the levels of geneticin 
normally required to kill 50% of the cells transfected (e.g. IC50 for DLKP cells is 65|ig/ml; 
cells were fed with media containing 200(j,g/ml geneticin). When the cells grew readily in 
this concentration of geneticin, the concentration was increased step-wise to a final 
concentration of lmg/ml. The final concentration used of hygromycin B used was 140(j,g/ml. 
At this stage the cells were plated out in 96-well plates (Costar, 3596) at a clonal density of 
one cell/3 wells. Clonal populations were propagated from these wells, and transfected cells 
were periodically challenged with geneticin to maintain stability of transfectants and prevent 
cross-contamination with non-transfected cells.
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2.4.5.3 Optimisation of plasmid transfection protocol
Before transient transfections were carried out, the transient transfection protocol was first 
optimised for each of the parameters involved. The DNA used was the pCHllO plasmid 
which codes for beta-galactosidase activity.
The target cell line was trypsinised in the usual fashion (Section 2.2.3) and set up in a 6- 
well plate, at two different cell concentrations (i.e. lxlO5 cells and 2xl05 cells in 1ml 
medium). Following incubation overnight at 37°C, 5% CO2, the cells were transfected 
according to the transfection protocol for the transfectant used, i.e. Fugene 6 (Boehringer 
Mannheim, 1 814 443). Only the volumes of transfectant and concentration of DNA were 
altered to ascertain the most efficient combination. Cells were transfected either in the 
presence of serum overnight or for four hours in the absence of serum, both at 37°C. After 
transfection, the cells were washed 2X with PBS and fixed by the addition of fix solution 
(0.4mls 25% glutaraldehyde (Sigma, G-7526), lOmls 0.5M Sodium Phosphate buffer (pH 
7.3), 2.5ml 0.1 EDTA (pH 8.0) (Sigma, E-0396), 0.1ml 1.0M MgCl2 (Sigma, M-8266), 
37ml UHP) for 10 mins. The cells were then washed for 10 mins. in wash solution (40ml 
0.5M Phosphate buffer (pH 7.3), 10ml 1.0M MgCl2 (Sigma, M-8266), 20mg Sodium 
deoxycholate (Sigma, D-4297), 40li1 Nonidet P-40 (Sigma 1-3021), 160ml UHP). Staining 
was carried out on the cells using 2.5ml of stain solution (10ml rinse solution, 0.4ml X-gal 
(Sigma, B-4252) (25mg/ml in dimethylformamide), 16.5mg potassium ferricyanide (Sigma, 
P-8131), 16.5mg potassium ferrocyanide (Sigma, P-9387)) overnight at 37°C. After 
staining, the cells were washed with lOmls rinse solution and examined microscopically. 
Positive cells were those stained blue. The combination resulting in the highest number of 
blue colonies, was thereafter used for that cell line.
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2A.5.4 Transient transfection o f DNA  using Fugene 6 reagent
i • • (
The day before the transfection experiment, cell were seeded into a 25cm flask at a cell 
density of 1.5 x 10s cells/ml (in 4ml medium). Fugene 6 reagent:DNA comlex was used at 
a 3:2 ratio which was found to be an optimal ratio (other ratios included 3:1 and 6:1). The 
Fugne:DNA complex was made up according to manufacturer’s recommendations and cells 
were transfected will 100|il of the complex mixture in a dropwise fashion. Cells were 
returned to a 37°C incubator until the following day. Cells were harvested for RNA and 
protein at 24, 48, 72 hour and 5day time intervals, or seeded in 96-well plates for in vitro 
toxicity testing (Section 2.3.1.1), or used for preparing cytospins on glass slides for 
TUNEL assay (Section 2.3.2.1) for detection o f apoptosis.
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2.5 Invasion Techniques
2.5.1 Invasion Assay
Invasion assays were performed using the method of Albini (1998). ECM (Sigma E-1270) 
(llmg/lml) was diluted to lmg/ml in serum-free DMEM. lOOfil of lmg/ml ECM was 
placed into each invasion chamber/insert (Falcon 3097) (8.0(j,m pore size, 24 well format) 
which was placed in a 24-well plate (Costar). This was carried out on ice to prevent the 
ECM from solidifying during the process. The inserts were incubated overnight at 4°C. The 
following day, the cells were harvested and re-suspended in media-containing fetal calf 
serum, at a concentration of lxlO6 cell/ml. The inserts were washed with serum-free 
DMEM, then lOOpl of the cell suspension were added to each insert and 300jil of media 
containing serum was added to the well underneath the insert. Cells were incubated at 37°C 
for 48 hours. After this time, the inner side of the insert was wiped with a wet cotton swab 
while the outer side of the insert membrane was stained with 0.25% crystal violet for 10 
minutes and then rinsed with PBS and allowed to dry. The inserts were then viewed under 
the microscope
The procedure for the ready-coated inserts was very similar to the procedure described 
above, with the exception that the inserts were not coated with ECM (as they were pre­
coated with matrigel), but were re-hydrated for 2 hours prior to use, by adding serum-free 
media and incubating at 37°C, following the manufacture’s instructions (Beckton 
Dickinson).
For a quantitative method of invasion analysis, assessment of cell migration to the outer 
side of the insert was determined by acid phosphatase assay (Section 2.3.1.2). Cells were 
incubated for the time indicated above, after which, the inner side of the insert was wiped 
with a wet cotton swab and the media in the well was replaced with 200ul of freshly 
prepared phosphatase substrate (lOmM /»-nitrophenol phosphate (Sigma 104-0) in 0.1M 
sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH 5.5). The plates were 
wrapped in aluminium foil and incubated in the dark at 37°C, 5% CO2, for 2 hours.
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The enzymatic reaction was stopped by the addition of 50 (j.1 of 1M NaOH to each well. 
lOOfol aliquots were removed from the wells, placed in a 96-well plate, and read in a dual 
beam plate reader at 405 nm with a reference wavelength of 620 nm,
Another quantitative method was also used in come cases whereby the crystal violet dye 
was eluted with 200 (0.1 of 33 % glacial acetic acid/well. 100 |J,1 aliquots were transferred 
from each well to corresponding wells of a 96 well plate and the absorbance was read at 
570 nm.
2.5.1.1 Invasion Inhibition Assays
The procedure for carrying out MMP inhibition assays was identical to that of invasion 
assays (section 2.5.1), with the exception that 200(j.g/ml MMP inhibitor I, 10(j.g/ml MMP 
inhibitor HI or 10 jog/ml MMP-2 inhibitor I was added both to the cell suspension in the 
insert and to the medium in the well underneath the insert before the cells were incubated at 
37°C, 5%C02, for 48 hours. All three MMP inhibitors were purchased from CalBiochem 
(Nottingham, UK). Table 2.5.1 illustrates details provided by manufactures about the 
function of each inhibitor
Table 2.5.1 MMP inhibitors used in invasion inhibition assays and the MMP whose 
activity they inhibit.
Inhibitor MMP inhibited Catalogue number
MMP inhibitor I MMP-1, -3, -8 and-9 444250
MMP inhibitor IE MMP-1, -2, -3, -7 and-13 444264
MMP-2 inhibitor I MMP-2 444244
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2.5.2 M otility Assay
The procedure for carrying out motility assays was identical to the procedure used for 
invasion assays (section 2.5.1) with the exception that the inserts were not coated with 
ECM. Incubation times were 12, 24 and 48 hours. The procedure for quantitative analysis 
was identical to that of the invasion assays.
2.5.3 Adhesion Assay
Adhesion assay was preformed using the method of Torimura et al. (1999). Collagen Type 
IV (Sigma C-5533), fibronectin (Sigma F-2006) and laminin (Sigma L-2020) were 
reconstituted in PBS to a stock concentration of 500(j,g/ml. Stocks were aliquoted into 
sterile Eppendorfs. Fibronectin and collagen stocks were stored at -20°C and laminin 
stocks were stored at -80°C. ECM (Sigma E-1270) was diluted to lmg/ml in serum-free 
DMEM, aliquoted and stored at -20°C. ECM undergoes thermally activated polymerization 
when brought to 20-40°C to form a reconstituted basement membrane.
When the solutions were ready for use, each of the ECM proteins, collagen, fibronectin and 
laminin, was diluted to 25jog/ml with PBS, while ECM was diluted to lmg/ml with serum- 
free DMEM. 250(0.1 aliquots were placed into wells of a 24-well plate. The plates were 
tapped gently to ensure that the base of each well was completely covered with solution. 
The plates were then incubated at 4°C overnight. The ECM solutions were then removed 
from the wells and the wells were rinsed twice with sterile PBS. 0.5ml of a sterile 0.1% 
BSA/PBS solution was dispensed into each well to reduce non-specific binding. The plates 
were incubated at 37°C for 20 minutes and then rinsed twice with PBS.
Cells were harvested and resuspended in serum-free DMEM medium. The cells were then 
plated at a concentration of 2.5x104 cells per well and incubated at 37°C for 60 minutes. 
After that time, the media was removed from the wells and the wells were rinsed gently 
with PBS. The cells were then stained with 0.5ml of 0.25% crystal violet dye for 10 
minutes. The plates were then rinsed and allowed to dry. The dye was eluted with 200(xl of
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33% glacial acetic acid and lOOjal aliquots were transferred to a 96-well plate and the 
absorbance was read at 570 nm (Torimura et al., 1999).
2.5.4 Zymography
Zymography was used to assess the level of proteolytic activity of different proteinases. 
The choice of substrate incorporated into the resolving gel depends on substrate specificity 
of the species of enzyme to be detected (Johansson et al., 1986). Gelatin is a substrate for 
matrix metalloprotienases (MMPs), serine and cysteine proteinases.
The gel was prepared by incorporating gelatin within the polymerized acrylamide matrix. 
10% acrylamide gels were used. The quantities for one gel is given in Table 2.5.4a.
Table 2.5.4a Preparation of resolving and stacking gel for zymography
Components Resolving gel (10%) Stacking gel
Acrylamide stock* 3.3 mis 0.5 mis
3mg/ml Gelatin 2.5 mis
1.875M-Tris/HCl, pH 8.8 2.5 mis
1.25M-Tris/HCl, pH 6.8 “ 0.8 mis
Ultrapure water 1.7 mis 2 mis
10% Ammonium persulphate 
(Sigma, A-1433)
33 jils 33 jj! s
TEMED 
(Sigma, T-8133)
5 (ils 5 pis
* Acrylamide stock solution consists o f 29.lg  acrylamide (Sigma, A8887) and 0.9g N N ’-methylene bis- 
acrylamide (Sigma, 7256) dissolved in 60ml UHP water and made up to 100ml final volume. The solution was 
stored in the dark at 4°C for up to 1 month. All components were purchased from Sigma, SDS (L-4509), NH4- 
persulphate (A-1433), TEMED, N,N,N,N’-tetramethylethylenediamine (T-8133) and Gelatin (G-8150).
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Cells were grown in cell culture Petri dishes (Greiner). When the cells were 80% confluent, 
they were rinsed twice with sterile PBS, followed by 4-hour incubation with serum-free 
medium. The cells were then grown in fresh serum-free medium for another 24-72 hours 
(depending on their growth rate). After the relevant time period, supernatants were 
collected as samples. Samples were mixed 3:1 with 4X sample buffer (10% glycerol; 
0.25M Tris-HCl, pH 6.8; 0.1% (w/v) bromophenol blue) and were loaded onto the gel. 5(4.1 
of boiled Broad size range protein marker (New England Biolabs, 7708S) was also loaded 
onto the gel. The gels were run at 30 mA per gel in running buffer (as in section 2.4.1.3) 
until the dye front reached the bottom of the gel. Following electophoresis, the gels were 
soaked in 2.5% Triton-X-100 with gentle shaking for 30 minutes at room temperature. The 
gels were then rinsed in substrate buffer (50mM Tris-HCl, pH8.0; 5mM CaCh) and then 
incubated for 24 hours in substrate buffer at 37°C. The gels were then stained with 
Coomassie blue (2.5mg/ml) for 2 hours by shaking and destained in destain solution (50ml 
acetic acid; 150ml isopropanol; 300 ml distilled water) until clear bands were visible. The 
gels were then scanned.
To identify the different classes of proteinases that are being secreted, inhibitors of 
proteinases were added to 2.5% Triton-X-100 in substrate buffer. The inhibitors used in 
this study are listed in Table 2.6.4b.
Table 2.5.4b Inhibitors of different classes of proteinases used in gelatin zymography
Inhibitor Enzyme inhibted Concentration used
EDTA MMPs 30 mM
PMSF Serine proteinases 1 mM
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2.6 D NA M icroarray analysis technique
2.6.1 RNA Extraction
High quality RNA was isolated from the DLKP parental cells and the DLKP MDR variants 
using the Rneasy mini kit (Qiagen 74104). The Rneasy extraction is based on guanidine 
thiocyanate method of extraction. The procedure was carried out according to the 
manufacturer’s recommendations. Affymetrix recommends a minimum of 5pg of total 
RNA at a concentration 0.5p.g /p i 1 Ojag of RNA was used for all cell lines included in this 
study.
2.6.2 Sample, Array and Data processing
After RNA isolation, quantification, and purification, cDNA was synthesised using the 
GeneChip T7-01igo(dT) Promoter Primer kit (Affymetrix; 900375). First strand cDNA 
synthesis was then carried out using the Superscript choice kit (Biosciences 11917-010). 
First strand cDNA synthesis involved “primer hybridisation” where the T7-oligo(dT) 
primer was incubated with the RNA and DEPC-treated H2O at 70°C for lOmins, followed 
by a short incubation on ice; “temperature adjustment” where 5X first strand buffer, DTT 
and dNTP mix were added to the RNA mix and incubated at 42°C for 2mins; and “first 
stand synthesis” where SuperScript II RT was added to the mix and incubated at 42°C for 
lhr. Second strand cDNA synthesis was carried out and purified using GeneChip Sample 
Cleanup module (Affymetrix 900371) as recommended by the manufacturers.
cRNA was synthesised and biotin-labelled using the Enzo BioArray HighYield RNA 
Transcript Labelling Kit (Affymetrix 900182). Biotin-labelled cRNA was purified using 
the GeneChip Cleanup module kit (Affymetrix 900371) and quantified. The value obtained 
was adjusted to reflect carry over of unlabeled total RNA. A sample of biotin-labelled 
cRNA was taken for gel electrophoresis analysis. The labelled cRNA was then fragmented 
before hybridisation onto GeneChip probe arrays. An aliquot of fragmented and un­
fragmented cRNA was checked by gel electrophoresis. Fragmented sample RNA was 
stored at -20°C (for a maximun of 48hrs, if possible) until ready to perform the
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hybridisation. Hybridisation of RNA onto GeneChip probe human arrays (Hul33A; 
Affymetrix ) was carried out in the Conway Institute, University College Dublin, where the 
Affymetrix Hybridisation Oven and Fluidics Station is set up along with the Affymetrix 
Scanner, which exported the data directly to the Affymetrix analysis software, Micro Array 
Suite 5.1 (MAS 5.1).
The Affymetrix Genechips have short oligonucleotides synthesised in situ on glass slides, 
with 22 spots (11 Perfect Match and 11 Mismatch) for each gene. The mismatch oligos 
have a single base difference to the perfect match oligos in the middles of the strand. The 
values for each of the 22 spots are considered by the software to produce a Flag Call (e.g. 
Present or Absent) and a Raw Value (in Affymetrix units) for each probe set.
The data from the MAS 5.1 is transferred into the Genespring, a Gene Expression Analysis 
program, where it was first normalised so that the results from different chips can be 
compared with each other. There are three stages in the normalization: The first stage is a 
‘data transformation’ where negative numbers are converted to a small positive value, such 
as 0.0001. Negative numbers may be a problem because the analysis programs may try to 
log transform a column of data which contained some negative numbers and would fail. 
The second stage is a Ter Chip’ normalisation. This centres all of the chips in the 
experiment around the same median and enables us to compare one chip with another. It is 
done to eliminate minor differences in hybridisation conditions etc. In this case, each gene 
on the chip is normalised to the 50th percentile of all the measurements on that chip. The 
final step is a ‘Per Gene’ normalisation, where the measurement for a particular gene is 
divided by its measurement in a designated control sample. This allows us to discuss the 
level of a particular transcript relative to a particular control condition.
In this analysis, the data was loaded into Genespring and the levels o f a particular list of 
genes that had already been investigated by PCR were looked at. Only changes of 2- or 
greater -fold were considered to be ‘real changes’.
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Results
3.1 Analysis of Galectin-3 expression in RPMI Drug-resistant cell lines
Two MDR variants of RPMI-2650 (a nasal carcinoma cell line) were established in the 
NICB (Y. Liang, PhD, 1999) and were termed RPMI-taxol and RPMI-melphalan. Both 
cell lines exhibited increased multiple drug resistance. In addition, RPMI-melphalan 
resistant cell line exhibited increased invasiveness and metastasis compared to the non- 
invasive parental cell line.
In order to determine the effect of induced MDR in cancer cell lines on gene expression, 
an investigation was carried out to establish the change in the expression level of two 
anti-apoptotic genes, galectin-3 (section 3.1.1) and survivin (section 3.2.1).
3.1.1 Galectin-3 expression in RPMI-Taxol and RPMI-Melphalan
3.1.1.1 Investigation of Galectin-3 expression in RPMI-Taxol and RPM1- 
Melphalan resistant cell lines using RT-PCR analysis
RNA was extracted from the RPMI-2650 cell lines using the TRI Reagent method 
(section 2.4.3.2). RT-PCR was carried out using galectin-3 primers, which amplified a 
band of 281 bp and P-actin primers, acting as in endogenous control, which amplified a 
band of 383 bp (see section 2.4.3.5 for RT-PCR technique). Galectin-3 mRNA 
expression was shown to increase slightly in the RPMI-melphalan variant compared to 
RPMI parent, while galectin-3 mRNA expression was down-regulated in the RPMI- 
taxol variant (Fig 3.1.1.1A). Densitometry was carried out on the results and the 
galectin-3 bands were normalised to the P-actin bands (Fig. 3.1.1.IB). RT-PCRs were 
carried out in triplicate and the results were reproducible. The molecular weight marker 
“<|)-X174” Hae ill digest was used as a size reference (Figure 3.1.1.1).
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Figure 3.1.1.1 (A) Gel electrophoresis of galectin-3 RT-PCR results on RPMI,
RPMI-taxol and RPMI-melphalan resistant cell lines. MW=molecular weight marker; 
(B) Densitometrie analysis o f RT-PCR results. (n=3).
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Protein was isolated from the RPMl-2650 cell lines and Western blot was carried out on 
the RPMI-2650 parental cell line and the RPMI-2650-taxol and RPMI-2650-melphalan 
variants using a galectin-3 primary antibody, which detects a band of 30 kDa, 
corresponding to galectin-3 protein (see section 2.4.1 for western blotting technique). 
Galectin-3 protein expression was shown to increase in the RPMI-melphalan variant 
compared to RPMI parent and RPMI-taxol. MCF-7 cell line was used a positive control 
for galectin-3 protein expression (Figure 3.1.1.2). Experiments were carried out in 
triplicate and results were reproducible.
3.1.1.2 Investigation o f  G alectin-3 expression in R PM I-T axol and RPM I-
M elphalan resistant cell lines using W estern blot analysis
RPMI (Parent) RPMI (Taxol) RPMI (Melphalan) MCF-7
RPMI-parent RPMI-Taxol RPMI-Melphalan
Cell Line
Fig. 3.1.1.2 (A) Galectin-3 Western blot analysis on RPMI, RPMI-taxol and
RPMI-melphalan resistant cell lines. MCF-7 cell line was used as a positive control; (B) 
Densitometric analysis o f western blot results. (n=3)
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3.1.2 Galectin-3 cDNA Transfection into DLKP cells.
To further elucidate the role of galectin-3 in cancer cells, galectin-3 was transfected into 
the lung carcinoma cell line, DLKP, a cell line developed in the NICB.
Galectin-3 cDNA in pREB9 plasmid was transfected into DLKP cells using Lipofectin. 
Selection using geneticin was carried out until a mixed population (MP) and 3 clones 
(C2, C12 and C l3) were obtained. The concentration of geneticin at which this was 
achieved was 1 mg/ml. The mixed population along with the three clones were 
characterised by RT-PCR and Western blot analysis. The sensitivity of the galectin-3 
clones to a range of chemotherapeutic drugs was determined and compared to DLKP 
parent cell line drug sensitivity by carrying out toxicity assays using the acid 
phosphatase method (see section 2.3.1).
3.1.2.1 Analysis of DLKP- Galectin-3 clones using RT-PCR for Galectin-3
RNA was extracted from the DLKP-galectin-3 clones and RT-PCR analysis was carried 
out. Results indicate that DLKP-Gal-3 clone 12, clone 13 and the mixed population 
over-express galectin-3 mRNA whereas clone 2 had similar levels as the parent cell 
line and the empty pREB9 vector in the mock transfection (Fig. 3.1.2.1 A). 
Densitometry was carried out on the results by normalising the galectin-3 bands to the 
(3-actin bands (Fig. 3.1.2.IB). RT-PCR analysis were carried out at least three times in 
order to maximise the accuracy of the results. As mentioned in section 3.1.1.1, the 
molecular weight marker “<j)-X174” Hae III digest was used as a size reference. Sterile 
water was used as a negative control in the majority of RT-PCR results presented in this 
thesis.
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Fig. 3.1.2.1 (A) Gel electrophoresis of Gal-3 RT-PCR results on DLKP-Gal-3 cDNA
transfectants. Neg = sterile water; (B) Densitometrie analysis o f RT-PCR results. (n>3)
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3.1.2.2 Analysis of DLKP- Galectin-3 clones using W estern blotting for Galectin-3
Protein was isolated from the clones, the mixed population and the parent cell line, 
DLKP, and Western blot was carried out using a galectin-3 primary antibody. The 
results were consistent, to a certain extent, with those of the RT-PCR analysis and 
showed that DLKP-Gal-3 clone 12, clone 13 and the mixed population over-expressed 
galectin-3 protein, whereas clone 2 shows a down-regulation of galectin-3 protein 
compared to the parent cell line (Fig. 3.1.2.2A). Densitometry was carried out on the 
results comparing the clones and MP to the DLKP parent cell line (Fig. 3.1.2.2B). 
Western blot analysis was carried out over three times and results were reproducible.
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Fig. 3.1.2.2 (A) Galectin-3 Western blot analysis o f DLKP-Gal-3 cDNA
transfectants; (B) Densitometrie analysis o f Western blot results. (n>3)
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3.1.2.3 Analysis of DLKP-Gal-3 cDNA transfectants using in vitro toxicity testing
The sensitivity of the galectin-3 transfectants to a range of chemotherapeutic drugs was 
determined and compared to DLKP parent cell line drug sensitivity. Cells were exposed 
to a selection of chemotherapeutic drugs. The chosen drugs were carboplatin, 
adriamycin and taxol. The cells were exposed to the drugs over a range of 
concentrations, which included the IC50 values for each drug for the DLKP cell line. At 
the end of the 5-7 day toxicity assay, the cells were analysed using the acid-phosphatase 
assay (section 2.3.1). The results represent a mean of at least three repeats of the 
experiment and the standard deviation (see Table 3.1.2.3A).
Whereas galectin-3 over-expression did not affect cell sensitivity to adriamycin and 
taxol, cells over-expressing galectin-3 tended to be more resistant to carboplatin (Table 
3.1.2.3B).
Cell Line Adriamycin
(ng/ml)
Carboplatin
(Hg/ml)
Taxol
(ng/ml)
DLKP 14.2+0.78 1.86+0.12 2.11+0
Vector 14.91±0.94 1.73+0.08 1.18+0.08
C2 20.45+0.61 1.12+0.06 0.97+0.05
C12 10.51+0.86 2.36+0.12 1.06+0,04
C13 9.23+0.74 2.83+0.11 1,08+0.06
MP 13.92+0.92 4.41+0.28 2.51+0.2
Table 3.1.2.3A Table of IC50 values for DLKP parent cells and DLKP Galectin-3 
transfectants to a range of chemotherapeutic drugs.
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(B)
Cell Line Adriamycin Carboplatin Taxol
DLKP 1 1 1
Vector 1.05 0.93 0.56
C2 1.44 0.6 0.46
C12 0.74 1.27 0.5
C13 0.65 1.52 0.51
MP 0.98 2.37 1.19
Table 3.1.2.3B Table of fold resistance of DLKP Galectin-3 transfectants to a 
range of chemotherapeutic drugs, compare to the parental cell line.
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3.1.2.4 Analysis o f DLKP-galectin-3 transfectants using in vitro Invasion assays.
In order to determine the effect of galectin-3 over-expression on the invasive properties 
of DLKP cell line, invasion assays were carried out using ECM-coated inserts. Cells 
were grown in the inserts for 48 hours before being stained with crystal violet, as 
described in section 2.5.1.
It was found that galectin-3 over-expression in DLKP correlated with increased 
invasiveness. DLKP parental cells are considered to be non-invasive. This was also the 
case with DLKP cells transfected with the empty vector. DLKP-C2, which does not 
over-express galectin-3, was also non-invasive. However, C l2, C13 and the MP, which 
all over-express galectin-3, were found to have developed an invasive phenotype due to 
galectin-3 transfection. RPMI-2650, a nasal carcinoma cell line, was used as a negative 
control in this experiment as they have been found to lack invasive properties. HT- 
1080, a highly invasive fibrosarcoma was used as a positive control.
For a quantitative analysis of the assay, the crystal violet dye was eluted from the inserts 
using 33 % glacial acetic acid and the absorbance was read at 570 nm. Results from this 
elution, as shown in figure 3.1.2.4b correlated with the photographic representation in 
figure 3.1.2.4a.
Invasion assays were carried out three times and the results were found to be 
reproducible.
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Figure 3.1.2.4a Invasion assays of (A) DLKP parent; (B) DLKP-vec; (C) DLKP- 
C2; (D) DLKP-C12; (E) DLKP-C13; (F) DLKP-MP, (G) HT-1080; (H) RPMI-2650 
(4X). (n=3).
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Figure 3.1.2.4b Absorbance values o f each eluted insert from invasion assays 
carried out on the DLKP transfectants. Read at 570 nm. Results represent the mean of 
three separate experiments +/- standard deviations.
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3.1.2.5 Analysis o f DLKP-galectin-3 transfectants using in vitro M otility assays.
In order to determine the effect of galectin-3 over-expression on the motility o f DLKP 
cell line, motility assays were carried out using the same method as that used for 
invasion assays, except that the inserts were not coated with ECM (section 2.5.2). Cells 
were grown in the inserts for 48 hours before being stained with crystal violet.
It was found that galectin-3 over-expression in DLKP correlated with increased 
motility. This also correlated with the invasion assay results i.e. the more invasive the 
cells, the more motile they were found to be. DLKP parental cells had low motility, as 
were DLKP cells transfected with the empty vector. DLKP-C2, which does not over­
express galectin-3 was also non-motile. However, C l2, C l3 and the MP, which all 
over-express galectin-3 were found to have increased motility due to galectin-3 
transfection. RPMI-2650 was used as a negative control in this experiment as they have 
been found to be non-motile. HT-1080 was used as a positive control.
For a quantitative analysis of the assay, the crystal violet dye was eluted from the inserts 
using 33 % glacial acetic acid and the absorbance was read at 570 nm. Results from this 
elution, as shown in figure 3.1.2.5b, correlated with the photographic representation in 
figure 3.1.2.5a.
Motility assays were carried out three times and the results were found to be 
reproducible.
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Figure 3.1.2.5a Motility assays of (A) DLKP parent; (B) DLKP-vec; (C) DLKP- 
C2; (D) DLKP-C12; (E) DLKP-C13; (F) DLKP-MP; (G) HT-1080; (H) RPMI-2650
(4X). (n=3)
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Figure 3.1.2.5b Absorbance values of each eluted insert from motility assays 
carried out on the DLKP transfectants. Read at 570 nm. Results represent the mean of 
three separate experiments +/- standard deviations.
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3.1.2.6 Analysis o f DLKP-galectin-3 transfectants using in vitro Adhesion assays.
To detect the adhesiveness of the DLKP parental cell line compared to the DLKP- 
galectin-3 transfectants to extracellular matrix and its components, collagen type IV, 
laminin and fibronectin, adhesion assays were carried out as described in section 2.5.3. 
As with invasion and motility assays, RPMI-2650, was used as a negative control in this 
experiment. HT-1080 was used as a positive control.
The adhesion assays with ECM, as shown in Figure 3.1.2.6, demonstrates that DLKP- 
gal-3 C l2, C13 and MP were the most adhesive to ECM, therefore suggesting that 
galectin-3 over-expression supports DLKP adhesion to ECM. DLKP parent, DLKP-vec 
and DLKP-gal-3 C2 were all less adhesive. RPMI-2650 was less adhesive to ECM 
while, HT-1080 was as adhesive as MP. As shown in figure 3.1.2.6, all cell lines were 
equally adhesive to collagen IV, suggesting that galectin-3 over-expression does not 
correlate with DLKP adhesion to collagen IV. As with ECM, galectin-3 over-expression 
correlates with DLKP adhesion to fibronectin. DLKP-gal-3 C l2, C13 and MP were the 
most adhesive to fibronectin. DLKP-gal-3 C l2, C13 and MP were slightly more 
adhesive to laminin than the parental cell line, DLKP-vec and DLKP C2 (Figure 
3.1.2.6). Adhesion assays were carried out in triplicate and results were reproducible.
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Figure 3.1.2.6 Absorbance values of each eluted insert from adhesion assays to
ECM, collagen IV, fibronectin and laminin, carried out on the DLKP transfectants. 
Read at 570 nm. Results represent the mean of three separate experiments +/- standard 
deviations.
123
3.1.2.6 Proliferation rate of DLKP-galectin-3 transfectants
To determine the proliferation rate of cells, their growth is monitored over consecutive 
24 hour time periods, as described in section 2.5.
Doubling times were determined for all DLKP transfectants including the parent cells. 
As shown in Table 3.1.2.7, doubling times did not differ greatly between the cell lines 
and did not correlate with galectin-3 over-expression. Although the doubling time for 
MP was similar to the other transfectants, the lag time before exponential growth was 
longer for MP than the other transfectants.
Cell Line Doubling Time (Hour)
DLKP 28.9 + 1.6
Vector 31.8 ± 2.2
C2 30.3 + 1
C12 30.7 + 1.8
C13 24.2 + 2.1
M P 32.3 ±3
Table 3.1.2.7 Doubling times of DLKP galectin-3 transfectants. Results
represent the mean of three separate experiments +/- standard deviations.
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3.2 Analysis of Survivin expression in RPMI-2650 drug-resistant cell lines
In order to determine the effect of induced MDR on survivin expression in RPMI-2650 
cells, an investigation was carried out to establish the change in the expression level of 
this anti-apoptotic gene.
The two MDR variants of RPMI-2650, RPMI-taxol and RPMI-melphalan resistant cell 
lines, as previously mentioned, exhibit increased multiple drug resistance compared to 
the parent cell line. In addition, RPMI-melphalan resistant cell line exhibited an 
increase in invasiveness compared to the non-invasive parental cell line.
3.2.1 Survivin expression in RPM I-Taxol and RPM I-M elphalan
3.2.1.1 Investigation o f Survivin expression in RPM I-Taxol and RPM I-M elphalan  
resistant cell lines using RT-PCR analysis
RNA was extracted from the RPMI-2650 cell lines using the TRI Reagent method 
(section 2.4.3.2). RT-PCR was carried out using survivin primers, which amplifies the 
three splice variants of survivin (survivin-2B (500bp), survivin (431 bp), and survivin- 
AEx3 (329bp)). Survivin RT-PCR was carried out on RPMI-2650 parent cell line, 
RPMI-Taxol and RPMI-melphalan resistant cell lines. The results showed a decrease in 
survivin mRNA expression in RPMI-taxol compared to RPMI parent and RPMI- 
melphalan. As in section 3.1.2.1, (3-actin was used as an endogenous control and sterile 
water was used at a negative control. The molecular weight marker “(|)-X174” Hae III 
digest was used as a size reference (Fig. 3.2,1.1). RT-PCR analysis was carried out in 
triplicate and was reproducible.
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Figure 3.2.1.1 Gel electrophoresis of survivin RT-PCR results on RPMI,
RPMI-taxol (Tax) and RPMI-melphalan (Mel) resistant cell lines. MW=molecular 
weight marker and Neg = negative control (n=3)
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Survivin Western blots were also carried out on the RPMI variants using a survivin anti­
rabbit antibody (see Table 2.4.2) which detects a band of 16.5KDa, and in agreement 
with the RT-PCR analysis of mRNA levels, survivin protein was down-regulated in 
RPMI-taxol compared to RPMI parent and RPME-melphalan. a-Tubulin was used as an 
endogenous control to ensure equal protein loading (Fig. 3.2.1.2). Western blot analysis 
was carried out in duplicate and was reproducible.
3.2.1.2 Investigation of Survivin expression in RPMI-Taxol and RPMI-Melphalan
resistant cell lines using Western blot analysis
(A)
RPMI Taxol Melphalan
^■Survivin
16.5KDa
a-T ubulin
50KDa
Fig. 3.2.1.2 Survivin and a-tubulin Western blot analysis on RPMI, RPMI-
taxol and RPMI-melphalan resistant cell lines. (n=2)
3.2.2 Survivin cDNA Stable Transfection into DLKP cell.
To investigate the role of survivin in lung cancer cells, survivin cDNA in pTarget 
plasmid was transfected into DLKP cells using Lipofectin. Selection using geneticin 
was carried out until 5 clones, Cl, C2, C3, C9 and CIO, were obtained. The 
concentration of geneticin at which this was achieved was 1 mg/ml. The five clones 
were characterised by RT-PCR and Western blot analysis. The sensitivity of the 
survivin clones to a range of chemotherapeutic drugs was determined and compared to 
DLKP parent cell line drug sensitivity by carrying out toxicity assays using the acid 
phosphatase method (section 2.3.1).
3.2.2.1 Analysis of DLKP-survivin clones using RT-PCR
RNA was extracted from the clones, the mixed population and the parent cell line, 
DLKP, and RT-PCR was carried out using survivin primers, which amplified survivin 
and its two splice variants, survivin 2B and survivin-delta Exon 3. Bands of 431 bp, 
500bp and 329bp were amplified for each of the splice variants, respectively. |3-actin 
primers, acting as endogenous control, were included amplifying a band of 142 bp. 
Results showed that none of the DLKP transfectants over-expressed survivin mRNA 
(Fig. 3 .2.2.1 A). Densitometry was carried out on the results by normalising the survivin 
bands to the (3-actin bands (Fig. 3.2.2. IB). As in section 3.1, RT-PCRs were carried out 
at least three times and sterile water was used as a negative control. The molecular 
weight marker “<|)-X174” Hae III digest was used as a size reference
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Fig. 3.2.2.1 (A) Gel electrophoresis photograph of survivin RT-PCR results
on DLKP-survivin cDNA transfectants. Neg=negative control and MW=molecular 
weight marker; (B) Densitometrie analysis o f RT-PCR results (n=3).
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3.2.2.2 Analysis of DLKP-survivin clones using Western Blot
Protein was isolated from the clones and the parent cell line, DLKP (see section
2.4.1.1), and Western blot (section 2.4.1) was carried out using a survivin primary 
antibody, supplied by Alpha Diagnostics (see Table 2.4.2), which detects a band of 16.5 
kDa, corresponding to survivin protein. The results, as seen with the RT-PCR analysis, 
showed no up-regulation of survivin protein (Fig. 3.2.2.2). As in section 3.2.1.2, a- 
tubulin was used to ensure equal loading of protein. Western blot analysis was carried 
out in triplicate and results were reproducible.
(A)
DLKP Cl C2 C3 C9
Survivin
(16.5KDa)
a-T ublin
(50KDa)
Fig. 3.2.2.2 Survivin and a-tubulin Western blot analysis of DLKP-survivin
cDNA transfectants (n=3).
The sensitivity o f the survivin transfectants to a range of chemotherapeutic drugs was 
determined and compared to DLKP parent cell line drug sensitivity. As in section
3.1.2.3, cells were exposed to chemotherapeutic drugs. The chosen here drugs were 
adriamycin and carboplatin. The cells were exposed to the drugs over a range of  
concentrations, which included the IC50 values for each drug for the DLKP cell line. At 
the end of the 5-7 day toxicity assay, the cells were analysed using the acid-phosphatase 
assay as in section 2.3 .1.
No resistance to any of the drugs was observed when compared to the parent cell line. 
(Fig. 3.2.2.3A and B). Toxicity assays were carried out once with adriamycin and twice 
with carboplatin.
3.2.2.3 Analysis of DLKP-survivin cDNA transfectants using in vitro toxicity
testing
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Fig. 3.2.2.3 (A) Effect of survivin on Adriamycin resistance in DLKP-
survivin cDNA clones (n=l); (B) Effect o f survivin on carboplatin resistance in DLKP- 
survivin cDNA clones (n=2).
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3.2.3. SKOV-3- Tet off: (The inducible system)
A second attempt was made at creating another stably transfected cell line over­
expressing survivin. The cell line chosen was the ovarian carcinoma cell line, SKOV3. 
This was chosen for two reasons, firstly, this cell line was found to express intermediate 
levels of survivin compared to DLKP and MCF-7; and secondly this cell line was stably 
transfected with the Tet-Off (T.O) by Helena Joyce, M.Sc., in the NICB. The advantage 
of this gene expression system is that it allows regulation of mammalian gene 
expression with tetracycline or tetracycline derivatives. For the purpose of these studies, 
doxocycline was used. In the Tet-Off system, gene expression is turned on when 
doxocycline (Dox) is removed; in contrast to the Tet-On system, where expression is 
turned on by the addition of Dox.
Initial work on SKOV-3-Tet Off cell line involved checking its inducibility with the 
addition of doxocycline. A transient transfection of the Luciferase gene, using Fugene 
6, was carried out for that purpose and the cell line was found to be inducible with all 
concentrations of Fugene to DNA (Fig. 3.2.3.1 A). The ratio of fugene to DNA that gave 
the highest fold difference between ‘on’ and ‘o ff of gene expression was the 3:2 ratio 
(see Figure 3.2.3.IB) This ratio was the one used when survivin cDNA was being 
transfected (see section 2.4.5.4). These results indicate that the SKOV-3-Tet Off cell 
line was most inducible at the 3:2 ratio of Fugene to DNA. This optimization procedure 
was carried out once.
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Fig. 3.2.3.1 (A) Results of Lueiferase assay in the presence and absence of
doxocycline as read on a luminometer; (B) Representation of the fold difference in 
inducicilty between the different Fugene:DNA ratios. (n=l).
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3.2.3.1 Survivin cDNA Stable Transfection into SKOV3 ‘Tet offP cell line
Survivin cDNA was sub-cloned into the pTRE plasmid by Cytomyx and it was co­
transfected with the selection plasmid, PTK-Hyg into SKOV3 ‘Tet o ff cells, using 
Fugene 6 as the transfection agent. Selection using hygromycin was carried out, starting 
at 75ug/ml and increased until a mixed population and 12 clones were obtained. The 
concentration of hygromycin at which this was achieved was 140 ug/ml. The twelve 
clones were characterised by RT-PCR and Western blot analysis in the presence and 
absence of doxocycline. The sensitivity of the survivin clones to two chemotherapeutic 
drugs was determined and compared to SKOV3-T.O. parent cell line drug sensitivity by 
carrying out toxicity assays using the acid phosphatase method.
3.2.3.1.1 Analysis of SKOV3-T.O.- survivin clones using RT-PCR
RNA was extracted from the SKOV3-‘T.O.’ survivin clones and the mixed population, 
and RT-PCR was carried out using the same survivin primers as mentioned in section
3.2.2.1. The same P-actin primers as used in section 3.2.2.1 were also used. Results 
from the gel electrophoresis and the densitometric analysis show that the SKOV3- 
survivin clones fail to over-express survivin mRNA (Fig 3.2.3.1.1 A and B).
In addition, clones 2 and 5 and the mixed population were grown in the presence and 
absence of doxocycline and RT-PCR was carried out on them in their “off’ and “on” 
states, respectively. This, however, seemed to have little or no effect on their expression 
of survivin mRNA (Fig. 3 .2.3.1.1C and D).
As previously mentioned all RT-PCRs were carried out in triplicate. The gel shown in 
Figure 3.2.3.1.1 is not, however, a good representation of the repeat experiments for 
clone 8 (C8). Survivin mRNA expression was not always found to be down-regulated in 
this clone. Results from the repeat experiments taken together suggest no change in 
survivin mRNA expression in any of the clones. Sterile water used as a negative 
control. The molecular weight marker Hinf I digest of <{>-X174 DNA was used as a size 
reference.
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Fig. 3.2.3.1.1 (A) Gel electrophoresis photograph of survivin RT-PCR results
on SKOV3-T.O. survivin cDNA clones. Neg=negative control and MW=molecular 
weight marker; (B) Densitometrie analysis o f RT-PCR results (n=3)
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Fig. 3.2.3.1.1 (C) Gel electrophoresis of survivin RT-PCR results on SKOV3-
T.O. survivin clone 2, clones 5 and the mixed population in the presence and absence of 
doxocycline. Neg=negative control and MW=molecular weight marker; (D) 
Densitometric analysis of RT-PCR results (n=3).
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3.2.3.1.2 Analysis of SKOV3-T.O.- survivin clones using Western Blot
Protein was isolated from the clones and the parent cell line, SKOV-3 ‘T.O’ (see section
2.4.1.1), and Western blot was carried out using the same survivin primary antibody as 
in sections 3.2.1.2 and 3.2.2.2. The clones failed to increase in survivin protein levels 
and the results were not very reproducible. Figures 3.2.3.1.2A and B show the results o f  
the survivin western blot, in addition to the a-tubulin western blot used to ensure equal 
protein loading.
As in section 3.2.3.1.1, clones 2 and 5 and the mixed population were grown in the 
presence and absence of doxocycline and western blotting was carried out on them in 
their “off’ and “on” states, respectively. Similar to the RT-PCR results, this didn’t seem 
to effect their expression of survivin protein, a-tubulin was used as an endogenous 
control to ensure equal protein loading and densitometry was carried out by normalising 
the survivin bands to the a-tubulin bands (Fig. 3.2.3.1.2C). Western blots for all SKOV- 
3 ‘T.O’ clones were carried out in duplicate and both experiments showed no survivin 
protein over-expression.
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Fig. 3.2.3.1.2 (A) Survivin and a-tubulin Western blot analysis of SKOV3-
T.O. survivin clones 1-6; (B) Survivin Western blot of SKOV3-T.O. survivin clones 8- 
15 (n=2).
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Fig. 3.2.3.1.2 (C) Survivin and a-tubulin Western blot analysis of SKOV3-
T.O. survivin clone 2, clones 5 and the mixed population in the presence and absence of 
doxocycline; (D) Densitometric analysis o f Western blot (n=2).
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3.2.3.1.3 Analysis of SKOV3-survivin cDNA transfectants using in  vitro  
toxicity testing
The sensitivity of the survivin transfectants to carboplatin and taxol was determined and 
compared to SKOV3-‘T.O.’ parent cell line drug sensitivity. As in section 3.2.2.3, the 
cells were exposed to the drugs over a range of concentrations, which included the IC50 
values for each drug for the SKOV3-‘T.O.’ cell line. At the end of the 5-7 day toxicity 
assay, the cells were analysed using the acid-phosphatase assay. This was carried out on 
all clones in the absence of doxocylcine (i.e. in their “on” state), as shown in Figures
3.2.3.1.3 A and B, and on two clones and the mixed population in both the presence and 
absence of doxocyline (i.e. in their “o ff’ and “on” states, respectively) (Figures
3.2.3.1.3 C and D).
With the exception of the resistance of clone 8 to carboplatin (Fig 3.2.3.1.3A), the 
remaining survivin clones failed to show any increase in resistance to either carboplatin 
or taxol when compared to the parent cell line (Fig. 3.2.3.1.3A and B). However, there 
seemed to be a slight increase in resistance to carboplatin between the “on” and “o ff’ 
states of clone 5 (C5) (Fig. 3.2.3.1.3C) and to taxol in clone 2 (C2) and clone 5 (C5) 
(Fig 3.2.3.1.3D). The results are a mean of IC50 values taken from two experiments.
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Fig. 3.2.3.1.3 (A) Effect of survivin on Carboplatin resistance in SKOV3-
survivin cDNA clones; (B) Effect of survivin on Taxol resistance in SKOV3-survivin 
cDNA clones (n=l).
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Fig. 3.2.3.1.3 (C) Effect of survivin on Carboplatin resistance in SKOV3-
survivin cDNA clones 2 and 5 and the mixed population in the presence and absence of 
doxocycline; (D) Effect of survivin on Taxol resistance in SKOV3-survivin cDNA 
clones 2 and 5 and the mixed population in the presence and absence of doxocycline.
(n=2).
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3.2.4 SKOV-3 Transient Transfection
As described in sections 3.2.2 and 3.2.3, two separate stable transfections of survivin 
cDNA into two cell lines, DLKP and SKOV3-‘T.O.’, were carried out and both failed to 
show over-expression of survivin mRNA or protein. Also neither transfection rendered 
the cells more resistant to chemotherapeutic drugs. This led to the belief that perhaps 
there is a mechanism within cells whereby the level of survivin expression is kept 
constant at all times, making it impossible to stably over-express, or down-regulate, 
survivin expression.
Transient transfections were then carried out to try over-expressing survivin in SKOV3- 
T.O. cells over a short period of time.
3.2.4.I. Transfection efficiency
A transfection efficiency experiment was set up first to check the percentage 
transfection efficiency of the SKOV-3 cell line. As described in section 2.4.5.3, the 
PCH110 plasmid which codes for P-galactosidase activity was transfected into SKOV3- 
‘T.O.’ cells. The cells were stained at 6 and 24 hours post-transfection. Successfully 
transfected cells were stained blue/green as shown in figure 3.2.4.1 A.
SKOV3-T.O. was found to have a 30% transfection efficiency. Cells were set up at 2 
different concentrations: lxlO5 and lxlO2 in 2ml of media. Example results are shown 
in Figure 3.2.4.1 for concentration of lxlO5. This experiment was carried out in 
duplicate.
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Fig. 3.2.4.1 (A) Cells stained with X-gal P-galactosidase (i) 6 hours and (ii)
24 hours after transfection; (B) P-galactosidase staining increasing with incubation 
time. (n=2).
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3.2.4.2 Transient Transfection of Survivin cDNA into SKOV-3 ‘Tet ofP ceils
Once the transfection efficiency had been determined and was considered to be of a 
sufficiently high percentage, transient transfections were carried out using Fugene 6 as a 
transfection agent at the ratio of 3:2 of fugene to DNA (see section 2.4.5.4), as 
mentioned in section 3.2.3.
Cells were set up in 25cm2 flasks at a concentration of 1.5xl05 cells/ml, transfected with 
cDNA, or the empty pTRE vector, and taken down at several time points for analysis by 
RT-PCR and Western blot analysis. These time points were: 24 hours, 48 hours, 72 
hours and 5 days after the start of transfection. Furthermore, toxicity assays were 
carried out using taxol and carboplatin. Immunofluorescence and invasion assays were 
also carried out on the transient transfections of survivin cDNA.
3.2.4.2.1 Analysis o f SKOV3-T.O. Survivin cDNA transfectants using RT-PCR
Cells were harvested and RT-PCR was carried out on the SKOV3-‘T.O.’ survivin 
cDNA transfections at the time points mentioned above. Cells were treated with dox. 
and compared to untreated cells. Results showed that at 24 hours after transfection, in 
the absence of dox., survivin mRNA expression had increased by approximately 18 fold 
(see Figure 3.2.4.2.1 A and B). In the presence of dox., the increase detected was 
approximately 9-fold, suggesting that there was a 50 % inhibition of survivin mRNA 
expression when the expression was turned off. At 48 hours after transfection, the 
increase in survivin mRNA expression in the absence of dox., was approximately 8- 
fold. Similarly the inhibition of expression was 50 % in the presence of dox. The 
difference in expression between the ‘on’ and ‘o ff states is not as obvious at 72 hours 
and at 5 days the effect of the transfection disappears as survivin mRNA returns to 
almost basal level. The effect of turning expression ‘o ff at the 5 day time-point seems 
to be reversed in all experiments carried out. Survivin mRNA expression seems higher 
in the ‘o ff state than in the ‘on’ state at the 5 day time-point (Fig. 3.2.4.2.1A and B).
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To ensure that this finding was due to survivin cDNA transfection, a control transient 
transfection was carried out using the pTRE empty plasmid. Results showed a constant 
level of expression of survivin mRNA, with no over-expression (Fig. 3.2.4.2.1C and D), 
proving that the effect seen with the cDNA transfection is a real effect. P-actin was used 
as an endogenous control and densitometry was carried out on the results by 
normalising the survivin bands to the P-actin bands (Figure 3.2.4.IB and D). As with 
most RT-PCRs presented, sterile water was used as a negative control and RT-PCRs 
were carried out in triplicate and found to be reproducible. The molecular weight 
marker Hinf I digest of <()-X174 DNA was used as a size reference.
The PCR presented in Figure 3.2.4.2.1A was carried out at 18 cycles to avoid saturation 
of the product bands due to the dramatic over-expression of survivin mRNA at 24 
hours. This, therefore, resulted in a weak survivin band for the parental cell line. The 
PCR in Figure 3.2.4.2.1C, however, was carried out at 30 cycles because there was no 
risk of saturation of the product bands as survivin mRNA was not being over-expressed 
in the control transfection. This resulted in a strong survivin band for the parental cell 
line as well as the three time-points. RT-PCR analysis should be repeated for the 
survivin cDNA transfections and the pTRE mock transfections using the same cycle 
number. At present it is not known if the expression of survivin-Ex3 in the mock 
transfection (Figure 3.2.4.2.1C), but not in the survivin cDNA transfection (Figure
3.2.4.2.1 A), was due to differences in cycle number or due to different transfected 
plasmid.
147
(A)
Time-point
Fig. 3.2.4.2.1 (A) Gel electrophoresis photograph of survivin RT-PCR results
on SKOV3-T.O. survivin cDNA transient transfection at 24,48,72hrs and 5day time 
points in the presence and absence of doxocycline. Neg=negative control and 
MW=molecular weight marker; (B) Densitometric analysis of the RT-PCR results 
(n=3).
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Fig. 3.2.4.2.1 (C) Gel electrophoresis photograph of survivin RT-PCR results
on SK0V3-T.0. pTRE mock transfection at 24, 48 and 72 hour time points. 
Neg=negative control and MW=molecular weight marker; (D) Densitometrie analysis 
of the RT-PCR results (n=3).
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Cells were harvested, protein was extracted and western blotting was carried out (see 
section 2.4.1) on the SKOV3-T.O.’ survivin cDNA transfections 24hr, 48hr, 72hr and 5 
days after transfection. No change in survivin protein expression as observed at any of 
the time-points. Transfections experiments were repeated more than three times and 
Western blots were carried using a range of protein concentrations. These included 
10(j,g, 20(j,g and 30 (ig of protein, but there was still no change in survivin protein 
expression (Figure 3.2.4.2.2 A, B and C). At a concentration of 30 (j.g protein, there 
seems to be an increase in survivin protein at 48 hours post-transfection (Figure 
3.2.4.2.2C). This was not reproducible and was not, therefore, considered to be a ‘real’ 
result. a-Tubulin was used as an endogenous control to ensure equal protein loading. 
Each western blot was carried out in duplicate for each protein concentration.
Western blot analysis was also included on cells treated with dox. Results, however, 
showed no increase in survivin protein expression at any of the four time points. There 
was also no difference between cells plus or minus dox. (Figure 3.2.4.2.2D). a-Tubulin 
western blot analysis was carried out to ensure equal protein loading and densitometry 
was carried out on this western blot by normalising the survivin bands to the a-Tubulin 
bands (Figure 3.2.4.2.2E). Western blot analysis was carried out in duplicate.
In addition, western blot analysis was carried out on a control transfection with the 
empty pTRE plasmid and there was no change in survivin protein expression (Figure 
3.2.4.2.2F). a-Tubulin was used as an endogenous control to ensure equal protein 
loading. Western blot for the control transfection was carried out once.
3.2.4.2.2 Analysis of SKOV3-T.O. Survivin cDNA transient transfectants using
Western blotting
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Fig. 3.2.4.2.2 (A) Survivin and a-Tubulin western blot on SKOV3-T.O.
survivin cDNA transient transfection at 24,48,72hrs and 5days at a conc. of 10[_ig 
protein; (B) Survivin Western blot on SKOV3-T.O. survivin cDNA transfection at 
24,48,72hrs and 5days at a conc. of 20(j,g protein; (C) Survivin Western blot on 
SKOV3-T.O. survivin cDNA transfection at 48,72hrs and 5days at a conc. of 30|j,g 
protein (n=2).
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Fig. 3.2.4.2.2 (D) Survivin and a-Tubulin western blot on SK0V3-T.0.
survivin cDNA transfection at 24,48,72hrs and 5day time points in the presence and 
absence of doxocycline; (E) Densitometric analysis of the Western blot results (n=2).
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Fig. 3.2.4.2.2(F) Survivin and a-Tubulin western blot on SKOV3-‘T.O.’ pTRE 
transfection at 24,48,72hrs and 5day time-points. (n=l).
Parent 24Hrs 48Hrs 72Hrs 5days
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Further analysis of the SKOV3-‘T.O.’ survivin cDNA transient transfections for protein 
expression included immunofluorescence (see section 2.4.2.2). Cells were seeded in 6- 
well plates, transfected, and after 48 hours were fixed with methanol and analysed by 
immunofluorescence. A control transfection was also carried out. Results showed 
survivin protein expression in the cells’ cytoplasm following the survivin cDNA 
transfection and the pTRE transfection (Fig. 3.2.4.2.3). In addition, the staining was of 
similar intensity in both transfections. Therefore there was apparently no survivin 
protein over-expression, in correlation with the results obtained by western blot 
analysis. This experiment was carried out once.
3.2A.2.3 Analysis of SKOV3-T.O. Survivin cDNA transient transfectants
using Immunofluorescence
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(A)
Fig. 3.2.4.2.3 (A) Immunofluorescence on SKOV3-‘T.O.’ survivin cDNA
transient transfection under (i) white light and (ii) fluorescent light; (B) 
Immunofluorescence on SKOV3-T.O. pTRE control transfection under (i) white light 
and (ii) fluorescent light (n=l).
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3.2.4.2.4 Analysis o f SKOV3-T.O. survivin cDNA transient transfections using in 
vitro toxicity testing
The sensitivity of the survivin transient transfectants to taxol and cisplatin was 
determined and compared to SKOV3-T.O. parent cell line drug sensitivity, using in 
vitro toxicity assays (section 2.3 .1).
Cells were transfected in 96-well plates, and drug was added to the plates at 0, 24, 48 
and 72 hours after transfection. Cells were exposed to the drugs for 5-7 days, and were 
then analysed using the acid-phosphatase assay. This was carried out on transfected 
cells plus and minus dox. and on pTRE-transfected cells. Control plates are plates 
without any plasmid or transfection agent.
The results showed no increase in the IC50 values of the survivin cDNA transfected cells 
compared to pTRE transfected cells or non-transfected cells to taxol and cisplatin. 
There was also no difference between the IC50 values of cells transfected in the presence 
and absence of dox. as shown in Figure 3.2.4.2.4. Toxicity assays were carried out in 
duplicate.
Therefore, survivin cDNA transient transfectants are not more resistant to 
chemotherapy drugs, taxol and cisplatin, than the parental population.
3.2.4.2.5 Analysis o f SKOV3-T.O. survivin cDNA transient transfections 
using TUNEL assay
TUNEL assay was carried out on the SKOV3-T.O. parental cells and SKOV3-‘T.O.’- 
survivin cDNA (see section 2.3.2.1) to determine whether or not the transfected cells 
had developed resistance to apoptosis. Taxol was used to induce apoptosis in the cells 
for 48 hours, after which the cells were harvested and TUNEL technique was carried 
out as described in section 2.3.21. Slides were analysed using a fluorescence 
microscope. The results were difficult to analyse, due to non-specific labeling of the 
dividing cells. However, there was no apparent difference in viability between the 
parental cells and the transfected cells (Figure 3.2.4.2.5). The technique was difficult to 
optimise and was carried out successfully once.
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Fig. 3.2.4.2.4 (A) Effect of survivin on taxol resistance in SKOV3-survivin
cDNA transfectants; (B) Effect of survivin on cisplatin resistance in SKOV3-survivin 
cDNA transfectants (n=2).
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Figure 3.2.4.2.5 (A) SK0V3 ‘T.O.’ parent cells under fluorescent light (blue
arrows indicate dividing cells, red arrow indicates apoptotic cell); (B) SKOV3 ‘T.O.’ 
parent cells under white light; (C) SKOV3 ‘T.O’-survivin cDNA under fluorescent 
light; (D) SKOV3 ‘T.O’-survivin cDNA under white light. (n=l)
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To investigate survivin’s role in invasion, cells were set up and transfected with 
survivin cDNA, in the presence and absence of dox., and with pTRE empty vector. 
Invasion assays were set up a day after transfection and cells were incubated for 48 
hours before they were stained using crystal violet (see section 2.5.1).
At first there seemed to be a decease in invasiveness o f cells transfected with survivin 
cDNA compared to cells transfected with pTRE or non-transfected cells (Fig. 3.2.4.2.6). 
These results, however, were not reproducible and it now seems that there is in fact no 
change in invasiveness.
RPMI-2650 parent cells were used a negative control, while RPMI-2650 melphalan- 
resistant cells were used as a positive control.
3.2.4.2.6 Analysis of SKOV3-T.O. survivin cDNA transient transfections using in
vitro Invasion Assays
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Fig. 3.2.4.2.6 Invasion assays of (A) SKOV3-T.O. parent cells; (B) SKOV3-
T.O.- pTRE; (C) SKOV3-T.O.-survivin cDNA (+Dox); (D) SKOV3-T.O.-survivin 
cDNA (-Dox); (E) RPMI (parent); (E) RPMI (Melphalan) (n=3).
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3.2.5 Transient Transfection of Survivin cDNA into DLKP cells
To try and determine the reason for survivin mRNA over-expression, but lack of 
survivin protein over-expression in SKOV-3 ‘T.O.’ transient transfections, a second cell 
line was chosen to study this effect. DLKP was also transiently transfected with 
survivin cDNA. Cells were set up in 25cm2 flasks as described in section 2.4.5.4, 
transfected with cDNA in pTarget vector, and taken down at several time points for 
analysis by RT-PCR and Western blot analysis. These time points were 24 hours, 48 
hours, 72 hours and 5 days after the start of transfection.
3.2.5.1 Analysis o f DLKP Survivin cDNA transfectants using R T-PCR
Cells were harvested and RT-PCR was carried out on the DLKP survivin cDNA 
transfections at the time points mentioned above. Results showed that at 24 hours after 
transfections, survivin mRNA expression had increased dramatically and at 48 hours 
after transfection, there was a slight drop in survivin mRNA expression, which 
continued until the 5 day time point (see Figure 3.2.5.1). P-actin was used as an 
endogenous control. Sterile water was used as a negative control and the molecular 
weight marker “<|)-X174” Hae III digest was used as a size reference. RT-CPR analysis 
was carried out once.
3.2.5.2 Analysis o f DLKP Survivin cDNA transient transfectants using W estern  
blotting
Cells were harvested, protein was extracted and Western blotting was carried out on the 
DLKP survivin cDNA transfections at 24hr, 48hr and 72hr post-transfection. Results, 
however, showed no increase in survivin protein expression at any of the four time 
points. Similar to the results obtained from the SKOV3-‘T.O.’ transient transfections, 
the DLKP survivin cDNA transient transfection showed a significant increase in 
survivin mRNA expression, but no increase in survivin protein expression. a-Tubulin 
was used as an endogenous control to ensure equal protein loading (see Figure 3.2.5.2). 
This suggests that the same mechanism being used by the SKOV3-‘T.O.’ cells to block 
survivin translation is being used by DLKP cell. This experiment was carried out once.
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Fig. 3.2.5.1. Gel electrophoresis photograph of survivin RT-PCR results on DLKP 
survivin cDNA transient transfection at 24,48,72hrs and 5day time points. M=molecular 
weight marker. (n=l)
DLKP 24hr 48hr 72hr
<— Survivin (16.5kDa)
<— a-Tubulin  (50kDa)
Fig. 3.2.5.2 Survivin and a-Tubulin western blot on DLKP. Survivin cDNA
transfection at 24,48, and 72hrs post-transfection. (n=l).
3.2.6 Transient Transfection of Survivin cDNA into MCF-7 ‘Tet offP cells
A third attempt was made at transiently over-expressing the survivin protein and the cell 
line chosen for this was MCF-7 ‘Tet off. Like SKOV-3 ‘Tet o ff, this cell line was 
stably transfected with the Tet-Off plasmid by Helena Joyce, M.Sc., in the NICB. As 
discussed in section 3.2.3, the advantage of this gene expression system is that it allows 
regulated mammalian gene expression with tetracycline or tetracycline derivatives, in 
this case, doxocycline. In the Tet-Off system, gene expression is turned on when 
doxocycline (Dox) is removed; in contrast to the Tet-On system, where expression is 
turned on by the addition of Dox.
As in the previous transient transfection experiments, cells were set up in 25 cm2 flasks, 
transfected with cDNA or the empty pTRE vector, and taken down at several time 
points for analysis by RT-PCR and Western blot analysis. These time points were: 24 
hours, 48 hours, 72 hours and 5 days after the start of transfection.
3.2.6.1 Analysis o f M CF-7 T.O. survivin cDNA transient transfections using RT- 
PCR
Cells were harvested and RT-PCR was carried out on the MCF-7 T.O. survivin cDNA 
transfections at the time points mentioned above. Results showed that at 24 hours after 
transfections, survivin mRNA expression had increased dramatically (Figure 3.2.6.1 A). 
To ensure that this finding was due to survivin cDNA transfection, a mock transient 
transfection was carried out using the pTRE empty plasmid.
Results showed a constant level of expression of survivin mRNA, proving that the 
effect seen with the cDNA transfection is a real effect. The transfection was also carried 
out in the presence and absence of Dox, to determine whether the inducible system 
working in the MCF-7 cells, as it was in the SKOV3 cells. This was however, found not 
be the case, as RT-PCR results showed no difference in the two states of expression (i.e. 
in the ‘on’ and ‘off states) (Figure 3.2.6.IB). The molecular weight marker “<|)-X174” 
Hae III digest was used as a size reference. P-actin was used as an internal control in all 
RT-PCR analysis. As with most RT-PCRs presented here, sterile water was used as a 
negative control and RT-PCRs were carried out in triplicate.
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<— P-actin (s)
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< - P-actin (s)
Lane 1: MW marker, Lane 2: MCF-7 parent, Lane 3: pTRE 24hr,
Lane 4: Surv -dox 24hr, Lane 5: Surv +dox 24hr, Lane 6: pTRE 48hr 
Lane 7: Surv -dox 48hr, Lane 8: Surv +dox 48hr, Lane 9: pTRE 72hr 
Lane 10: Surv -dox 72hr, Lane 11: Surv +dox 72hr, Lane 12: pTRE 5days 
Lane 13: Surv -dox 5days, Lane 14: Surv +dox 5days, Lane 15: Neg
Fig. 3.2.6.1 (A) Gel electrophoresis photograph of survivin RT-PCR results
on MCF-7 ‘T.O.’ survivin cDNA transient transfection at 24,48,72hrs and 5day time 
points. (B) Gel electrophoresis photograph of survivin RT-PCR results on MCF-7- 
‘T.O.’ survivin cDNA transient transfection in the presence and absence of Dox. 
MW=molecular weight marker and Neg=negative control. (n=3).
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MCF-7 ‘T.O.’ transient transfection was carried out more than three times. The first 
time, as can be clearly seen in Figure 3.2.6.2A, there was a large increase in survivin 
protein at the 24 hour time-point as seen by western blot analysis. However, when this 
was repeated, the survivin protein over-expression was lost (Figure 3.2.6.2B), leaving 
only an over-expression in survivin mRNA. a-Tubulin was used as an endogenous 
control to ensure equal protein loading. Transfections of MCF-7-‘T.O’and western blot 
analysis were carried out five times. Western blot analysis was carried out on cells 
treated with dox. Results showed no change in survivin protein expression at any of the 
four time points. There was also no difference between cells plus or minus dox. (Figure 
3.2.6.2B). This was carried out three time, using a-Tubulin as an internal control to 
ensure equal protein loading.
Control transfections using the empty pTRE vector were carried out and the level of 
survivin protein remained constant (Figure 3.2.6.2C). As with all survivin western blot 
analysis, a-Tubulin was used as an endogenous control to ensure equal protein loading. 
Control transfections were carried out in triplicate.
3.2.6.2 Analysis of MCF-7 T.O. Survivin cDNA transient transfectants using
Western blotting
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Fig. 3.2.6.2 (A) Survivin and a-Tubulin western blots on MCF-7-‘T.O.’
survivin cDNA transfection at 24, 48, 72hrs and 5 day time points. (n=5); (B) Survivin 
and a-Tubulin western blot on MCF-7-‘T.O.’. survivin cDNA transfection at 24, 48, 
72hrs and 5 day time points in the absence and presence of Dox, when experimented 
were repeated. (n=3).
24hr 48nr 72hr 5days
Par -dox +dox -dox +dox -dox +dox - dox +dox
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MCF-7 24hr 48hr 72hr Sdays
Fig. 3.2.6.2 (C) Survivin and a-Tubulin western blots on M CF-7-T.0’ pTRE
control transfection at 24, 48, 72hrs and 5 days post-transfection. (n=3).
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3.3 Analysis of DLKP Drug-resistant Variants
DLKP is a well characterised squamous lung carcinoma cell line developed in the 
NICB. In this section of the thesis, drug resistant variants of this cell line were 
developed by pulse exposure of cells, to increasing concentrations of chemotherapeutic 
drug, following weekly 4-hour exposure to the drug (see section 2.3.3). Starting 
concentration and highest concentration of drug used are presented in Table 3.3.1.
Selection Drug Starting Cone. H ighest Cone.
Vincristine (n-g/ml) 0.04 40
5-Fluorouracil (|ig/m l) 10 250
Taxotere (ng/ml) 2 8000
Table 3.3.1 Concentrations of chemotherapeutic drug used for the selection of DLKP 
cells.
3.3.1 Analysis o f DLKP resistant variants using in vitro  toxicity testing
To investigate the resistance profiles of the established variants of DLKP cell line, 
toxicity assays were carried out as described in section 2 .3 .1 .  The chemotherapeutic 
agents included the selective drug, taxotere, 5-FU or vincristine, as well as other 
chemotherapy drugs such as, adriamycin, carboplatin, taxol and CCNU.
3.3.1.1 Toxicity Profile o f each variant to its selection drug
Table 3 .3 .1 .1 .a represents the IC50 values of each of the chemotherapeutic agents that 
the DLKP parent cell line were selected with, resulting in 3 variants, DLKP-5- 
Fluorouracil (DLKP-5-FU), DLKP-Taxotere (DLKP-TXT) and DLKP-Vincristine 
(DLKP-VCR). The results demonstrate that DLKP-VCR and DLKP-TXT variants 
exhibited resistance to vincristine and taxotere, respectively, while DLKP-5FU didn’t 
show resistance to 5-Fluorouracil as shown in Table 3.3.1.1.
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Cell line V CR  (ng/ml) 5FU (ng/m l) Taxotere (ng/ml)
DLKP Parent 0.266+0.02 0.92+0.1 0.3+0.1
Drug resistant variant 1417.6+296 0.93+0.1 134+41
Table 3.3.1.1 (a) IC50 values for DLKP, DLKP-vincristine, DLKP 5-FU and DLKP- 
taxotere variants to selection drug. (n=3).
Cell line VCR 5FU Taxotere
DLKP Parent 1 1 1
Resistant Variant 5329.3 1.01 421
Table 3.3.1.1 (b) Fold resistance of the DLKP variants to their selecting drug relative to 
the parental DLKP cell line. (n=3).
3.3.1.2 Cross resistance profile o f the DLKP variants to range o f drugs
The resistance of the DLKP variants to a range of chemotherapy drugs, as well as their 
selection agents, was carried out to determine whether the variants have become 
multiple drug resistant. The drugs selected for determining this were: Taxotere, Taxol 
Vincristine, 5-FU, Adriamycin, CCNU, and Cisplatin. Table 3.3.1.2(a) represents the 
IC50 values of each of the chemotherapeutic agents for the DLKP variants and DLKP 
parental cell line. The results demonstrate that the DLKP-vincristine resistant and 
DLKP-taxotere resistant variants exhibited cross resistance to vincristine, taxotere, taxol 
and adriamycin, all of which are substrates to P-glycoprotein.
Table 3.3.1.2(b) represents the fold differences of DLKP variants compared to the 
parental cell line to each chemotherapeutic drug.
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Cell line Taxotere Taxol Vincristine Adriamycin Cisplatin CCNU 5FU
(ng/ml) (ng/ml) (ng/ml) (Hg/ml) (ng/ml) (ng/ml) (ng/ml)
DLKP 0.3+0.1 2.2+0.5 0.266+0.02 13.9+0.7 0.24+0.04 5.7+0.9 0.92+0.1
(n=3) (n=3) (n=3) (n=3) (n=4) (n~3) (11=3)
DLKP-VCR 74+48 272±13.1 1417.6+296 364.6+26 0.06+0.002 4.1+0.4 1.02+0.2
(n=3) (n~3) (n=3) (n=3) (n=4) (n=3) (n=3)
DLKP-5FU 0.3±0.1 1.35+0.4 0.24+0.002 6.4+1.1 0.138+0.006 5.6+0.6 0.93+0.1
(n=3) (n=3) (n=3) (n=3) (n=4) (n=3) (n=3)
DLKP-TXT 134+41 463+96 1771+235 725+116 0.3+0.08 7.6+1.8 0.8+0.1
(n=3) (n=3) (n=3) (n=3) (n=4) (n~3) (n=3)
Table 3.3.1.2 (a) IC50 values for DLKP, DLKP-vincristine, DLKP-5-FU and DLKP-taxotere variants to a range of drugs.
Cell line Taxotere Taxol Vincristine Adriamycin Cisplatin CCNU 5FU
D L K P 1 1 1 1 1 1 1
D L K P -V C R 233 124 5329 26 0.25 0.72 1.17
D L K P -5F U 1 0.61 0.9 0.5 0.6 0.98 1.02
D L K P -T X T 421 210 6657 52 1.2 1.3 0.9
Table 3.3.1.2 (b) Fold resistance of DLKP variants to a range of chemotherapy drugs relative to the parental DLKP cell line.
3.3.2 Morphological Analysis of DLKP and its MDR variants
Following exposure to the chemotherapeutic drugs, taxotere, vincristine and 5- 
fluorouracil, the morphology of the DLKP variants was examined and was found to 
change in some cases. During the selection procedure, the DLKP 5-FU variant became 
very elongated compared to the parental cell line. The DLKP-VCR variant also became 
elongated, but to a much lesser extent than the DLKP-5-FU variant. The DLKP-TXT 
variant changed very slightly in morphology, also becoming slightly elongated 
compared to the parental cells. However, unlike DLKP-5-FU and DLKP-VCR, this 
change was barely noticeable (see figure 3.3.2.1).
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Fig. 3.3.2.1 The morphology of DLKP and its MDR variants. (A) DLKP parental cell 
line, (B) DLKP-TXT, (C) DLKP-5-FU, (D) DLKP-VCR (10X).
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3.3.3 Analysis of DLKP resistant variants using in vitro Invasion assays
In order to investigate the invasive ability of the DLKP MDR variants compared to the 
parental cell line, invasion assays were carried out as described in section 2.5.1. Cell 
culture inserts were coated with ECM before cells were added.
Invasion assays have been carried out in triplicate on ready coated inserts available from 
Becton-Dickinson (see Figure 3.3.3.1) results indicate that DLKP-vincristine and 
DLKP-5FU are non-invasive, while DLKP-taxotere (termed DLKP-TXT-1 in sections
3.3.3, 3.3.4 and 3.3.5) is highly invasive (Fig. 3.3.l.C). This has been confirmed by 
invasion assays carried out, more than three times, on standard inserts coated with two 
different batches of ECM as shown in Figure 3.3.33. Findings from DLKP-5FU and 
DLKP-TXT-1 are contradictory to Dr. Liang’s finding from her previous selections of  
DLKP-5FU and DLKP-taxotere (termed DLKP-TXT-2 in sections 3.3.3, 3.3.4 and 
3.3.5) as shown in Figure 3.3.3.1, while the findings from DLKP-vincristine are in 
agreement with those reported by Dr. Liang. The invasiveness of two batches of DLKP 
parent was also tested and it was found that one batch (termed DLKP-1 in section 3.3.3,
3.3.4 and 3.3.5) exhibited lower invasiveness than the second (termed DLKP-2 in 
sections 3.3.3, 3.3.4 and 3.3.5). The nasal carcinoma cell line, RPMI-2650, was used as 
a negative control as it is considered to be a non-invasive. DLKP-2 and DLKP-TXT-2 
are used only in invasion, inhibition and motility assays for comparison purposes and 
were not included in any other part of the analysis.
A quantitative method for detecting invasion in these assays was developed, whereby 
cell on the bottom of the invasion chamber are exposed to acid phosphatase enzyme, 
which detects viable cells and a yellow colour is observed. This is then read on plate 
reader at 405nm. The results were plotted on a histograph as shown in figure 3.3.3.2. 
The graph shows that DLKP-TXT-1 exhibits the highest level of invasiveness, followed 
by DLKP-2. This is in agreement with the photographic representation in Figure 3.3.3.1 
and 3.3.3.3. DLKP-5FU and DLKP-VCR exhibit that lowest level of invasiveness and 
RPMI is almost non-invasive. Quantitative analysis was carried out once on the ready- 
coated insert (i.e. on the photographs shown in Figure 3.3.3.1, but not photographs in 
Figure 3.3.3.3).
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Figure 3.3.3.1 Invasion assays of (A) DLKP-1, (B) DLKP-2, (C) DLKP-TXT-1,
(D) DLKP-TXT-2, (E) DLKP-5-FU, (F) DLKP-VCR using the ready-coated invasion
chambers (4X) (n=3).
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Figure 3.3.3.2 Absorbance values o f invasion assay results using Acid
Phosphatase and reading at 405nm (n=l). A photograph of RPMI-2650 invasion assay
is shown in figure 3.3.4.2.
Figure 3.3.3.3 Invasion assays of (A) DLKP-1, (B) DLKP-2, (C) DLKP-TXT-1,
(D) DLKP-TXT-2, (E) DLKP-5-FU, (F) DLKP-VCR using standard invasion chambers
(1 OX) (n>3).
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3.3.4 MMP Inhibition Assays on DLKP and its MDR variants
Invasion assays were carried on the MDR variant, DLKP-TXT-1, in the presence and 
absence of matrix metalloproteases inhibitors (see section 2.5.1.1). When the cells were 
incubated with MMP inhibitor I, which inhibits MMP-1, -3, -8 and MMP-9, or MMP-2 
inhibitor I, which inhibits MMP-2, cell invasion was decreased compared to cells that 
were not incubated with any inhibitor. When cells were incubated with MMP inhibitor 
III, which inhibits MMP-1, -2, -3, -7 and MMP-13, the inhibition of cell invasion was 
more pronounced than the decease caused by MMP inhibitor I or MMP-2 inhibitor I 
(Figure 3.3.4.1). This assay was carried out once.
Further inhibition assays were carried out using MMP inhibitor III on the DLKP-1 and 
DLKP-2, as well as DLKP-TXT-1, DLKP-5-FU and DLKP-VCR variants (Figure 
3 .3.4.2). Quantitative analysis was carried out on this assay using acid phosphatase, as 
described in section 3.3.3 and in section 2.5.1 of the material and methods section. A 
graph representing the findings is shown in Figure 3.3.4..3. This shows that MMP 
inhibitor HI caused a decease in cell invasion of DLKP-TXT-1 and DLKP-2 and to a 
lesser extent, DLKP-1. The inhibitor had no great effect on DLKP-5FU and DLKP- 
VCR, which are non-invasive. This indicates that MMP inhibitor III does not inhibit cell 
invasion, but slows it down. This assay was carried out once.
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Figure 3.3.4.1 MMP Inhibition assays of (A) DLKP-TXT-1 with no inhibitors,
(B) DLKP-TXT-1 with MMP inhibitor I, (C) DLKP-TXT-1 with MMP inhibitor IE, 
(D) DLKP-TXT-1 with MMP-2 inhibitor I (10X) (n=l).
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Figure 3.3.4.2 MMP Inhibition assay, with MMP inhibitor IE, of (A) DLKP-1, 
(B) DLKP-2, (C) DLKP-TXT-1, (D) DLKP-5-FU, (E) DLKP-VCR, (F) RPMI-2650 
negative control for invasion and inhibition assays (4X) (n=l)
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Figure 3.3.4.3 Absorbance values o f MMP inhibition assay results (Figure
3.3.4.2) using acid phosphatase and reading at 405nm (n=l).
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Motility assays were carried out to compare the locomotive ability of DLKP parental 
cell line and its selected variants. The procedure used to demonstrate cell motility was 
similar to that used for the invasion assays except that the inserts were not coated with 
ECM prior to the addition of the cells. The assays was taken down at three time points: 
12 hours, 24 hours and 48 hours. The results obtained demonstrated that DLKP 
taxotere-1 showed significantly higher motility than the DLKP-TXT-2, at all time 
points. It also showed significantly higher motility than DLKP-5-FU and DLKP-VCR at 
all the time points. In addition, DLKP-TXT-1 showed significantly higher motility than 
DLKP parental cells from both batches, in particular, DLKP-1. However, at 48 hours 
the difference between DLKP-TXT-2 and DLKP-2 was not as obvious. The results for 
each time point are shown in Figure 3.3.5.1a, b, and c. RPMI-2650 parent was used as a 
negative control for all motility assays (Figure 3.3.5.Id)
The motility assays, in general, correlate with the invasion assay results, i.e. cells that 
tend to be more invasive display an increase in motility and vice versa. A quantitative 
representation of the results is shown in Figure 3.3.5.2. The graphs show two 
quantitative methods of analysis as described in section 2.5.1. The acid phosphatase 
method (Figure 3.3.5.2A) seems to be more accurate than the crystal violet elution 
method (Figure 3.3.5.2B). Both graphs support the photographic analysis presented in 
Figures 3.3.5.1a, b, c and d, illustrating that DLKP-2 and DLKP-TXT-1 are the most 
motile. Motility increases dramatically after 48 hours in DLKP-1 and DLKP-2 and the 
four variants (Figure 3.3.5.2A). In Figure 3.3.5.2B the difference between 24 hours and 
48 hours is not as dramatic as in Figure 3.3.5.2A.
3.3.5 Analysis of DLKP resistant variants using in vitro Motility assays
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Figure 3.3.5.1a Motility assays of (A) DLKP-1, (B) DLKP-2, (C) DLKP-TXT-1,
(D) DLKP-TXT-2, (E) DLKP-5-FU, (F) DLKP-VCR at 12 hours (4X) (n=3)
183
I ’ v  ' A'. • ■
• *  • *
#r  I f
* **'v . ?  * '*  • . '  • i
e1 *  -  - V  >  V •!•: V '  •
Figure 3.3.5.1b Motility assays of (A) DLKP-1, (B) DLKP-2, (C) DLKP-TXT-1,
(D) DLKP-TXT-2, (E) DLKP-5-FU, (F) DLKP-VCR at 24 hours (4X) (n=3).
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Figure 3.3.5.1c Motility assays of (A) DLKP-1, (B) DLKP-2, (C) DLKP-TXT-1,
(D) DLKP-TXT-2, (E) DLKP-5-FU, (F) DLKP-VCR at 48 hours (4X) (n=3).
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Figure 3.3.5.1d Motility assays of (A) RPMI-2650 at 12 hours, (B) RPMI-2650 at
24 hours, (C) RPMI-2650 at 48 hours (4X) (n=3).
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Figure 3.3.5.2 (A) Absorbance values of motility assay results using acid
phosphatase and reading at 405nm, (B) Absorbance values of each eluted insert from 
motility assays at 12 hour, 24 hour and 48 hour time points and reading at 570 nm.
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3.3.6 Studies o f M M Ps in the DLKP selected variants
Matrix metalloproteinases (MMPs), which may be secreted by cells, play an important 
role in degrading extracellular martix. To investigate the mechanisms underlying the 
invasive phenotype of the DLKP parental cell line and its variants, studies of MMPs 
were carried out as described in section 2.5.
3.3.6.1 Zymography of MMPs in the DLKP variants
Zymography gels have been carried out on concentrated supernatants collected from the 
3 variants. Figure 3.3.6.1 shows that DLKP parent and its three variants showed bands 
representing MMP-2, MMP-9 and a third band which may be MMP-13.
Figure 3.3.6.1 Zymograph of proteinases in the DLKP parent cell line and its variants.
M=size marker (n=3)
3.3.6.2 Zym ography with proteinase inhibitors or enhancer
To confirm that the three bands are MMPs, proteinase inhibitors were added to 
inactivate their corresponding substrates.
3.3.6.2.1 The effect of EDTA
EDTA is a chelating agent which can bind the zinc and calcium which are needed for 
the activation of MMPs. After the gel was incubated with EDTA the three bands in all 
cell lines dissappeared. Therefore, indicating that the three bands are MMPs.
Fig. 3.3.6.2.1 Zymograph of proteinases in DLKP parent and its variants when
incubated with EDTA. M=size marker (n=2).
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3.3.6.2.2 The effect of PMSF
PMSF is a serine protease inhibitor, which does not inhibit MMP secretion. PMSF was 
used to establish that the bands observed are due to MMP secretion, not serine protease 
secretion. After the gel was incubated with PMSF, all bands were still visible, 
suggesting that all three are MMP bands.
M DLKP VCR 5FU TXT
iv®: <— MMP-9
f -  MMP-2
<- MMP-13
3.3.6.2.2 Zymograph of proteinases in the DLKP parent cell line and its variants
incubated with PMSF. M=size marker (n=2).
190
3.3.7 Analysis o f DLKP resistant variants using RT-PCR analysis
To detect the expression of MDR- and apoptosis-related genes at the RNA level, RT- 
PCR was carried out as described in section 2.2. All RT-PCR reactions were carried out 
on 3 independent RNA isolations on the DLKP variants. 10 genes were studied. The 
results are presented below.
In all RT-PCR gels (Figures 3.3.7.1-3.3.7.10), MW represent molecular weight marker, 
Hinfl of (j)-X174 DNA. Negative control is ultra pure water, and positive control, where 
included, is a purified plasmid of the gene in question. Except in the case of survivin 
RT-PCR, where positive control was a cell line transfected with survivin cDNA (Figure 
3.3.7.10). All RT-PCRs were carried out in triplicate and were reproducible, with the 
exception of E-cadherin RT-PCR (see section 3.3.7.8).
3.3.7.1 Mdr-1 expression in DLKP cell line and its selected variants by RT-PCR
RT-PCR analysis showed that mdr-1 expression was undetectable in the DLKP parental 
cell line as well as the DLKP-5FU variant. Mdr-1 was highly over-expressed in the two 
variants, DLKP-vincristine and DLKP-taxotere.
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Figure 3.3.7.1 (a) RT-PCR analysis of mdr-1 expression in the DLKP parent
cell line and its variants, (b) Densitometry of RT-PCR. MW=Molecular weight marker;
Neg=negative control (n=3).
Densitometry of DLKP variants Mdr-1 RT-PCR
DLKP parent DLKP VCR DLKP 5-FU DLKPTxt Neg
Cell Line
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3.3.7.2 MRP-1 expression in DLKP cell line and its variants by RT-PCR
RT-PCR analysis on MRP-1 shows that there was no change in MRP-1 mRNA
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Figure 3.3.7.2 (a) RT-PCR analysis of MRP-1 expression in the DLKP parent
cell line and its variants, (b) Densitometry on RT-PCR. MW=Molecular weight marker;
Neg=negative control (n=3).
3.3.7.3 M RP-2 expression in DLKP cell line and its variants by RT-PCR
RT-PCR analysis on MRP-2 (cMOAT) shows that there was no detectable expression 
of MRP-2 mRNA in DLKP parent or DLKP variants.
(a)
MW DLKP VCR 5FU TXT POS NEG
<- (i-actin
<— MRP2
Figure 3.6.7.3 (a) RT-PCR analysis of MRP-2 expression in the DLKP parent
cell line and its variants. MW=Molecular weight marker; Neg=negative control (n=3).
3.3.7.4 M RP-3 expression in DLKP cell line and its variants by RT-PCR
RT-PCR analysis on MRP-3 shows that there was no detectable expression of MRP-3 
mRNA in DLKP parent, DLKP-vincristine or DLKP-taxotere. There was, however, a 
band representing MRP-3 mRNA expression in the DLKP-5FU variant.
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Figure 3.3.7.4 (a) RT-PCR analysis of MRP-3 expression in the DLKP parent
cell line and its DLKP variants, (b) Densitometry on RT-PCR. MW=Molecular weight
marker; Neg=negative control (n=3).
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3 . 3 .1 .5  M RP-4 expression in DLKP cell line and its variants by RT-PCR
RT-PCR analysis on MRP-4 shows a very faint band (almost un-detectable) for MRP-4 
mRNA expression in DLKP parent and its three variants. The band is strongest in 
DLKP-vincristine.
MW DLKP VCR 5FU TXT POS NEG MW
(b)
Densitometry of DLKP variants MRP4 RT-PCR
Cell Line
Figure 3.3.7.5 (a) RT-PCR analysis of MRP-4 expression in the DLKP parent
cell line and its variants, (b) Densitometry on RT-PCR. MW=Molecular weight marker;
Neg=negative control (n=3).
3.3.7.6 M R P-5 expression in DLKP cell line and its variants by R T-PC R
RT-PCR analysis on MRP-5 shows undetectable levels of MRP-5 mRNA expression in 
DLKP parent and its three variants.
MW DLKP VCR 5FU TXT POS
< — MRP5 
<— p-actin
Figure 3.3.7.6 (a) RT-PCR analysis of MRP-5 expression in the DLKP parent
cell line and its variants. MW=Molecular weight marker; Neg=negative control (n=3).
3.3.7.7 BCRP expression in DLKP cell line and its variants by R T-PC R
RT-PCR analysis on BCRP shows very low levels of BCRP mRNA expression in 
DLKP parent and its three variants.
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Figure 3.3.7.7 (a) RT-PCR analysis of BCRP expression in the DLKP parent
cell line and its variants, (b) Densitometry of RT-PCR. MW=Molecular weight marker;
Neg=negative control (n=3).
3.3.7.8 E-cadherin expression in DLKP cell line and its variants by R T-PC R
RT-PCR analysis shows expression of E-cadherin mRNA all cell lines studied. DLKP- 
taxotere displays the strongest expression of E-cadherin mRNA compared to DLKP 
parent and the other two variants. This was only observed in one experiment, however, 
and could be a random result. Repeat experiments showed no change.
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Figure 3.3.7.8 (a) RT-PCR analysis of E-cadherin expression in the DLKP
parent cell line and its variants, (b) Densitometry of RT-PCR. MW=Molecular weight
marker; Neg=negative control (n=3)
DLKP parent DLKP VCR DLKP 5-FU DLKP Txt Neg
Cell Line
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3.3.7.9 Galectin-3 expression in DLKP cell line and its variants by RT-PCR
RT-PCR analysis on galectin-3 (Gal-3) shows that there was no change in galectin-3 
mRNA expression in the DLKP variants compared to the parent cell line.
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Figure 3.3.7.9 (a) RT-PCR analysis of galectin-3 expression in the DLKP parent
cell line and its variants, (b) Densitometry on RT-PCR. MW=Molecular weight marker;
Neg=negative control (n=3).
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RT-PCR analysis of survivin indicates that survivin mRNA expression is not greatly 
changed in the DLKP variants compared to DLKP parental cell line. Similarly, 
survivin-delta Ex3 mRNA expression was unaltered, while Survivin-2B mRNA 
expression was undetectable in all of the cell lines.
(a)
MW DLKP VCR 5FU TXT POS NEG
3.3.7.10 Survivin expression in DLKP cell line and its variants by RT-PCR
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Figure 3.3.7.10 (a) RT-PCR analysis of survivin expression in the DLKP parent
cell line and its variants, (b) Densitometry of RT-PCR. MW=Molecular weight marker; 
Neg=negative control (n=3).
201
3.3.8 Analysis o f DLK P resistant variants using W estern blot analysis
To detect the expression of relevant markers at the protein level, Western blotting was 
carried out as described in section 2.3. Western blots were carried out on 3 independent 
protein extractions from the DLKP variants. Four proteins were analysed (MDR1/P- 
170), MRP1, E-cadherin and survivin). The results are presented below.
3.3.8.1 P-170 expression in the DLKP cell line and its variants by western blot 
analysis
Western blot analysis of Mdr-1, demonstrates a dramatic increase in P-170 protein in 
the two MDR variants, DLKP-VCR and DLKP-TXT compared to the DLKP parent cell 
line and the DLKP-5-FU variant. This result was reproducible when western blot 
analysis was carried out in triplicate on three separate protein extractions. a-Tubulin 
was used as an endogenous control to ensure equal protein loading.
DLKP VCR 5-FU TXT
P-170
a-Tubulin
Figure 3.3.8.1 Western blot analysis of P-170 protein expression in DLKP 
parent and its selected variants, using a-Tubulin as an internal control to demonstrate 
equal loading (n=3).
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3.3.8.2 MRP-1 expression in the DLKP cell line and its variants by western blot
analysis
Western blot analysis of MRP-1 demonstrates an increase in MRP-1 protein expression 
in the DLKP-TXT variant compared to the DLKP parent cell line and the DLKP-VCR 
and DLKP-5FU variants. This was successfully carried out twice and the results were 
reproducible. An RPMI-2650 drug-selected variant was used as a positive control as has 
been previously shown to express MRP-1 protein by other researchers in the NICB. a- 
Tubulin was used as an internal control to ensure equal protein loading.
DLKP VCR 5-FU TXT Pos
< - MRP-1 
<— a-Tubulin
Figure 3.3.8.2 Western blot analysis of MRP1 protein expression in DLKP
parent and its selected variants, using a-Tubulin as an internal control to demonstrate 
equal loading (n=2).
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3.3.8.3 E-cadherion expression in the DLKP cell line and its variants by western
blot analysis
E-cadherin protein expression was analysed by western blot analysis in the DLKP 
selected variants. Results indicate a slight increase in E-cadherin protein expression in 
the DLKP-TXT variants compared to the DLKP parent cell line and the DLKP-VCR 
and DLKP-5-FU variants. This experiments was only carried out once and may need to 
repeated to confirm this finding. a-Tubulin was used as an internal control.
DLKP VCR 5-FU TXT
E-Cadherin
a-Tubulin
Figure 3.3.8.3 Western blot analysis of E-cadherin protein expression in DLKP
parent and its selected variants, using a-Tubulin as an internal control to demonstrate 
equal loading (n=l).
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Western blot analysis was carried out on the DLKP parent cell line and its variants to 
study the expression of survivin protein. Results demonstrate the survivin protein is 
dramatically down-regulated in the two MDR variants, DLKP-VCR and DLKP-TXT 
compared to the DLKP parent cell line and the DLKP-5-FU variant. This result was 
reproducible when the western blot analysis was repeated three times on three separate 
protein extractions. All three western blots are shown in Figure 3.3.8.4 (A B and C). a - 
Tubulin was used as an internal control to ensure equal protein loading in all 
experiments.
3.3.8.4 Survivin expression in the DLKP cell line and its variants by western
blot analysis
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(A) DLKP VCR 5-FU TXT
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Figure 3.3.8.5 Western blot analysis of survivin protein expression in DLKP
parent and its selected variants, using a-Tubulin as an internal control to demonstrate
equal loading (n=3).
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3.3.9 DNA Microarray Analysis
DNA microarray technique was used to identify changes in gene expression may have 
occurred due to drug exposure of DLKP cells. The cell lines included in this study were 
DLKP-1, DLKP-2, DLKP-VCR, DLKP-TXT-1 and DLKP-TXT-2.
The apoptosis- and MDR-related genes analysed by RT-PCR and/or western blot 
analysis were selected for preliminary DNA array analysis. These are listed in Table
3.3.9.1 and the fold changes in the three resistant cell lines, DLKP-TXT-1, DLKP-TXT- 
2 and DLKP-VCR is given. A fold-change of less than 2 was not considered to be a 
‘real’ change. Table 3.3.9.1 also indicates (where relevant) if the findings agree with the 
RT-PCR results.
G e n e  o f  
i n t e r e s t
D L K P - 1 D L K P - V C R D L K P - T x t - 1 D L K P - T x t - 2
M d r - 1 l 92.5 (Y) 300 (Y) 44
M R P 1 l 0.9 (Y) 1 0 0 0.9
* M R P 2 l 4.2 (N) 1.8 (N) 1.4
* M R P 3 l 0.7 (Y) 1.4 0 0 1.1
M R P 4 l 1(Y) 0.3 (N) 1.1
M R P 5 l 1 .1 0 0 1 0 0 0.7
* B C R P l 1 .1 0 0 0.6 CO 2
G a l e c t in - 3 l 0.9 (Y) 0.6(Y) 0.7
S u r v iv in l 1(Y) 0.6 0 0 1
* E - c a d h e r in l 0.4 (N) 0.5 (N) 0.2
* Genes gave a very low reading and should have been recorded as ‘absent’.
Table 3.3.9.1 Genes of interest and their fold changes as detected by DNA Microarray 
analysis (Y=Result agreed with RT-PCR; N=Result did not agree with RT-PCR).
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3.4 Establishment of RPMI-2650 variants
RPM3-2650 is nasal carcinoma cell line found to have a very high level of sensitivity to 
cancer chemotherapeutic drugs. The aim of this section of the thesis was to establish 
drug resistant variants of this cell line through sequential pulsing of the cells. The 
RPMI-2650 cells were pulse selected with a range of chemotherapy drugs over a period 
of 10 to 14 weeks. This was carried out by exposing the cells to sequential pulses of an 
increasing concentration of drug once a week. Depending on the conditions of the cells, 
however, this period was extended until the cells regained confluency.
Initial concentrations of drug, which were chosen based on IC50 values for the RPMI- 
2650 cell line as determined by previous studies in the NICB, did not result in much cell 
death (see Table 3.4.1 for starting concentrations). After 3 pulses, this concentration 
was increased and cells started to die (see Table 3.4.1 for these intermediate 
concentrations which caused cell death). Drug concentration was gradually increased 
until 10, 12 or 14 pulses were reached (see Table 3.4.1 for highest concentrations of 
drug reached).
Seven drugs were used in this study, resulting in 5 viable cell lines. The selections were 
carried out in duplicate and treated as separate cell lines throughout the procedure, but 
not all selections survived the process to the end. Cells were frozen down at different 
stages of pulsing for future analysis (these included cells at 2, 4, 8 and 10 pulses).
Selection
Drug
Starting Cone, of 
drug
(Hg/ml)
Intermediate Cone 
of Drug 
(¿ig/ml)
Highest conc. of 
drug
(M'g/ml)
Carboplatin 1 20 120
5FU 10 15 45
Vincristine 0.004 0.02 0.08
Epirubicin 0.05 0.2 1
CCNU 10 30 35
Table 3.4.1 Concentrations of Drug used for the selection of RPMI-2650 cells.
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3.4.1 Morphology of the RPMI-2650 variants
During the selection procedure the morphology of the cells changed dramatically. The 
cells became elongated and spindle-shaped. A number of week after the selection was 
finished, however, the majority of the cells reverted back to their original morphology. 
Figure 3.4.1.1 illustrates the morphology of the parental cells and the morphology of 2 
of the variants after receiving 10, 12 and 14 pulses of 5-Fluorouracil or Vincristine. The 
RPMI-2650 parental cell are small cells which grow in isolated clusters. The 
morphological change of the variants is less noticeable at 10 pulses, but increases with 
further drug exposure, as they become elongated and spread-out (Figure 3.4.1.1).
Figure 3.4.1.1a The morphology of the RPMI-2650 parental cell line ( 10X)
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Figure 3.4.1.1b The morphology of the RPMI-2650 5-FU selected variant (A) 
after 10 pulses, (B) after 12 pulses, (C) after 14 pulses (10X).
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Figure 3.4.1.1c The morphology of the RPMI-2650 Vincristine-selected variant
(A) after 10 pulses, (B) after 12 pulses, (C) after 14 pulses (10X).
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3.4.2 Cross resistance profile of RPMI-2650 variants to a range of chemotherapy 
drugs
To investigate the resistance profiles of the RPMI-2650 variants, toxicity assays were 
carried out as described in section 2.3.1. The chemotherapeutic agents used included the 
selection drug, as well as other chemotherapy drugs to determine whether the variants 
have become multiple drug resistant. Initial results on a number of the variants revealed 
some level of resistance, however, when experiments were repeated, the cells seem to 
have to have lost their resistance. Variants that received additional pulses developed 
increased resistance again, however, this seems to be lost again with time (with the 
exception of VCR2-12p (Table 3.4.2b)). Tables 3.4.2a, b and c represents the fold 
differences of each variant to each drug tested on three separate repeat experiments. The 
duration from one experiment to the next is included in italics in Tables 3.4.2b and c. In 
addition, the passage number of each variant is included in brackets to show the number 
of subcultures that took place from first to second and third experiments. Interesting 
variants which showed initial/continued resistance are highlighted in bold text and 
toxicity assays were carried out a third time on these variants (Tables 3.4.2c and 3.4.3c).
To determine whether the loss in resistance was due to continuous sub-culturing of the 
cells, frozen stocks of 3 of the variants (which were frozen before toxicity testing 
started) were thawed and toxicity assays were carried out again. The results are 
illustrated in Table 3.4.4. Ten days had elapsed between thawing the cells and carrying 
out the toxicity assays. Cells were thawed a third time and toxicity assays were carried 
out 5 days later. The results were different in these variants, and the reason for this is 
unclear. This is illustrated in Table 3.4.5.
In addition, two variants, RPMI-5-FU and RPMI-VCR, that had received 12 pulses 
were chosen for further pulsing, bringing the total number of pulses to 14. Toxicity 
assays were carried out twice, over a nine day period, on these 2 variants and the results 
are presented in Table 3.4.6 (a and b). These results were slightly different and it may 
be due to the density at which the cells were set up at. It was observed that these cells 
grow extremely slowly, and when toxicity assays were being repeated, the cells were set 
up at a higher density (2xl03 cell/well) to allow the cells to reach 80 %  grow in a period 
of 6-7 days. IC50 values of parent RPMI-2650 and variants are shown in Tables 3.4.3a, 
b, c and d.
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00
Cell line 5FU VCR CCNU Carboplatin
RPMI
(p37)
1 1 1 1
RPMI-5FU1
(p40)
3.1 1.1 1.6 3.6
RPMI-5FUl-12p
(p43)
14.5 32 1.1 7.7
RPMI-5FU2
(p42)
1 . 9 0.88 1.1 0 . 9 2
RPMI-Carboplatinl
(p46)
3 . 1 1 0.8 2
RPMI-Carboplatin2
(p40)
2 1 . 1 4 1 . 3 2.8
RPMI-VCR1
(p42)
3.7 1.1 2.4 8.7
RPMI-VCRl-12p
(p45)
1.6 1.6 2.1 0 . 4
RPMI-VCR2
(p39)
4 1.3 1.3 8
RPMI-VCR2-12p
(p42)
5.6 1.5 1.7 14.2
RPMI-CCNU1
(p44)
0 . 4 1 . 3 1.1 1.8
RPMI-CCNU2
(p41)
14.4 15.7 3.5 9.1
RPMI-Epirubicinl
(p42)
1.6 1 1 . 5
RPMI-Epirubicin2
(p40)
2.2 0 . 8 5 1.1 2
Table 3.4.2a Fold resistance of RPMI variants to a range of chemotherapy drugs
relative to the parental RPMI-2650 cell line. First experiment.
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(b)
Cell line 5FU VCR CCNU Carboplatin
RPMI (p39) 1 1 1 1
RPMI-5FU1 (p41)
19 days a fte r  1st assay
0.9 1 1.4 0.3
RPMI-5FUl-12p (p44)
10 days a fte r  1st assay
1.2 1.1 1.4 2.1
RPMI-5FU2 (p43)
6 days a fte r  1st assay
1.5 0.9 0,97 1.4
RPMI-C ar boplatin 1 (p47)
10 days a fte r  1st assay
0.9 1.1 1.8 3.9
RPMI-Carboplatin2 (p41)
6 days a fte r  1st assay
0.9 1 1.2 3.4
RPMI-VCR1 (p46)
19 days a fte r  1st assay
1.8 1.7 1.1 1.9
RPMI-VCRl-12p (p47) 
10 days a fte r  1st assay
1.4 1.1 1.7 2.1
RPMI-VCR2 (p41)
19 days a fte r  1st assay
1.4 1 0.6 1
RPMI-VCR2-12p (p43)
10 days a fte r  1st assay
14.5 3.2 2.5 9.7
RPMI-CCNU1 (p46)
10 days a fte r  1st assay
0.3 1.1 1.6 1.6
RPMI-CCNU2 (p43)
19 days a fte r  1st assay
4 2.2 0.9 3
RPMI-Epirubicinl (p43)
10 days a fte r  1st assay
1.3 1.4 1.4 2.6
RPMI-Epirubicin2 (p41)
6 days a fte r  1st assay
0.4 1.1 1 0.8
Table 3.4.2b Fold resistance of RPMI variants to a range of chemotherapy drugs
relative to the parental RPMI-2650 cell line. Second experiment.
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(C)
Cell line 5FU VCR CCNU Carboplatin
RPMI (p40) 1 1 1 1
RPMI-5FU1 (p43)
10  days a fte r  2nd assay
0.89 0.98 1.46 1
RPMI-5FUl-12p (p47)
5 w eeks a fte r  2nd assay
1.26 1.11 0.87 0.2
RPMI-VCR1 (p47)
10 days a fte r  2?d assay
1.6 1 1.8 2.4
RPMI-VCR2 (p42)
10 days a fte r  2nd assay
1.1 1 1.1 1
RPMI-VCR2-12p (p47)
5 w eeks a fter  2nd assay
2.4 2.6 1.1 3.4
RPMI-CCNU2 (p44)
10  days a fte r  2nd assay
1.5 3.3 2.5 9.7
Table 3.4.2c Fold resistance of RPMI variants to a range of chemotherapy drugs 
relative to the parental RPMI-2650 cell line. Third experiment.
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Cell line 5FU
(Hg/ml)
VCR
(ng/ml)
CCNU
(Hg/inl)
Carboplatin
(ng/ml)
RPMI-5FU1 (p40) 0.23±0.04 0.7i02 3.73+0.03 2.78+0.03
RPMI-5FUl-12p (p43) 2.61±0.03 20.54+0.01 7.52+0.02 13.57+0.03
RPMI-5FU2 (p42) 0.16+0.11 0.65+0.17 5.35+0.44 0.81+0.13
RPMI-Carboplatinl
(p46)
0.56+0.04 0.64+0.08 5.6+0.05 3.5+0.06
RPMI-CarbopIatin2
(p40)
0.17±0.05 0.84+0.03 6.17+0.03 2.46+0.04
RPMI-VCR1 (p42) 0.27±0.12 0.67+0.19 5.4+0.16 6.73+0.11
RPMI-VCRl-12p (p45) 0.29+0.03 1.01+0.02 14.33+0.04 0.68+0.01
RPMI-VCR2 (p39) 0.3±0.07 0.81+0.06 3.02+0.11 6.15+0.06
RPMI-VCR2-12p (p42) 1.01+0.06 0.95+0.06 11.23+0.01 25.4+0.01
RPMI-CCNU1 (p44) 0.07+0.05 0.82+0.02 7.65+0.04 3.16+0.08
RPMI-CCNU2 (p41) 1.07+.005 9.66+0.007 7.8+0.01 7.05+.0.009
RPMI-Epirubicinl (p42) 0.28+0.01 0.65+0.04 “ 2.65+0.01
RPMI-Epirubicin2 (p40) 0.17+0.01 0.71+0.009 5.24+0.01 1.8+0.02
RPMI-5FU2-14p (p47) 1.04+0.003 3.24+0.005 8.18+0.003 14.12+0.004
RPMI-VCR2-14p (p48) 18.58+0.008 14.4+0.01 36.5+0.009
*The Standard deviation presented is a standard deviation calculated from t îe IC50
values of eight replicate wells in each experiment (- = out of range).
Table 3.4.3a IC 50 values of RPMI variants to a range of chemotherapy drugs (1st Exp)
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Cell line 5FU
(ng/ml)
VCR
(ng/ml)
CCNU
(ng/ml)
Carboplatin
(ng/ml)
RPMI-5FU1 (p41)
19 days a fte r  1st assay
0.16±0.03 061+0.2 9.37+0.07 0.6+0.24
RPMI-5FUl-12p (p44) 
10 days a fte r  1st assay
0.23+0.03 0.76+0.01 4.22+0.05 2.2+0.02
RPMI-5FU2 (p43)
6 days a fte r  1st assay
0.25+0.12 0.65+0.09 6.02+0.11 1.6+0.14
RPMI-Carboplatinl (p47) 
10  days a fte r  1st assay
0.16+0.03 0.8+0.026 5.5+0.06 4.04+0.02
RPMI-Carboplatin2 (p41)
6  days a fte r  1st assay
0.15+0.1 0.74+0.09 7.45+0.21 1.36+0.03
RPMI-VCR1 (p46)
19 days a fte r  1st assay
0.33+0.06 1.04+0.06 7.2+0.03 3.42+0.03
RPMI-VCRl-12p (p47)
10 days a fte r  1st assay
0.25+0.01 0.8+0.05 5.07+0.3 2.18+0.3
RPMI-VCR2 (p41)
19 days a fte r  1st assay
0.25+0.08 0.64+0.056 4.1+0.09 1.7+0.08
RPMI-VCR2-12p (p43)
10  days a fte r  1st assay
2.68+0.1 2.28+0.21 7.6+0.25 10.13+0.6
RPMI-CCNU1 (p46)
10  days a fte r  1st assay
0.06+0.02 0.8+0.04 4.76+0.04 1.71+0.03
RPMI-CCNU2 (p43) 
19 days a fte r  1st assay
0.72+0006 1.38+0.006 5.81+0.005 5.32+0.007
RPMI-Epirubicinl (p43)
10 days a fte r  1st assay
0.25+0.03 0.98+0.07 4.22+0.01 2.77+03
RPMI-Epirubicin2 (p41)
6 days a fte r  1st assay
0.06+0.04 0.76+0.03 6.16+0.02 0.95+0.03
RPMI-5FU2-14p (p47) 2.27+0.004 25.2+0.08 9+0.01 12.5+0.005
RPMI-VCR2-14p (p48) “ 20+0.01 10+0.02
*The Standard deviation presented is a standard deviation ca culated from t îe IC50
values of eight replicate wells in each experiment (- = out of range).
Figure 3.4.3b IC50 values of RPMI variants to a range of chemotherapy drugs (2nd Exp)
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Cell line 5FU
(ng/ml)
VCR
(ng/ml)
CCNU
(ng/ml)
Carboplatin
(ng/ml)
RPMI-5FU1 (p43)
10  days a fte r  2nd assay
0.15+0.55 0.75+0.07 7.6+0.05 1.06+0.03
RPMI-5FUl-12p (p47)
5 w eeks a fte r  2 ,d assay
0.21+0.08 0.8+0.03 5.43+0.07 0.22+0.03
RPMI-VCR1 (p47)
10  days a fte r  2nd assay
0.3+0.05 0.75+0.04 5.47+0.03 2.53+0.07
RPMI-VCR2 (p42)
10  days a fte r  2nd assay
0.08+0.1 0.77+0.1 5.77+0.06 1.09+0.1
RPMI-VCR2-12p (p47)
5 w eeks a fte r  2nd assay
0.4+0.04 1.87+0.03 6.7+0.07 3.76+0.05
RPMI-CCNU2 (p44) 
10  days a fte r  2nd assay
0.28+0.01 1.3+0.01 5.07+0.02 0.51+0.06
*The Standard deviation presented is a standard deviation calculated from the IC50
values of eight replicate wells in each experiment.
Table 3.4.3c IC50 values of RPMI variants to a range of chemotherapy drugs (3rd Exp)
Cell line 5FU
(ng/ml)
VCR
(ng/ml)
CCNU
(ng/mi)
Carboplatin
(ng/mi)
RPMI-2650 0.13+0.04 0.68+0.05 6.41+1.32 1.21+0.4
*The results presented in 1fable 7.3.4 are an average of six separate experiments.
Table 3.4.3d IC50 values of RPMI-2650 parent cells to a range of chemotherapy drugs.
Cell line 5FU VCR CCNU Carboplatin
RPMI 1 1 1 1
RPMI-5FU1 0.9 1 1.23 1
RPMI-VCR2 0.5 1 0.9 1
RPMI-CCNU2 1.66 1.75 0.8 0.5
Table 3.4.4 Fold resistance of RPMI variants to a range of chemotherapy drugs 
relative to the parental RPMI-2650 cell line, when variants were thawed first time.
Cell line 5FU VCR CCNU Carboplatin
RPMI 1 1 1 1
RPMI-5FU1 2.16 - 1.1 1.5
RPMI-VCR2 2.14 1.1 1.1 3
RPMI-CCNU2 19.5 9.5 2 4.2
Table 3.4.5 Fold resistance of RPMI variants to a range of chemotherapy drugs 
relative to the parental RPMI-2650 cell line, when variants were thawed second time.
Cell line 5FU VCR CCNU Carboplatin
RPMI 1 1 1 1
RPMI-5FUl-14p 4.3 3.3 1 4.3
RPMI-VCR2-14p 76.5 >300 1.7 11
Table 3.4.6a Fold resistance of RPMI-5-FU-14p and RPMI-VCR-14p to a range of 
chemotherapy drugs relative to the parental RPMI-2650 cell line. Run 1
Cell line 5FU VCR CCNU Carboplatin Adriamycin
RPMI 1 1 1 1 1
RPMI-5FUl-14p 18 23 1.55 7.3 23
RPMI-VCR2-14p >150 >500 3.47 5.8 77
Table 3.4.6b Fold resistance of RPMI-5-FU-14p and RPMI-VCR-14p to a range of
chemotherapy drugs relative to the parental RPMI-2650 cell line. Run 2
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3.4.3 Analysis of RPMI-2650 variants using in vitro Invasion assay.
To investigate the invasive ability of RPMI-2650 variants compared to the parental cell 
line, invasion assays were carried out as described in section 2.4. Cell culture inserts 
were coated with ECM before cells were added. After a 48 hour incubation period, 
invasive cells were stained with crystal violet and observed under a microscope. RPMI- 
2650 melphalan-resistant, a highly invasive cell line previously generated in the NICB, 
was used as a positive control. RPMI-2650 parental cell line is a non-invasive cell line. 
As shown in Figure 3.4.3.1, 3.4.3.2 and 3.4.3.3, the RPMI-2650 parent cells and all 
variants were non-invasive compared to the positive control. Invasion assays were 
carried out in duplicate
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Figure 3.4.3.1a Invasion assays of (A) RPMI-2650-5FU1, (B) RPMI-
2650-5FUl-12p, (C) RPMI-2650-VCRl, (D) RPMI-2650-VCRl-12p (4X) (n=2).
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Figure 3,4.3.1b Invasion assays of (A) RPMI-2650-Carboplatinl, (B)
RPMI-2650-CCNUl, (C) RPMI-2650-Epirubicinl (4X) (n=2).
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Figure 3.4.3.2 Invasion assays of (A) RPMI-2650-VCR2-10p, (B) RPMI-2650- 
VCR2-12p, (C) RPMI-2650-5FU2, (D) RPMI-2650-Carboplatin2, (E) RPMI-2650- 
CCNU2, (F) RPMI-2650-Epirubicin2 (4X) (n=2).
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Figure 3.4.3.3 Invasion assays of (A) RPMI-2650 parent, (B) RPMI-26 50-
Melphalan (4X) (n=2).
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3.4.4 Analysis of RPMI-2650 variants using in vitro Motility assays
Motility assays were carried out to compare the locomotive ability of the RPMI-2650 
parental cell line and two of its variants. Similar to the invasion assays, motility assays 
were incubated for 48 hours, before being stained with crystal violet. Motility assays 
were not carried out on all RPMI-2650 variants as there was no increase in invasiveness 
due to drug selections. However, motility assays were carried out on the two variants 
that were pulsed 14 times. The results shown in Figure 3.4.4.1 demonstrate that despite 
the large increase in drug resistance of RPMI-5FUl-14p and RPMI-VCR2-14p, there 
was no change in their motility profile. The motility assay was set up on the same day 
as the second toxicity assay which is shown in Figure3.4.5b. Motility assays were 
carried out once.
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Figure 3.4.4.1 Motility assays of (A) RPMI-2650 parent cells, (B) RPMI-2650-5FU1-
14p, (C) RPMI-2650-VCR2-14p (4X) (n=l)
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3.4.5 Analysis of RPMI-2650 variants using RT-PCR
To detect the expression of relevant markers at the RNA level, RT-PCR was carried out 
as described in section 2.2. Eight genes were analysed. These are: MDR-1 (Pgp), 
MRP1, MRP2 (cMOAT), MRP3, MRP4, MRP5, Galectin-3 and Survivin and its splice 
variant. All RT-PCRs were carried out twice and the results were very similar in most 
cases, unless otherwise stated. Densitometry analysis was carried out using (3-actin to 
normalise the results. A plasmid for each gene was used as a positive control, with the 
exception of Galectin-3 and Survivin. Sterile water was used as a negative control in 
each PCR.
3.4.5.1 MDR-1 mRNA expression in RPMI-2650 and its variants
RT-PCR analysis (Figure 3.4.5.1) showed that MDR-1 was expressed in the RPMI- 
2650 parental cell line as well as all the variants, with the exception of RPMI-2650- 
VCR2-12p, however, this may be due to low levels of expression as this was not the 
case in a previous experiment. There was no change in expression levels between the 
variants and the parental cell line.
3.4.5.2 MRP1 mRNA expression in RPMI-2650 and its variants
RT-PCR analysis (Figure 3.4.5.2) on MRP1 showed that MRP1 was expressed in all 
cell lines, including the parental cells. There seems to be an increase in expression in 
most of the variants. This increase is greatest in RPMI-VCR1, RPMI-carboplatinl, and 
RPMI-CCNU2.
3.7.5.3 MRP2 (cMOAT) mRNA expression in RPMI-2650 and its variants
RT-PCR analysis (Figure 3.4.5.3) on MRP2 (cMOAT) shows that there was no 
detectable expression of MRP2 mRNA in RPMI-2650 or RPMI-2650 variants.
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Figure 3.4.5.1 (a) RT-PCR analysis of MDR-1 expression in the RPMI-2650
parent cell line and its variants, (b) Densitometry of RT-PCR (n=2).
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Figure 3.4.5.2 (a) RT-PCR analysis of MRP 1 expression in the RPMI-2650
parent cell line and its variants, (b) Densitometry of RT-PCR (n=2).
229
<—P-actin
Figure 3.4.5.3 (a) RT-PCR analysis of MRP2 expression in the RPMI-2650
parent cell line and its variants (n=2).
3.4.5.4 MRP3 mRNA expression in RPMI-2650 and its variants
RT-PCR analysis of MRP3 (Figure 3.4.5.4) shows that MRP3 is detected in RPMI-2650 
parental cells and the RPMI-2650 variants. RPMI-VCR2-12p shows an over-expression 
of MRP3 compared to the parental cells. This PCR has proven problematic due to the 
many background bands present and it was successfully carried out once.
3.4.5.5 MRP4 mRNA expression in RPMI-2650 and its variants
RT-PCR analysis of MRP4 (Figure 3.4.5.5) shows it is expressed in RPMI-2650 
parental cells and the RPMI-2650 variants, RPMI-VCR2-10p, RPMI-VCR2-12p, 
RPMI-CCNU2 and RPMI-Epirubicin2 show an over-expression of MRP4 compared to 
the parental cells.
3.4.5.6 MRP5 mRNA expression in RPMI-2650 and its variants
RT-PCR analysis of MRP5 (Figure 3.4.5.6) shows it is detected in RPMI-2650 parental 
cells and the RPMI-2650 variants. RPMI-CCNU2 and RPMI-Epirubicin2 show an over­
expression of MRP5 compared to the parental cells.
3.4.5.7 GaIectin-3 mRNA expression in RPMI-2650 and its variants
RT-PCR analysis of galectin-3 (Figure 3.4.5.7) shows it is detected in RPMI-2650 
parental cells and the RPMI-2650 variants. There is no dramatic change in expression 
levels of the variants.
3.4.5.8 Survivin expression mRNA in RPMI-2650 and its variants
RT-PCR analysis of Survivin (Figure 3.4.5.8) shows it is detected in RPMI-2650 
parental cells and the RPMI-2650 variants. RPMI-5FU2, RPMI-VCR2-10p, RPMI- 
VCR2-12p, and RPMI-Carboplatin2 show an up-regulation of survivin. However, the 
expression of the two splice variants, survivin-2B and survivin-AEx3, remained 
unchanged. A survivin cDNA-transfected cell line was used as a positive control.
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Figure 3.4.5.4 (a) RT-PCR analysis of MRP3 expression in the RPMI-2650
parent cell line and its variants, (b) Densitometry of RT-PCR (n=l).
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Figure 3.4.5.5 (a) RT-PCR analysis of MRP4 expression in the RPMI-2650
parent cell line and its variants, (b) Densitometry of RT-PCR (n=2).
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Figure 3.4.5.6 (a) RT-PCR analysis of MRP5 expression in the RPMI-2650
parent cell line and its variants, (b) Densitometry of RT-PCR (n=2)
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Figure 3.4.5.7 (a) RT-PCR analysis of Galectin-3 expression in the RPMI-2650
parent cell line and its variants, (b) Densitometry of RT-PCR (n=2)
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Figure 3.4.5.8 (a) RT-PCR analysis of Survivin expression in the RPMI-2650
parent cell line and its variants, (b) Densitometry of RT-PCR (n=2).
3.5 Analysis of Gene expression in Breast Tumour specimens
A clinical study was carried out on breast tumour specimens to identify genes that may 
be useful as prognostic markers for breast cancer. Genes included in this study were the 
apoptosis-related genes, galectin-3 and survivin and the MDR-related gene, MRP1.
RNA was extracted (see section 2.4.3.8 for procedure) and RT-PCR analysis was 
carried out on 165 breast tumour specimens. Statistical analysis was carried out on 106 
of these tumour specimens, by Dr. Lorraine O’Driscoll, using the SPSS 10.1 software 
package. The association of two of the three genes (survivin and MRP1) with patient 
clinicopathological characteristics was evaluated using Chi-square test. Tumour 
characteristics included, tumours size and grade, diagnosis, treatment, ER status, lymph 
node involvement, age of patient at diagnosis, relapse-free and overall survival. 
Survival analysis (5 year relapse-free and overall survival probabilities) was performed 
using the Kaplan-Meier method and Chi-square analysis. The log rank test was carried 
out to assess the statistical differences between categories of each potential prognostic 
factor. Multivariate and univariate analysis using Cox’s proportional hazards models 
were performed, as relevant, to test independent significance of parameters of interest. 
A P value below 0.05 was considered to be statistically significant. Six normal tissue 
samples were also analysed by RT-PCR for the expression of the three genes mentioned 
above.
3.5.1 Survivin mRNA Expression in Breast Tumour Biopsies
RT-PCR analysis was carried out on the tumour specimens using the survivin primers 
which amplify the three survivin splice variants (see Appendix A). A survivin-over- 
expressing cell line or a purified plasmid containing survivin cDNA were used as 
positive controls in some cases (Figure 3.5.1.5A 3.5.1.6B and 3.5.1.8) and sterile water 
was used as a negative control. P-Actin was used as an endogenous control and 
densitometry was carried out on the majority of results by normalising the survivin 
bands to the P-actin bands (see Figures 3.5.1.1-3.5.1.8).
Results of survivin RT-PCR demonstrate survivin mRNA expression in 68% of cases. 
Survivin-2B mRNA was detected in 9.4% and survivin-AEx3 mRNA was detected in
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54.7% of cases. Analysis of normal tissue samples indicated no survivin mRNA 
expression. Statistical results indicate a significant correlation between the mRNA 
expression of the survivin variants, i.e. between survivin and survivin-AEx3 (p<0.0001), 
survivin and survivin-2B (p=0.022) and survivin-2B and survivin-AEx3(p=0.003) as 
shown in Table 3.5.1.1
Chi-squared analysis revealed that survivin mRNA expression in the breast specimens 
did not correlate with prognosis or any of the clinicopatholigical parameters, including, 
tumour size, type and grade, chemotherapy treatment or tamoxifen, lymph node or ER 
status or age at diagnosis (see Table 3.5.1.2).
Kaplan-Meier analysis indicated no correlation between disease-free survival or overall 
survival (survival rate) and survivin, survivin-AEx3 or survivin-2B mRNA expression 
as shown in Figure 3.5.1.
mRNA Survivin Survivin-AEx3 Survivin-2B
+ P + P + P
Survivin (-) 
Survivin (+)
1/34
57/72
<0.0001
*
0/34
10/72
0.022*
Sur-AEx3 (-) 
Sur-AEx3 (+)
15/48
57/58
<0.0001
*
0/48
10/58
0.003*
Surv-2B (-) 
Surv-2B (+)
62/69
10/10
0.022* 48/96
10/10
0.003*
Table 3.5.1.1 Correlation between the survivin splice variants. P value from X 2
analysis; * indicates significant parameter.
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Characteristics No. of 
cases
Sur
(%)
P No. of 
cases
S-AEx3
(%)
P No. of 
cases
S-2B
(%)
P
Age (yr.)
<50 19/29 65.5 0.745 12/29 41.4 0.090 3/29 10.3 0.844
>50 53/77 68.8 46/77 59.7 7/77 9.1
Tumour size
T1 (<2 cm) 12/18 66.7 8/18 44.4 1/18 5.6
T2 (2-5 cm) 58/84 69.0 0.722 48/84 57.1 0.606 9/84 10.7 0.639
T3 (> 5cm) 2/4 50.0 2/4 50.0 0/4 0.0
Lymph node
metastasis
Negative 34/45 75.6 0.148 28/45 62.2 0.182 4/45 8.9 0.869
Positive 38/61 62.3 30/61 49.2 6/61 9.8
Histology grade
I 6/11 54.5 5/11 45.5 1/11 9.1
II 29/41 70.7 0.588 22/41 53.7 0.757 4/41 9.8 0.996
III 37/54 68.5 31/54 57.4 5/54 9.3
Histology type
IDC 59/84 70.2 50/84 59.5 9/84 10.7
ILC 10/17 58.8 0.608 5/17 29.4 0.073 1/17 5.9 0.627
Special 3/5 60.0 3/5 60.0 0/5 0.0
ER status
Negative 24/34 70.6 0.763 21/34 61.8 0.398 3/34 8.8 0.814
Positive 46/68 67.6 36/68 52.9 7/68 10.3
Chemotherapy
No 31/45 68.9 0.971 23/45 51.1 0.301 3/45 6.7 0.410
Yes 36/52 69.2 32/52 61.5 6/52 11.5
Tamoxifen
No 19/26 73.1 0.768 15/26 57.7 0.938 2/26 7.7 0.594
Yes 49/70 70.0 41/70 58.6 8/70 11.4
Table 3.5.1.2 Correlation between the survivin (Sur), survivin-2B (S-2B) and
survivin-AEx3 (S-AEx3) expression with clinicopathological parameters using Chi- 
squared test. P value from X 2 analysis.
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Figure 3.5.1 (A) and (B) Kaplan-Meier survival curves showing survivin mRNA did 
not correlate with disease free survival (P=0.9933) or overall survival (P=0.2391).
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Figure 3.5.1 (C) and (D) Kaplan-Meier survival curves showing survivin-AEx3 
mRNA did not correlate with disease free survival (P=0.5923) or overall survival 
(P=0.2978).
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Figure 3.5.1 (E) and (F) Kaplan-Meier survival curves showing survivin-AEx3 
mRNA did not correlate with disease free survival (P=0.9946) or overall survival 
(P=0.9060).
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Fig. 3.5.1.1 (A) and (B) Gel electrophoresis of survivin RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.1.1 (C) Densitometric analysis of RT-PCR
results. M=Molecular weight marker; Neg=negative control. (n=l).
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Fig, 3.5.1.2 (A) and (B) Gel electrophoresis of survivin RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.1.2 (C) Densitometrie analysis of RT-PCR
results. M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.1.3 (A) and (B) Gel electrophoresis of survivin RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.1.3 (C) Densitometrie analysis of RT-PCR
results. M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.1.4 (A) and (B) Gel electrophoresis of survivin RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.1.4 (C) Densitometric analysis of RT-PCR
results. M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.1.5 (A) and (B) Gel electrophoresis of survivin RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.1.5 (C) Densitometrie analysis of RT-PCR
results. M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.1.6 (A), (B) and (C) Gel electrophoresis o f survivin RT-PCR results on
breast tumour tissue specimens; M=Molecular weight marker; Postpositive control;
Neg=negative control.
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Fig. 3.5.1.7 (A), (B), (C) and (D) Gel electrophoresis of survivin RT-PCR results on
breast tumour tissue specimens. M=Molecular weight marker; Neg=negative control.
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Fig. 3.5.1.8 (A) Gel electrophoresis o f survivin RT-PCR results on normal breast
tissue specimens (N1-N6) and one tumour sample (Tumour); Fig. 3.5.1.8 (B) 
Densitometrie analysis o f RT-PCR results. M=Molecular weight marker; Pos= positive 
control; Neg=negative control. (n=l).
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3.5.2 Galectin-3 mRNA Expression in Breast Tumour Biopsies
RT-PCR analysis was carried out to detect galectin-3 mRNA expression in the breast 
tumour specimens. Galectin-3 mRNA expression was detected in 99% o f cases. 
Galectin-3 mRNA expression was detected in 83% of cases o f normal tissue specimens. 
Due to its expression in almost all the tumour specimens analysed, galectin-3 mRNA 
expression showed no correlation with prognosis or any o f the clinicopathological 
parameter. No statistical analysis was carried out on these results. RT-PCR results are 
presented in this section (Figures 3.5.2.1-3.5.2.8). P-actin was used as an endogenous 
control and, as before, sterile water was used as a negative control.
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Fig. 3.5.2.1 (A) and (B) Gel electrophoresis of Gal-3 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.2.1(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.2.2 (A) and (B) Gel electrophoresis of Gal-3 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.2.2(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.2.3 (A) and (B) Gel electrophoresis of Gal-3 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.2.3(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.2.4 (A) and (B) Gel electrophoresis of Gal-3 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.2.4(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight; Neg=negative control. (n=l).
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Fig. 3.5.2.5 (A) and (B) Gel electrophoresis of Gal-3 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.2.5(C) Densitometrie analysis of RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.2.6 (A) and (B) Gel electrophoresis of Gal-3 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.2.6(C) Densitometrie analysis of RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.2.7 (A) and (B) Gel electrophoresis of Gal-3 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.2.7(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.2.8 (A) Gel electrophoresis o f Gal-3 RT-PCR results on normal breast tissue
specimens (N1-N6) and one tumour; Fig. 3.6.2.8 (B) Densitometrie analysis o f RT-PCR 
results. M=Molecular weight marker; Neg=negative control. (n=l).
3.5.3 MRP-1 mRNA Expression in Breast Tumour Biopsies
RT-PCR analysis was carried out for to detect MRP1 mRNA expression in the breast 
tumour specimens. Results indicate that 72.8% of tumour specimens express MRP1 
mRNA while 66% of normal samples express MRP1 mRNA.
Chi-squared analysis revealed that MRP1 mRNA expression in the breast specimens did 
not correlate with prognosis or with the clinicopatholigical parameters, including, 
tumour size, type and grade, chemotherapy treatment or tamoxifen, lymph node or ER 
status or age at diagnosis (see Table 3.5.3.1). Kaplan-Meier analysis indicated no 
correlation between disease-free survival (P=0.2531) or overall survival (survival rate) 
(P=0.3942) and MRP1 mRNA expression as shown in Figure 3.5.3.
P-actin was used as an endogenous control in the RT-PCR analysis and sterile water 
was used as a negative control (see Figures 3.5.3.1-3.5.3.8).
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Characteristics No. of cases MRP-1
(%)
P
Age (yr.)
<50 17/22 77.3 0.591
>50 50/70 71.4
Tumour size
T1 (<2 cm) 11/15 73.3
T2 (2-5 cm) 55/74 74.3 0.294
T3 (> 5cm) 1/3 33.3
Lymph node 
metastasis
Negative 29/39 74.4 0.777
Positive 38/53 71.7
Histology grade
I 10/11 90.9
n 24/33 72.7 0.329
m 33/48 68.8
Histology type
I DC 53/73 72.6
1LC 10/14 71.4 0.930
Special 4/5 80.0
ER status
Negative 26/31 83.9 0.092
Positive 39/58 67.2
Chemotherapy
No 27/40 67.5 0.376
Yes 35/46 76.1
Tamoxifen
No 17/24 70.8 0.784
Yes 45/61 73.8
Table 3.5.3.1 Correlation between MRP1 expression with clinicopathological
parameters using Chi-squared test. P value from X 2 analysis.
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Figure 3.5.3 (A) and (B) Kaplan-Meier survival curves showing MRP1 mRNA did 
not correlate with disease free survival (P=0.2531) or overall survival (P=0.3942).
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Fig. 3.5.3.1 (A) and (B) Gel electrophoresis of MRP-1 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.3.1(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight marker; Neg=Negative control. (n=l).
263
(A)
M T34 T39 T40 T41 T43 T44 T45 T46 T47 T48 T49 Nep
(B)
M  T50 T51 T52 T55 T56 TS7 T58 T59 T60 T61 T62 T63 T64 NeP
«■ ß-actin  
«■MRP-1
R
m
(C )
i
^  ^  ^  ^  ^  ^  ^  ¿S> £  ^  *<$> ^  ^  ^  ^
Tumour number
Fig. 3.5.3.2 (A) and (B) Gel electrophoresis of MRP-1 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.3.2(C) Densitometrie analysis of RT-PCR results.
M=Molecular weight; Neg=negative control. (n=l).
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Fig. 3.5.3.3 (A) and (B) Gel electrophoresis of MRP-1 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.3.3(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.3.4 (A) and (B) Gel electrophoresis of MRP-1 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.3.4(C) Densitometrie analysis of RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
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Fig. 3.5.3.5 (A) and (B) Gel electrophoresis o f MRP-1 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.3.5(C) Densitometrie analysis of RT-PCR results.
M=Molecular weight marker; Neg=negative control. (n=l).
267
(A)
M  SI S2 S4 S5 S6 S7 SH S9 S10 Neo
^  ß-actin
«■MRP-1
(B)
M  S i l  S12 S13 S14 S15 S16 S17 S18 S20 Neg
« -  ß-actin  
«■MRP-1
(C)
1
0.18
0.16
0.14
0.12
0.1
0.00
0.06
0.04
0.02
0
I f  _ 1y
s
mÄ
n w
n  jr.
a i m L  in
■  m i
■  m n i i i u .  fl . 1 .
^  & #  £
Tumour number
Fig. 3.5.3.6 (A) and (B) Gel electrophoresis o f MRP-1 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.3.6(C) Densitometrie analysis o f RT-PCR results.
M=Molecular weight; Neg=negative control. (n=l).
268
(A)
M  S21 S22 S23 S24 S25 S26 S27 S28 S29 S30 Neu
«- ß-actin 
«■MRP-1
(B)
M  S31 S32 S33 S34 S35 S36 S37 S38 S39 Nep
«- ß-actin 
«■MRP-1
(C)
I
0.2
0.1-
0
I B  m i  F i
m  i  i  i i p i i  I i  r r n
1 1 1 1 1 1 1  r i  1 1 1  i i  1 1 1 1
<$• <$y <$■ <§> #  <$> <$- ^  g  ^  <$■
Tumour number
Fig. 3.5.3.7 (A) and (B) Gel electrophoresis of MRP-1 RT-PCR results on breast
tumour tissue specimens; Fig. 3.5.3.7(C) Densitometrie analysis of RT-PCR results.
M=Molecular weight marker; Neg=Negative control. (n=l).
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Fig. 3.5.3.8 (A) Gel electrophoresis o f  MRP-1 RT-PCR results on normal breast
tissue specimens; Fig. 3.5.3.8 (B) Densitometrie analysis o f  RT-PCR results. 
M=Molecular weight marker; Neg=negative control. (n=l).
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D i s c u s s i o n
4.1 Analysis of apoptosis-related gene expression in MDR and invasiveness
Apoptosis is a genetically regulated biological process that is fundamental to the 
development o f organisms and to homeostasis o f tissues (Kerr et al., 1972). It is regulated 
by many genes in normal tissues. The protein products o f these genes can influence cell 
viability, either by promoting or inhibiting cell death. Cancer cells develop gene mutations 
enabling them to escape the normal tendency to die (Vaux et al., 1988). When the 
expression o f pro-apoptotic and anti-apoptotic genes is imbalanced, cells are predisposed to 
tumorigenic conversion and resistance to chemotherapeutic drugs (Roy et al., 2000; 
Schmitt e t  a l ,  1997). Previous studies at the NICB have shown that chemotherapeutic drug 
treatment alters the expression o f apoptosis-related genes, Bel and caspase family genes.
This thesis investigates the role o f two apoptosis-related genes, galectin-3 and survivin, in 
drug resistance and invasiveness which may be associated with such resistance. In addition, 
the impact o f increasing the expression o f these genes in drug sensitive cell lines is 
investigated through transfection experiments.
4.2 Analysis of Galectin-3
One o f the most devastating aspects o f cancer is the emergence o f metastases in organs 
distant from the primary tumor and most deaths from cancer are related to metastases (see 
section 1.3) (Keleg et al., 2003). Most deaths from breast cancer, for example, result from 
metastasis to the bone, lung, brain, and liver (Moon et al., 2001). It is therefore vital to 
identify the mechanisms underlying the processes o f invasion and metastasis. One o f the 
genes that has been linked to tumour cell invasion and metastasis is galectin-3 (see section
1.5.3) (Matarrese et al., 2000). Galectin-3 has been shown to induce in vitro invasiveness, 
in addition to inhibiting apoptosis and accelerating cell growth and proliferation. Although 
there are conflicting reports regarding the association o f  galectin-3 with metastasis and 
invasion, with reports o f it being down-regulated (Irimura e t  al., 1991; Infusa et al., 2001)
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or up-regulated (Castronovo et al., 1992) in tumour metastasis, there are many reports 
supporting its involvement in metastasis.
4.2.1 Expression of Galectin-3 in RPMI-2650 and its MDR variants
The expression o f galectin-3 in the non-invasive nasal carcinoma cell line, RPMI-2650, 
was investigated and found to be expressed at the mRNA and protein level, by RT-PCR 
and western blot analysis, respectively. In addition galectin-3 expression was also 
investigated in two MDR-variants o f RPMI-2650, RPME-taxol resistant and RPMI- 
melphalan resistant cells lines, developed at the NICB by continuous exposure to taxol and 
melphalan, respectively (Dr. Y. Liang, PhD 1999). The RPMI-taxol resistant variant 
exhibits an MDR phenotype, compared to the RPMI-2650 parent cell line, with a large 
fold-resistance to adriamycin, vincristine, vinblastine, taxol and 5-fluorouracil. The RPMI- 
melphalan-resistant variant exhibits an invasive, as well as an MDR phenotype, with a 
large fold-increase to VP-16, melphalan, cisplatin and cadmium chloride (Liang et al., 
2001).
In agreement with the literature on the involvement o f galectin-3 in metastasis (see section
1.5.3) (Bresalier et a l ., 1998; Choi Kim e t  a l ., 1999 and Matarrese et al., 2000), it was 
found, by western blot analysis (section 2.4.1) that galectin-3 protein was highly over- 
expressed in RPMI-melphalan, an MDR variant with an increased invasive, motile and 
adhesive phenotype. Galectin-3 protein was not, however, over-expressed in RPMI-taxol, 
an MDR variant with an unaltered invasive, motile and adhesive phenotype (see section
3.1.1.2), suggesting that galectin-3 over-expression is associated with in vitro invasiveness 
and metastasis in RPMI-2650 nasal carcinoma cell line. These results were carried out in 
triplicate and proved to be reproducible. RT-PCR analysis (see section 2.4.3.5) results 
indicate a small increase o f galectin-3 mRNA (in contrast to the large increase in protein 
level) in the RPMI-2650 melphalan-resistant cells, suggesting the involvement o f post- 
transcriptional regulation of galectin-3 protein in this cell line. Galectin-3 mRNA  
expression was down-regulated in the RPMI-2650 taxol resistant variant (see section
3.1.1.1), however, direct evaluation o f any possible galectin-3 association with drug 
resistance in the RPMI variants cannot be made from these experiments.
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To further analyse the role o f galectin-3 in drug resistance and invasiveness, up-regulation 
of galectin-3 in a non-invasive cancer cell line was carried out. By over-expressing 
galectin-3 in a non-invasive, drug-sensitive, cell line, we can study the phenotypic changes 
that may be associated with the up-regulation of this protein, and thereby gain further 
insight into its function.
4.2.2 Galectin-3 transfection and up-regulation in DLKP cells
Galectin-3 up-regulation alters the invasive potential o f certain cell lines, including colon 
(Bresalier et ah, 1998), breast (Choi Kim et ah, 1999 and Matarrese et ah, 2000), and 
thyroid follicular cells (Takenaka et ah, 2003). Galectin-3 also plays a role in apoptosis and 
has been shown to protect cells from apoptosis induced by anti-Fas and staurosporine 
(Yang e t  ah, 1996), cisplatin (Akahini e t  ah, 1997) and nitric oxide (Moon et al., 2001) 
(see section 1.5.2).
In an attempt to establish the significance o f the increased galectin-3 expression in the 
invasive RPMI-melphalan resistance cell line and to further elucidate the role o f galectin-3 
in invasion and metastasis, as well as its role in inhibiting apoptosis, galectin-3 cDNA was 
transfected into the non-invasive, drug-sensitive, RPMI-2650 parental cells. Due to the 
nature o f this cell line, however, and its poor growth rate at low cell density, it was not 
possible to carry out the transfection successfully. RPMI-2650 cells fail to grow from 
single cells, making the cloning procedure very difficult.
The non-invasive, drug-sensitive, lung carcinoma cell line, DLKP was therefore chosen to 
over-express galectin-3, by carrying out a stable transfection o f galectin-3 cDNA and 
successfully selecting mixed population and three clonal populations resistant to geneticin 
at a concentration o f 1 mg/ml (see section 2.4.5). Three clones (C2, C12 and C13), in 
addition to the mixed population (MP) were established and analysed for galectin-3 mRNA 
and protein expression by RT-PCR and western blot analysis, respectively. A control 
transfection was also carried out in which DLKP cells were transfected with the empty 
vector PREP9.
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Results from RT-PCR analysis revealed an up-regulation o f galectin-3 by 1.6 fold in C12, 
by 2.2 fold in C l3 and by 3.5 fold in the MP. There was, however, no up-regulation of 
galectin-3 in C2 or the mock transfectant (Vec), indicating that the galectin-3 mRNA over­
expression is due to galectin-3 cDNA transfection (section 3.1.2.1). Western blot analysis 
results supported the RT-PCR findings, revealing an up-regulation o f galectin-3 by 2 fold 
in C12, 1.9 fold in C13 and by 5.7 fold in the MP. Galectin-3 protein was dramatically 
down-regulated in C2, for unknown reasons (section 3.1.2.2). These results were 
reproducible when the RT-PCR and western blot analysis were carried out in triplicate.
4.2.3 Galectin-3 up-regulation and drug resistance in DLKP
The effect o f galectin-3 over-expression on resistance to chemotherapeutic drugs has been 
determined in the breast cancer cell line, BT549, by exposing cells transfected with plasmid 
cDNA containing inserts, in either the sense or the antisense orientation, encoding human 
galectin-3, as well as parental cells, to cisplatin (Akahani e t  al., 1997). The findings 
indicated that only galectin-3 expressing cells were protected against apoptosis induced by 
cisplatin (> 60 %  viability), while the parental cells and the antisense control cells were not 
(< 30 % viability) (Akahani et al., 1997), proving that galectin-3 functions as an anti- 
apoptotic gene (see section 1.5.2). In a separate study, galectin-3 over-expression in human 
leukemia T-cells was found to enhance resistance to apoptosis induced by anti-Fas antibody 
and staurosporine (Yang et al., 1996).
In our experiments, the effect o f galectin-3 over-expression on resistance to three 
chemotherapy drugs, taxol, carboplatin and adriamycin, was determined by carrying out in 
vitro toxicity assays (section 2.3.1). These chemotherapeutic drugs were selected to include 
a range of structurally and mechanistically different classes o f drugs, i.e., the taxanes, the 
platinum compounds and the anthracyclines, respectively (for detail on these classes of 
chemotherapy drugs see section 1.1.1). It was found, however, that galectin-3 over- 
expressing clones did not show changes in drug resistance or sensitivity, suggesting that 
galectin-3 may not play a role in drug resistance in this cell line. It is interesting to note, 
however, that DLKP-MP cells were associated with increased resistance to carboplatin,
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showing a 2.4-fold resistance compared to the parental cells lines and the mock transfection 
(see section 3.1.2.3). This may suggest resistant populations may be present in the mixed 
population and it may be useful to clone out further populations from this cell line, to 
identify those with drug resistance, for further analysis. In conclusion, however, galectin-3 
over-expression failed to protect the cells from drug-induced death and therefore failed to 
induce an MDR phenotype in the over-expressing clones.
4.2.4 Galectin-3 up-regulation in DLKP is associated with induction of an invasive 
phenotype
As previously mentioned (section 4.2.2), galectin-3 over-expression has been found to 
induce metastasis in colon, breast and thyroid follicular cell lines. In a study by Bresalier et 
al. (1998), it was shown that the down-regulation o f  galectin-3, using antisense methods, 
resulted in marked decrease in the metastatic potential of a highly metastatic colon cell line, 
HM7, while the up-regulation of galectin-3 enhanced the metastatic potential o f  a low  
metastatic colon cell line, LS174T. Similar results were obtained by another group in 2002 
using a human breast cancer cell line, BT549, which was transfected with galectin-3 cDNA  
and injected into the spleen o f nude mice. The mice developed tumours in both the spleen 
and the liver, indicating that galectin-3 can enhance the metastatic potential o f BT549 cells 
(Song e t  al., 2002). Furthermore, the over-expression o f galectin-3 also confers a malignant 
phenotype on TAD-2 thyroid follicular cells (Takenaka et a l ., 2003). TAD-2 cells 
transfected with galectin-3 cDNA showed anchorage-independent growth and loss o f  
contact inhibition, suggesting that galectin-3 plays an important role in malignant 
transformation in thyroid follicular cells (Takenaka e t  al., 2003).
In agreement with these studies, our experiments show that galectin-3 over-expression in 
lung tumour cells is also associated with induced invasion. DLKP parent has been shown to 
be non-invasive (Y. Liang, PhD, 1999). Transfection with the control vector did not alter 
that (Figure 3.1.2.4). However, the DLKP transfectants over-expressing galectin-3, i.e. 
C12, C13 and MP, demonstrated a large increase in invasiveness compared to the parental 
cells (see section 3.1.2.4). C2, the only clone with no galectin-3 mRNA or protein over­
expression, had the same non-invasive properties as DLKP-parent, correlating with the fact
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that it has basal levels o f galectin-3 expression. The same was true for motility (see section 
3.1.2.5), suggesting that galectin-3 plays a role in invasion and motility. These experiments 
were carried out in triplicate and were reproducible, suggesting that galectin-3 over­
expression induces a stable invasive and motile phenotype in the transfected cells. In 
addition the invasion and motility assays were quantitatively assessed by dye elution and 
the colormetric analysis was supportive o f the microscopic analysis (see Figures 3.1.2.4 
and 3.1.2.5). Galectin-3 was also found to be associated with increased adhesion to a range 
of extra cellular matrix proteins, namely, ECM, fibronectin and laminin (see section
4.2.4.1).
4.2.4.1 Galectin-3 up-regulation in DLKP is associated with increase adhesion to ECM 
proteins.
Extracellular matrix (ECM), as purchased from sigma, is an artificial reconstituted 
basement membrane. It contains components o f the natural basement membrane. The 
adhesion assays with ECM, demonstrates that DLKP-gal-3 C l2, C l3 and MP were the 
most adhesive to ECM, therefore suggesting that galectin-3 over-expression supports 
DLKP adhesion to ECM. DLKP parent, DLKP-vec and DLKP-gal-3 C2 were all less 
adhesive. RPMI-2650 was least adhesive to ECM and was used as a negative control, while 
HT-1080 was as adhesive as MP and was used as a positive control in these experiments 
(as well as in the invasion and motility assays). Fibronectin is a major component o f the 
extra cellular matrix (see section 1.3.1). As with ECM, galectin-3 over-expression 
correlates with DLKP adhesion to fibronectin. DLKP-gal-3 C12, C13 and MP were the 
most adhesive to fibronectin. Laminin is another major component o f the basement 
membrane. Result o f the adhesion assays show that DLKP-gal-3 Cl 2, C l3 and MP were 
slightly more adhesive to laminin than the parental cell line, DLKP-vec and DLKP C2. 
Collagen type IV is another major component o f  the basement membrane. All the DLKP 
cell lines were equally adhesive to collagen IV, suggesting that galectin-3 over-expression 
does not correlate with DLKP adhesion to collagen IV. These results were reproducible 
when carried out in triplicate, as can be seen from the standard deviation bars on the graph 
representing the finding of these assays (see Figure 3.1.2,6).
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Our results on adhesion studies support some o f those o f  Warfield et al. (1997), where a 
study was carried out on the breast carcinoma cell line, BT549, and galectin-3 over­
expressing clones were found to adhere more rapidly to laminin and fibronectin. In 
addition, the cells were also able to invade through matrigel-coated filters at approx. three 
times the rate o f parental cells. Contrary to our results, however, the results o f  Warfield et 
al., suggest that galectin-3 is essential for adhesion o f breast carcinoma cells to laminin and 
collagen IV, but not to fibronectin. Taken together, our results indicate galectin-3 
involvement in promoting cell adhesion to ECM, fibronectin and laminin in the DLKP cell
4.2.5 Galectin-3 up-regulation in DLKP is not associated with increased cell 
proliferation rate
In addition to its association with invasion, metastasis and apoptosis control, galectin-3 has 
also been associated with changes in growth rates o f certain cancer cell types. Growth 
properties o f human leukemia T cells transfected with galectin-3 cDNA, and over- 
expressing galectin-3 protein, were examined by Yang et al. (1996). It was found that cells 
over-expressing galectin-3 displayed higher growth rates than cells that do not over-express 
this protein. This suggests that galectin-3 is a cell growth regulator and appears to confer 
cell survival by inhibiting apoptosis.
In our experiments, however, we found no evidence o f changing growth rates o f DLKP 
clones over-expressing galectin-3, compared to parental cells or mock transfectants, and 
therefore conclude that galectin-3 up-regulation in DLKP is not associated with an 
increased proliferation rate in these cells (see section 3.1.2.7).
277
Survivin is a protein that inhibits apoptosis and regulates cell division (Altieri et al., 1999). 
Recently there has been great interest in survivin as a diagnostic marker and potential drug 
target because o f its predominantly cancer-specific expression in adult human organ 
tissues. Survivin is expressed in most human cancers, but not in the majority o f normal, 
adult tissues (Ambrosini et al., 1997, Adida et al., 1998a and O’Driscoll et al., 2003) (see 
section 1.6.3 for more detail).
Studies have shown that survivin expression is up-regulated in association with the 
development o f drug resistance (Notarbartolo e t  al., 2002) and in response to apoptotic 
stimuli (Ikeguchi e t  al., 2002, Muenchen et al., 2001 and Kennedy e t  al., 2000), thereby 
protecting cells from apoptosis and promoting the development o f cancerous tissue. The 
aim of this section o f the thesis was to investigate the role o f survivin in drug resistance. 
The RPMI-2650 drug resistant variants (Liang et al., 2001) were used as a model for the 
initial part o f the analysis as they were for the initial galectin-3 study (section 4 .2.1).
4.3.1 Expression of Survivin in RPMI-2650 and its MDR variants
Survivin up-regulation correlation with drug resistance was demonstrated in a study by 
Notarbartolo et al. (2002), where the human leukemia cell line, HL60, was compared with 
its multidrug resistant, P-gp overexpressing, variant HL60R. In HL60R cells, there was an 
increase in survivin mRNA compared to the parental cells. This suggests that the selection 
of the MDR HL60R cell line, by exposure to Doxycycline hydrochloride, had induced the 
expression o f factors opposing apoptosis, including IAPs. This, in turn, suggests that the 
inability o f cancer cells to undergo apoptosis may contribute to the complex phenomenon 
of drug resistance.
In our experiments, survivin expression was studied in the nasal carcinoma cells, RPMI- 
2650 and it two MDR variants, RPMI-taxol and RPMI-melphalan resistant cell lines. 
Contrary to findings by Notarbartolo e t  al., we found survivin mRNA and protein to be
4.3 Analysis of Survivin levels in drug resistant cell lines
down-regulated in the RPMI-taxol resistant variant compared to both the parental cells and 
the RPMI-melphalan resistant variant (see sections 3.2.1.1 and 3.2.1.2). The results were 
reproducible in repeat experiments. RPMI-taxol resistant cells are highly resistant to their 
selection drug, taxol (226-fold) and are cross-resistant to doxorubicin, vincristine, 
vinblastine and VP-16, but not to melphalan, cadmium chloride, cisplatin or 5-FU, 
indicating the involvement of P-gp in its MDR phenotype (Liang e t al., 2001). The role of 
survivin down-regulation in this taxol-resistant cell line, if  any, is unknown at present.
4.3.2 Survivin cDNA stable transfection into DLKP cells
In an attempt to establish the significance o f the down regulation o f survivin mRNA and 
protein in RPMI-taxol resistance cells, as discussed in the previous section, survivin cDNA  
was stably transfected into DLKP cells. It was hoped that by over-expressing survivin in a 
drug-sensitive cell line, we could gain further insight into its role in drug-resistance. 
Survivin expression was previously analysed in three cell lines; DLKP, a lung carcinoma 
cell line, SKOV-3, an ovarian carcinoma cell line, and MCF-7, a breast carcinoma cell line. 
It was found that DLKP expressed intermediate levels o f survivin protein compared to 
SKOV-3 and MCF-7 and was therefore selected for the cDNA transfection.
Survivin cDNA was sequenced and it was found that the correct survivin coding sequence 
was inserted into pTarget plasmid. This plasmid was transfected into DLKP using 
lipofectin, and five clones, resistant to geneticin at a concentration o f 1 mg/ml, were 
successfully established (section 2.4.5). The clones were analysed for changes in survivin 
mRNA and protein expression by RT-PCR and western blot analysis, respectively. Despite 
their resistance to geneticin, none o f the clones showed a consistent change in survivin 
mRNA or protein expression (see Figures 3.2.2.1 and 3.2.2.2). This may suggest that levels 
of survivin mRNA and protein may not be altered in DLKP cells due to mechanisms within 
the cells preventing over-expression. This may be linked to expression o f EPR-1 (see 
section 1.6.4 in the introduction), which may be acting as a natural antisense to survivin, 
keeping its level of expression constant.
279
Despite the lack o f detectable survivin over-expression in the DLKP clones, in vitro  
toxicity assays were carried out on three o f the five clones to determine whether survivin 
cDNA transfection was perhaps causing small increases in survivin level, thereby having 
any effect on protecting the cells from drug-induced death. Two chemotherapy drugs were 
used in this experiment: adriamycin and carboplatin. However, none of the three DLKP- 
survivin clones appeared to have any increased resistance to these drugs compared to 
DLKP parent cells (see section 3.2.2.3). This may be due to the lack o f up-regulation o f  
survivin as seen by RT-PCR and western blot analysis. The toxicity assays were carried out 
once using adriamycin and twice using carboplatin and were not reproducible, however, a 
mean of the two assays using carboplatin is shown in Figure 3.2.2.3B.
Other groups have, however, successfully transfected survivin cDNA into different cell 
lines (Tamm e t al. 1998; Li et al., 1998; Islam et al., 2000a; Kasof et al., 2001a; Tran et al., 
2002). Islam et al. (2000a) stably transfected a survivin cDNA construct into CHP 134, a 
human neuroblastoma cell line. Similar to our technique, lipofectamine was also used and 
geneticin was used to select two clones. The clones over-expressed survivin mRNA as 
demonstrated by northern blot analysis. Furthermore, one o f the survivin over-expressing 
clones was protected from apoptosis induced by retinoic acid, highlighting the role o f  
survivin in apoptosis inhibition (Islam et al., 2000). A second attempt was, therefore, made 
at over-expressing survivin in a different cell line. The cell line selected was SKOV-3 ‘Tet 
o ff , a human ovarian carcinoma cells line, containing a tetracycline inducible plasmid (see 
section 4.3.3).
4.3.3 Survivin cDNA stable transfection into SKOV-3 ‘Tet off Cells
The SKOV-3 ‘Tet o ff  (T.O.) cell line was chosen for the survivin cDNA transfection as it 
allows gene expression to be turned on when tetracycline or doxycycline (Dox; a 
tetracycline derivative), is removed from the culture media, or turned off when they are 
added. This theoretically allows the expression o f genes to be tightly regulated in response 
to varying concentrations of tetracycline or doxycycline and thereby allows loss or gain of 
gene function, as required.
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The system consists of two plasmids, one encoding the tetracycline controllable 
transactivator protein (tTA) under control o f a cytomegalovirus (CMV) promoter, and the 
second, pTRE containing the tet operator (tetO) minimal promoter driving the gene of 
interest. It involves constitutive expression o f the tet transactivator protein (tTA) in 
response to human CMV. tTA is a fusion protein composed o f the tet repressor of 
Escherichia coli and the transcriptional activation domain of the VP16 protein o f herpes 
simplex virus. In the absence of tet, the tet repressor portion o f tTA mediates high affinity, 
specific binding to sequences from the tet resistance operator o f TnlO (tetO), resulting in 
gene expression. In the presence o f tet, however, a conformational change in tet repressor 
prevents tTA from binding to its operator, inhibting gene expression as shown in Figure
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Figure 4.1 Schematic representation o f gene regulation in the Tet-Off system. The 
tetracycline-controlled transactivator (tTA) is a fusion of the wild-type Tet repressor (TetR) 
to the VP16 activation domain of the herpes simplex virus. The tet-responsive element 
(TRE) is located upstream of the minimal immediate early promoter o f the cytomegalovirus 
(PminCMv), which is silent in the absence o f activation. tTA binds the TRE, and thereby 
activates transcription o f gene of interest, in the absence of tetracycline (Tc) or doxycycline 
(Dox) (Figure adapted from Clontech Laboratories user manual).
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Survivin cDNA, originally cloned into pTarget plasmid, was subcloned into pTRE plasmid, 
and was stably transfected into SKOV-3 ‘T.O.’ using Fugene 6 as the transfection agent 
(this technique was first optimized by carrying out a luciferase assay to achieve maximum 
transfection efficiency (see section 3.2.3)). A second plasmid, PTK-Hyg, was co­
transfected with survivin cDNA-containing pTRE and clones were selected in hygromycin 
(see section 2.4.5.2).
Twelve SKOV-3 ‘T.O’ survivin clones and a mixed population (MP) were established and 
characterised by RT-PCR and western blot analysis initially (Figures 3.2.3.1.1 and
3.2.3.1.2), to determine if survivin expression was up-regulated in these cell lines. 
However, as with the DLKP stable transfection, there was no consistent change in survivin 
mRNA or protein expression. RT-PCR analysis was carried out in triplicate, and no up- 
regulation o f survivin mRNA was observed in the repeat experiments. Western blot 
analysis was also carried out in triplicate and no up-regulation o f survivin protein was 
observed. Toxicity profiles o f the clones were analysed using carboplatin and taxol, to 
determine if  survivin cDNA transfection had any effect on the drug resistance profile o f the 
clones. Again, survivin cDNA transfection played no role in protecting the cells from drug- 
induced death (see Figure 3.2.3.1.3). This was probably due to the fact that there was no 
apparent survivin mRNA or protein up-regulation detected by RT-PCR or western blot 
analysis. Since the clones established were all resistant to hygromycin, it was assumed that 
the transfection experiment was successful and no further analysis was carried out to check 
if  survivin cDNA was actually transfected into the cells. It is possible that the cells 
developed resistance to the selection antibiotic, hygromycin; therefore, PCR analysis needs 
to be carried out to determine whether transfection of survivin cDNA was successful.
Furthermore, two o f the clones, C2 and C5, along with the mixed population were selected 
for further analysis, using the inducible system to switch survivin expression on and off, by 
sub-culturing the cells in the absence and presence o f doxycycline. RT-PCR and western 
blot analysis was carried out on the clones and the MP, however, there was no change at 
the mRNA level between the ‘on’ state and the ‘o ff  state (see Figure 3.2.3.1.1C and D). 
This experiment was repeated three times and no change in survivin mRNA expression was 
apparent in any o f the repeated RT-PCR experiments.
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There was only a very slight change at the protein level between survivin expression in the 
‘on’ and the ‘o ff  states, with C2, displaying the most variation, a 1.35-fold increase in 
survivin protein in the ‘on’ state, compared to the ‘o ff  state (see Figure 3.2.3.1.2E and F). 
This was, however, observed in one experiment and was not evident in the repeated 
western blot. Toxicity assays also showed a very slight difference between the ‘on’ and 
‘ofF states o f survivin expression, with C5 showing slightly more resistance in its ‘on’ state 
to carboplatin (1.5-fold) and to taxol (1.66-fold) (see Figure 3.2.3.1.3C and D). Results 
represent a mean o f two separate experiments, which were reproducible.
Overall, it is concluded that survivin cDNA stable transfection into SKOV-3 ‘T.O.’ showed 
no change in survivin mRNA or survivin protein expression and did not induce a drug 
resistance profile in these cells. This leads us to believe that, if survivin cDNA has been 
successfully transfected, EPR-1 may be acting as a natural antisense to survivin in the 
SKOV-3 ‘Tet o f f  cell line, as well as in the DLKP cell line (as mentioned in section 4.3.2). 
It was believed, therefore, that the only way to overcome this difficulty was to carry out 
transient transfections o f survivin cDNA into these cell lines in order to see a more 
immediate affect on survivin expression without giving the cells a chance to adjust their 
intracellular levels o f survivin/EPR-1 expression.
4.3.4 Survivin cDNA transient transfection into SKOV-3 ‘Tet ofP cells
The majority o f studies involving survivin cDNA transfections into cancer cell lines have 
been through transient transfections. The reason for this may be that it is not always 
possible to create stable transfections over-expressing survivin. This may be due to 
processes within the cell that prevent the up-regulation o f survivin mRNA and protein, 
perhaps due to effector cell protease receptor-1 (EPR-1) acting as a natural antisense to 
survivin, and thereby keeping survivin’s levels constant in the cell. Survivin was reported 
to be highly complementary to EPR-1 (Ambrosini et al., 1997) (see section 1.6.4). Due to 
their complementary sequences, it has been suggested that there may be functional 
intereactions between survivin and EPR-1 proteins and that EPR-1 may act as a natural 
antisense to survivin (Ambrosini e tah ,  1997).
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Transient transfection allows rapid analysis o f a gene function. The use o f transient 
transfections in apoptosis research has been widely reported (Wrone-Smith e t  al., 2001; 
Kuo e ta l . ,  2001; Townsend et al., 1999; Katoh e ta l . ,  1998; Los e ta l . ,  1997).
Our attention was, therefore, turned to the use o f transient transfection techniques to over- 
express survivin cDNA in the SKOV-3 ‘Tet o f f  cell line (section 2.4.5.4). The transient 
transfection technique was first optimized to achieve maximum transfection efficiency. 
This was carried out using the 5-bromo-4-chloro-3-indolyl-P-D-galactopy-ranoside (X-Gal) 
staining method (section 2.4.5.3). Previous studies in this lab by Dr. Deirdre Cronin 
showed that various cell lines gave different transfection efficiencies, such as Hela cells, 
where up to 40% transfection efficiency was achieved and DLKP cells, where up to 35% 
transfection efficiency was achieved (D. Cronin, PhD, 2002). For our current cell line of 
interest, SKOV-3 ‘Tet o ff , a transfection efficiency o f approximately 30% was achieved 
using Fugene 6 (see section 3.2.4.1). This apparently allowed sufficient expression of 
survivin cDNA to show increases in survivin at the mRNA. No increase in survivin protein 
levels was detected (see sections 4.3.4.1 and 4.3.4.2).
4.3.4.1 Survivin cDNA transient transfection caused survivin mRNA up-regulation in 
SKOV-3 ‘Tet ofP
RT-PCR analysis was carried out on RNA from cells harvested at a range o f time intervals. 
These were 24, 48, 72 hours and 1 week post transfection. There was a dramatic increase of 
survivin mRNA levels after 24 hours (approx. 18-fold, see Figure 3.2.4.2.IB). This 
increase was maintained at 48 and 72 hours, but in some repeat experiments, survivin 
mRNA expression dropped to almost basal levels after 5 days as shown in Figures
3.2.4.2.1 A and 3.2.4.2.IB. This is to be expected at the survivin cDNA-containing plasmid 
would be degraded in the cells; stable transfections involve drug selection o f the very small 
proportion o f cells, which have incorporated the plasmid into their chromosomal DNA. 
Furthermore, the function of the inducible system was tested in the transient transfection by 
carrying out the transfection procedure in the presence and absence o f doxycycline to turn 
survivin expression ‘o f f  and ‘on’, as discussed in section 4.3.3. This proved to work 
successfully and the effect o f this inducibility was most dramatic at 24 hours, with a 50 %
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inhibition o f survivin mRNA expression in the presence o f dox, i.e. in the ‘o f f  state 
compared to the ‘on’ state. The effect is still obvious at 48 and 72 hours, but not to the 
same extent (see Figure 3.2 4.2.1A and B). Surprisingly, the survivin mRNA expression 
after 5 days seems to be lower in the ‘on’ state than the ‘o f f  state (see Figure 3.2.4.2.1A  
and B). This has been found in repeat experiments, and the reason for this is not clear. To 
prove that the effects seen were due to survivin over-expression, a control transfection 
containing the empty pTRE vector was carried out and the level o f survivin mRNA 
remained constant at all time points (time points included on this experiment are 24, 48, 
and 72 hours) as shown in Figure 3.2.4.2.1C and D. These experiments were carried out in 
triplicate and the results were reproducible. It is important to mention that in all RT-PCR 
analysis using the survivin primers which pick up the three splice variants o f survivin, 
suvivin-2B isoform was undetectable and in some, but not all, cases survivin-AEx3 was 
detected. The reason for this variation is unknown.
4.3.4.2 Survivin cDNA transient transfection caused no survivin protein up-regulation 
in SKOV-3 ‘Tet off*
Western blot analysis was carried out on protein extracted at 24, 48, 72 hours and 5 days 
post-transfection. However, there was no survivin protein up-regulation seen at any o f the 
time points as shown in Figures 3.2.4.2.2A  B, C and D. Numerous attempts were made to 
over-express the survivin protein in the cells, but this was not possible. This was also 
carried out using different concentrations of protein ranging from 10 to 30 ng, in an attempt 
to avoid protein saturation, but no survivin protein over-expression was detected in any of 
the western blots carried out. Immunofluorescence was also carried as another means of 
detecting survivin protein over-expression. Survivin protein was found to be expressed in 
the cytoplasmic region o f the cells (see Figure 3.2 4.2.3), in agreement with similar 
findings by several groups (Ambrosini e ta l . ,  1997; Kawasaki e ta l . ,  1998; Lu e ta l . ,  1998; 
Adida e t  al., 1998; Tanaka et al., 2000; Muzio et al., 2001; Satoh et al., 2001). Despite 
numerous experiments, survivin protein over-expression could not be obtained. The reason 
for this is unclear and may be due to some translational block by these cells.
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In addition, survivin expression is cell cycle dependent with up-regulation o f survivin in the 
cells during the G2/M phase o f the cell cycle, followed by a rapid decline in the G1 phase 
(Li e ta l . ,  1998) (see section 1.6.6). Zhoa e ta l .  (2000) carried out a study showing that the 
ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent 
manner and that structural changes destabilise the survivin protein. The group found that 
proteosome inhibitors prolonged the half-life o f survivin, thereby proving that proteosomes 
are involved in survivin degradation (Zhoa e ta l . ,  2000) (see section 4.7). This may help to 
explain why we were unable to detect an increase in survivin protein by transient 
transfection equivalent to the increase in survivin mRNA that was observed.
Some research papers carrying out survivin transfection experiments do not present 
changes in survivin protein expression, but proceed to show functional changes in the cells 
caused by survivin up-regulation (Islam e t  al., 2000; Kasof et al. 2001) or down-regulation 
by antisense (Olie e ta l . ,  2001). We, therefore, proceeded to carry out experiments to detect 
changes in the cells that may be caused by the transfection o f survivin cDNA.
4.3.4.3 Does Survivin cDNA transient transfection protect the cells from drug-induced 
apoptosis?
Despite the lack of survivin protein over-expression following the SKOV-3 ‘Tet o ff  
transient transfection, we took the analysis of this experiment further and went on to try and 
determine whether the transfection resulted in any functional changes within the cells and 
whether the survivin was protecting the cells from drug-induced apoptosis. This was 
carried out first, by standard in vitro toxicity assays (see Figure 3.2.4.2.4), whereby drug 
(taxol and cisplatin) was added at different time points (24, 48 and 72 hours) post 
transfection, to include all periods o f survivin mRNA up-regulation detected by RT-PCR, 
and cells were incubated for the 5-7 days before being assessed for cell viability. However, 
despite numerous attempts to optimize this technique, a consistent result showing increased 
resistance o f the cells, could not be achieved. The inducible system was also tested as well 
as the mock transfection and in all cases the IC50 values remained unchanged.
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Technically, the toxicity assay was difficult to optimize as cells were being monitored over 
five to seven days when the survivin mRNA level was reverting back to that o f parental 
cells. Further optimization o f in vitro toxicity testing is needed, perhaps by carrying out 
short-term toxicity assays. Taxol and cisplatin were chosen because they have been used by 
other research groups when studying the effect o f survivin up- or down-regulation on drug 
resistance in various cell line models. Taxol has previously been used to induce apoptosis 
in cell transfected with survivin cDNA (Li e ta l . ,  1998) or with survivin dominant-negative 
mutant (Tran e t  al., 2002). Cisplatin has been used to induce apoptosis in cells transfected 
with survivin ribozyme (Pennati et al., 2002) or with survivin dominant-negative mutant 
(Grossman e ta l . ,  2001 and Tran e ta l . ,  2002).
The role o f survivin in drug resistance was examined in endothelial cells (ECs). EC 
chemoprotection can be induced by VEGF (vascular endothelial growth factor). Recent 
reports suggest that in addition to EC protection by VEGF, survivin over-expression can 
also protect ECs from drug-induced cell death by preserving the microtubule network (Tran 
et al., 2002). This was demonstrated through the transfection o f survivin cDNA in HUVEC 
(human umbilical vein endothelial cells), followed by the use o f the chemotherapy drugs, 
CDDP and taxol to induce apoptosis. Survivin over-expression protected ECs from 
apoptosis induced by these drugs. When survivin wild-type transfection was replaced by a 
survivin mutant, this protection against cisplatin and taxol-induced apoptosis was lost (Tran 
et al., 2002). Zaffaroni et al. (2002) studied the effects o f survivin on drug resistance and 
found that stable transfection o f human ovarian carcinoma with survivin cDNA caused a 4- 
6-fold increase in cell resistance to taxol and taxotere (Zaffaroni eta l . ,  2002).
The second method we used to determine whether survivin transfection is protecting the 
cells from drug induced apoptosis was the TUNEL (terminal deoxynucleotide transferase- 
mediated deoxyuridine phosphate nick end-labelling) assay. This is an assay designed to 
detect apoptosis in cells, by labeling extensive DNA strand breaks, a process which occurs 
during apoptosis (see section 2.3.2.1). Before the assay was carried out, transfected and 
parental cells were treated with taxol, a microtubule-stabilising drug previously used in 
survivin studies to induce apoptosis, as survivin-microtubule interaction is required for 
apoptosis inhibition (Li e ta l . ,  1998). No changes were detected in the levels of apoptosis in 
the survivin transfectants compared to the control cells as shown in Figure 3.2.4.2.5. The
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experiment was not always successful. As non-apoptotic cells undergoing cell division, 
also fluoresced, this made it difficult to distinguish apoptotic cells from dividing cells.
This method of apoptosis detection (i.e. TUNEL) was also used by Shankar et al. (2001) to 
assess the level o f apoptosis induction caused by survivin expression inhibition, when 
survivin antisense oligonucleotides were added to a human neuroblastoma and an 
oligodendroglioma resulting in reduction in survivin protein levels and spontaneous 
apoptosis (Shankar et al., 2001). TUNEL assay was also used in detecting apoptosis 
induced by transfection o f survivin antisense oligonucleotide into human choriocarcinoma 
cell lines (JEG-3 and BeWo) and a human trophoblast cell line (tPA30-l). Results indicated 
up to 9-fold increase in TUNEL-positive cells (apoptotic cells), when these cells were 
transfected with survivin antisense (Shiozaki e ta l . ,  2003). Other groups have used transient 
transfection techniques to over-express or down-regulate survivin in different cell lines and 
were able to show functional changes within the cells as a result o f survivin over­
expression.
In a study by Kasof et al. (2001b), Hela cells were transfected with apoptotic genes in the 
Ptracer vector containing a green fluorescence protein (GFP) marker for accessing viability. 
Transfection with pro-apoptotic genes, e.g. Bax, led to approx. 90% reduction in viability. 
However, co-transfection of Bax with survivin, or livin, a novel member o f  the IAP family 
and closely related to survivin (Vucic et al., 2000; Kasof et al., 2001b) (see section
1.6.5.2), resulted in a 4-6-fold increase in viability. A similar study was carried out by 
Tamm et al. (1998), where survivin cDNA transient transfection in 293 cells was able to 
partially inhibit apoptosis induced by the co-transfection o f Bax or Fas. Survivin expression 
also protected 293 cells from apoptosis induced by over-expression o f pro-caspase-3 and - 
7, as well as inhibiting the processing of these two zymogens into active caspases (Tamm et  
al., 1998).
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To date there has not yet been a direct correlation between survivin expression in cancer 
cells and the induction of an invasive and metastatic phenotype. Survivin expression in 
tumours has, however, been associated with a more metastatic tumour, with poor prognosis 
and that is more resistant to therapy (Yoshida et al., 2003; Ikehara et al., 2002). The 
clinical aspect o f survivin will be discussed in further detail in section 4.5.
Here we attempted to establish whether or not there is a correlation between survivin over­
expression in SKOV-3 ‘tet o ff  and invasiveness by examining the in vitro  invasiveness o f  
the SKOV-3 ‘Tet off-survivin transfected cells compared to the parental cells and the 
control transfections.
Cells were set up in invasion chambers 24 hours post-transfection and the results were 
obtained 48 hours later (see section 2.5.1). Initial experiments suggested a decrease in 
invasiveness between the transfected cells and the parental cells or the mock transfection. 
There also seemed to be a decrease in invasiveness between the transfected cells in their 
‘on’ state o f expression compared to their ‘o f f  state. RPMT-2650 parent cells were used as 
a negative control and RPMI-melphalan-resistant cells were used as a positive control for 
the invasion assay (see section 3.2.4.2.6). When the experiment was repeated, however, this 
decrease in invasiveness was no longer apparent. Experiment was repeated several times 
and the change in invasiveness was not reproducible, suggesting that the effect seen the 
first time was not a real effect and that survivin was having no effect on in vitro 
invasiveness of the transfected cells. The reason behind the lack o f any functional change 
caused by survivin transient transfection may be due to the lack o f protein over-expression 
in the transfected cells. No further analysis was carried out in these cell lines.
4.3.5 Survivin cDNA transient transfection into DLKP cells
To establish whether the lack of survivin protein over-expression in SKOV-3 ‘Tet o f f  cells 
is cell line specific, DLKP was chosen for transient transfection experiments. Survivin 
cDNA in pTarget was transiently transfected into DLKP cells using the same technique as 
in section 4.3.4 (also see section 2.4.5.4). As in section 4.3.4, RT-PCR analysis was carried
4.3.4.4 Does Survivin cDNA transient transfection induce an invasive phenotype?
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out on RNA from cells harvested at different time intervals, i.e. 24, 48, 72 hours and 5 days 
post transfection. There was a dramatic increase o f survivin mRNA after 24 hours as shown 
by RT-PCR analysis. This increase was maintained even after 72 hours, after which it 
started to drop to almost basal levels at 5 days as shown in Figure 3.2.5.1.
Western blot analysis, on the other hand, did not show any survivin protein up-regulation at 
24, 48 or 72 hour time points (see Figure 3.2.5.2), suggesting that lack o f survivin protein 
in transient transfections may not be cell line specific. However, to further investigate this 
finding, a third cells line was selected for further analysis.
4.3.6 Survivin cDNA transient transfection into MCF-7 ‘Tet off* cells
The human breast carcinoma cell line, MCF-7 ‘Tet o f f ,  is similar to the ovarian carcinoma 
cell line, SKOV-3 ‘Tet o f f  previously used in survivin transfection experiments, in that it 
contains the ‘Tet o f f  plasmid which allows gene expression to be turned on when 
tetracycline or doxycycline is removed from the culture media, or turned off when they are 
added, allowing the expression o f clones genes to be tightly regulated. This cell line, as 
with the SKOV-3 ‘Tet o ff  cell line, was developed in our lab. by Helena Joyce, M.Sc.
Survivin cDNA (which, as previously mentioned, was subcloned into the pTRE plasmid) 
was transiently transfected into MCF-7 ‘Tet o ff , and as in sections 4.3.4 and 4.3.5, RT- 
PCR analysis was carried out on RNA from cells harvested at different time intervals, i.e. 
24, 48, 72 hours and 5 days post transfection. There was a dramatic increase in survivin 
mRNA levels after 24 hours, as demonstrated by RT-PCR analysis. This increase was 
maintained even after 72 hours but dropped to almost basal levels after 5 days (see Figure
3.2.6.1 A). Transfection o f the empty pTRE plasmid into the cells did not show any change 
in survivin mRNA expression (Figure 3.2.6.1C). Furthermore, the function o f the inducible 
system was tested in the MCF-7 ‘Tet o f f  transiently transfected cells by carrying out the 
transfection procedure in the presence and absence o f doxocycline to turn survivin 
expression ‘o f f  and ‘on’, respectively, as discussed in section 4.3.3 and 4.3.4. RT-PCR 
analysis showed no difference between the two states o f survivin expression, i.e. the over­
expression o f survivin mRNA in the transfected cells was not down-regulated or inhibited
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by the addition o f doxocycline as shown in Figure 3.2.6.IB. This suggests that the 
inducible, Tet off plasmid does not function in the MCF-7 cell line as it did in the SKOV-3 
cells. As with all survivin RT-PCR analysis presented in this thesis, the survivin primers 
used are primers that were previously used by Mahotka et al. (1999), which pick up the 
three splice variants o f survivin; survivin-2B, survivin and survivin-delta Ex3, however, 
only the original survivin variant was detected in these cells.
Western blot analysis was carried out on protein extracted at the same time points as 
before. Interestingly, we observed survivin protein up-regulation for the first time in our 
experiments at 24 hours post-transfection. As with all survivin western blots presented in 
this thesis, a-tubulin was used as an endogenous control to detect equal loading o f protein 
samples as shown in Figure 3.2.6.2A. When the transfection as repeated a second time, we 
were unable to reproduce the initial result o f survivin protein up-regulation (Figure 
3.2.6.2B). The experiment was repeated several times in an attempt to reproduce the initial 
results, but without success. The reason for this is unknown and further transient 
transfection studies in a wider range o f cell lines may be needed. This may help identify 
cell lines that, for unknown reasons at present, have the ability to over-express survivin 
protein.
The objective of the survivin studies was to establish a role for survivin in drug resistance 
and determine whether or not survivin played a role in in vitro invasiveness. This was to be 
achieved through over-expression o f survivin in drug-sensitive cancer cells. Despite several 
attempts, however, we were unsuccessful in identifying a cell line which over-expresses 
both survivin mRNA and protein, simultaneously. As described above, neither survivin 
mRNA nor protein over-expression was attainable through stable transfection experiments. 
Survivin mRNA but not protein, was over-expressed through transient transfection of 
survivin cDNA in three cell line models (SKOV-3 ‘Tet o f f ,  DLKP and MCF-7 ‘Tet o ff). 
Survivin mRNA over-expression alone was not enough to induce any phenotypic 
(functional) changes in the cells. We were not able, therefore, to establish a role for 
survivin in any of the cell lines.
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4.4 Survivin expression in MDR cells
Our findings that survivin mRNA and protein was reduced in the RPMI-2650 taxol- 
resistant variant, as discussed in section 4.3 and the finding that galectin-3 was over­
expressed in RPMI-2650 melphalan-resistant variant as discussed in section 4.2, led to the 
establishment of DLKP and RPMI-2650 drug resistant variants, which were to provide a 
model for studying the expression o f survivin and galectin-3 to further elucidate their role 
in drug resistance and invasiveness. In addition, studies were designed so as to help us 
establish a relationship between drug resistance and invasiveness. It has previously been 
shown in our laboratories that induction o f an MDR phenotype, through drug exposure, has 
been accompanied by induction o f an invasive phenotype in RPMt-2560 cells (Liang et ah, 
2001) and DLKP cells (Liang et al., in prep), both ‘normally’ non-invasive.
4.4.1 Establishment of MDR variants of DLKP cell line
DLKP is a poorly differentiated squamous lung cancer cell line, which was established 
from a lymph node metastasis biopsy by bronchoscopy in this Centre (Law et ah, 1992). 
There has been much characterisation carried out on this cell line since it was established. 
Toxicity assay results indicate that this cell line is very sensitive to adriamycin, vincristine, 
VP-16 and cisplatin (Clynes e t  ah, 1992). RT-PCR analysis shows that DLKP cells express 
low levels o f MRP-1 mRNA but lacks MDR-1 mRNA expression (NicAmhlaoibh et ah, 
1999). DLKP was derived from a secondary site of the primary tumour. However, invasion 
assays demonstrate a low level o f invasiveness in this cell line, suggesting that although 
DLKP cells are apparently metastatic in vivo , this is not the case in vitro (Y. Liang, PhD, 
1999; O’Driscoll et al., 2002).
In order to study phenotypic and genotypic features related to acquired chemoresistance, 
Liang et ah (manuscript in prep.) established ten MDR variants o f the DLKP cell line by 
sequential pulse exposure to increasing concentrations o f ten commonly used 
chemotherapy drugs. The drugs chosen were: etoposide, vincristine, taxotere, mitoxantrone, 
5-fluorouracil, methotrexate, CCNU, BCNU, cisplatin and chlorambucil. Results revealed
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that all ten drugs induced drug resistance and over-expression of P-glycoprotein (P-gp) in 
DLKP cells.
Multiple drug resistance, MDR, is the mechanism developed by tumour cells upon 
treatment with chemotherapy drugs, whereby the tumour develops cross-resistance to 
functionally and mechanistically unrelated drugs (see section 1.2). It constitutes one o f the 
main problems in cancer therapy and is cause o f chemotherapy failure in cancer treatment 
(Clynes e ta l . ,  1992). The first insight into this phenomenon was revealed in the 1960s, and 
much attention has been drawn to the study of MDR since then (Royal et al., 1968). Many 
cell lines have been used as models to elucidate the mechanism involved in 
chemoresistance (Benard et al., 1989). It has been widely reported that the induction of 
MDR is strongly associated with the over-expression o f P-gp and MRP1 (multiple drug 
resistance protein) (Clynes e t  al., 1990; Goldstein et al., 1989; Lum et al., 1993; Harrison 
et al., 1995; El-Deiry e t al., 1997). Several structurally and functionally unrelated agents, 
including the anthracyclines, the vinca alkoids, actinomycin D, the epipodophyllotoxins 
and the taxanes are substrates for P-gp and are strongly associated with MDR.
In the DLKP selection studies carried out by Liang et al. (in prep), taxotere appeared to 
induce the highest level o f MDR and was associated with the highest level o f over­
expression of P-gp and MRP-1 in this variant, demonstrated by RT-PCR and western blot 
analysis. Furthermore, findings by Liang et al. indicate that DLKP exposure to certain 
drugs, namely, mitoxantrone, BCNU, chlorambucil, 5-FU, methotrexate and cisplatin, 
induced an invasive phenotype in the resulting variants, whereas etoposide, vincristine, 
taxotere and CCNU did not induce such invasiveness. These findings, along with previous 
findings in this Center indicating that melphalan causes an induction o f invasiveness in the 
nasal carcinoma cell line, RPMI-2650 (Liang et al., 2001), suggest a strong link between 
drug resistance and cancer invasion/metastasis.
To further elucidate the role o f cancer chemotherapeutic drugs in the enhancement o f 
invasion and metastasis in the DLKP cell line and to determine whether the effects caused, 
by certain drugs, on in vitro invasiveness, is a random affect on cells or whether induction 
of in vitro invasiveness is cell type and drug specific, we repeated the work carried out by 
Liang e t al. (in prep.) using three o f the ten drugs previously included. The drugs selected
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for the purpose o f this thesis were taxotere, vincristine and 5-FU. These drugs were 
selected with the RPMI-2650 drug selection study in mind. It was intended to choose drugs 
that over-lap in order to compare their effects on the two cell lines (DLKP and RPMI-2650) 
(see section 4.5). The cells were exposed to sequential pulses o f a stepwise increased 
concentration o f drug for approx. ten weeks, after which they were analysed by toxicity 
assays, in vitro invasion assays, gelatin zymography studies, and gene expression was 
examined by RT-PCR and, in some cases, by western blot analysis. The findings from this 
study are summarised in Table 4.1.
DLKP selection variants were developed by pulse exposure o f cells to sub-lethal 
concentrations of drug, following weekly 4-hour exposure to the drug for approx. 3 months. 
(Part o f this work was carried out by Mr. John Cahill, NICB). The method o f pulse- 
selection, instead o f continuous selection, which is occasionally used in in vitro studies 
(Liang et al., 2001) was used in this thesis, to try to mimic clinical drug resistance, where 
drug is administered to patients on a weekly basis for a period o f 2-3 months, depending on 
the type o f cancer in question.
Resistant variants o f the human colon tumour cell line, LoVo, has been developed by this 
method of pulse-selection with adriamycin and have been shown to possess a more stable 
and different toxicity profile to a variant developed by continuous exposure to the same 
drug (Yang and Trujillo, 1990). Similarly, intermittent exposure o f the human 
myeloidleukemic cell line, K562, to epirubicin or vinblastine over a 3-month period 
resulted in the establishment of resistant variants which were maintained as resistant with 
the re-exposure to the selecting agent for a period o f 4 days every 4-5 weeks (Marks e t al., 
1993).
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4.4.1.1 Induction of a multiple drug resistance phenotype in DLKP selected
variants
The MDR phenotype has been developed in animal and human cell lines in tissue culture 
through exposure o f sensitive cells to increasing sublethal concentrations o f  a particular 
selecting agent, i.e. a cytotoxic drug. High degrees o f resistance can be achieved by this 
method o f selection. In vitro, broad resistance to structurally and functionally unrelated 
drugs is observed intrinsically or after intermittent or prolonged exposure o f tumour cells to 
a single agent. This classical multidrug resistance is typically characterised by cross­
resistance to four classes o f commonly used natural product drugs, the anthracylines, vinca 
alkaloids, taxanes and epipdophyllotoxins (Hipfner e ta l . ,  1999).
In our studies, exposure o f DLKP cells to two o f  the three drugs, taxotere and vincristine, 
induced drug resistance to their selection agents, i.e. taxotere and vincristine, respectively. 
Cross-resistance to a range o f structurally and functionally related (taxotere, taxol, 
vincristine) and un-related (adriamycin) chemotherapy drugs was also induced. Exposure to 
5-FU, on the other hand, did not induce drug resistance, but did induce a dramatic change 
in the morphology o f the cells, as discussed in section 4.4.3. Results from all the DLKP 
variants are summarised in Table 4.1.
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Variant Drug resistance Gene expression 
(RT-PCR/W estern blot)
M orphology change Invasive/motile
phenotype
M M P secretion
DLKP-TXT TXT, TAX, VCR, 
ADR
T Pgp mRNA+protein 
T MRP1 protein 
t  E-cad mRNA+protein 
iSurvivin protein
Cells became very 
slightly stretched
Yes MMP-2, 9 & -13
T
I
DLKP-VCR TXT, TAX, VCR, 
ADR
T Pgp mRNA+protein 
T MRP4 mRNA 
iSurvivin protein
Cells became 
stretched and slightly 
elongated
No MMP-2, 9 & -13
t
DLKP-5-FU None T MRP3 mRNA Cell became very 
stretched, elongated 
and branch-like
No MMP-2, 9 & -13
t
TXT= Taxotere; TAX= Taxol; VCR= Vincristine; ADR= Adriamycin; E-cad=E-cadherin
Table 4.1 Summary o f phenotypic and genotypic changes induced by DLKP drug-selection.
4.4.2.1 Taxotere and Cross-resistance
The DLKP-taxotere resistant variant was found to be approximately 420-fold resistant to 
taxotere and 210-fold resistant to taxol. Given the similarities o f these two taxanes, it is not 
surprising that the taxotere resistant variant is also resistant to taxol. DLKP-taxotere was 
found to be approximately 6650-fold resistant to vincristine, a vinca alkaloid, which, 
similarly to the taxanes, functions by disrupting the tubulin/microtubule equilibrium, 
resulting in cell cycle arrest at metaphase (see section 1.1.1.1 and 1.1.1.2) (Wilson et ah, 
1975). DLKP-taxotere is 52-fold resistant to adriamycin, an anthracycline with different 
structural and functional properties to the taxanes and the vinca alkaloids, but also 
associated with MDR. The DLKP-taxotere MDR variant was not found to be cross resistant 
to 5-FU, CCNU or cisplatin (section 3.3.1). The toxicity assays were all repeated at least 
three times and the majority were reproducible. However, in some cases the standard 
deviation values were quite high (see Table 3.6.1.2a). This may be due to a small loss o f  
resistance resulting from prolonged growth o f  cells in the absence o f selection pressure. In 
future experiments it may be beneficial to expose cell to their selecting agent occasionally 
to avoid loss o f resistance in this heterogenous cell line. The need to re-expose drug- 
resistant cell line to their selection agent occasionally to maintain their resistance levels has 
previously been found in DLKP-lOp, an adriamycin-resistant cell line variant established in 
the NICB (Cleary, PhD, 1995). Taken together, the findings from the in vitro toxicity 
testing demonstrate a pattern o f multiple drug resistance similar to findings by many other 
groups.
To investigate the phenomenon o f development o f resistance to chemotherapeutic agents, 
osteosarcoma cells, TE-85, were exposed to increasing doses o f taxol or taxotere over a 
period o f nine months (Bums et ah, 2001). Variants that were highly resistant to taxol and 
taxotere, respectively, were developed. The taxol resistant cell line, showed >1000-fold 
resistance to taxol and taxotere and 60-fold resistance to adriamycin. Similarly, the 
taxotere-resistant cell line, showed >1000 to taxol, 800-fold resistance to taxotere and 90- 
fold resistance to adriamycin. There was little cross-resistance to topotecan and enhanced 
sensitivity to cisplatin. This is in agreement with our findings in the DLKP-TXT variant 
with regard to cross-resistance to taxol and lack o f resistance to cisplatin. Similarly, a
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recent study was carried out by Liu et a l  (2001b), where the pancreatic adenocarcinoma 
cell line, SUIT-2, was selected by exposure to taxotere and was found to be significantly 
resistant to taxotere, as well as showing cross-resistance to adriamycin, but no resistance to 
5-FU (Liu et al., 2001b). Furthermore, Ikubo e t  al., (1999) studied the cytotoxicity o f anti­
microtubule agents to human small-cell lung cancer cell lines including, a primary cell line 
from an untreated patient, cell lines from treated patients as representatives o f intrinsic 
drug-resistance and cell lines selected by continuous exposure to increasing concentrations 
of adriamycin, etoposide or cisplatin, as representative o f acquired drug resistance. Results 
showed that the cell lines treated with adriamycin or etoposide were highly resistant to 
taxol, taxotere, vincristine, vindesine and vinblastine as well being resistant to their 
selection agents. The cell line treated with cisplatin, however, showed no cross-resistance 
to the anti-microtubule agents (Ikubo et al., 1999). In a study by Bhalla et al. (1993), the 
human myeloid leukemia cell line, HL-60, cell line was exposure to progressively higher 
concentrations o f taxol, which resulted in two taxol-resistant cell lines. The cells also 
displayed a variable degree o f cross-resistance to taxotere, vincristine and adriamycin, but 
were sensitive to the antimetabolite, cytosine arabinoside (Ara-C) (Bhalla et al., 1993).
Taken together, these findings support the theory that some forms o f taxotere resistance are 
typical o f a classic MDR phenotype. There are, however, conflicting reports suggesting this 
not to be the case. In a study by Hill e t  al. (1994), cross-resistance to taxotere was not 
apparent in four epipodophyllotoxin-selected cell lines with alterations in topoisomerase n, 
suggesting that taxotere cross-resistance is not automatically expressed by classic MDR  
tumour cells.
Despite the discrepancies in the literature, our current finding correlate with a previous 
study carried out by Liang et al. (2003; in prep) in so far as, although the fold differences 
varied greatly in some cases, the drug resistance profiles were similar. Liang et al. (2003, in 
prep), found that the DLKP-taxotere resistant variant was approx. 36-fold resistant to 
taxotere, 262-fold resistant to vincristine and 33-fold resistant to adriamycin. Although 
cross-resistance o f this variant to 5-FU and CCNU was not tested, DLKP-taxotere MDR  
variant was not resistance to cisplatin, in agreement with our findings. Our findings also 
correlate with a previous study carried out in our lab. (Liang e t  al., 2001), on the nasal 
carcinoma cell line, RPMI-2650, where it was found that an RPMI-2650 taxol-resistant
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variant was found to be resistant to taxol (226-fold) and cross-resistant to adriamycin, 
vincristine, vinblastine, and VP-16. However, there was no significant resistance to 
melphalan, cisplatin or 5-FU.
4.4.2.2 Changes in expression of apoptosis and MDR-related genes associated with 
taxotere resistance
To date, some specific mechanisms o f drug resistance have been elucidated, among which 
the best understood are increased expression o f mdr-1 encoded Pgp (Lu e t  al., 2000; Liu et  
al., 1999; Zhang e ta l . ,  1999; Xu et al., 1998), MRP1 (Kommann e ta l . ,  1999; Liang et al., 
2001; Yu e t  al., 2001) and LRP (Aszalos et al., 1998; Liu e t  al., 2001). These membrane 
transporter proteins play an important role in multiple drug resistance involving drug efflux 
(section 1.2).
As discussed in section 1.2.1, P-gp was identified as a membrane efflux pump that results 
in decreased drug accumulation and diminished cytotoxicity (Lum et al., 1993). P-gp is 
widely expressed in tumour specimens o f patients with a variety o f hematological and solid 
tumours, and has been reported to increase in expression after the development o f  clinical 
resistance to chemotherapy (Pastan et al., 1988; Beck eta l . ,  1991; Ling e ta l . ,  1992). MRP1 
is also associated with the MDR phenotype and has been identified in non-Pgp multidrug 
resistant cell lines from a variety of tumour types, including leukemias, fibrosacrcoma, 
non-small cell lung, small cell lung, breast, cervix, prostate and bladder carcinomas 
(Izquierdo et al. 1996), as well as in many normal human tissues (Sugawara et al., 1997; 
Loe eta l . ,  1996a; Zaman e ta l . ,  1993; Cole e ta l . ,  1992; Kool e ta l . ,  1997).
In an attempt to identify the mechanisms o f MDR in the DLKP-taxotere resistant MDR  
variant, alterations in the expression levels o f a number of MDR markers were investigated. 
In agreement with the cross-resistance pattern o f this variant (i.e., its cross-resistance to 
taxol, vincristine and adriamycin and its lack of resistance to cisplatin, 5-FU and CCNU, all 
indicators o f the involvement of Pgp in its MDR phenotype), dramatic over-expression of 
P-gp mRNA and protein were detected in the DLKP-taxotere resistant variant by RT-PCR 
and western blot analysis when compared to the parental cells (section 3.3.7.1 and 3.3.8.1).
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This is also in agreement with findings by other groups when studying the mechanisms of 
drug resistance with respect to taxane-related-resistance. In a study by Liu et al. (2001a), 
intrinsic and acquired taxotere resistant cell lines have shown the expression o f mdr-1 gene.
Other groups that found similar cross-resistance patterns as we did in taxotere-resistant 
cells, found that MDR was mainly mediated by Pgp (Van Ark-Otte e t  al., 1998; Bums et al, 
2001; Liu e t  al., 2001a and 2001b; Bhalla et al., 1994; Liang et al., 2001; Shirawaka et al., 
1999) but not by MRP (Liu et al., 2001a and 2001b; Liang e ta l . ,  2001). As well as proving 
that taxotere resistance in the pancreatic adenocarcinoma cell line, SUIT-2, was mediated 
by Pgp, Liu et al. (2001a) also confirmed that taxotere resistance in these cells was not 
mediated by MRP, by RT-PCR, and also by using a specific inhibitor o f MRP. The MRP 
inhibitor indomethacin, sensitised the taxotere-resistant cells to taxotere, but had no 
sensitising effect to taxotere cytotoxicity, indicating that the taxotere-related drug 
resistance in these cells is mainly mediated by Pgp and not MRP.
In agreement with this, we found no over-expression o f MRP1 mRNA as seen by RT-PCR 
analysis (section 3.3.7.2) in the DLKP taxotere-resistant variant. However, it was surprising 
to find over-expression in MRP1 protein in the DLKP taxotere-resistant variant by western 
blot analysis (section 3.3.8.2). However, this is in agreement with previous findings by 
Liang et al. (manuscript in prep), in the DLKP taxotere-resistant variant previously 
established, suggesting a possible involvement of post-transcriptional regulation in 
expression o f MRP1 protein. In addition, these findings support previous findings 
suggesting that cancer cells that over-express Pgp or MRP1 do not show cross-resistance to 
platinum-containing compounds (e.g. cisplatin), alkylating agents and anti-metabolites (e.g.
5-FU) (Taniguchi et al., 1996; Koike et al., 1997). MRP2 (cMOAT) (Figure 3.6.7.3), 
MRP3 (Figure 3.3.7.4) and MRP5 (Figure 3.3.7.6) were undetectable by RT-PCR in the 
DLKP-taxotere MDR variant, suggesting that they play no role in drug resistance o f  this 
variant, while low traces of MRP4 and BCRP mRNA were present (Figures 3.3.7.5 and 
3.3.7.7). These experiments were carried out in triplicate and found to be reproducible.
Galectin-3 mRNA expression and survivin mRNA and protein expression were analysed in 
the DLKP taxotere-resistant variant. Based on the previous findings in the RPMI-2650 
variants, where galectin-3 was over-expressed in the RPM-2650 melphalan-resistant and
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invasive cell line (see sections 3.1.1.2 and 4.2.1), indicating a role for galectin-3 in in vitro 
invasiveness, we expected to detected galectin-3 over-expression in the DLKP taxotere- 
resistant variant. As will be discussed in the next section, this is a variant, which exhibited 
an elevated invasive phenotype. This was not, however, found to be the case. Galectin-3 
mRNA was un-changed in the DLKP taxotere-resistant cell line when compared to the 
parental cells as shown in Figure 3.3.7.9. This was carried out in triplicate and the results 
were reproducible. It is important to remember, however, that galectin-3 mRNA was not 
dramatically over-expressed in the RPMI-2650 melphalan-resistant variant (see section
3.1.1.1) and the over-expression was only observed at the protein level as shown by 
western blot analysis. In our current experiments, galectin-3 protein expression was not 
analysed and it will be interesting to carry out western blot analysis for this protein in 
future studies.
As previously mentioned, survivin mRNA was found to be down regulated in previous 
studies on the RPMI-2650 taxol-resistant cell line (see section 3.2.1.1. and 4.3.1). This was 
an unexpected result as previous studies have reported survivin up-regulation in response to 
chemotherapy treatment in vitro (Notarbartolo et al., 2002; Kennedy e t  a l ,  2000; 
Muenchen et al., 2001; Ikeguchi e t  al., 2002). Survivin mRNA expression in the DLKP 
taxotere-resistant variant remained unchanged, as shown by RT-PCR analysis (See Figure 
3.3.7.10). Survivin protein, however, was dramatically down regulated and its expression 
was almost completely inhibited in the DLKP taxotere resistant variant, as shown by 
western blot analysis. This was consistent in the repeat experiments, where the western blot 
analysis was carried out on three different protein extractions and a-tubulin was used as an 
internal control to ensure equal loading o f protein, as shown in Figure 3.3.8.4. Change at 
the protein but not at the mRNA levels, indicates the involvement o f post-transcriptional 
regulation in the expression o f survivin protein (see section 4.7).
DNA micorarray analysis was carried out on the DLKP parent and DLKP taxotere-resistant 
cell lines. Analysis o f all the genes mentioned above (i.e. Mdr-1, MRP-1, -2, -3, -4, and 5, 
BCRP, galectin-3 and survivin) matched RT-PCR results. Mdr-1 expression was up 
regulated by 300-fold in the DLKP-taxotere variant when compared to the parental cell 
line. The remaining genes were unchanged (see Table 3.3.9.1). Changes lower than 2-fold 
were not considered to be ‘real’ results. The DLKP taxotere-resistant variant (DLKP-
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TXT2) established previously by Liang et al. (manuscript in prep.) was included in the 
array analysis for comparison with our current DLKP-taxotere MDR variant (DLKP- 
TXT1) and the results from the two variants were in agreement. With Mdr-1 showing a 
much smaller fold increase (44-fold) (Table 3.3.9.1). The DNA microarray needs to be 
repeated to obtain reliable results.
4.4.2.3 In vitro invasiveness and motility in DLKP Taxotere-resistant cell line
Invasion and metastasis o f tumour cells, as discussed in section 4.2 is a major cause of 
death for cancer patients. Statistics show that approximately 50% of all cancer patients may 
develop metastasis (Fidler et al., 1994). Invasion is one of the most critical steps of 
metastasis in cancer. Studies o f  drug resistance and cancer invasion and metastasis have not 
always been studied in tandem. However, more studies have started to focus on a possible 
correlation between cancer invasion/metastasis and drug resistance in cancer, as increasing 
evidence is proving that the drug resistance phenotype may induce the invasive phenotype 
in cancer cells (Kondo e ta l . ,  1961; Kerbel et al., 1982; Takenaga e ta l . ,  1986; McMillan et 
a l ,  1987).
The aim of this part of the thesis was to determine whether the induction o f an invasive 
phenotype in cancer cells is drug-specific or a random process. Previous findings show that 
taxol does not induce an invasive phenotype in RPMI-2650 (Liang et a l ,  2001). In the 
study by Liang et al. (2001), RPMI-2650M1 (melphalan resistant) and RPMI-2650Tx 
(Taxol resistant) cell lines were established through continuous selection with melphalan 
and taxol, respectively. Both sublines exhibited a multiple drug resistant phenotype. 
However, RPMI-2650M1, but not RPMI-2650Tx, exhibited a highly invasive phenotype, 
with increased expression o f MMP-2 and MMP-9 as well as increased adhesion to collagen 
type IV, laminin, fibronectin and matrigel (Liang et al., 2001).
Through exposure to increasing concentration o f taxotere, the pancreatic adenocarcinoma 
cell line, SUIT-2/TXT acquired resistance to taxotere and increased Mdr-1 mRNA  
expression. In addition taxotere exposure had a large inhibitory effect on tumour cell 
invasion (Liu et a l ,  2001c). It is postulated that the reason may be due to taxotere
interference with the function o f the fundamental part o f the cyoskeleton by inducing 
changes in the microtubules, which are important components o f cell motility and 
intracellular transport (Eckert et al., 1997). In a study by Belotti et al. (1996), the effect o f 
taxol on the adhesive and motility properties o f human ovarian carcinoma cell lines, 
OVCAR 5, SK-OV-3, and HOC-IOTC, was investigated. Taxol was found to significantly 
inhibit the motility o f these cell lines, but it did not effect their adhesion to the 
subendothelial matrix, proving that taxol is a potent inhibitor of ovarian carcinoma cell 
motility and that this activity is independent o f its cytotoxic activity. In a similar, but 
separate study by the same group, results indicated that taxol has a strong antiangiogenic 
activity, a property that might contribute to its antineoplastic activity in vivo (Belotti et al., 
1996).
In breast cancer, taxol and taxotere, in combination with bisphosphonates (which are often 
used in combination with standard chemotherapy or hormonal therapy for the treatment of 
cancer-associated osteolytic metastases), may be useful for the treatment of patients with 
cancer types that are known to metastasize to bone. The bisphosphonate, ibandronate, was 
found to enhance the anti-tumour activity of taxoids against invasion and cell adhesion to 
bone (Magnetto et al., 1999), confirming the anti-invasive properties o f taxanes. These are 
all important findings regarding the taxanes’ ability to inhibit metastasis and should be 
taken into account in clinical trials where tumour angiogenesis is being targeted. Grant et 
al. (2003) compared the effect o f the two taxanes, taxol and taxotere, on angiogenic 
processes in vitro, in human umbilical vein endothelial cells (HUVEC) and in vivo in 
HT1080 tumour growth. They found both taxanes to block angiogenesis mainly by 
inhibition o f proliferation and also by induction of cell death, with taxotere proving more 
potent at inhibiting angiogenesis than taxol.
In the DLKP studies previously carried out by Liang e t  al. (manuscript in prep) pulse 
selection with taxotere had no effect on the invasiveness o f DLKP cells. Our current 
results, however, contradict this finding in DLKP cells and the findings by other groups in 
other taxol and taxotere-induced resistant cell line, as discussed above. We found selection 
with taxotere to greatly increase the invasiveness o f DLKP cells (see section 3.3.3). 
Invasion assays were repeated numerous times and results were always conclusive for this 
DLKP variant, showing increased invasiveness in every experiment. The invasion assays
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were carried out in two types of invasion chambers. This included inserts with no matrigel 
coating and this was carried out before the assay was set up and inserts that were purchased 
with a matrigel already coating the inserts. The results from both of these types o f invasion 
chambers were compared and proved to very similar as shown in Figure 3.3.3.1 and
3.3.3.3.
In addition taxotere-resistance caused a huge increase in the motility o f the cells as noted 
over three time points, 12, 24 and 48 hours after motility assays were initially set up. The 
difference in motility between the parental cell line and the taxotere-resistant variant is 
most dramatic at 12 and 24 hours where the fold increase is 3- and 4-fold, respectively 
(section 3.3.5). Invasion assays were carried out in triplicate and were reproducible.
There are a small number o f published reports supporting our current findings, indicating 
that taxol increases motility and invasion. Silbergeld e t a l  (1995) found taxol to increase in 
vitro motility in glioblastoma cells. This motility was increased with increasing 
concentration o f taxol. Welch e ta l .  (1989) found that some cytoskeleton disrupting agents, 
such as vincristine, colcemid and colchicines, inhibited invasion, whereas taxol did not 
(Welch et al., 1989).
Furthermore, this invasiveness o f DLKP-taxotere resistant cells was inhibited using MMP 
inhibitors. The MMP inhibitors used were: MMP inhibitor I, which inhibits MMP-1, -3, -8 
and MMP-9; MMP inhibitor HI, which inhibits MMP-1, -2, -3, -7 and MMP-13; and MMP- 
2 inhibitor I, which inhibits MMP-2. The most effective agent at inhibiting invasion in 
DLKP-taxotere was MMP inhibitor HI (see Figures 3.3.4.1 and 3.3.4.2). These experiments 
were carried out once and need to be repeated for confirmation o f results.
MMPs are thought to play a very important role in cancer invasion and metastasis as they 
are used by many types o f cancer to break down matrix barriers, and thereby allowing 
tumour cells to penetrate tissues, gain access to blood vessels, exit blood vessels and 
metastasis to a distant sites (Denis and Verweij, 1997). The development o f matrix 
metalloproteinases inhibitors (MMPIs) as an anti-cancer agent is therefore very important. 
The challenge however, in the development o f MMPIs is to identify which types o f cancer 
involve MMPs and therefore might respond to these inhibitors (Denis and Verweij, 1997).
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In the early 1980s, pharmaceutical companies became involved in the search for synthetic 
MMPIs, and a series o f highly effective MMPIs have been successful in restricting tumour 
growth and inhibiting tumour metastasis. Many o f these are being studied in clinical trials 
(Yu e ta l . ,  1997).
The invasion and motility assays for the DLKP selected variants presented in this thesis 
include DLKP-taxotere resistant cells previously established by Liang et al. (2003 in prep) 
for comparison purposes. This is denoted DLKP-Taxotere-2. The DLKP-taxotere resistant 
cell line established for the purpose o f these studies is denoted DLKP-Taxotere-1 (sections
3.3.3 and 3.3.5). In addition, the invasion and motility assays (and the second invasion 
inhibition assay (Figure 3.3.4.2)) presented in the results section include two DLKP parent 
cell lines (sections 3.3.3, 3.3.4 and 3.3.5). The reason for this is that some batches o f this 
cell line were found to be more invasive (DLKP-2) than other batches (DLKP-1). As 
previously mentioned, DLKP is a non-invasive cell line and the DLKP variants were thus 
established from a non-invasive DLKP cell line (section 4.3). The finding that different 
batches o f  the same cell line may exhibit two different invasive phenotypes is surprising 
and the reason for this is unknown. However, it was brought to our attention after the 
experiments were carried out that DLKP-2 may have been M ycoplasma  contaminated and 
this may have caused the increased invasive phenotype. This is not certain, however, as 
there were other batches o f DLKP parent cell line tested that were found to be more 
invasive than DLKP-1. In all other analysis of the DLKP MDR variants, including toxicity 
assays (section 3.3.1), RT-PCR (section 3.3.7), western blot analysis (section 3.3.8) and 
zymography analysis (section 3.3.6), DLKP-1 and DLKP-taxotere-1 were analysed.
Colormetric analysis was also carried out on the invasion and motility assays to obtain a 
quantitative method o f analysis. Initially this was carried out by using acetic acid to elute 
the crystal violet dye from the bottom o f the invasion chambers, following staining o f the 
cells, which have invaded and attached to the other side o f the invasion chamber. The 
absorbance o f the eluted dye was read at 570nm. This method was found to be 
unsatisfactory due to high background staining from the invasion chambers and this 
resulted in inaccurate readings. This high background staining was, however, not found 
with previous studies using such inserts (Liang et al., 2001; O’Driscoll et al., 2002) and 
may be due to batch-to-batch variation o f inserts. A second method o f quantitation was
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used, whereby cell that are attached to the underside o f the invasion chambers were not 
stained with crystal violet as per usual, but instead were incubated in acid phosphatase 
substrate-containing buffer at 37°C for 2 hours, after which the reaction was stopped and 
samples were read on a plate reader at 405nm. This method resembles the in vitro toxicity 
assays discussed in section 2.3. For this method, invasion, inhibition or motility assays 
were carried out in duplicate to allow for the staining and the photography o f  the cells that 
were attached to the underside o f the invasion chamber. RPMI-2650 parent cell line was 
used as a negative control for invasion and motility assays.
To further assess the role o f MMPs in the invasiveness o f the DLKP taxotere-resistant cell 
line, we examined the secretion of MMPs in the resistant cells compared to the parental, 
sensitive cells using gelatin zymography. Results demonstrate that the DLKP taxotere- 
resistant variant had slightly weaker of MMP-13 activity than the parental cells. MMP-9 
and MMP-2 secretion was unchanged (See section 3.3.6). This doesn’t fully agree with 
previous finding in the DLKP selections by Liang e t  al. (in prep.), where DLKP taxotere- 
resistant cells had the weakest activity o f MMP-9 and MMP-13 compared to the other, 
highly invasive variants, such as DLKP-mitoxantrone. However, whereas this result was 
not surprising for DLKP-taxotere-2, due to its lack o f invasive properties, it is surprising in 
our current DLKP-taxotere variant (DLKP-taxotere-1), given its very high invasive and 
metastatic properties. Further analysis of MMP secretion, including western blot analysis, 
would be beneficial to help explain these results.
E-cadherin is involved in cancer invasion and metastasis (see section 1.3.1). It is a member 
of a family o f transmembrane glycoproteins that appear to function by connecting cells to 
each other by homophilic interactions (Liang et al., 2002). The expression o f the cell 
adhesion molecule, E-cadherin, was analysed by RT-PCR and western blot analysis in the 
DLKP taxotere-resistant variant. E-cadherin mRNA expression seemed to be slightly over- 
expressed in the DLKP taxotere-resistant variant (see Figure 3.3.7 8), which would 
correlate with the invasive phenotype o f this cell line. However, in repeat experiments this 
was not observed. E-cadherin mRNA expression was un-changed in the DLKP taxotere- 
resistant variant that was developed by Liang et al. (2003, in prep).
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E-cadherin protein was over-expressed in the DLKP-taxotere variant, as shown by western 
blot analysis in Figure 3.3.8.3. This experiment was only carried out once and it needs to be 
repeated for confirmation o f this result. It is surprising that E-cadherin protein was detected 
by western blot in the DLKP cell line and its drug resistant variants, as Liang e t  al. found 
no E-cadherin protein expression in any o f the DLKP cell lines (Liang e t  al., 2003, in 
prep.). The reasons for this discrepancy is not known and RT-PCR and western blot 
analyses need to be repeated for confirmation o f these findings
DNA microarray results were not, however, in agreement with the RT-PCR results. E- 
cadherin was down regulated in our current DLKP-taxotere MDR variant (DLKP-TXT1) 
by 2-fold (see Table 3.3.9.1). The DLKP-taxotere MDR variant established by Liang et al. 
(manuscript in prep.) (DLKP-TXT2), showed a 5-fold down-regulation o f E-cadherin 
expression. A repeat o f the DNA microarray analysis is needed for accurate results.
307
4.4.3.1 Cross resistance pattern of Vincristine-selected DLKP cells
The DLKP-vincristine resistant variant was approximately 5330-fold resistant to 
vincristine, 233-fold resistant to taxotere, 124-fold resistant to taxol and 26-fold resistant to 
adriamycin - all MDR associated drugs. Similar to DLKP-taxotere, the DLKP-vincristine 
MDR variant was not resistant to 5-FU, CCNU or cisplatin, therefore exhibiting a typical 
MDR profile (see section 3.6.1.2). Toxicity assays were carried out in triplicate and as 
mentioned in section 4.4.2.1, while the majority of results were reproducible, the standard 
deviation for a minority of the drugs, namely taxotere and vincristine were quite high and 
cells may need to be exposed to their selecting agent again to avoid changes in resistance 
levels. In general these findings show similar trends, to some extent, with the findings from 
the previous study on DLKP selection, where the DLKP-vincristine resistant variant was 
only 1.9-fold resistant to vincristine, and 1.7-fold resistant to adriamycin, with no resistance 
to cisplatin. Similar patterns of resistance were observed by many other research groups 
(Gupta et al., 1985; Haber et al., 1989; Toffoli et al., 1992; Sekiya et al., 1992; Zhang et 
al., 1994).
This type of MDR-related cross-resistance has been shown by other groups to be typical of 
the vinca alkaloids. Gupta et al. (1985) established resistant variants of Chinese hamster 
ovary (CHO) cells, after selection using vinblastine. The cross-resistance pattern of the 
resistant variant to a wide variety of anti-cancer drugs was determined. The vinblastine- 
resistant cells were found to exhibit patterns of cross-resistance to a number of anti-mitotic 
inhibitors, namely, vinblastine, vincristine, vindesine, taxol, podophyllotoxin and 
colchicines, as well as a large number of other compounds (Gupta et al., 1985). Zhang et 
al. (1994) established a vincristine-resistant clone of human epidermal carcinoma, KB 
cells, by a stepwise selection of cells through exposure to increasing doses of vincristine. 
The resistant cells were found to be 175-fold resistant to vincristine and cross-resistant to 
taxol, colchicine and adriamycin. Verapmil, which is a calcium channel blocker that 
reverses drug resistance, caused an increase in vincristine accumulation in the cells and 
reversed vincristine resistance (Zhang et al., 1994). Similar studies were carried out on a 
hepatocellular carcinoma (HCC) cell line. Hepatocellular carcinoma is one of the malignant 
tumours with poor chemosensitivity to anticancer drugs (Huang et al., 1999). The human 
HCC cell line, Bel 7402, was found, by Huang et al. to have innate resistance to adriamycin,
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the most frequently used drug for HCC therapy. This led to further investigation of this 
cells line with respect to its cross-resistance properties. As previously discussed, 
adriamycin, vincristine and taxol have been proven to be transported by Pgp. Cross­
resistance of the adriamycin-resistant cell line, Bel 7402, to these (vincristine and taxol) and 
other drugs (5-FU), was examined. Huang et al. (1999), found Bel 7402 to be resistant to 
taxol and highly resistant to vincristine, when compared to the drug sensitive human 
epidermal carcinoma cell line, KB. The adriamycin-resistant cell line was only slightly 
resistant to 5-FU. This innate resistance to the three Pgp transporting drugs was 
dramatically reversed by verapamil, while verapamil had no effect on 5-FU resistance, 
indicating that innate resistance in this HCC cell line may be associated with an MDR 
phenotype.
Studies in murine leukemic T cell line showed that vincristine resistant variants exhibit 
cross-resistance to adriamycin, VP-16, dexamethasone and methotrexate (Lopes et al.,
2001). Kotechetov et al. (2003) established two variants of the neuroblastoma cell line, 
UKF-NB, through the treatment with vincristine or adriamycin. Both variants exhibited 
high resistance to vincristine and adriamycin, but did not show any cross-resistance to 
cisplatin.
Taken together, all these results, support our findings and show that vincristine resistance 
in this variant, similar to taxotere resistance, follows a typical MDR pattern of resistance, 
showing cross resistance to several structurally and functionally unrelated agents, including 
the anthracyclines, the vinca alkoids, actinomycin D, the epipodophyllotoxins and the 
taxanes, which are all substrates for P-gp.
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4.4.3.2 Changes in expression of apoptosis and MDR-related genes associated with 
vincristine resistance
The P-glycoprotein is a receptor for vinca alkaloids and tumour cell drug resistance is 
proportional to the amount of Pgp (Zhou et al., 1992). To investigate whether mdrl gene 
products are involved in conferring the chemoresistant phenotype in the DLKP vincristine- 
resistant variants, we examined the expression profile of a number of MDR-related genes, 
including Pgp and the MRPs.
We found Pgp mRNA and protein expression to be dramatically over-expressed in DLKP- 
vincristine compared to DLKP parent, by RT-PCR and western blot analysis (see Figures
3.3.7.1 and 3.3.8.1). Results were carried out in triplicate and were reproducible. As 
discussed in section 4.3.2.2, Pgp over-expression is an indicator of an MDR phenotype and 
since vincristine resistance is typical of an MDR phenotype, it is not surprising to find 
over-expression of Pgp in the DLKP vincristine-resistant variant. Pgp was found to be 
over-expressed by western blot analysis in the previous DLKP vincristine-resistant variant 
established by Liang et al. (in prep.). Liang et al., however, found no change in Pgp 
mRNA suggesting the involvement of post-transcriptional regulation in the expression of 
this protein. MRP-1 mRNA and protein expression were unchanged in the DLKP 
vincristine-resistant variant in the present study (see Figure 33.1.2 and 3.3.8.2) in 
agreement with the previous study by Liang et al (2003; in prep.), suggesting that MRP-1 
does not play a role in vincristine resistance.
These results correlated with findings by other research groups. The innate resistance to 
adriamycin in the HCC cell line, Bel 7402, discussed in the previous section, caused an MDR 
phenotype in the cells, as seen by the pattern of cross resistance (see section 4.4.3.1). To 
further illustrate that resistance seen in this cell line was associated with classical MDR 
mechanisms, the expression of Pgp protein was investigated in the cells by 
immunocytochemistry. Pgp staining was present in a greater proportion of Bel 7402 cells and 
staining was more intense than that in the sensitive KB cells, indicating that Pgp plays an 
important role in the intrinsic resistance of Bel 7402 cells to adriamycin, vincristine and taxol 
(Huang et al., 1999). In 1997, this group had also demonstrated that vincristine or taxol 
resistant HL60 cells express high levels of Pgp, while adriamycin-resistant HL-60 cells
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possess high levels of MRP-1. Pgp, but not MRP-1, over-expression inhibited taxol 
accumulation and taxol-induced apoptosis, indicating that MRP-1 over-expression is not 
responsible for taxol resistance in HL-60 cells (Huang etal., 1997).
Real-time PCR analysis of a rhabdomyosarcoma cell line and its vincristine-resistant 
variant revealed an increase in Pgp mRNA expression, which led to resistance to 
vincristine, etoposide, and doxorubicin but not cisplatin, which is not a substrate for P-gp. 
This resistance was inhibited in the presence of MDR modulators, whereas MRP-1 
modulators were unable to prevent the development of resistance to vincristine. This 
indicates that the development of vincristine resistance in this cell line is caused by Pgp and 
not MRP-1. Furthermore, MRP-1 mRNA expression was unaltered in the vincristine- 
resistant cell lines, as demonstrated by real-time PCR (Cocker etal., 2001).
In our DLKP vincristine resistant variant, the expression of MRP2 (cMOAT), MRP3 and 
MRP5 were undetectable by RT-PCR in the DLKP-vincristine MDR variant (see Figures 
3.3.7.3, 3.3.7.4 and 3.3.7.6), while traces of MRP4 and BCRP mRNA were present (see 
Figures 3.3.7.5 and 3.3.7.7).
Galectin-3 mRNA expression was analysed in the DLKP vincristine-resistant variant and 
there was no change in its expression compared to the DLKP parent cells (see Figure 
3.3.7.9). The studies were carried out in triplicate and were found to be reproducible. This 
result is not surprising since DLKP-vincristine is an MDR variant, which did not develop 
an invasive phenotype. This may suggest that galectin-3 does not play a role in drug 
resistance to vincristine in the DLKP cells. Survivin mRNA and protein expression were 
also analysed by RT-PCR and western blot analysis, to determine the role of survivin in 
vincristine drug resistance.
Survivin mRNA expression was not greatly altered in the DLKP vincristine-resistant 
variant as shown in Figure 3.3.7.10. Survivin protein, however, was dramatically down 
regulated in this variant (see Figure 3.3.8.4). As in section 4.4.2.2, this survivin down- 
regulation at the protein level, but not at the mRNA level, suggests the involvement of 
post-transcriptional regulation in expression of survivin protein in this MDR variant (see
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section 4.7). These results were reproducible as seen in the three experiments as shown in 
Figure 3.3.8.5.
As mentioned in section 4.4.2.2 DNA micorarray analysis was carried out on the DLKP 
parent and DLKP taxotere-resistant cell lines, as well as the DLKP vincristine-resistant cell 
line. Analysis of all the genes mentioned above (i.e. Mdr-1, MRP-1, -2, -3, -4, and 5, 
BCRP, galectin-3 and survivin) matched RT-PCR results, with the exception of MRP2; 
which was up-regulated by 4.2-fold in the DLKP-vincristine variant. Mdr-1 expression was 
up regulated by 92.5-fold in the DLKP-vincrisitne variant when compared to the parental 
cell line. The remaining genes were unchanged (see Table 3.3.9.1). As mentioned in section
4.4.2.2 changes lower than 2-fold were not considered to be ‘real’ results. The DNA 
microarray needs to be repeated to obtain reliable results.
4.4.3.3 In vitro invasiveness and motility of the Vincristine-resistant variant
As discussed in section 4.4.2.3, the aim of this part of the thesis was to determine whether 
the effect of drug resistance on the induction of an invasive phenotype in the cells was a 
drug-specific feature or a random event. Previous findings in the DLKP selections carried 
out by Liang et al., showed that the DLKP vincristine-resistant variant did not show an 
increase in invasiveness. This is in agreement with out current findings, where, compared 
to the parental DLKP cells, the DLKP-vincristine MDR variant was non-invasive (see 
figure 3.3.3.1 and 3.3.3.2) and showed no increase in motility at any of the three time 
points analysed, including 12, 24 and 48 hours (see Figures 3.3.5.1 and 3.3.5.2), suggesting 
that vincristine-resistance does not induce an invasive or motile phenotype in DLKP cells. 
As with the invasion and motility assays discussed in section 4.4.2.3, the assays were 
carried out in triplicate and were reproducible. In addition, the two types of invasion 
chambers were used and the same colormetric analysis was carried out to establish a 
quantitative method of invasion and motility analysis.
This trend was also found to be the case in a murine T-cell lymphoid leukemia cell line, 
selected in increasing concentrations of vincristine. In fact this vincristine-resistant cell line 
was less invasive than the parental cell line (Lopes et al., 2002). Similarly, a study carried
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out by Hikawa et al. (2000) on a human glioma cell line, illustrated that when this cell line 
is selected with certain drugs (etoposide, vincristine and adriamycin), and becomes drug- 
resistant, it expresses higher levels of integrins which, in turn, leads to an increase in the 
adhesive ability of the cells in a drug concentration-dependent manner. This increase in 
adhesion was not, however, linked to an increase in cell invasion of the cells. In fact, the 
cells invasion of the drug-resistant cell line was dramatically lower than the cell invasion of 
the parental cells line (Hikawa eta/., 2000).
On the contrary, a study by Kotchetkov et al. (2003) on a vincristine-resistant 
neuroblastoma cell line, revealed that vincristine resistance resulted in an approximately 2- 
fold increase in cell growth in vitro, as well as enhanced adhesion, trans-endothelial 
penetration and higher tumorigenicity in vivo, indicating that drug resistance in this cell line 
may contribute to the poor prognosis in advanced forms of neuroblastoma, due to increased 
malignancy (Kotchetkov etal., 2003).
Furthermore, to assess the role of MMPs in the invasiveness of the DLKP vincristine- 
resistant cell line, we examined the secretion of MMPs in the resistant cells compared to 
the parental, sensitive, cells using gelatin zymography. These studies indicate that the 
DLKP-vincristine variant showed a similar level of MMP-9 and MMP-2 secretion to the 
parental cells. However, the secretion of MMP-13 seems to have been almost completely 
inhibited in the DLKP-vincristine MDR variant. Finding by Liang etal. on MMP secretion, 
by gelatin zymography in the DLKP-vincristine variant, show that MMP secretion of 
MMP-2, -9 and -13 were unchanged compared to the parental cells.
Finally, our findings, as with the finding of Liang et al., show an unchanged level of 
expression of E-cadherin in the DLKP vincristine-resistant cell line, by both RT-PCR (see 
Figure 3.3.7.8) and western blot analysis (see Figure 3.3.8.3). This further supports the 
finding that vincristine resistance has no effect on the invasive ability of DLKP cells. DNA 
Microarray results, however, contradict this result. E-cadherin expression is down regulated 
by 2-fold in the DLKP-vincristine-resistant variant (Table 3.3.9.1). The reason for this 
discrepancy is not known and further analysis of E-cadherin expression in this variant is 
needed.
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4.4.4.1 5-FIuorouracil Selection
5-fluorouracil (5-FU) is a member of a class of antimetabolite drugs called the 
antipyrimidines. The mechanism of action of 5-FU is complicated and may consist of 
several steps. These can be summerised as follows: incorporation into DNA, followed by 
incorporation into RNA, leading to thymidylate synthase inhibition and thereby DNA 
synthesis inhibition due to lack of thymidylate formation (Van Triest et al., 1997). 5-FU 
has been found to act through two different pathways, depending on the does of the drug. In 
human colorectal cell lines, a low dose exposure to 5-FU induced G2 -M phase arrest, while 
at higher doses, 5-FU induced Gi-S phase arrest of the cell cycle (Yoshikawa et al., 2001). 
As with the two drugs already discussed in this section of the thesis, i.e. vincristine and 
taxotere, the problem of inherent or acquired resistance of certain tumours to cytotoxic drug 
therapy remains a problem even with non Pgp-transported drugs, like the antimetabolites.
In our current studies (section 3.3) on the DLKP 5-FU-selected variant, we found no 
increase in drug resistance to 5-FU, or any of the other drugs tested (taxotere, taxol, 
vincristine, adriamycin, cisplatin or CCNU). On the contrary, we found slight sensitivity of 
DLKP 5-FU-selected variant to taxol (0.6-fold), adriamycin (0.5-fold) and cisplatin (0.6- 
fold). In the previous DLKP selections, this was not the case, however. Liang et al. (2003; 
in prep) reported the DLKP-5FU variant to be 2-fold resistance to 5-FU, and cross­
resistance to vincristine. There was no resistance to adriamycin (1.2-fold), taxotere (1.3- 
fold) or methotrexate (1.39-fold) and there was slight sensitivity to cisplatin (0.56-fold) 
(see section 3.3.1.1). This shows that the MDR phenotype is lacking in this selected 
variant.
On the contrary, Chung et al. (2000) have found 5-FU-resistant, gastric cancer cell lines to 
be highly resistant to 5-FU (800-fold), with cross-resistance to taxol, cisplatin and 
adriamycin. Furthermore, an increased expression of thymidine kinase (TK) was observed 
in the 5-FU-resistant cells (Chung et al., 2000). Another 5-FU-resistant gastric carcinoma 
cell line was approx. 140-fold more resistant to 5-FU than parental cells, as well as 
exhibiting cross-resistance to mitomycin C. The cells were morphologically different to the 
parent cell and had developed a more malignant phenotype than that of the parental cell 
line (Yue et al., 1993).
314
In addition, we analysed the expression of MDR-related gene, mdr-1, and MRPs in the 5- 
FU-selected variant and found no over-expression of Pgp by RT-PCR (see section 3.3.7.1) 
and western blot analysis (see section 3.3.8.1). Similarly, we found no over-expression of 
MRP-1 by RT-PCR and western blot analysis. No MRP-2 (cMOAT), MRP-4 or MRP-5 
expression was detected in this variant. MRP-3 mRNA expression was up regulated, 
however in this variant as shown in Figure 3.3.7.4. In contras to results from this thesis, 
Liang et al. (2003 in prep) found Pgp to be over-expressed the DLKP-5FU variant by 
western blot analysis, but not by RT-PCR. However, none of the other genes mentioned 
above were found to be up regulated in this variant.
To assess whether selection with 5-FU had an effect on the invasive phenotype of the cells, 
invasion assays and motility assays were carried out on the DLKP-5-FU selected variant. 
Compared to the parental cell line, DLKP, DLKP-5-FU had no increased invasive 
phenotype (see section 3.3.3.1 and 3.3.3.2). This is in contrast with DLKP-5-FU cells 
selected previously by Liang et al., where the DLKP-5-FU variant was approximately 3- 
fold more invasive than the parent cells DLKP-5FU selected variant showed no increased 
motility at any of the three time points studied, including 12, 24, and 48 hours (see Figure
3.3.5.1 and 3.3.5.2). The experiments were carried out in triplicate and as with the taxotere- 
resistant and vincristine-resistant variants, two types of invasion chambers were used and 
the assays were analysed quantitatively. We noted, however, a dramatic change in the 
physical morphology of the 5-FU selected cells. DLKP cells, which normally grow in the 
shape of ‘cobble-stone’, became a lot more elongated when exposed to 5-FU (Figure 
3.3.2.1). This change in morphology was not noted in the more invasive DLKP-5-FU 
variants previously established. The reason for the discrepancy between the two variants is 
unclear.
The analysis of MMP secretion by gelatin zymography, showed a large increase in MMP-2 
secretion in the 5-FU selected variant when compared to DLKP parent (see section 3 .3 .6.1). 
This was not observed by Liang etal., but an increase in MMP-9 secretion was observed in 
the 5-FU variant. Finally, the expression of E-cadherin remained unchanged in this variants 
as seen by RT-PCR (see Figure 3.3.7.8) and western blot analysis (see Figure 3.3.8.3), 
supporting the finding that 5-FU does not induce an invasive phenotype in the DLKP cells 
in this study.
315
4.5 Establishment of MDR variants of RPMI-2650 cell line
RPMI-2650 is a nasal carcinoma cell line established by Moore and Sandberg (1963). This 
cell line was derived from a 52-year-old male who had an extensive malignant tumour of 
the nasal septum removed. The pathological diagnosis was anaplastic squamous cell 
carcinoma. The patient subsequently developed bilateral cervical lymph node metastases. 
RPMI-2650 cell line is a heterogenous population with many sub-clones exhibiting 
different characteristics (Moore and Sandberg, 1963).
This cell line has been previously characterised in this laboratory by Dr. Yizheng Liang (Y. 
Liang, PhD, 1999). Characterisation included analysis of gene expression (mainly MDR- 
related genes) and cytotoxicity analysis, including a number of chemotherapy drugs. 
Results revealed Pgp and MRP1 expression, demonstrated by RT-PCR, western blot and 
immunocytochemistry analysis. In addition, the cells were found to be very sensitive to 
chemotherapeutic drugs. Chemotherapy drugs tested included adriamycin, vincristine, 
vinblastine, etoposide, taxol, melphalan, 5-FU and cisplatin, suggesting that Pgp and/or 
MRP1 may be non-functional in this cell line. This was further confirmed by adriamycin 
distribution studies, where strong adriamycin accumulation was noted in the nuclei of 
RPMI-2650, indicating that very little drug efflux was occurring, and hence that Pgp and/or 
MRP1 may not be functioning as drug efflux pumps. Further characterisation, using 
invasion assays, was carried out to determine whether RPMI-2650 expressed an invasive 
phenotype. Although the patient from whom this cell line was derived developed cervical 
lymph node metastases, invasion assays revealed that RPMI-2650 is non-invasive in vitro, 
suggesting that the final outcome of invasion/metastasis depends on the interaction of the 
host and the tumour (Y. Liang, PhD, 1999).
In an attempt to establish if MDR could be induced in the RPMI-2650 cell line and to 
subsequently identify the mechanisms of drug resistance in established variants, as well as 
to investigate the effect of chemotherapy drugs on cell invasion, drug selection studies were 
carried out by Liang et al. (2001) on the RPMI-2650 cell line. Two commonly used 
chemotherapeutic drugs were selected for this study, namely, melphalan (an alkylating 
agent) and taxol (see section 1.1.1.2) (an anti-mitotic anticancer drug).
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Through continuous exposure of the parental cells to increasing concentrations of 
melphalan over a period of nine months or to taxol over a period of six months, two RPMI- 
2650 drug resistant variants were established. These were RPMI-2650 melphalan resistant 
(RPMI-2650M1) and RPMI-taxol resistant (RPMI-2650-Tx) cell lines (Liang etal., 2001). 
Alterations in a number of MDR-related genes were investigated, as well as the toxicity 
profile of the selected variants.
Results of RT-PCR and western blot analysis revealed over-expression of MRP1, MRP2 
and Pgp, leading to decreased accumulation of drug in the RPMI-2650M1 variant, as 
demonstrated by circumvention studies. Furthermore, RPMI-2650-M1 variant was found to 
be 11-fold more resistant to melphalan compared to the parental cells, in addition to 
exhibiting cross-resistance to a number of other drugs, showing a cross-resistance profile 
that is consistent with the involvement of MRP family members and Pgp. RPMI-2650-Tx 
variant was found to be 226-fold more resistant to taxol compared to the parental cells, and 
also exhibited cross-resistance to a number of other chemotherapeutic drugs, showing a 
cross-resistance profile that is consistent with the involvement of Pgp. In addition to a 
multiple drug resistant phenotype, melphalan selection caused a dramatic induction of an 
invasive phenotype in the RPMI-2650M1 resistant MDR variant. Taxol selection, however, 
had no effect on invasiveness. The induction of a MDR phenotype in the RPMI-2650 cells 
(and in the case of RPMI-2650-M1, an invasive phenotype) was accompanied by a dramatic 
change in the morphology compared to the parent cell line (Liang etal., 2001).
These results, along with our findings in the DLKP-taxotere-resistant cell line, as well as 
many other reports (Giavazzi etal., 1983; Scaddan etal., 1993; Lucke etal., 1994; Haga et 
al., 1997; Staroselsky et al., 1996, Choi et al., 1999 and Liu et al., 2001c), suggest that 
invasion and metastasis may sometimes be associated with an MDR phenotype.
In this part of the thesis, we aimed to investigate this phenomenon further and try to 
establish which other drugs/family of drugs may have a similar effect on in vitro 
invasiveness of RPMI-2650 cells, by carrying out further drug selections on this cell line. 
This would also provide us with drug-resistant RPMI-2650 cell lines for analysing the 
expression of galectin-3 and survivin.
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Pulse selections, using seven drugs, were carried out on RPMI-2650 parent cell line, by 
exposing the cells to an increasing concentration of drug for 4 hours, once a week, for a 
period of approx. 3 months. The chemotherapy drugs selected for this study were: taxotere, 
vincristine, 5-FU, epirubicin, CCNU, carboplatin and melphalan. Melphalan and taxotere 
were selected to act as ‘control drugs’ to reproduce the findings by Liang et al. through 
continuous exposure to melphalan and taxol (Y. Liang, PhD, 1999; Liang et al., 2001). 
However, for reasons that are not clear, the selection procedure was not successful for these 
two drugs. The remaining five drugs were used for the pulse selection procedure. This work 
was carried out in duplicate to assess reproducibility. All selected variants were given a 
number (1 or 2) for each replicated drug.
RPMI-2650 nasal carcinoma, cells are very small, with a morphology similar to that of 
normal nasal epithelial cells (Moore and Sandberg, 1963). They grow as tightly packed cell 
clumps, forming a dense sheet on the base of a culture flask or plate. Throughout the 
selection procedure with all drugs, the cells underwent a dramatic change in morphology. 
They became elongated and spindle-shaped. However, a number of weeks after the cells 
were removed from selection pressure, the majority of cells reverted back to their original 
morphology (Figure 3.4.1.1 a, b and c).
Preliminary analysis was carried out on the 10 selected variants to investigate their toxicity 
profile (see section 3.4.2), their in vitro invasiveness (see section 3.4.3.) and motility (see 
section 3.4.4), as well as alterations in a number of MDR and apoptosis-related genes (see 
section 3.4.5), which may have occurred.
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4.5.1 The effect of Pulse selection on the toxicity Profile o f RPMI-2650
Initial investigation of the toxicity profile of the RPMI-2650 pulse-selected variants after 
ten pulses revealed an increase in drug resistance of some, but not all the variants to their 
selecting agent and to other unrelated drugs. For example, RPMI-2650 5-FUi-selected 
variant, showed a 3-fold increase in resistance to 5-FU, 1.6-fold increase in resistance to 
CCNU and a 3.6-fold increase in resistance to carboplatin. RPMI-2650 VCRi-selected 
variants, showed no increase in resistance to vincristine, but did show cross-resistance to 5- 
FU (3.7-fold), CCNU (2.4-fold) and carboplatin (8.7-fold). RPMI-2650 CCNU2-selected 
variant showed the highest level of cross-resistance, with a 3.5-fold increase in resistance to 
CCNU, a 14.4-fold increase in resistance to 5-FU, a 15.7-fold increase in resistance to 
vincristine and a 9.1-fold increase in resistance to carboplatin. Furthermore, cells that were 
given extra pulses had further increased in resistance (section 3 .4.2).
When toxicity assays were repeated a number of weeks later, however, this resistance was 
lost, suggesting that the resistance initially seen was a transient effect. To establish why the 
resistance initially observed was gone after a period of time, two of most the variants which 
were initially drug resistant, namely, RPMI 2650-5FUi and RPMI-2650 VCR2 were pulsed 
further, with 5-FU and vincristine, respectively, bringing the total number of pulses to 14. 
This caused a dramatic increase in resistance, especially in RPMI-VCR2 , which became 
over 300-fold more resistant to vincristine than the parental cells (see Table 3.4.6a). When 
toxicity assays were repeated on these two variants a second time, drug resistance was 
maintained, although the levels differed greatly between the experiments (see Table 
3.4.6b). Both variants showed cross-resistance to 5-FU, vincristine, adriamycin and to a 
much lesser extent CCNU and carboplatin. Adriamycin was included in the drugs tested to 
try to establish the mechanism of drug resistance that may be taking place. RPMI-2650 
5FUi was 23-fold resistant to adriamycin, while RPMI-2650 VCR2 showed a 77-fold 
increase in resistance to adriamycin, suggesting a typical MDR phenotype in the two 
variants. Further toxicity testing needs to be carried out on these variants, to determine 
whether the extra drug pulsing is causing transient or permanent resistance.
Taken together, however, the result from the RPMI-2650 drug-selected variants suggest 
that unstable multiple drug resistance is taking place. This resistance is lost during
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subculturing and this may be due to the decline or the loss of expression of some MDR- 
related genes. Similar findings have been reported in the adriamycin-resistant Chinese 
hamster V79 cell line (Howell et al., 1984), where is was found that an adriamycin- 
resistance in this cell line can be increased after a multi-step selection process involving 
continuous growth of the cells to adriamycin, making the cells 3000 times more resistant to 
adriamycin than is the parental V79 line. This high-level resistance phenotype, however, 
was unstable and was lost upon culture in the absence of drug. Similar findings were 
observed by Tohda et al. (1997), where a Chinese hamster ovary cell line resistant to 
okadaic acid expressed an MDR phenotype and increased expression of Pgp and 
topoisomerase II (topoll). In the absence of okadaic acid, however, the MDR was 
decreased and this was accompanied by a decrease in Pgp and topoll expression.
In our studies, as in the studies by Tohda et al., the MDR phenotype seems to be reversible. 
This may help identify novel MDR-related genes that may be useful as therapeutic drug 
targets.
4.5.2 The effect of pulse selection on the Invasive/Motility Phenotype of RPMI-2560
To investigate the effect of chemotherapy drugs on cell invasion and motility, invasion 
assays were carried out on all ten variants, including three of the variants at 12 pulses. 
However, unlike the finding by Liang et al. (2001) in the RPMI-melphalan resistant 
variant, no increase in invasiveness was seen in any of the variants, compared to the 
parental cells (see section 3.4.3). This may be due to the difference in selection procedure 
used. Whereas Liang et al. (2001) used continuous selection to induce an invasive 
phenotype, we used pulse selection method and this may have inhibited invasiveness 
developing in this cell line. Motility assays were carried out once on some, but not all, the 
RPMI-2650 variants. None of the variants showed an increase in motility compared to the 
parent cells. Furthermore, motility assays were carried out on the two variants at 14 pulses, 
RPMI-2650 5FUi and RPMI-2650 VCR2, however, there was no increase in motility, as 
shown in Figure 3.4.4.1. This was only carried out once. Invasion assays have not been 
carried out on these two variants and will need to be performed in future to determine if the 
extra drug pulses induce an invasive phenotype in these variants.
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4.5.3 The effect of Pulse selection on gene Expression of RPMI-2650.
MDR is usually accompanied by an up-regulation of Pgp expression and/or expression of 
MRP genes. In our current study, preliminary RT-PCR analysis revealed no up-regulation 
in Mdr-1 mRNA expression compared to the parent cells (see section 3.4.5.1). There was a 
small increase in MRP-1 expression in the RPMI variants (see section 3.4.5.2). MRP2 
expression was lacking (Figure 3.4.5.3), while MRP3 expression was up regulated in 
RPMI-2650 VCR2-12p (see Figure 3.4.5 4). RPMI-2650 VCR2-10p and VCR2-12p over- 
express MRP4 (see Figure 3.4.5.5), while MRP5 and galectin-3 mRNA expression was 
unchanged (see Figures 3.4.5.6 and 3.4.5.7). Survivin mRNA expression seems to be up- 
regulated in a number of variants, however the bands on the gels seem to over-saturated, 
making it difficult to determine whether the over-expression is a real result (section 
3.4.5.8).
All RT-PCR analysis was carried out twice and need to be repeated for confirmation of 
these findings. The RT-PCR results are difficult to explain at present since drug-resistance 
in the RPMI variants is unstable. Cell may need to be further pulsed to obtain stable 
resistance and RT-PCR analysis should be carried out again to be sure of that any changes 
in gene expression are stable and due to drug resistance. It is also important to determine 
whether the sudden increase in resistance in RPMI-2650-5FUi-14p and RPMI-2650-VCR2- 
14p is a stable resistance and if it is, further analysis such as RT-PCR, western blot analysis 
and invasion assay needs to be carried out on these variants.
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4.6 Analysis of gene expression in a panel of invasive breast tumour biopsies
4.6.1 An Overview of Breast Cancer
Breast cancer is the most common malignancy affecting women worldwide. One of the 
strongest risk factors for breast cancer is family history (Madigan et al., 1995; Dupont et 
ah, 1987), with studies showing increased breast cancer incidences in relatives of breast 
cancer patients compared with the general population, especially if diagnosis is at a young 
age (Claus et ah, 1990; Tulinius et ah, 1992). Elevated risk of ovarian cancer has also been 
found among relatives of breast cancer patients (Narod et al., 1994). Breast and ovarian 
cancer susceptibility genes are estimated to account for 7% of breast cancer cases and 10% 
of ovarian cancer cases in the general population (Claus et ah, 1996). BRCA1 and BRCA2 
have been identified as two important breast cancer susceptibility genes (Miki et ah, 1994; 
Wooster et ah, 1995) and have led to much medical interest. However, BRCA1 and 
BRCA2 mutations have also been identified in patients with no family history of this 
disease. Mammography screening for breast cancer is a very important process, especially 
for patients at higher risk of developing breast cancer due to family history. Randomised 
trials of breast screening using this method have shown a reduction, by over 30%, in 
mortality from breast cancer in women aged over 50 years (Nystrom et ah, 1993).
Chemotherapy plays a major role in the treatment of breast cancer. Adjuvant chemotherapy 
is therapy administered after surgery on breast cancer and it decreases the chances of 
recurrence by 24% (Leonessa et ah, 2003). Neoadjuvant chemotherapy is therapy 
administered before surgery to patients with advanced, but un-metastasised (local) breast 
cancer. This therapy can reduce the size of a breast tumour in 80-90% of patients (Kling et 
ah, 1997), allowing for a more constricted surgical approach. This also results in complete 
response or complete remission (CR) in approx. 20% of patients (Moll and Chumas, 1997; 
Sapunar and Smith, 2000). Complete remission is achieved if the disease has not returned 
within five years post-treatment. Metastatic breast cancer may also show response to first- 
line chemotherapy (in approx. 25-55% of cases) (Winer et ah, 2001).
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The antimetabolites, 5-FU and methotrexate, as well as the alkylating agent, 
cyclophosphamide, have all been routinely used for breast cancer treatment. However, the 
anthracyclines and the taxanes are the most effective and active agents in metastatic breast 
cancer, with response rates of over 30% in patients who have not been previously treated 
with any chemotherapeutic drugs (Ellis et ah, 2000; Bishop et ah, 1997 and 1999). 
Although anthracyclines have been described as the most effective single agent in the 
treatment of breast cancer, drugs such as adriamycin do not discriminate between normal 
and caner cells, resulting in severe side effects for the patient. Furthermore such treatment 
is associated with the development of a multiple drug resistance phenotype commonly seen 
in relapsed breast cancer patients, resulting in poor prognosis and lack of response to 
second line chemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil). 
Combination therapy is commonly used in breast cancer instead of single agent treatments. 
Anthracycline and taxane combinations have been found to induce over 50% response rates 
with complete remission occurring in approx. 15% of cases (Miller and Sledge, 1999). 
Although the figures may look promising, breast cancer remains an incurable disease for 
many patients, especially at advanced stages. One important reason for this is multiple drug 
resistance.
The aim of this study is to identify a panel of genes that may be clinically relevant markers 
to predict the outcome and possibly the drug resistance of tumours in individual patients. 
For the purpose of this study, mRNA levels of a number of genes that were identified, from 
the literature, as being potentially of relevance to breast cancer, were analysed. RT-PCR is 
a highly sensitive technique and small amounts of tissue are needed for analysis. The main 
problem, however, is that the specimens being analysed may not be pure tumour and genes 
in the surrounding ‘normal’ tissue may also be amplified, thereby giving false positive 
results. Therefore, one needs to bear this mind when carrying out such analysis. The ideal 
method of analysis of tumour tissue would be to use laser micro-dissection techniques, 
where the ‘pure’ tumour tissue is identified and selected for analysis leaving behind 
‘normal’ tissue. However, this is not yet an option for analysis in the NICB, and standard 
methods of RNA extraction and RT-PCR were used throughout the clinical study.
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4.6.2 The Clinical Study
The clinical study was done to investigate if a reliable method of analysis could be obtained 
using basic laboratory analytical procedures to analyse the mRNA expression of galectin-3, 
survivin and MRP-1 in a panel of breast tumour specimens and to investigate the 
prognostic and predictive potential of galectin-3, survivin and MRP-1.
This work was part of a collaboration study with St. Vincent’s University hospital (SVUH) 
in Dublin. Tumour samples were donated by Dr. Susan Kennedy, Dept, of Pathology, 
SVUH. Tumour tissue was collected over a number of years (1993-1997) from breast 
cancer patients and was stored at -80°C until needed. Sufficient RNA was extracted from 
approximately 165 tumours using RNA extraction techniques previously optimised by Dr. 
Doolan (PhD, 2001). This method (discussed in more detail in section 2.4), involved 
dissecting the tumour very finely using a homogeniser or a sterile blade before re- 
suspending the tumour in Tri Reagent and freezing prior to the RNA extraction procedure. 
Other RNA extraction methods, from tumour samples, developed in this lab. involved RNA 
extraction from fresh, ’snap’ frozen tissue and archival paraffin-embedded breast tissue (P. 
Doolan, PhD, 2001; O’Driscoll etal., 1996),
A number of clinical and pathological parameters were obtained from patients’ charts 
including details on patient age at diagnosis, tumour type, size and grade, chemotherapy 
and hormonal treatment received, and outcome for patients in terms of relapse-free survival 
and overall survival. Most patients received tamoxifen and/or CMF chemotherapy. Some 
received adriamycin or taxol in addition to CMF, while some patients did not receive any 
drug treatment. Statistical analysis was performed, by Dr. Lorraine O’Driscoll, using the 
SPSS 10.1 software package, on 106 of the 165 tumours analysed by RT-PCR. The reason 
for exclusion of 59 cases was the lack of relevant clinical information on all these 
specimens. The clinical database was built in Excel, compiling information from a series of 
smaller databases and, subsequently, crosschecking and obtaining outstanding information 
from clinical records, where relevant. This information was systematically converted to a 
format recognised for analysis by the SPSS, resulting in a database of more than 18,000 
data points. Univariate and multivariate statistical analyses of the results was then 
performed using the SPSS 10.1 software package. Descriptive statistics was used to
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summarise patient characteristics. Statistical analysis of the results was performed using 
Pearson’s X2 test, systematically analysing groups of parameters in pairs, to investigate 
relationships between reverse transcriptase-polymerase chain reaction, 
immunohistochemical and clinicopathological and histopathologic findings. Kaplan-Meier 
survival curves were established and were subsequently checked using the log-rank, 
Breslow and Tarone-ware tests (p-values represent log-rank, unless otherwise indicated) to 
assess the relevance of potential prognostic factors. Multivariate survival analyses were 
performed using the Cox regression backward stepwise likelihood ratio. The data was 
censored at 5 years for multivariate analysis. A value of p <0.05 was considered 
statistically significant. Six non-cancerous (normal) breast biopsies (N1-N6) were also 
included in the analysis. The tumours were all given a ‘T’ or an ‘S’ number as a method of 
coding.
To gain insight into the genes that are perhaps likely to influence prognosis and teach us 
more about this disease by understanding the roles played by the different genes/family of 
genes, a number of gene transcripts were examined in this study (Table 4.2). The majority 
of transcripts analysed are of apoptosis-related genes, with the exception of one, which is 
related to multiple drug resistance (MRP1). This work was divided between two people, as 
indicated in Table 4.2.
Apoptosis is usually induced by anticancer agents as a mechanism of their death-inducing 
activity (Clynes et a l, 1998). This mechanism of cell death is similar to cell death 
mechanisms caused by DNA damage or deprivation of growth factors (Bottini etal., 2003). 
Therefore, over-expression of genes that inhibit the apoptotic pathway could produce drug 
resistant tumours that are not being killed in response to drug. Bcl-2 has been shown to 
protect cells against death induced by most chemotherapeutic drugs, suggesting that Bcl-2 
over-expression may play a role in resistance to chemotherapy. High expression of Bcl-2 
has been associated with chemotherapy resistance in neuroblastoma and acute myeloid 
leukemia. Bcl-2 expression has, surprisingly, been associated with good prognosis in many 
cancers (Bottini et a l, 2003). Survivin has also been associated with resistance to 
chemotherapy in advanced ovarian carcinoma, where high levels of survivin protein were 
significantly associated with clinical resistance to a taxol/platinum-based regimen 
(Zaffaroni e ta l, 2002). Furthermore, the survivin gene is generally considered to be a very
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interesting diagnostic marker and potential drug target because of its predominantly cancer- 
specific expression in adult human organ tissues. As discussed in previous sections of the 
thesis, survivin is expressed in most human cancers, but not in the majority of normal, adult 
tissue (see section 1.6.3) (Ambrosini et ah, 1997 Adida etal., 1998a and O’Driscoll et ah,
2003).
The results of the clinical study that will be discussed in this thesis are the results from the 
analysis of the first three genes listed in Table 4.2. The results of the analysis carried out on 
the remaining genes have been discussed in the PhD thesis of Dr. D. Cronin (PhD, 2002).
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GeneTranscript of interest Function Analysed by
Survivin* Anti-apoptotic R. Linehan
Survivin-2B* Pro-apoptotic R. Linehan
Survivin-AEx3 * Anti-apoptotic R. Linehan
Galectin-3 Anti-apoptotic R. Linehan
MRP-1 MDR R. Linehan
Bcl-2 Anti-apoptotic D. Cronin
Bax-a Pro-apoptotic D. Cronin
Bag-1 Anti-apoptotic D. Cronin
Mcl-1 Anti-apoptotic D. Cronin
* Survivin and its two splice variants (Survivin-2B and Survivin-AEx3) were co-studied using one set of 
primers, which amplifies the three transcripts (see appendix A).
Table 4.2 Markers analysed by RT-PCR in clinical study
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4.6.3 Survivin mRNA Expression in Breast tumour Biopsies
The aim of this part of the clinical study was to investigate the expression of survivin 
mRNA in invasive breast carcinomas by RT-PCR analysis. The mRNA expression levels 
of the extra two survivin splice variants, survivin 2B (retains part of intron 2 as a cryptic 
exon), and survivin-delta Ex 3 (lacks exon 3), identified in 1999 by Mahotka et al., were 
co-analysed in the tumour samples.
Survivin mRNA expression was detected in 68% (72/106) of cases. Survivin was the 
dominant transcript in the tumour specimens. Survivin-2B mRNA expression was detected 
in 9.4% (10/106), while survivin-AEx3 mRNA was detected in 54.7% (58/106) of cases. 
Analysis of ‘normal’ tissue samples revealed no survivin, survivin-2B or survivin-AEx3 
mRNA expression, confirming findings by many other groups that survivin is not 
expressed in the majority of normal adult tissue (Ambrosini et al., 1997). Survivin protein 
was detected in 60% of breast tumours analysed by immunohistochemistry (Kennedy et al, 
2003). This study was carried out on a larger number of tumour samples (293), but 
included all of the 106 tumours that were analysed by RT-PCR.
Survivin mRNA expression has been widely reported in many other types of cancers as 
well as breast cancer. A recent study of survivin expression in breast cancer revealed 90% 
of tumours expressed survivin mRNA with 23% expression in normal tissue (Nasu et al.,
2002). Sarela et al. (2000) reported survivin mRNA expression in 63.5% of specimens of 
colorectal cancer and found that its expression was correlated with a poor survival rate. 
They also reported 29% survivin mRNA expression in normal tissue (Sarela et al., 2000). 
Survivin mRNA was expressed in 13% of gastric tumours, with no expression reported in 
normal tissue, and no correlation of survivin expression with survival (Ikeguchi and 
Kaibara, 2001), while survivin mRNA expression in neuroblastoma (Tajira et al., 2001) 
and esophageal cancer (Kato et al., 2001) was correlated with poor prognosis and poor 
survival, respectively.
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Not many groups have studied the expression of all three survivin splice variants. Kappler 
et al. (2001) examined the expression of the three splice variants in soft tissue sarcoma 
specimens and found, similar to our own finding, survivin to be the dominant transcript, 
while survivin-2B was the least dominant. They found survivin mRNA expression in 64% 
of cases, survivin-AEx3 mRNA expression in 42% and no survivin-2B mRNA expression 
in any of the samples analysed. Survivin mRNA expression was correlated with a poor 
survival rate (Kappler et al., 2001). Krieg et al. (2002) also studied the expression of the 
three survivin spice variants. In gastric cancer all three splice variants (survivin being the 
dominant transcript) were detected by RT-PCR in all the specimens analysed, irrespective 
of their histological type, grade or stage. Survivin mRNA expression was found in normal 
gastric tissue also. In addition, they found that the expression of survivin-2B mRNA was 
dramatically decreased in advanced stages of gastric cancer, which might support the 
suggestion by Islam et al. (2000) that survivin-2B is acting as a natural antagonist to 
survivin and survivin-AEx3. Similar findings were reported by Mahotka et al. (2002), 
where renal carcinomas were found to express all three survivin variants, with survivin-2B 
mRNA down-regulation associated with advanced stages of the disease.
While the majority of studies of survivin expression in cancer indicate an association with 
poor prognosis, there are small number of cases where this is not the case. Other methods 
of detection of survivin expression include immunohistochemistry. This has been used by 
many researchers to identify localisation of survivin protein in tumour tissues and also to 
correlate survivin protein expression with clinical outcome. As mentioned, in a recent 
immunohistochemical study of 293 breast tumour specimens (including the 106 cases 
studied by RT-PCR), we found that survivin protein expression to be located mainly in the 
nuclei (but also present in the cytoplasm in a small number of tumour tissues) of tumour 
cells (Kennedy et al., 2003). Results from this study indicate that survivin protein 
expression in the nucleus may be a favourable prognostic indicator (Kennedy et al., 2003). 
This is in disagreement with studies carried out by Tanaka et al. (2000) on 167 cases of 
breast tumours, where they found that survivin expression in breast cancer resulted in poor 
prognosis. In the study reported by Tanaka et al. (2000), survivin protein staining was 
found in the cytoplasm of the cells, suggesting that survivin localisation in tumour cells 
may be correlated with disease outcome.
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In our studies, statistical analysis indicated no significant association between survivin 
mRNA expression and disease outcome. In addition, we found no correlation between 
survivin mRNA expression and age of patient (P=0.745), tumour size (P=0.722), clinical 
stage (P=0.588), histology type (P=0.608), lymph node status (P= 0.148) or estrogen 
receptor status (P=0.763). There was no correlation between survivin mRNA expression 
and disease-free survival (P=0.993) or overall survival (P=0.243), as indicated by Kaplan- 
Meier analysis (The P-values presented here are for the main, dominant survivin transcript. 
For full results on all splice variant, see section 3.5.2). Although Nasu etal. (2002) did not 
investigate association of survivin mRNA expression and patient outcome, they did report 
that they found no significant association between survivin mRNA expression and age of 
patient at diagnosis, tumour size, clinical stage, histology type, lymph node status or 
estrogen receptor status (Nasu etal., 2002).
Furthermore, we found no correlation between survivin mRNA expression and survivin 
protein expression in breast carcinoma (P=0.283). There was, however, a significant 
correlation between the expression of the three survivin variants, with survivin and 
survivin-AEx3 (P<0.0001), survivin and survivin-2B (P=0.022), and survivin-AEx3 and 
survivin-2B (P=0.003).
Survivin protein expression has previously been found to correlate with Bcl-2 protein 
expression (Tanaka etal., 2000; Kawasaki et al., 1998; Lu etal., 1998; Sarela etal., 2002). 
In our studies of survivin mRNA expression and survivin protein expression (Kennedy et 
al., 2003) in breast carcinoma, there was no correlation between survivin and Bcl-2 
expression. Survivin mRNA expression did not correlate with the expression of the other 
markers included in our study, although there was an apparent association between 
survivin-AEx3 mRNA expression and Mcl-1 mRNA expression (analysis of Mcl-1 carried 
out by D. Cronin, PhD, 2002).
330
4.6.4 Galectin-3 mRNA Expression in Breast tumour Biopsies
Galectin-3, a P-galactosidas-binding-protein, has been proposed to regulate cell growth, to 
mediate cell adhesion and to inhibit apoptosis (see sections 1.5.2 and 1.5.3) (Matarrese et 
a l, 2000; Akahani et al., 1997). The aim of this part of the clinical study was to investigate 
the expression of galectin-3 mRNA in invasive breast carcinoma by RT-PCR analysis. 
Galectin-3 mRNA expression was detected in approximately 99% of cases analysed.
Galectin-3 protein expression has been reported in many types cancer, including breast 
(Castronovo et a l, 1996; Idikio, 1998), colorectal (Sanjuan et al., 1997; Nakamura et al., 
1999; Legendre et al., 2003; Nagy et al., 2003) pancreatic (Berberat et al., 2001 and Kunzli 
et al., 2002) non-small cell lung cancer (Gabius et al., 2002; Yoshimura et al., 2003), 
ovarian (Van der Brule et al., 1994), and gastric cancers (Miyazaki et al., 2002) (see 
section 1.5.4). The majority of the findings from these studies indicate that decreased 
expression of galectin-3 protein and/or mRNA is associated with progression of cancer. 
This was found to be the case in breast cancer, where decreased galectin-3 expression was 
also associated with an invasive phenotype and a more aggressive tumour. In intra-ductal 
and invasive carcinoma, a large down-regulation of galectin-3 was observed, while breast 
cancer cells metastatic to the lymph nodes exhibited very low or undetectable levels of 
galectin-3. Furthermore, all normal and benign breast specimens examined exhibited 
detectable galectin-3 expression, as seen by immunohistochemistry (Castronovo et al., 
1996). Similar results were reported by Idikio et al. (1998), where the expression of 
galectin-3 was determined in 27 invasive breast cancers by immunocytochemistry. Results 
suggested that increasing histological grade of breast cancer leads to reduced galectin-3 
expression and possibly reduced matrix binding and increased cancer cell motility (Idikio et 
a l, 1998).
In our studies, galectin-3 mRNA expression was found in 83% (5/6) cases of normal tissue 
specimens (see section 3.5.3). Due to its expression in almost all the breast tumour tissue 
analysed, statistical evaluation of galectin-3 mRNA expression was not appropriate. Results 
from this study suggest that expression of galectin-3 at the gene transcript level cannot be 
considered as a prognostic indicator of disease outcome for breast cancer patients.
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4.6.5 MRP1 mRNA Expression in Breast tumour Biopsies
As previously mentioned (see section 4.6.1), chemotherapy plays a major part in the 
treatment of breast cancer and development of a multiple drug resistance phenotype is the 
main set back in the treatment of breast cancer, as is the case with most common cancers. 
The study of MDR-related genes in cancer is, therefore, an important step in understanding 
the mechanisms of development of this phenotype. The expression of the membrane 
transporter, MRP1, which confers a MDR phenotype similar to that conferred by Pgp was 
investigated by RT-PCR in the breast tumour biopsies to establish whether its expression 
correlates with response to chemotherapy and with other clinicopathological parameters.
MRP1 mRNA expression was detected in 72.8% (77/106) of tumour specimens and in 66% 
(4/6) of normal tissue specimens. MRP1 protein expression was investigated by S. 
Kennedy’s group in 176 breast tumour specimens, using immunohistochemistry technique. 
We found no correlation between MRP1 mRNA expression and MRP1 protein expression 
in breast carcinoma (P=0.333), using Chi-square univariate analysis.
The expression of MDR-related genes in breast cancer have been carried out by several 
other research groups (Filipits et ah, 1999; Zochbauer-Muller et ah, 2001; Burger et ah,
2003). mRNA expression levels of BCRP, LRP, MRP1, MRP2 and MDR1 were 
investigated in 59 primary breast tumours specimens from patients who received 
chemotherapy treatment. It was found that the expression of these MDR-related genes was 
higher in non-responding tumours compared with responding tumours. This was most 
significant for MDR1, where overall response was much lower in tumours that expressed 
high levels of MDR-1 mRNA with high expression levels of MDR1 significantly 
associated with a poor relapse-free survival. In addition, there was a correlation between 
BCRP and MRP1 mRNA expression and progression-free survival in patients who received 
CAF (cyclophosphamide, adriamycin, 5-fluorouracil) treatment, but not in patients who 
received CMF (cyclophosphamide, methotrexate, 5-fluorouracil). There was no correlation 
between the expression of any of the five MDR-related genes and overall survival (Burger 
et al., 2003).
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In a study by Filipits et al. (1999), MRP1 protein expression in 100 breast tumour 
specimens was studied using immunohistochemistry. MRP1 was expressed in 80% of 
specimens and was more frequent in ER (estrogen receptor) and PR (progesterone receptor) 
negative carcinomas, but it was independent of tumour size and lymph node involvement. 
Patients who had MRP1 negative tumours had longer overall survival and disease-free 
survival, whereas patients who had MRP1 positive tumours had worse prognosis (Filipits et 
al., 1999).
Taken together, these results suggest that MRP1 expression is indicative of poor prognosis 
in breast cancer patients. However, we found no correlation between MRP1 mRNA 
expression and the outcome of the disease. This is in agreement with a similar study by 
Kanzaki et al. (2001), where, MRP1, MDR1, BCRP, and LRP mRNA expression was 
analysed by RT-PCR in 43 untreated breast tumour patients; the majority of whom 
subsequently received doxorubicin-based chemotherapy after surgery. The expression of 
these four genes was independent of age, and estrogen or progesterone receptor status, and 
was also unrelated to the relapse-free or overall survival of the patients who received 
chemotherapy (Kanzaki etal., 2001).
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4.7 Possible role of Survivin in post-transcription modification
Degradation of several intracellular proteins involved in cell cycle control and tumour 
growth is regulated by the ubiquitin-dependent multicatalytic protease complex 
(proteasome) (Soligo e ta l,  2001). The ubiquitin-proteosome pathway plays a central role 
in the regulation of essential processes such as cell cycle control, antigen processing, 
transcription and signal transduction. Two steps are involved in ubiquitin-proteosome- 
dependent degradation of protein: labeling of the target protein with multiple ubitquitin 
moieties and degradation of the tagged protein by the 26S proteosome (Zhao etal., 2000).
As discussed in section 1.6.6.2, expression of survivin is cell cycle-dependent with up- 
regulation in the G2/M phase and down-regulation in the G1 phase (Li et al., 1997). The 
pattern of survivin expression suggests that the ubiquitin-proteosome pathway may be 
involved in the regulation of survivin. Cycloheximide, a protein synthesis inhibitor, caused 
a down-regulation in survivin protein level, with half of the protein degraded after 30 
minutes. Proteosome inhibitors prevented this degradation, suggesting that proteosomes are 
involved in survivin degradation. Furthermore, results indicate that the decline of survivin 
protein level in the G1 phase of the cell cycle is a result of proteosome activity and 
demonstrate the presence of a post-transcriptional cell cycle-dependent mechanism of 
survivin regulation in vivo (Zhao etal., 2000).
In our current studies, survivin protein expression was dramatically down regulated in 
DLKP MDR variants, DLKP-taxotere (see sections 3.3.8.4 and 4.4.2.2) and DLKP- 
vincristine (see sections 3.3.8.4 and 4.4.3.2). Survivin mRNA expression was unaltered in 
these two MDR variants (see section 3.3.7.10). These findings suggest that survivin is post- 
transcriptionally regulated, and that treatment of DLKP cells with the microtubule- 
stabilising and -destablising drugs, taxotere and vincristine, respectively, may play a role in 
survivin protein degradation in this cell line. Survivin interacts with microtubules of the 
mitotic spindle during the beginning of mitosis resulting in the counteraction of cell death 
in the G2/M phase of the cell cycle. Disruption of survivin-microtubule interactions results 
in loss of survivin’s anti-apoptosis function (Li etal., 1998).
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Similar findings were reported by Wall et al. (2003), where exposure of breast carcinoma 
MCF-7 or cervical carcinoma HeLa cells to anticancer agents, including adriamycin, or 
taxol, resulted in increased survivin protein expression with no change in survivin mRNA 
expression. Transcription of the survivin genes was repressed by anticancer agents, which 
is consistent with similar findings observed with other G2/M-regulated genes containing 
cell-cycle dependent element (CDE) (Wall et al., 2003).
Taken together these results may suggest a decrease in protein synthesis and may explain 
the lack of protein over-expression, in SKOV-3 ‘T.O.’, DLKP and MCF-7 ‘T.O’ survivin 
cDNA transient transfections, where a dramatic over-expression in survivin mRNA was 
obtained (see sections 4.3.4, 4.3.5 and 4.3.6, respectively).
Survivin’s role in post-transcriptional modification in vivo may explain the discrepancies 
observed in the clinical study descried in section between the relevance of survivin mRNA 
and survivin protein in prognosis of breast cancer. As discussed in section survivin protein 
expression correlated with good disease prognosis (Kennedy etal., 2003), whereas survivin 
mRNA expression did not correlate with such prognosis.
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Conclusions & Future Work
5.1 Conclusions
The main objective of this thesis was to investigate the expression of apoptosis-related 
genes, galectin-3 and survivin, in human cancer cells and to establish their relationship with 
in vitro invasiveness and drug resistance.
1. Galectin-3 mRNA and protein expression was up-regulated in the RMPI-2650 
melphalan-resistant variant - a variant which developed a highly elevated adhesive, 
motile and invasive phenotype due to its exposure to melphalan, in addition to an 
MDR phenotype - compared to the RPMI-2650 parental cell line.
2. Galectin-3 cDNA was stably transfected into the non-invasive human lung 
carcinoma cell line, DLKP, and three clones (C2, C12 and Cl 3) along with the 
mixed population (MP) were generated under geneticin selection pressure. Different 
clones displayed up-regulated or down-regulated levels of galectin-3 expression, as 
shown by RT-PCR and Western blot analysis. Galectin-3 over-expressing clones 
were not resistant to the chemotherapeutic drugs, taxol, carboplatin and adriamycin, 
as demonstrated by in vitro toxicity assays. However, DLKP-MP (mixed 
population), which shows the highest level of galectin-3 mRNA and protein over­
expression, displayed a 2-fold increase in resistance to carboplatin. Galectin-3 over­
expression resulted in an increase in in vitro invasiveness, cell motility and 
adhesion to extracellular matrix, fibronectin and laminin, highlighting the 
association of galectin-3 over-expression with in vitro invasiveness and metastasis 
in lung cancer. Galectin-3 over-expression did not result in a change of proliferation 
rate of this cell line.
3. Evidence from the literature on survivin indicates that it may be responsible for an 
increase in resistance to some cytotoxic drugs, such as taxol, etoposide and 
cisplatin. Findings from analysing the expression of survivin in the RPMI-2650 
drug resistant variants, by RT-PCR and western blot analysis, showed that survivin 
expression was down-regulated in the RPMI-2650 taxol-resistant variant, a variant 
which did not develop an invasive phenotype but did develop a MDR phenotype.
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Survivin cDNA was firstly stably transfected into DLKP, generating 5 clones. The 
clones did not show any significant changes in survivin mRNA or protein survivin 
expression, as demonstrated by RT-PCR and western blot analysis. There was also 
no change in resistance levels to the chemotherapeutic drugs, carboplatin or 
adriamycin.
A second cell line was selected for another survivin cDNA stable transfection, 
namely, SKOV-3 ‘Tet off, an ovarian carcinoma cell line stably transfected with a 
tetracycline regulated plasmid, thereby allowing the expression of a transfected 
cDNA to be down-regulated by addition of tetracycline or doxocycline in the 
medium. Twelve clones were generated from the transfection; none exhibited any 
major change in survivin mRNA and protein expression. No change in resistance to 
the chemotherapeutic drugs carboplatin and taxol was observed. Further analysis 
was carried out on two of the SKOV-3 ‘Tet off survivin clones (C2 and C5) and 
the mixed population (MP) in the presence and absence of doxocycline. Survivin 
mRNA and protein expression remained un-changed between the ‘on’ and ‘off 
states of gene expression, and no change in resistance to carboplatin and taxol was 
observed.
A transient transfection of survivin cDNA into SKOV-3 ‘Tet off was carried out 
and survivin mRNA and protein expression was analysed at different time points 
post-transfection, namely, 24 hours, 48 hours, 72 hours and 5 days, by RT-PCR and 
western blot analysis, respectively. Results demonstrated survivin mRNA to be 
dramatically up regulated after 24 hours, with a 50% inhibition of this up-regulation 
resulting from the addition of doxocyline to the growth media, demonstrating the 
use of the inducible system in this cell line. This up-regulation was not observed 
when a control empty vector was transiently transfected into the cells. No up- 
regulation of survivin protein was observed by western blot analysis or by 
immunofluorescence. In vitro toxicity assays and the apoptosis detection assay, 
TUNEL, revealed that survivin mRNA up-regulation alone was not sufficient to 
induce a resistance phenotype in the cells and there was no protection from taxol or 
cisplatin-induced apoptosis. To determine if the up-regulation of survivin mRNA 
resulted in a change in the invasive phenotype of SKOV-3 cells, which are normally
invasive, in vitro invasion assays were carried out 24 hours prior to transfection. In 
vitro invasiveness of SKOV-3 remained unaltered.
The same experiment was carried out on two more cell lines (DLKP and MCF-7 
‘Tet O ff) in an effort to determine whether the effect observed was unique to this 
cell line. Transient transfection of DLKP was carried out and similar results to those 
observed in the SKOV-3 ‘Tet O ff cell line were obtained. Survivin mRNA was 
dramatically over-expressed after 24 hours of transfection, as demonstrated by RT- 
PCR, while survivin protein was un-changed, as demonstrated by western blot 
analysis. Transient transfection of MCF-7 ‘Tet O ff demonstrated that survivin 
mRNA was dramatically over-expressed after 24 hours. In addition, survivin protein 
was initially over-expressed after 24 hours, as demonstrated by western blot 
analysis. However, this observation of survivin protein over-expression was not 
reproducible. Taken together, these results suggest that there may be some 
translational block preventing the over-expression of survivin protein in these 
transfection experiments. An alternative explanation may be that EPR-1, which has 
been suggested to act as a natural antisense to survivin, is playing a role in 
preventing the over-expression of survivin protein. This does not explain, however, 
why other research groups succeeded in obtaining survivin over-expressing cell 
lines (including MCF-7), which resulted in apoptosis inhibition.
7. To further study the effect of MDR on the expression of the anti-apoptosis genes, 
galectin-3 and survivin, the lung carcinoma and the nasal carcinoma cell lines, 
DLKP and RPMI-2650 cells, respectively, were chosen.
The DLKP pulse selections yielded two MDR variants, namely, DLKP taxotere- 
resistant and DLKP vincristine-resistant sublines, which displayed approx. 420-fold 
and 5329-fold resistance to their selection agents, respectively, and 210-fold and 
124-fold resistance to taxol, respectively. A non-resistant variant, DLKP-5-FU also 
resulted. In addition to acquiring a MDR phenotype, DLKP taxotere-resistant 
(DLKP-taxotere-1) cells also acquired an invasive phenotype compared to the 
parental DLKP cell line. Previous results obtained by others in this laboratory,
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revealed that when the DLKP cell line was pulse selected with a range of 
chemotherapeutic drugs, the DLKP taxotere-resistant (DLKP-taxotere-2) and the 
DLKP vincristine-resistant variants did not acquire an invasive phenotype, whereas, 
DLKP 5FU-resistant variant did. These discrepancies suggest that perhaps the 
relationship between MDR and in vitro invasiveness is a random process, and not 
drug-specific or cell line-specific. DLKP parental cells are normally non-invasive in 
vitro (DLKP-1), however, a strain of DLKP (DLKP-2) was identified in the course 
of these studies, which exhibited a highly invasive phenotype. This finding was 
unexpected.
Galectin-3 mRNA expression was un-changed in all three variants compared to the 
parental cells. Similarly, survivin mRNA was also unchanged DNA Microarray 
analysis supported these findings. Survivin protein expression was dramatically 
down regulated in DLKP taxotere-resistant and DLKP-vincristine-resistant variants 
compared to DLKP-5FU and DLKP parent, as demonstrated by western blot 
analysis, suggesting the involvement of post-transcriptional regulation in the 
expression of survivin protein. Survivin expression was also down regulated in the 
RPMI-taxol resistant cell line. Taken together, these results suggest that survivin 
may play a role in vincristine, taxol and taxotere drug resistance, supporting 
findings by other research groups.
Further gene expression analysis in the DLKP variants, by DNA microarray, RT- 
PCR and western blot analysis, demonstrated dramatic over-expression of Mdr-1 
mRNA and protein in DLKP taxotere-resistant and DLKP vincristine-resistant 
variants, supporting the typical pattern of MDR resistance in there variants. RT- 
PCR results showed that MRP-1, -2, -4-, -5 and BCRP mRNA expression was not 
altered between the variants and the parental cells, while MRP-3 seems to be 
expressed in the DLKP-5FU variant, but not in the other two variant or the parental 
cells. DNA microarray analysis indicated an increase in MRP-2 expression in the 
DLKP-vincristine variant when compared to the parental cell line, while MRP-1, -3, 
-4. -5 and BCRP expression was unchanged in the two MDR variants. RT-PCR 
analysis indicate that E-cadherin mRNA expression was increased in the DLKP 
taxotere-resistant variants, supporting its role in the invasive phenotype of this
339
variant. DNA Microarray analysis, however, demonstrate a 2-fold down-regulation 
in this variant. MRP-1 protein expression was slightly up regulated in the DLKP 
taxotere-resistant variants, suggesting post-transcriptional regulation.
8. The RPMI-2650 pulse selections were carried out in duplicate. Preliminary findings 
suggest that a transient resistance was developing in the variants, which was being 
lost with sub-culturing. Similar finding have been reported by other researchers in 
hamster tumour cells. The RPMI-2650 drug-selected variants seem to regain their 
resistance when further pulsed. In vitro invasiveness and motility of the cells 
remained un-altered. Analysis of gene expression by RT-PCR, indicate no dramatic 
change in galectin-3, survivin, Mdr-1, MRP-1, -2, -3, -4, or MRP-5.
9. RT-PCR analysis on 165 breast tumour samples was carried out to examine the 
expression of survivin (and its two splice variants, survivin-AEx3, survivin 2B), 
galectin-3 and MRP1. This clinical tumour specimens study demonstrated the 
ability to extract high quality RNA and to generate reliable RT-PCR results from 
human tissue. Results on 106 cases indicated that none of the three genes correlated 
with disease outcome, suggesting that survivin, galectin-3 and MRP1 cannot be 
considered as prognostic indicators of disease outcome for breast cancer patients. 
The expression of these genes was also analysed in normal breast tissue. Survivin 
was undetected in these specimens, supporting many finding by other researchers 
that survivin is expressed in all common cancers, but not in most normal adult 
tissue, while both galectin-3 and MRP1 expression was detected in over 50% of 
normal specimens, supporting a role for these genes in normal cellular functions in 
human adult tissue.
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5.2 Future Work
Future work arising from this thesis is summarised in the following points:
1. Cancer invasion/metastasis is one of the major causes of death in cancer patients. 
Targeting naturally occurring genes that promote cancer invasion and metastasis 
may, in combination with other cancer therapies such as chemotherapy and/or 
radiotherapy, be effective in slowing down cancer growth and metastasis. Future 
work for examining this theory in vitro could include down-regulation of galectin-3 
expression in an invasive and MDR cancer cell line, e.g. RPMI-melphalan-resistant 
cell line, using antisense oligonucleotides, siRNA or ribozyme techniques. As we 
have shown that up-regulation of galectin-3 expression induces in vitro invasiveness 
in a lung cancer cell line, down-regulation of galectin-3 expression would be 
important to determine whether the inhibition of galectin-3 expression would inhibit 
in vitro invasiveness. The use of antisense oligonucleotides in down-regulating 
galectin-3 has already been reported in breast and colon cancer cell lines, 
successfully inhibiting in vitro invasiveness, but has not yet been used in a nasal 
carcinoma cell line. siRNA technique is a new method for down-regulating gene 
expression and has proven successful in down-regulating galectin-3 in pituitary 
tumours, slowing cellular proliferation rates.
2. DNA microarray technology may be used to identify novel invasion-related genes, 
which may be significantly altered in DLKP-galectin-3 clone 13. As previously 
mentioned, this is a clone which stably over-expresses galectin-3 mRNA and 
protein and expresses an invasive phenotype. Microarray analysis could help 
identify novel genes that play a role in invasion, motility, and adhesion, as well as 
other apoptosis-related genes that may be induced or inhibited by galectin-3 over­
expression. In addition, the DLKP-galectin-3 mixed population may be cloned out 
further to obtain additional clonal populations, which may be useful for further 
analysis.
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3. Survivin is an attractive target for cancer therapy due to its unique expression 
pattern. It is important, therefore, to obtain a cell line model where expression of 
survivin can be regulated and to study functional changes that may result from this 
regulation. We have successfully obtained a cell line where survivin mRNA 
expression can be regulated, using the ‘Tet’ regulatory system. However, we have 
not succeeded in developing a cell line to over-express survivin protein and, 
therefore, a functional change has not been observed. It would be useful to carry out 
survivin cDNA transient transfections in the presence of proteosome inhibitors to 
prevent degradation of survivin protein. This may allow survivin protein to be over­
expressed and a functional change may result.
4. DNA microarray analysis indicated changes in the expression of some gene 
between the DLKP MDR variants and the parental line. It would be useful to repeat 
the array experiment to ensure that the results are reproducible, to validate these 
results by RT-PCR, and to investigate (by western blot analysis) if these changes 
occurred at the protein level. This could identify novel genes that are playing a role 
in drug resistance and invasion, and could allow further analysis of their role via 
transfection studies.
5. Future characterisation of the DLKP MDR variants should include drug 
accumulation assays to compare the DLKP parent cells to their drug resistance 
variants. These studies can be carried out along with circumvention assays using 
agents such as verapamil or cyclosporin A to inhibit P-glycoprotein. A ribozyme to 
Mdr-1 has previously been designed and used in the NICB, showing promising 
results in DLKP adriamycin-resistant cells. This ribozyme may be transfected into 
DLKP vincristine-resistant and DLKP taxotere-resistant variants, which show 
dramatic Mdr-1 mRNA and protein over-expression. siRNA against Mdr-1 has also 
been designed in the NICB recently, and this may also be used in transfection 
experiments to down-regulate Mdr-1 expression in the two DLKP MDR variants, to 
determine if it will sensitise them to chemotherapeutic agents.
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7. Characterisation of the RPMI-2650 drug selected variants merits further research. 
Further in vitro toxicity testing should be carried out on cells pulsed 10 times, 
compared to cells pulsed 12 and 14 times. This may determine whether the initial 
resistance observed is a transient affect, which was lost over time. Cells may need 
to be further pulsed to re-gain resistance. Invasion assays need to be carried out on 
the RPMI-2650 VCR-14p and the RPMI-2650 5-FU-14p variants, as well as 
repeating motility assays on these two variants. In addition, RT-PCR and western 
blot analysis needs to be carried on these two variants. Further characterisation of 
the lOp and 12p variants should include repeating RT-PCR analysis on the MDR- 
related genes, in addition to galectin-3 and survivin. Western blot analysis should 
also be carried out on these variants. Once it has been determined whether the 
variants can remain resistant over a period of time, DNA microarray analysis may 
be carried out to identify novel genes that may play a role in drug resistance. 
Functional studies may then be carried out on genes of interest. These may include 
cDNA over-expression. Alternatively, ribozyme, antisense or siRNA for down- 
regulation of specific genes, identified as potentially being of interest, could be 
performed to elucidate their role(s).
8. Unstable drug resistance has previously been reported in a hamster tumour cell line, 
which is associated with changes in MDR-related gene expression. Our studies of 
the RPMI-2650 drug-selected variants may be useful to examine how unstable 
resistance is achieved. This may be important from a clinical aspect since drug 
resistance is a main cause of chemotherapy failure and if this can be averted it may 
lead to better cancer therapy. It would be useful to isolate RNA from the RPMI- 
2650 drug-treated variants at different intervals of sub-culturing and to study the 
patterns of MDR-related gene expression by DNA microarry and RT-PCR analysis. 
This may identify key genes, which may be down regulated or switched off through 
sub-culturing of initially resistant cells. Once such genes have been identified they 
may be targeted using antisense or siRNA techniques in stable drug-resistant cell 
lines and may ultimately lead to therapeutic targets.
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9 The breast tumour tissue specimens available at the NICB provide a source of 
information that can be used for further gene expression analysis. It would be 
important, therefore, to extract RNA from these specimens, for real-time, 
quantitative PCR analysis, using laser capture micro-dissection to isolate tumour 
tissue which is not at risk of being contaminated with normal tissue that may be 
surrounding the tumour. This would provide accurate information on gene 
expression specific to tumour tissue, which may be compared to normal tissue. It 
may also be beneficial to analyse the expression and localisation of galectin-3 
protein by immunohistochemistry in the tumour specimens, as galectin-3 
localisation seems to be an important prognostic factor. The breast tumour samples 
may also be used for DNA microarray studies to identify a much larger number of 
genes (possibly including novel genes) that may play an important role in breast 
cancer and may be used as prognostic or predictive markers for this disease.
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Appendices
7.1 Appendix A
7.1.1 Primers used for RT-PCR gene expression analysis
T ab le  7.1.1 Primer Sequences used for R T -PC R  analysis
G ene P rim ers (5 ’-3 ’) A n n ea lin g  T em p  (°C) P ro d u ct  
S ize (bp)
G aIectin-3 F get ggg cca ctg att gtg cct tat 
R  acc agt act tgt att ttg aatggt
54 281
Survivin F gca tgg gtg ccc cga cgt tg 
R  get ccg gcc aga ggc ctc aa
62 329
431
500
S urviv in  R T agg aac ctg cag ctc aga
M dr-1 F gtt caa act tetget cctga 
R  ccc ate att gca ata gca gg
54 157
M R P 1 F gta cat taa cat gat ctg gtc 
R  cgt tea tea get tga tcc gat
54 2 0 2
M R P 2 F ctg cct ctt cag aat ett ag 
R  ccc aag ttg cag get ggc c
54 241
M R P 3 F gat acg ctc g cc  aca gtc c  
R  cag ttg gcc gtg atg tgg ctg
63 2 62
JV1RP4 F cca ttg aag ate ttc ctg g  
R ggtg tt caa tctgtg tgc
42 2 39
Table 7.1.1 continued Primer Sequences used for RT-PCR analysis
G ene P rim ers (5 ’-3 ’) A n n ea lin g  T em p  (°C) P ro d u ct  
S ize (bp)
M R P 5 F gga taa ctt ctc agt ggg 49 
R  gga atg gca atg ctc taa ag
381
B C R P F aga ctt atg ttc cac ggg cc 63 
R  caa ggc cac gtg att ctt cc
1113
E -cad h erin F age cat ggg ccc ttg gag 65 
R  cca gag get ctg tea cct tc
653
P-actin (L) F gaa ate gtg cgt gac att aag gag aag ct 
R  tea gga gga gca atg ate ttg a
383
P-actin (S) F tgg aca tee gca aag ace tgt ae 55 
R tea gga gga gca atg ate ttg a
142
F=Forward primer, R=Reverse primer, p-actin (L)= P-actin(Long), p-actin (S)= p-actin(Short).
7.1.2 Coding sequences for Survivin and Galectin-3 genes
(1) S u rv iv in  C od ing  S eq uence A ccession  n um ber: N M  001168
50 a tgggtgcccc gacgttgccc cctgcctggc agccctttct caaggaccac cgcatctcta cattcaagaa 
ctggcccttc ttggagggct gcgcctgcac cccggagcgg atggccgagg ctggcttcat ccactgcccc 
actgagaacg agccagactt ggcccagtgt ttcttctgct tcaaggagct ggaaggctgg gagccagatg 
acgaccccat agaggaacat aaaaagcatt cgtccggttg cgctttcctt tctgtcaaga agcagtttga 
agaattaacc cttggtgaat ttttgaaact ggacagagaa agagccaaga acaaaattgc aaaggaaacc 
aacaataaga agaaagaatt tgaggaaact gcgaagaaag tgcgccgtgc catcgagcag ctggctgcca 
tggattga 478
(2) G alectin -3  C od ing  Seq uence A ccession  num ber: A B 0 0 6 7 8 0
54 atggcag acaatttttc gctccatgat gcgttatctg ggtctggaaa cccaaaccct caaggatggc
ctggcgcatg ggggaaccag cctgctgggg cagggggcta cccaggggct tcctatcctg gggcctaccc 
cgggcaggca cccccagggg cttatcctgg acaggcacct ccaggcgcct accctggagc acctggagct 
tatcccggag cacctgcacc tggagtctac ccagggccac ccagcggccc tggggcctac ccatcttctg 
gacagccaag tgccaccgga gcctaccctg ccactggccc ctatggcgcc cctgctgggc cactgattgt 
gccttataac ctgcctttgc ctgggggagt ggtgcctcgc atgctgataa caattctggg cacggtgaag
cccaatgcaa acagaattgc tttagatttc caaagaggga atgatgttgc cttccacttt aacccacgct
tcaatgagaa caacaggaga gtcattgttt gcaatacaaa gctggataat aactggggaa gggaagaaag 
acagtcggtt ttcccatttg aaagtgggaa accattcaaa atacaagtac tggttgaacc tgaccacttc 
aaggttgcag tgaatgatgc tcacttgttg cagtacaatc atcgggttaa aaaactcaat gaaatcagca
aactgggaat ttctggtgac atagacctca ccagtgcttc atataccatg atataa 806
7.2 Appendix B Drug Dilutions used in in vitro Toxicity Assays
T ab le  7.2.1 Range o f  Chemotherapeutic Drug Dilutions used in in vitro  Toxicity Assays 
for DLKP-Galectin-3 and Survivin transfectants
A d riam ycin  (ng/m l) T axo l (ng/m l) C arb op la tin  (|xg/m l)
250 62.5 100
125 31.25 50
62.5 15.62 25
15.62 7.81 12.5
7.81 3.9 6.25
3.9 1.95 3.125
1.95 0.97 1.56
0.97 0.48 0.78
0.48 0.24 0.39
T ab le  7 .2 .2  Range o f  Chemotherapeutic Drug Dilutions used in in v itro  Toxicity Assays 
for DLKP Drug-treated variants
T axotere
(ng/m l)
T axol
(ng/m l)
V in cristin e
(ng/m l)
5-F U
(Hg/ml)
A d riam ycin
(n g/m l)
C isp la tin
(Hg/ml)
500 62.5 5000 10 250 50
250 31.25 2500 5 125 25
125 15.62 1250 2.5 62.5 12.5
62.5 7.81 625 1.25 15.62 6.25
31.5 3.9 62.5 0.62 7.81 3.125
7.8 1.95 31.25 0.31 3.9 1.56
1.95 0.97 3.12 0.15 1.95 0.78
0.97 0.48 1.56 0.078 0.97 0.39
0.48 0.24 0.39 0.039 0.48 0.15
T a b le  72.3 Range of Chemotherapeutic Drug Dilutions used in in vitro Toxicity Assays 
for RPMI 2650-Drug-treated variants
V incristine
(ng/m l)
5-FU
(ng/m l)
CCNU
(Hg/n>!)
Adriam ycin
(ng/m l)
Carboplatin
(ng/m l)
300 20 25 250 60
150 10 12.5 125 30
75 5 6.25 62.5 15
37.5 2.5 1.56 15.62 7.5
18.75 1.25 0.78 7.81 3.75
9.38 0.62 0.39 3.9 1.88
4.69 0.31 0.19 1.95 0.94
2.34 0.15 0.09 0.97 0.47
1.17 0.078 0.04 0.48 0.23
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